mm	O
&	O
m	O
's	O
top	O
health	O
technology	O
stories	O
of	O
2016	O
photo	O
credit	O
:	O
jon	ORG
simon/feature	ORG
photo	ORG
service	ORG
for	ORG
ibm	ORG
1	O
.	O
how	O
watson	O
for	O
oncology	O
is	O
advancing	O
cancer	O
care	O
three	O
years	O
ago	O
,	O
memorial	O
sloan-kettering	O
and	O
ibm	ORG
watson	O
formed	O
a	O
partnership	O
to	O
develop	O
watson	O
for	O
oncology	O
,	O
a	O
cognitive	O
computing	O
system	O
that	O
can	O
analyze	O
large	O
volumes	O
of	O
data	O
including	O
medical	O
literature	O
,	O
patient	O
health	O
records	O
,	O
and	O
clinical	O
trials	O
,	O
to	O
offer	O
personalized	O
,	O
evidence-based	O
treatment	O
recommendations	O
for	O
cancer	O
patients	O
.	O
photo	O
credit	O
:	O
klick	O
health	O
2	O
.	O
3	O
health	O
tech	O
innovations	O
experts	O
say	O
will	O
revolutionalize	O
healthcare	O
“	O
this	O
is	O
the	O
most	O
interesting	O
time	O
in	O
the	O
history	O
of	O
healthcare	O
and	O
medicine	O
,	O
”	O
says	O
zen	O
chu	O
,	O
md	O
of	O
accelerated	O
medical	O
ventures	O
and	O
senior	O
lecturer	O
at	O
the	O
mit	ORG
sloan	ORG
school	ORG
of	O
management	O
.	O
“	O
we	O
've	O
got	O
so	O
many	O
new	O
technologies	O
and	O
redesigned	O
experiences	O
impacting	O
both	O
the	O
value	O
we	O
deliver	O
,	O
and	O
also	O
the	O
value	O
patients	O
are	O
getting	O
from	O
healthcare.	O
”	O
photo	O
credit	O
:	O
facebook	ORG
3	O
.	O
10	O
things	O
for	O
pharma	ORG
marketers	O
to	O
know	O
about	O
facebook	ORG
and	O
instagram	ORG
“	O
when	O
you	O
think	O
back	O
in	O
the	O
day	O
,	O
people	O
used	O
to	O
have	O
really	O
personal	O
relationships	O
with	O
their	O
physician	O
and	O
pharmacist	O
.	O
we	O
got	O
a	O
little	O
away	O
from	O
that	O
,	O
but	O
we	O
believe	O
that	O
facebook	ORG
can	O
help	O
bring	O
that	O
back	O
and	O
help	O
pharma	ORG
reconnect	O
with	O
people	O
one-on-one	O
,	O
”	O
said	O
facebook	ORG
health	O
industry	O
manager	O
danielle	PERS
salowski	PERS
.	O
photo	O
credit	O
:	O
uncalno	ORG
tekno/creative	ORG
commons	ORG
4	O
.	O
8	O
ways	O
for	O
pharma	ORG
to	O
improve	O
the	O
way	O
it	O
uses	O
twitter	ORG
when	O
it	O
comes	O
to	O
incorporating	O
digital	O
and	O
social	O
media	O
in	O
their	O
marketing	O
strategies	O
,	O
drugmakers	O
'	O
efforts	O
are	O
still	O
overshadowed	O
by	O
fear	O
.	O
that	O
's	O
according	O
to	O
mary	PERS
ann	PERS
belliveau	PERS
,	O
twitter	ORG
's	O
national	O
health	O
and	O
wellness	O
director	O
.	O
there	O
's	O
a	O
misperception	O
that	O
drugmakers	O
ca	O
n't	O
use	O
the	O
platform	O
because	O
of	O
regulatory	O
limitations	O
but	O
in	O
fact	O
many	O
firms	O
are	O
doing	O
it	O
and	O
doing	O
it	O
well	O
,	O
she	O
noted	O
.	O
photo	O
credit	O
:	O
andy	ORG
de/creative	ORG
commons	ORG
5	O
.	O
pharma	ORG
turns	O
to	O
mobile	O
,	O
population	O
data	O
to	O
market	O
to	O
docs	O
there	O
are	O
myriad	O
reasons	O
doctors	O
tell	O
marketers	O
they	O
'd	O
like	O
to	O
be	O
approached	O
through	O
digital	O
channels	O
.	O
some	O
point	O
to	O
their	O
status	O
as	O
employees	O
of	O
a	O
system	O
or	O
organization	O
that	O
limits	O
(	O
or	O
even	O
bans	O
)	O
contact	O
with	O
sales	O
reps	O
,	O
while	O
others	O
merely	O
note	O
that	O
they	O
're	O
extremely	O
busy	O
.	O
but	O
for	O
many	O
others	O
,	O
perhaps	O
it	O
's	O
because	O
—	O
like	O
people	O
in	O
basically	O
every	O
other	O
profession	O
—	O
they	O
sure	O
love	O
them	O
some	O
digital	O
.	O
photo	O
credit	O
:	O
creative	O
commons/btnhd	O
production	O
6	O
.	O
pharma	ORG
companies	O
turn	O
to	O
wearables	O
to	O
improve	O
r	O
&	O
d	O
pfizer	ORG
,	O
ucb	ORG
,	O
apple	ORG
,	O
and	O
ibm	ORG
are	O
just	O
a	O
few	O
of	O
the	O
other	O
companies	O
testing	O
out	O
mobile	O
technology	O
for	O
patients	O
with	O
parkinson	O
's	O
.	O
apple	ORG
's	O
researchkit	O
and	O
pfizer	ORG
's	O
and	O
ibm	ORG
's	O
wearable	O
sensor	O
system	O
are	O
both	O
being	O
used	O
to	O
gather	O
data	O
in	O
real	O
time	O
to	O
better	O
understand	O
the	O
disease	O
.	O
7	O
.	O
healthcare	O
marketers	O
:	O
do	O
n't	O
forget	O
about	O
the	O
baby	O
boomers	O
this	O
is	O
a	O
ripe	O
demographic	O
for	O
digital	O
health	O
services	O
and	O
devices	O
.	O
in	O
fact	O
,	O
it	O
's	O
now	O
a	O
matter	O
of	O
urgency	O
:	O
boomers	O
are	O
less	O
healthy	O
and	O
more	O
costly	O
,	O
from	O
a	O
systemic	O
perspective	O
,	O
than	O
previous	O
generations	O
.	O
photo	O
credit	O
:	O
sermo	O
8	O
.	O
sermo	O
opens	O
up	O
platform	O
to	O
healthcare	O
marketers	O
sermo	O
,	O
a	O
social-networking	O
platform	O
for	O
physicians	O
,	O
launched	O
a	O
new	O
free	O
feature	O
that	O
allows	O
pharma	ORG
and	O
healthcare	O
marketers	O
to	O
engage	O
with	O
its	O
roughly	O
550,000	O
physician	O
members	O
.	O
photo	O
credit	O
:	O
insulet	O
9	O
.	O
devicemakers	O
eye	O
market	O
for	O
drug	O
adherence	O
a	O
number	O
of	O
new	O
companies	O
are	O
developing	O
technologies	O
that	O
seek	O
to	O
address	O
how	O
patients	O
take	O
their	O
medicines	O
,	O
as	O
part	O
of	O
a	O
broader	O
effort	O
to	O
improve	O
adherence	O
among	O
those	O
patients	O
.	O
insulet	O
is	O
one	O
example	O
.	O
the	O
company	O
produces	O
small	O
skin-adhesive	O
pods	O
called	O
omnipods	O
that	O
administer	O
the	O
delivery	O
of	O
subcutaneous	O
drugs	O
.	O
photo	O
credit	O
:	O
sproutel	O
10	O
.	O
how	O
a	O
startup	O
is	O
educating	O
kids	O
with	O
diabetes	O
with	O
a	O
teddy	O
bear	O
through	O
the	O
use	O
of	O
animated	O
books	O
and	O
sensors	O
installed	O
using	O
an	O
android	O
tablet	O
in	O
sproutel	O
's	O
jerry	O
the	O
bear	O
,	O
children	O
can	O
learn	O
more	O
about	O
their	O
condition	O
by	O
acting	O
as	O
caregivers	O
themselves	O
,	O
feeding	O
food	O
to	O
the	O
bear	O
,	O
administering	O
insulin	O
,	O
and	O
monitoring	O
his	O
blood	O
glucose	O
levels	O
.	O
medical	O
marketing	O
&	O
media	O
return	O
to	O
top	O
mm	O
&	O
m	O
's	O
top	O
health	O
technology	O
stories	O
of	O
2016	O
december	O
28	O
,	O
2016	O
photo	O
credit	O
:	O
jon	ORG
simon/feature	ORG
photo	ORG
service	ORG
for	ORG
ibm	ORG
1	O
.	O
how	O
watson	O
for	O
oncology	O
is	O
advancing	O
cancer	O
care	O
three	O
years	O
ago	O
,	O
memorial	O
sloan-kettering	O
and	O
ibm	O
watson	O
formed	O
a	O
partnership	O
to	O
develop	O
watson	O
for	O
oncology	O
,	O
a	O
cognitive	O
computing	O
system	O
that	O
can	O
analyze	O
large	O
volumes	O
of	O
data	O
including	O
medical	O
literature	O
,	O
patient	O
health	O
records	O
,	O
and	O
clinical	O
trials	O
,	O
to	O
offer	O
personalized	O
,	O
evidence-based	O
treatment	O
recommendations	O
for	O
cancer	O
patients	O
.	O
photo	O
credit	O
:	O
klick	O
health	O
2	O
.	O
3	O
health	O
tech	O
innovations	O
experts	O
say	O
will	O
revolutionalize	O
healthcare	O
“	O
this	O
is	O
the	O
most	O
interesting	O
time	O
in	O
the	O
history	O
of	O
healthcare	O
and	O
medicine	O
,	O
”	O
says	O
zen	O
chu	O
,	O
md	O
of	O
accelerated	O
medical	O
ventures	O
and	O
senior	O
lecturer	O
at	O
the	O
mit	ORG
sloan	ORG
school	ORG
of	O
management	O
.	O
“	O
we	O
've	O
got	O
so	O
many	O
new	O
technologies	O
and	O
redesigned	O
experiences	O
impacting	O
both	O
the	O
value	O
we	O
deliver	O
,	O
and	O
also	O
the	O
value	O
patients	O
are	O
getting	O
from	O
healthcare.	O
”	O
photo	O
credit	O
:	O
facebook	ORG
3	O
.	O
10	O
things	O
for	O
pharma	ORG
marketers	O
to	O
know	O
about	O
facebook	ORG
and	O
instagram	ORG
“	O
when	O
you	O
think	O
back	O
in	O
the	O
day	O
,	O
people	O
used	O
to	O
have	O
really	O
personal	O
relationships	O
with	O
their	O
physician	O
and	O
pharmacist	O
.	O
we	O
got	O
a	O
little	O
away	O
from	O
that	O
,	O
but	O
we	O
believe	O
that	O
facebook	ORG
can	O
help	O
bring	O
that	O
back	O
and	O
help	O
pharma	ORG
reconnect	O
with	O
people	O
one-on-one	O
,	O
”	O
said	O
facebook	ORG
health	O
industry	O
manager	O
danielle	PERS
salowski	PERS
.	O
photo	O
credit	O
:	O
uncalno	ORG
tekno/creative	ORG
commons	ORG
4	O
.	O
8	O
ways	O
for	O
pharma	ORG
to	O
improve	O
the	O
way	O
it	O
uses	O
twitter	ORG
when	O
it	O
comes	O
to	O
incorporating	O
digital	O
and	O
social	O
media	O
in	O
their	O
marketing	O
strategies	O
,	O
drugmakers	O
'	O
efforts	O
are	O
still	O
overshadowed	O
by	O
fear	O
.	O
that	O
's	O
according	O
to	O
mary	PERS
ann	PERS
belliveau	PERS
,	O
twitter	ORG
's	O
national	O
health	O
and	O
wellness	O
director	O
.	O
there	O
's	O
a	O
misperception	O
that	O
drugmakers	O
ca	O
n't	O
use	O
the	O
platform	O
because	O
of	O
regulatory	O
limitations	O
but	O
in	O
fact	O
many	O
firms	O
are	O
doing	O
it	O
and	O
doing	O
it	O
well	O
,	O
she	O
noted	O
.	O
photo	O
credit	O
:	O
andy	ORG
de/creative	ORG
commons	ORG
5	O
.	O
pharma	ORG
turns	O
to	O
mobile	O
,	O
population	O
data	O
to	O
market	O
to	O
docs	O
there	O
are	O
myriad	O
reasons	O
doctors	O
tell	O
marketers	O
they	O
'd	O
like	O
to	O
be	O
approached	O
through	O
digital	O
channels	O
.	O
some	O
point	O
to	O
their	O
status	O
as	O
employees	O
of	O
a	O
system	O
or	O
organization	O
that	O
limits	O
(	O
or	O
even	O
bans	O
)	O
contact	O
with	O
sales	O
reps	O
,	O
while	O
others	O
merely	O
note	O
that	O
they	O
're	O
extremely	O
busy	O
.	O
but	O
for	O
many	O
others	O
,	O
perhaps	O
it	O
's	O
because	O
—	O
like	O
people	O
in	O
basically	O
every	O
other	O
profession	O
—	O
they	O
sure	O
love	O
them	O
some	O
digital	O
.	O
photo	O
credit	O
:	O
creative	O
commons/btnhd	O
production	O
6	O
.	O
pharma	ORG
companies	O
turn	O
to	O
wearables	O
to	O
improve	O
r	O
&	O
d	O
pfizer	ORG
,	O
ucb	ORG
,	O
apple	ORG
,	O
and	O
ibm	O
are	O
just	O
a	O
few	O
of	O
the	O
other	O
companies	O
testing	O
out	O
mobile	O
technology	O
for	O
patients	O
with	O
parkinson	O
's	O
.	O
apple	ORG
's	O
researchkit	O
and	O
pfizer	ORG
's	O
and	O
ibm	O
's	O
wearable	O
sensor	O
system	O
are	O
both	O
being	O
used	O
to	O
gather	O
data	O
in	O
real	O
time	O
to	O
better	O
understand	O
the	O
disease	O
.	O
7	O
.	O
healthcare	O
marketers	O
:	O
do	O
n't	O
forget	O
about	O
the	O
baby	O
boomers	O
this	O
is	O
a	O
ripe	O
demographic	O
for	O
digital	O
health	O
services	O
and	O
devices	O
.	O
in	O
fact	O
,	O
it	O
's	O
now	O
a	O
matter	O
of	O
urgency	O
:	O
boomers	O
are	O
less	O
healthy	O
and	O
more	O
costly	O
,	O
from	O
a	O
systemic	O
perspective	O
,	O
than	O
previous	O
generations	O
.	O
photo	O
credit	O
:	O
sermo	O
8	O
.	O
sermo	O
opens	O
up	O
platform	O
to	O
healthcare	O
marketers	O
sermo	O
,	O
a	O
social-networking	O
platform	O
for	O
physicians	O
,	O
launched	O
a	O
new	O
free	O
feature	O
that	O
allows	O
pharma	ORG
and	O
healthcare	O
marketers	O
to	O
engage	O
with	O
its	O
roughly	O
550,000	O
physician	O
members	O
.	O
photo	O
credit	O
:	O
insulet	O
9	O
.	O
devicemakers	O
eye	O
market	O
for	O
drug	O
adherence	O
a	O
number	O
of	O
new	O
companies	O
are	O
developing	O
technologies	O
that	O
seek	O
to	O
address	O
how	O
patients	O
take	O
their	O
medicines	O
,	O
as	O
part	O
of	O
a	O
broader	O
effort	O
to	O
improve	O
adherence	O
among	O
those	O
patients	O
.	O
insulet	O
is	O
one	O
example	O
.	O
the	O
company	O
produces	O
small	O
skin-adhesive	O
pods	O
called	O
omnipods	O
that	O
administer	O
the	O
delivery	O
of	O
subcutaneous	O
drugs	O
.	O
photo	O
credit	O
:	O
sproutel	O
10	O
.	O
how	O
a	O
startup	O
is	O
educating	O
kids	O
with	O
diabetes	O
with	O
a	O
teddy	O
bear	O
through	O
the	O
use	O
of	O
animated	O
books	O
and	O
sensors	O
installed	O
using	O
an	O
android	O
tablet	O
in	O
sproutel	O
's	O
jerry	O
the	O
bear	O
,	O
children	O
can	O
learn	O
more	O
about	O
their	O
condition	O
by	O
acting	O
as	O
caregivers	O
themselves	O
,	O
feeding	O
food	O
to	O
the	O
bear	O
,	O
administering	O
insulin	O
,	O
and	O
monitoring	O
his	O
blood	O
glucose	O
levels	O
.	O
medical	O
marketing	O
&	O
media	O
return	O
to	O
top	O
japanese	O
drugmakers	O
lead	O
the	O
way	O
in	O
digital	O
innovation	O
january	O
09	O
,	O
2017	O
bob	PERS
oliver	PERS
is	O
president	O
and	O
ceo	O
of	O
otsuka	ORG
america	ORG
pharmaceutical	ORG
.	O
photo	O
credit	O
:	O
duncan	PERS
kendall	PERS
bob	PERS
oliver	PERS
is	O
not	O
the	O
type	O
of	O
person	O
who	O
calls	O
out	O
his	O
colleagues	O
.	O
he	O
's	O
not	O
big	O
on	O
trash	O
talking	O
or	O
monday	O
morning	O
quarterbacking	O
.	O
but	O
when	O
he	O
's	O
asked	O
what	O
separates	O
the	O
health-tech	O
zealots	O
from	O
the	O
pretenders	O
,	O
the	O
true	O
innovators	O
from	O
the	O
me-toos	O
,	O
oliver	O
is	O
quick	O
to	O
identify	O
an	O
obvious	O
tell	O
.	O
“	O
it	O
's	O
the	O
[	O
companies	O
]	O
that	O
say	O
,	O
‘	O
we	O
're	O
not	O
afraid	O
to	O
fail	O
.	O
we	O
tell	O
our	O
people	O
that	O
it	O
's	O
ok	O
to	O
fail	O
,	O
'	O
”	O
he	O
explains	O
.	O
“	O
when	O
you	O
're	O
dealing	O
with	O
something	O
as	O
new	O
as	O
a	O
lot	O
of	O
digital	O
medicine	O
and	O
health-tech	O
are	O
,	O
and	O
something	O
that	O
requires	O
you	O
to	O
think	O
differently	O
than	O
you	O
always	O
have	O
,	O
not	O
everything	O
is	O
going	O
to	O
work	O
.	O
of	O
course	O
you	O
're	O
going	O
to	O
fail	O
.	O
but	O
there	O
's	O
failing	O
and	O
moving	O
on	O
,	O
and	O
then	O
there	O
's	O
failing	O
and	O
learning	O
from	O
it.	O
”	O
see	O
also	O
:	O
shark	O
tank	O
's	O
herjavec	ORG
shares	O
his	O
tips	O
for	O
innovation	O
competitions	O
oliver	O
,	O
president	O
and	O
ceo	O
of	O
otsuka	ORG
america	ORG
pharmaceutical	ORG
,	O
has	O
more	O
credibility	O
than	O
most	O
to	O
critique	O
efforts	O
in	O
and	O
around	O
the	O
space	O
.	O
in	O
september	O
2015	O
,	O
the	O
company	O
became	O
the	O
first	O
to	O
have	O
a	O
new	O
drug	O
application	O
for	O
a	O
true	O
digital	O
medicine	O
—	O
abilify	O
embedded	O
with	O
an	O
ingestible	O
sensor	O
made	O
by	O
proteus	O
digital	O
health	O
—	O
accepted	O
by	O
the	O
fda	ORG
.	O
however	O
,	O
the	O
application	O
remains	O
in	O
flux	O
.	O
this	O
past	O
april	O
,	O
the	O
companies	O
received	O
a	O
complete	O
response	O
letter	O
(	O
crl	O
)	O
from	O
the	O
agency	O
withholding	O
approval	O
and	O
requesting	O
more	O
information	O
,	O
but	O
industry	O
response	O
to	O
the	O
filing	O
surprised	O
and	O
even	O
awed	O
oliver	O
.	O
“	O
we	O
'd	O
just	O
had	O
a	O
bunch	O
of	O
launches	O
and	O
approvals	O
,	O
but	O
the	O
interest	O
for	O
[	O
the	O
digital	O
medicine	O
]	O
was	O
10	O
times	O
what	O
we	O
usually	O
see	O
.	O
while	O
we	O
had	O
a	O
setback	O
with	O
the	O
crl	O
,	O
the	O
anticipation	O
is	O
undiminished	O
,	O
”	O
he	O
notes	O
.	O
there	O
are	O
other	O
pharma	O
players	O
who	O
have	O
similarly	O
pushed	O
back	O
against	O
the	O
industry	O
's	O
usual	O
wait-and-see	O
philosophy	O
in	O
regard	O
to	O
all	O
things	O
new	O
and	O
somewhat	O
scary	O
.	O
see	O
also	O
:	O
pharma	O
is	O
reluctant	O
to	O
adopt	O
digital	O
in	O
r	O
&	O
d	O
:	O
survey	O
tomotaro	PERS
nagakawa	PERS
,	O
lead	O
partner	O
in	O
deloitte	ORG
japan	O
's	O
life	O
sciences	O
practice	O
,	O
points	O
to	O
astellas	O
,	O
which	O
established	O
digitx	ORG
partners	ORG
in	O
july	O
,	O
a	O
digital	O
health	O
investment	O
company	O
alongside	O
life	O
sciences	O
vc	O
firm	O
mpm	ORG
capital	ORG
,	O
and	O
takeda	ORG
,	O
which	O
launched	O
ibdata	O
in	O
september	O
,	O
a	O
digital	O
program	O
designed	O
to	O
improve	O
diagnostics	O
,	O
measurement	O
,	O
and	O
treatment	O
of	O
inflammatory	O
bowel	O
disease	O
,	O
as	O
particularly	O
prescient	O
and	O
forward-minded	O
.	O
then	O
there	O
's	O
daiichi	ORG
sankyo	ORG
,	O
which	O
started	O
working	O
with	O
partners	O
healthcare	O
on	O
a	O
mobile	O
adherence	O
tool	O
for	O
atrial	O
fibrillation	O
patients	O
way	O
back	O
in	O
2014	O
.	O
notice	O
a	O
trend	O
?	O
otsuka	O
,	O
astellas	O
,	O
takeda	ORG
,	O
and	O
daiichi	ORG
sankyo	ORG
share	O
a	O
degree	O
of	O
adventurousness	O
and	O
forward-mindedness	O
in	O
the	O
digital	O
realm	O
,	O
but	O
they	O
similarly	O
share	O
a	O
country	O
of	O
origin	O
.	O
is	O
there	O
something	O
that	O
japanese-based	O
pharma	O
companies	O
get	O
about	O
health-tech	O
that	O
ones	O
based	O
elsewhere	O
do	O
n't	O
?	O
if	O
so	O
,	O
what	O
are	O
the	O
lessons	O
the	O
have-nots	O
might	O
learn	O
from	O
the	O
digital	O
successes	O
of	O
these	O
organizations	O
?	O
an	O
innovation	O
gap	O
?	O
you	O
wo	O
n't	O
get	O
too	O
many	O
execs	O
at	O
u.s.	O
or	O
european	O
companies	O
to	O
go	O
on	O
the	O
record	O
about	O
a	O
possible	O
health-tech	O
innovation	O
or	O
attitude	O
gap	O
.	O
but	O
if	O
those	O
execs	O
do	O
n't	O
believe	O
such	O
a	O
gap	O
exists	O
,	O
their	O
off-the-cuff	O
comments	O
suggest	O
otherwise	O
.	O
they	O
speak	O
enviously	O
about	O
some	O
of	O
the	O
business	O
philosophies	O
,	O
such	O
as	O
the	O
willingness	O
to	O
tackle	O
problems	O
in	O
an	O
offbeat	O
manner	O
and	O
the	O
celebration	O
of	O
diverse	O
thinking	O
,	O
that	O
japanese	O
pharma	O
companies	O
embrace	O
more	O
openly	O
than	O
their	O
counterparts	O
.	O
they	O
compare	O
such	O
approaches	O
favorably	O
to	O
their	O
own	O
,	O
almost	O
resigned	O
that	O
infighting	O
and	O
overthinking	O
will	O
continue	O
to	O
hobble	O
them	O
as	O
they	O
attempt	O
to	O
keep	O
pace	O
with	O
the	O
industry	O
's	O
historic	O
transformation	O
.	O
see	O
also	O
:	O
what	O
10	O
innovation	O
teams	O
look	O
like	O
some	O
of	O
their	O
comments	O
ring	O
hollow	O
—	O
one	O
imagines	O
that	O
legal	O
and	O
regulatory	O
teams	O
at	O
japanese	O
companies	O
are	O
n't	O
exactly	O
waving	O
through	O
every	O
proposed	O
health-tech	O
initiative	O
with	O
a	O
grin	O
and	O
a	O
thumbs-up	O
—	O
but	O
the	O
point	O
remains	O
:	O
many	O
execs	O
believe	O
they	O
can	O
,	O
and	O
should	O
,	O
model	O
their	O
digital	O
modus	O
operandi	O
on	O
what	O
they	O
've	O
seen	O
from	O
companies	O
otsuka	O
,	O
astellas	O
,	O
takeda	ORG
,	O
and	O
daiichi	ORG
sankyo	ORG
.	O
tellingly	O
,	O
leaders	O
at	O
these	O
companies	O
do	O
n't	O
hold	O
themselves	O
up	O
as	O
health-tech	O
visionaries	O
.	O
rather	O
,	O
they	O
view	O
pushing	O
the	O
digital	O
envelope	O
as	O
merely	O
another	O
component	O
of	O
their	O
overarching	O
mission	O
to	O
better	O
support	O
patients	O
,	O
which	O
companies	O
say	O
ranks	O
among	O
their	O
biggest	O
catalysts	O
for	O
change	O
.	O
“	O
when	O
takeda	ORG
started	O
on	O
its	O
digital	O
journey	O
,	O
we	O
realized	O
we	O
had	O
pockets	O
of	O
experience	O
and	O
pockets	O
of	O
innocence	O
,	O
”	O
recalls	O
bruno	PERS
villetelle	PERS
,	O
the	O
company	O
's	O
chief	O
digital	O
officer	O
.	O
“	O
every	O
organization	O
is	O
facing	O
challenges	O
.	O
when	O
you	O
're	O
going	O
into	O
uncharted	O
territory	O
,	O
as	O
digital	O
and	O
digital	O
health	O
still	O
is	O
,	O
it	O
's	O
about	O
a	O
commitment	O
to	O
experimentation.	O
”	O
bruno	PERS
villetelle	PERS
is	O
takeda	ORG
's	O
chief	O
digital	O
officer	O
.	O
many	O
also	O
admit	O
they	O
ca	O
n't	O
tackle	O
the	O
digital	O
era	O
alone	O
.	O
mark	PERS
reisenauer	PERS
,	O
astellas	O
svp	O
of	O
oncology	O
,	O
believes	O
his	O
company	O
is	O
structured	O
in	O
a	O
way	O
that	O
facilitates	O
digital	O
innovation	O
and	O
is	O
philosophically	O
aligned	O
around	O
the	O
idea	O
that	O
fostering	O
this	O
innovation	O
is	O
a	O
must-do	O
.	O
still	O
,	O
he	O
says	O
astellas	O
oncology	O
's	O
finest	O
recent	O
moment	O
occurred	O
when	O
it	O
threw	O
its	O
weight	O
behind	O
the	O
c3	O
prize	O
competition	O
,	O
designed	O
to	O
address	O
gaps	O
in	O
the	O
nontreatment	O
aspects	O
of	O
cancer	O
care	O
—	O
adherence	O
,	O
care-coordination	O
,	O
and	O
more	O
.	O
“	O
i	O
've	O
been	O
in	O
oncology	O
for	O
22	O
years	O
,	O
so	O
i	O
thought	O
i	O
had	O
a	O
good	O
perspective	O
on	O
what	O
patients	O
were	O
facing	O
.	O
but	O
when	O
i	O
had	O
to	O
live	O
with	O
it	O
through	O
my	O
father	O
,	O
who	O
had	O
neck	O
cancer	O
,	O
it	O
became	O
obvious	O
how	O
much	O
we	O
do	O
n't	O
know	O
about	O
the	O
patient	O
experience	O
,	O
”	O
reisenauer	O
explains	O
.	O
“	O
one	O
thing	O
we	O
learned	O
was	O
the	O
importance	O
and	O
power	O
of	O
sourcing	O
innovation	O
externally	O
from	O
people	O
close	O
to	O
the	O
problem	O
.	O
you	O
learn	O
things	O
you	O
would	O
never	O
have	O
thought	O
of	O
in	O
50	O
years.	O
”	O
4	O
lessons	O
for	O
western	O
pharma	O
partner	O
up	O
.	O
that	O
is	O
the	O
first	O
lesson	O
digital-health	O
wannabes	O
might	O
learn	O
from	O
their	O
japanese	O
peers	O
:	O
those	O
who	O
go	O
it	O
alone	O
will	O
find	O
it	O
harder	O
to	O
gain	O
traction	O
than	O
those	O
who	O
embrace	O
nontraditional	O
partnerships	O
,	O
whether	O
with	O
entrepreneurs	O
,	O
vc	O
players	O
,	O
or	O
anyone	O
else	O
with	O
a	O
half-baked	O
idea	O
.	O
of	O
course	O
,	O
the	O
problem	O
is	O
medicine	O
manufacturers	O
have	O
n't	O
played	O
well	O
with	O
others	O
over	O
the	O
years	O
,	O
in	O
part	O
because	O
there	O
was	O
no	O
compelling	O
reason	O
for	O
them	O
to	O
do	O
so	O
.	O
if	O
the	O
industry	O
's	O
continuing	O
transformation	O
does	O
n't	O
prompt	O
a	O
swift	O
reconsideration	O
of	O
such	O
self-limiting	O
attitudes	O
,	O
it	O
's	O
unlikely	O
anything	O
will	O
.	O
dr.	O
joseph	PERS
kvedar	PERS
,	O
vp	O
,	O
connected	O
health	O
at	O
partners	O
healthcare	O
,	O
says	O
the	O
ability	O
and	O
willingness	O
to	O
collaborate	O
varies	O
wildly	O
from	O
pharma	O
company	O
to	O
pharma	O
company	O
.	O
see	O
also	O
:	O
pfizer	ORG
's	O
smoking-cessation	O
app	O
came	O
from	O
internal	O
competition	O
“	O
one	O
of	O
the	O
big	O
differentiators	O
is	O
how	O
much	O
of	O
a	O
vision	O
the	O
company	O
has	O
for	O
the	O
role	O
of	O
digital	O
tools	O
going	O
forward	O
,	O
versus	O
as	O
an	O
extension	O
of	O
already	O
existing	O
marketing	O
,	O
”	O
he	O
explains	O
.	O
“	O
that	O
's	O
one	O
of	O
the	O
things	O
daiichi	ORG
sankyo	ORG
got	O
from	O
the	O
outset	O
.	O
they	O
did	O
n't	O
act	O
the	O
way	O
you	O
might	O
expect	O
when	O
big	O
pharma	O
corporations	O
are	O
involved	O
,	O
which	O
is	O
,	O
‘	O
well	O
,	O
what	O
about	O
the	O
milestone	O
?	O
stick	O
to	O
the	O
plan	O
.	O
'	O
”	O
which	O
is	O
n't	O
to	O
say	O
these	O
partnerships	O
should	O
assume	O
the	O
form	O
of	O
a	O
casual	O
date	O
.	O
“	O
let	O
's	O
figure	O
it	O
out	O
as	O
we	O
go	O
along	O
”	O
agendas	O
have	O
even	O
less	O
place	O
in	O
health-tech	O
than	O
they	O
did	O
in	O
the	O
bygone	O
multiple	O
high	O
silos	O
era	O
.	O
“	O
it	O
is	O
often	O
the	O
case	O
that	O
a	O
pharma	O
company	O
is	O
having	O
discussions	O
with	O
potential	O
partners	O
without	O
a	O
clear	O
image	O
of	O
their	O
to-be	O
state	O
and-or	O
services	O
they	O
would	O
like	O
to	O
provide	O
by	O
using	O
digital	O
health	O
technologies	O
,	O
”	O
deloitte	ORG
's	O
nagakawa	O
notes	O
.	O
disband	O
the	O
digital	O
team	O
.	O
at	O
daiichi	ORG
sankyo	ORG
,	O
takeda	ORG
,	O
astellas	O
,	O
and	O
otsuka	O
,	O
there	O
's	O
no	O
such	O
thing	O
as	O
a	O
digital	O
team	O
.	O
otsuka	O
,	O
in	O
fact	O
,	O
has	O
spun	O
off	O
otsuka	O
digital	O
health	O
as	O
a	O
joint	O
venture	O
with	O
ibm	ORG
japan	ORG
.	O
and	O
while	O
the	O
inner	O
structural	O
workings	O
of	O
most	O
pharma	O
companies	O
are	O
sufficiently	O
opaque	O
as	O
to	O
prevent	O
overarching	O
statements	O
about	O
the	O
prevalence	O
of	O
such	O
units	O
,	O
it	O
's	O
fair	O
to	O
say	O
many	O
non-japanese-based	O
entities	O
have	O
n't	O
eliminated	O
them	O
.	O
see	O
also	O
:	O
the	O
fda	ORG
,	O
astellas	O
,	O
and	O
accenture	O
use	O
innovation	O
competitions	O
to	O
help	O
address	O
business	O
challenges	O
the	O
problem	O
seems	O
to	O
have	O
something	O
to	O
do	O
with	O
internal	O
politics	O
.	O
rather	O
than	O
impressing	O
the	O
need	O
to	O
change	O
with	O
the	O
times	O
upon	O
long-established	O
groups	O
and	O
divisions	O
,	O
many	O
companies	O
have	O
taken	O
the	O
easy	O
way	O
out	O
:	O
they	O
've	O
assembled	O
distinct	O
digital	O
teams	O
,	O
feisty	O
bands	O
of	O
upstarts	O
charged	O
with	O
imposing	O
their	O
digital	O
will	O
.	O
in	O
doing	O
so	O
,	O
they	O
've	O
essentially	O
made	O
digital	O
transformation	O
an	O
optional	O
activity	O
.	O
oliver	O
,	O
for	O
one	O
,	O
doubts	O
“	O
digital	O
dna	O
”	O
can	O
readily	O
be	O
embedded	O
into	O
a	O
company	O
's	O
genetic	O
sequence	O
.	O
“	O
[	O
digital	O
and	O
health-tech	O
]	O
are	O
things	O
that	O
were	O
traditionally	O
outside	O
our	O
core	O
,	O
but	O
now	O
they	O
're	O
as	O
essential	O
as	O
anything	O
in	O
our	O
core	O
,	O
”	O
he	O
explains	O
.	O
“	O
it	O
takes	O
intentionality	O
.	O
it	O
takes	O
intense	O
focus	O
.	O
you	O
ca	O
n't	O
just	O
say	O
to	O
a	O
few	O
people	O
,	O
‘	O
ok	O
,	O
go	O
tell	O
everybody	O
to	O
do	O
this	O
.	O
'	O
”	O
villetelle	O
agrees	O
.	O
“	O
digital	O
and	O
digital	O
health	O
does	O
n't	O
work	O
if	O
it	O
's	O
led	O
by	O
a	O
remnant	O
of	O
digital	O
natives	O
.	O
you	O
need	O
to	O
bring	O
everyone	O
on	O
the	O
journey	O
,	O
which	O
maybe	O
is	O
n't	O
so	O
common	O
in	O
this	O
industry.	O
”	O
start	O
early	O
.	O
in	O
his	O
time	O
at	O
partners	O
healthcare	O
,	O
kvedar	O
has	O
worked	O
with	O
companies	O
at	O
the	O
beginning	O
of	O
their	O
digital	O
transformation	O
and	O
ones	O
well	O
into	O
their	O
metamorphosis	O
.	O
what	O
separates	O
the	O
successful	O
from	O
the	O
less	O
successful	O
,	O
he	O
believes	O
,	O
is	O
a	O
depth	O
of	O
vision	O
.	O
for	O
the	O
collaboration	O
with	O
daiichi	ORG
sankyo	ORG
,	O
kvedar	O
and	O
his	O
team	O
were	O
brought	O
in	O
early	O
,	O
which	O
allowed	O
the	O
brands	O
to	O
align	O
philosophically	O
and	O
mechanically	O
.	O
“	O
i	O
do	O
n't	O
know	O
that	O
this	O
is	O
exclusive	O
to	O
companies	O
such	O
as	O
daiichi	ORG
sankyo	ORG
,	O
but	O
the	O
ideal	O
situation	O
in	O
pharma	O
is	O
doing	O
digital	O
as	O
much	O
more	O
than	O
a	O
late	O
add-on	O
,	O
”	O
kvedar	O
explains	O
.	O
“	O
you	O
want	O
the	O
company	O
to	O
come	O
in	O
thinking	O
,	O
‘	O
we	O
have	O
a	O
molecule	O
and	O
want	O
to	O
build	O
some	O
kind	O
of	O
digital	O
wraparound	O
or	O
something	O
that	O
adds	O
value	O
to	O
it	O
.	O
'	O
it	O
's	O
when	O
you	O
start	O
planning	O
midway	O
through	O
that	O
you	O
get	O
in	O
trouble.	O
”	O
see	O
also	O
:	O
how	O
a	O
startup	O
is	O
educating	O
kids	O
with	O
diabetes	O
with	O
a	O
teddy	O
bear	O
early	O
digital	O
planning	O
for	O
and	O
around	O
new	O
drugs	O
and	O
other	O
pharma	O
initiatives	O
should	O
also	O
help	O
the	O
industry	O
evolve	O
toward	O
what	O
might	O
come	O
next	O
.	O
“	O
we	O
think	O
that	O
someday	O
pharma	O
companies	O
will	O
be	O
in	O
the	O
software	O
business	O
,	O
either	O
in	O
addition	O
to	O
the	O
molecule	O
business	O
or	O
in	O
place	O
of	O
it	O
,	O
”	O
kvedar	O
continues	O
.	O
“	O
digital	O
tools	O
can	O
have	O
remarkable	O
therapeutic	O
effects	O
on	O
their	O
own.	O
”	O
pick	O
your	O
spots	O
.	O
villetelle	O
believes	O
takeda	ORG
's	O
successes	O
in	O
the	O
digital	O
realm	O
have	O
everything	O
to	O
do	O
with	O
an	O
approach	O
that	O
is	O
as	O
relentless	O
as	O
it	O
is	O
selective	O
.	O
for	O
example	O
,	O
takeda	ORG
in	O
mid-november	O
was	O
running	O
40	O
health-tech	O
experiments	O
across	O
geographies	O
,	O
brands	O
,	O
and	O
therapeutic	O
areas	O
.	O
some	O
are	O
destined	O
to	O
“	O
fail	O
fast	O
,	O
”	O
as	O
villetelle	O
puts	O
it	O
,	O
while	O
others	O
could	O
morph	O
into	O
something	O
entirely	O
different	O
than	O
first	O
envisioned	O
.	O
ultimately	O
,	O
though	O
,	O
it	O
's	O
not	O
just	O
about	O
the	O
success	O
of	O
a	O
given	O
project	O
.	O
an	O
important	O
side	O
benefit	O
comes	O
in	O
the	O
form	O
of	O
encouraging	O
people	O
at	O
all	O
levels	O
of	O
the	O
organization	O
to	O
prioritize	O
digital	O
thinking	O
and	O
empowering	O
them	O
to	O
translate	O
those	O
thoughts	O
into	O
action	O
.	O
see	O
also	O
:	O
uber	ORG
partners	O
with	O
startup	O
to	O
take	O
patients	O
to	O
the	O
doctor	O
“	O
small	O
,	O
lean	O
teams	O
exploring	O
new	O
areas	O
—	O
that	O
's	O
what	O
commitment	O
to	O
experimentation	O
looks	O
like	O
,	O
”	O
he	O
adds	O
.	O
“	O
i	O
do	O
n't	O
believe	O
there	O
's	O
such	O
a	O
thing	O
as	O
‘	O
digital	O
culture	O
'	O
or	O
‘	O
digital	O
mindset	O
.	O
'	O
you	O
learn	O
by	O
doing.	O
”	O
takeda	ORG
's	O
ibdata	O
program	O
satisfies	O
just	O
about	O
every	O
criteria	O
health-tech	O
leaders	O
at	O
the	O
japanese	O
companies	O
recommend	O
.	O
it	O
was	O
developed	O
in	O
partnership	O
with	O
two	O
important	O
allies	O
,	O
vanderbilt	ORG
university	ORG
medical	ORG
center	ORG
and	O
texas	O
digestive	O
disease	O
consultants	O
.	O
its	O
development	O
coincided	O
with	O
takeda	ORG
's	O
growth	O
within	O
the	O
ibd	O
category	O
.	O
it	O
developed	O
organically	O
,	O
rather	O
than	O
under	O
the	O
thumb	O
of	O
a	O
digital	O
leader	O
or	O
squadron	O
.	O
and	O
it	O
lends	O
itself	O
easily	O
to	O
an	O
elevator	O
pitch	O
:	O
patients	O
can	O
track	O
their	O
symptoms	O
and	O
lifestyle	O
factors	O
using	O
wearable	O
watch	O
technology	O
.	O
villetelle	O
has	O
high	O
hopes	O
for	O
this	O
and	O
other	O
digital	O
experiments	O
,	O
whether	O
efforts	O
to	O
show	O
the	O
mode	O
of	O
action	O
for	O
takeda	ORG
products	O
using	O
virtual	O
reality	O
or	O
a	O
program	O
alongside	O
wechat	O
in	O
china	O
to	O
bolster	O
patient	O
education	O
about	O
chronic	O
disease	O
.	O
he	O
believes	O
the	O
company	O
's	O
work	O
will	O
foster	O
a	O
sense	O
of	O
adventure	O
.	O
“	O
i	O
was	O
listening	O
to	O
entrepreneur	O
elon	PERS
musk	O
give	O
an	O
interview	O
recently	O
and	O
he	O
said	O
something	O
that	O
stuck	O
with	O
me	O
,	O
”	O
villetelle	O
says	O
.	O
“	O
it	O
was	O
something	O
along	O
the	O
lines	O
of	O
,	O
‘	O
life	O
needs	O
to	O
be	O
about	O
more	O
than	O
solving	O
problems	O
every	O
day	O
.	O
'	O
we	O
need	O
to	O
be	O
excited	O
about	O
the	O
future	O
.	O
[	O
digital	O
health	O
]	O
gets	O
us	O
to	O
that	O
place.	O
”	O
oliver	O
,	O
on	O
the	O
other	O
hand	O
,	O
recalls	O
a	O
business-magazine	O
article	O
from	O
years	O
ago	O
that	O
likened	O
the	O
pharma	O
industry	O
to	O
the	O
steel	O
industry	O
.	O
“	O
that	O
's	O
very	O
sobering	O
.	O
that	O
's	O
not	O
the	O
comparison	O
we	O
want	O
,	O
”	O
he	O
recalls	O
.	O
“	O
the	O
point	O
was	O
the	O
last	O
real	O
shakeup	O
in	O
pharma	O
was	O
when	O
the	O
fda	ORG
was	O
formed	O
,	O
130	O
years	O
ago	O
,	O
and	O
now	O
there	O
's	O
very	O
real	O
disruption	O
.	O
you	O
can	O
go	O
two	O
ways	O
when	O
that	O
happens	O
:	O
disrupt	O
yourself	O
or	O
be	O
disrupted	O
by	O
external	O
forces	O
.	O
having	O
the	O
courage	O
to	O
disrupt	O
themselves	O
is	O
what	O
's	O
going	O
to	O
make	O
or	O
break	O
a	O
lot	O
of	O
companies	O
in	O
the	O
next	O
decade.	O
”	O
from	O
the	O
january	O
2017	O
issue	O
of	O
mmm	O
»	O
medical	O
marketing	O
&	O
media	O
return	O
to	O
top	O
japanese	O
drugmakers	O
lead	O
the	O
way	O
in	O
digital	O
innovation	O
bob	PERS
oliver	PERS
is	O
president	O
and	O
ceo	O
of	O
otsuka	ORG
america	ORG
pharmaceutical	ORG
.	O
photo	O
credit	O
:	O
duncan	PERS
kendall	PERS
bob	PERS
oliver	PERS
is	O
not	O
the	O
type	O
of	O
person	O
who	O
calls	O
out	O
his	O
colleagues	O
.	O
he	O
's	O
not	O
big	O
on	O
trash	O
talking	O
or	O
monday	O
morning	O
quarterbacking	O
.	O
but	O
when	O
he	O
's	O
asked	O
what	O
separates	O
the	O
health-tech	O
zealots	O
from	O
the	O
pretenders	O
,	O
the	O
true	O
innovators	O
from	O
the	O
me-toos	O
,	O
oliver	O
is	O
quick	O
to	O
identify	O
an	O
obvious	O
tell	O
.	O
“	O
it	O
's	O
the	O
[	O
companies	O
]	O
that	O
say	O
,	O
‘	O
we	O
're	O
not	O
afraid	O
to	O
fail	O
.	O
we	O
tell	O
our	O
people	O
that	O
it	O
's	O
ok	O
to	O
fail	O
,	O
'	O
”	O
he	O
explains	O
.	O
“	O
when	O
you	O
're	O
dealing	O
with	O
something	O
as	O
new	O
as	O
a	O
lot	O
of	O
digital	O
medicine	O
and	O
health-tech	O
are	O
,	O
and	O
something	O
that	O
requires	O
you	O
to	O
think	O
differently	O
than	O
you	O
always	O
have	O
,	O
not	O
everything	O
is	O
going	O
to	O
work	O
.	O
of	O
course	O
you	O
're	O
going	O
to	O
fail	O
.	O
but	O
there	O
's	O
failing	O
and	O
moving	O
on	O
,	O
and	O
then	O
there	O
's	O
failing	O
and	O
learning	O
from	O
it.	O
”	O
see	O
also	O
:	O
shark	O
tank	O
's	O
herjavec	ORG
shares	O
his	O
tips	O
for	O
innovation	O
competitions	O
oliver	O
,	O
president	O
and	O
ceo	O
of	O
otsuka	ORG
america	ORG
pharmaceutical	ORG
,	O
has	O
more	O
credibility	O
than	O
most	O
to	O
critique	O
efforts	O
in	O
and	O
around	O
the	O
space	O
.	O
in	O
september	O
2015	O
,	O
the	O
company	O
became	O
the	O
first	O
to	O
have	O
a	O
new	O
drug	O
application	O
for	O
a	O
true	O
digital	O
medicine	O
—	O
abilify	O
embedded	O
with	O
an	O
ingestible	O
sensor	O
made	O
by	O
proteus	O
digital	O
health	O
—	O
accepted	O
by	O
the	O
fda	ORG
.	O
however	O
,	O
the	O
application	O
remains	O
in	O
flux	O
.	O
this	O
past	O
april	O
,	O
the	O
companies	O
received	O
a	O
complete	O
response	O
letter	O
(	O
crl	O
)	O
from	O
the	O
agency	O
withholding	O
approval	O
and	O
requesting	O
more	O
information	O
,	O
but	O
industry	O
response	O
to	O
the	O
filing	O
surprised	O
and	O
even	O
awed	O
oliver	O
.	O
“	O
we	O
'd	O
just	O
had	O
a	O
bunch	O
of	O
launches	O
and	O
approvals	O
,	O
but	O
the	O
interest	O
for	O
[	O
the	O
digital	O
medicine	O
]	O
was	O
10	O
times	O
what	O
we	O
usually	O
see	O
.	O
while	O
we	O
had	O
a	O
setback	O
with	O
the	O
crl	O
,	O
the	O
anticipation	O
is	O
undiminished	O
,	O
”	O
he	O
notes	O
.	O
there	O
are	O
other	O
pharma	O
players	O
who	O
have	O
similarly	O
pushed	O
back	O
against	O
the	O
industry	O
's	O
usual	O
wait-and-see	O
philosophy	O
in	O
regard	O
to	O
all	O
things	O
new	O
and	O
somewhat	O
scary	O
.	O
see	O
also	O
:	O
pharma	O
is	O
reluctant	O
to	O
adopt	O
digital	O
in	O
r	O
&	O
d	O
:	O
survey	O
tomotaro	PERS
nagakawa	PERS
,	O
lead	O
partner	O
in	O
deloitte	ORG
japan	O
's	O
life	O
sciences	O
practice	O
,	O
points	O
to	O
astellas	O
,	O
which	O
established	O
digitx	ORG
partners	ORG
in	O
july	O
,	O
a	O
digital	O
health	O
investment	O
company	O
alongside	O
life	O
sciences	O
vc	O
firm	O
mpm	ORG
capital	ORG
,	O
and	O
takeda	ORG
,	O
which	O
launched	O
ibdata	O
in	O
september	O
,	O
a	O
digital	O
program	O
designed	O
to	O
improve	O
diagnostics	O
,	O
measurement	O
,	O
and	O
treatment	O
of	O
inflammatory	O
bowel	O
disease	O
,	O
as	O
particularly	O
prescient	O
and	O
forward-minded	O
.	O
then	O
there	O
's	O
daiichi	ORG
sankyo	ORG
,	O
which	O
started	O
working	O
with	O
partners	O
healthcare	O
on	O
a	O
mobile	O
adherence	O
tool	O
for	O
atrial	O
fibrillation	O
patients	O
way	O
back	O
in	O
2014	O
.	O
notice	O
a	O
trend	O
?	O
otsuka	O
,	O
astellas	O
,	O
takeda	ORG
,	O
and	O
daiichi	ORG
sankyo	ORG
share	O
a	O
degree	O
of	O
adventurousness	O
and	O
forward-mindedness	O
in	O
the	O
digital	O
realm	O
,	O
but	O
they	O
similarly	O
share	O
a	O
country	O
of	O
origin	O
.	O
is	O
there	O
something	O
that	O
japanese-based	O
pharma	O
companies	O
get	O
about	O
health-tech	O
that	O
ones	O
based	O
elsewhere	O
do	O
n't	O
?	O
if	O
so	O
,	O
what	O
are	O
the	O
lessons	O
the	O
have-nots	O
might	O
learn	O
from	O
the	O
digital	O
successes	O
of	O
these	O
organizations	O
?	O
an	O
innovation	O
gap	O
?	O
you	O
wo	O
n't	O
get	O
too	O
many	O
execs	O
at	O
u.s.	O
or	O
european	O
companies	O
to	O
go	O
on	O
the	O
record	O
about	O
a	O
possible	O
health-tech	O
innovation	O
or	O
attitude	O
gap	O
.	O
but	O
if	O
those	O
execs	O
do	O
n't	O
believe	O
such	O
a	O
gap	O
exists	O
,	O
their	O
off-the-cuff	O
comments	O
suggest	O
otherwise	O
.	O
they	O
speak	O
enviously	O
about	O
some	O
of	O
the	O
business	O
philosophies	O
,	O
such	O
as	O
the	O
willingness	O
to	O
tackle	O
problems	O
in	O
an	O
offbeat	O
manner	O
and	O
the	O
celebration	O
of	O
diverse	O
thinking	O
,	O
that	O
japanese	O
pharma	O
companies	O
embrace	O
more	O
openly	O
than	O
their	O
counterparts	O
.	O
they	O
compare	O
such	O
approaches	O
favorably	O
to	O
their	O
own	O
,	O
almost	O
resigned	O
that	O
infighting	O
and	O
overthinking	O
will	O
continue	O
to	O
hobble	O
them	O
as	O
they	O
attempt	O
to	O
keep	O
pace	O
with	O
the	O
industry	O
's	O
historic	O
transformation	O
.	O
see	O
also	O
:	O
what	O
10	O
innovation	O
teams	O
look	O
like	O
some	O
of	O
their	O
comments	O
ring	O
hollow	O
—	O
one	O
imagines	O
that	O
legal	O
and	O
regulatory	O
teams	O
at	O
japanese	O
companies	O
are	O
n't	O
exactly	O
waving	O
through	O
every	O
proposed	O
health-tech	O
initiative	O
with	O
a	O
grin	O
and	O
a	O
thumbs-up	O
—	O
but	O
the	O
point	O
remains	O
:	O
many	O
execs	O
believe	O
they	O
can	O
,	O
and	O
should	O
,	O
model	O
their	O
digital	O
modus	O
operandi	O
on	O
what	O
they	O
've	O
seen	O
from	O
companies	O
otsuka	O
,	O
astellas	O
,	O
takeda	ORG
,	O
and	O
daiichi	ORG
sankyo	ORG
.	O
tellingly	O
,	O
leaders	O
at	O
these	O
companies	O
do	O
n't	O
hold	O
themselves	O
up	O
as	O
health-tech	O
visionaries	O
.	O
rather	O
,	O
they	O
view	O
pushing	O
the	O
digital	O
envelope	O
as	O
merely	O
another	O
component	O
of	O
their	O
overarching	O
mission	O
to	O
better	O
support	O
patients	O
,	O
which	O
companies	O
say	O
ranks	O
among	O
their	O
biggest	O
catalysts	O
for	O
change	O
.	O
“	O
when	O
takeda	ORG
started	O
on	O
its	O
digital	O
journey	O
,	O
we	O
realized	O
we	O
had	O
pockets	O
of	O
experience	O
and	O
pockets	O
of	O
innocence	O
,	O
”	O
recalls	O
bruno	PERS
villetelle	PERS
,	O
the	O
company	O
's	O
chief	O
digital	O
officer	O
.	O
“	O
every	O
organization	O
is	O
facing	O
challenges	O
.	O
when	O
you	O
're	O
going	O
into	O
uncharted	O
territory	O
,	O
as	O
digital	O
and	O
digital	O
health	O
still	O
is	O
,	O
it	O
's	O
about	O
a	O
commitment	O
to	O
experimentation.	O
”	O
bruno	PERS
villetelle	PERS
is	O
takeda	ORG
's	O
chief	O
digital	O
officer	O
.	O
many	O
also	O
admit	O
they	O
ca	O
n't	O
tackle	O
the	O
digital	O
era	O
alone	O
.	O
mark	PERS
reisenauer	PERS
,	O
astellas	O
svp	O
of	O
oncology	O
,	O
believes	O
his	O
company	O
is	O
structured	O
in	O
a	O
way	O
that	O
facilitates	O
digital	O
innovation	O
and	O
is	O
philosophically	O
aligned	O
around	O
the	O
idea	O
that	O
fostering	O
this	O
innovation	O
is	O
a	O
must-do	O
.	O
still	O
,	O
he	O
says	O
astellas	O
oncology	O
's	O
finest	O
recent	O
moment	O
occurred	O
when	O
it	O
threw	O
its	O
weight	O
behind	O
the	O
c3	O
prize	O
competition	O
,	O
designed	O
to	O
address	O
gaps	O
in	O
the	O
nontreatment	O
aspects	O
of	O
cancer	O
care	O
—	O
adherence	O
,	O
care-coordination	O
,	O
and	O
more	O
.	O
“	O
i	O
've	O
been	O
in	O
oncology	O
for	O
22	O
years	O
,	O
so	O
i	O
thought	O
i	O
had	O
a	O
good	O
perspective	O
on	O
what	O
patients	O
were	O
facing	O
.	O
but	O
when	O
i	O
had	O
to	O
live	O
with	O
it	O
through	O
my	O
father	O
,	O
who	O
had	O
neck	O
cancer	O
,	O
it	O
became	O
obvious	O
how	O
much	O
we	O
do	O
n't	O
know	O
about	O
the	O
patient	O
experience	O
,	O
”	O
reisenauer	O
explains	O
.	O
“	O
one	O
thing	O
we	O
learned	O
was	O
the	O
importance	O
and	O
power	O
of	O
sourcing	O
innovation	O
externally	O
from	O
people	O
close	O
to	O
the	O
problem	O
.	O
you	O
learn	O
things	O
you	O
would	O
never	O
have	O
thought	O
of	O
in	O
50	O
years.	O
”	O
4	O
lessons	O
for	O
western	O
pharma	O
partner	O
up	O
.	O
that	O
is	O
the	O
first	O
lesson	O
digital-health	O
wannabes	O
might	O
learn	O
from	O
their	O
japanese	O
peers	O
:	O
those	O
who	O
go	O
it	O
alone	O
will	O
find	O
it	O
harder	O
to	O
gain	O
traction	O
than	O
those	O
who	O
embrace	O
nontraditional	O
partnerships	O
,	O
whether	O
with	O
entrepreneurs	O
,	O
vc	O
players	O
,	O
or	O
anyone	O
else	O
with	O
a	O
half-baked	O
idea	O
.	O
of	O
course	O
,	O
the	O
problem	O
is	O
medicine	O
manufacturers	O
have	O
n't	O
played	O
well	O
with	O
others	O
over	O
the	O
years	O
,	O
in	O
part	O
because	O
there	O
was	O
no	O
compelling	O
reason	O
for	O
them	O
to	O
do	O
so	O
.	O
if	O
the	O
industry	O
's	O
continuing	O
transformation	O
does	O
n't	O
prompt	O
a	O
swift	O
reconsideration	O
of	O
such	O
self-limiting	O
attitudes	O
,	O
it	O
's	O
unlikely	O
anything	O
will	O
.	O
dr.	O
joseph	PERS
kvedar	PERS
,	O
vp	O
,	O
connected	O
health	O
at	O
partners	O
healthcare	O
,	O
says	O
the	O
ability	O
and	O
willingness	O
to	O
collaborate	O
varies	O
wildly	O
from	O
pharma	O
company	O
to	O
pharma	O
company	O
.	O
see	O
also	O
:	O
pfizer	ORG
's	O
smoking-cessation	O
app	O
came	O
from	O
internal	O
competition	O
“	O
one	O
of	O
the	O
big	O
differentiators	O
is	O
how	O
much	O
of	O
a	O
vision	O
the	O
company	O
has	O
for	O
the	O
role	O
of	O
digital	O
tools	O
going	O
forward	O
,	O
versus	O
as	O
an	O
extension	O
of	O
already	O
existing	O
marketing	O
,	O
”	O
he	O
explains	O
.	O
“	O
that	O
's	O
one	O
of	O
the	O
things	O
daiichi	ORG
sankyo	ORG
got	O
from	O
the	O
outset	O
.	O
they	O
did	O
n't	O
act	O
the	O
way	O
you	O
might	O
expect	O
when	O
big	O
pharma	O
corporations	O
are	O
involved	O
,	O
which	O
is	O
,	O
‘	O
well	O
,	O
what	O
about	O
the	O
milestone	O
?	O
stick	O
to	O
the	O
plan	O
.	O
'	O
”	O
which	O
is	O
n't	O
to	O
say	O
these	O
partnerships	O
should	O
assume	O
the	O
form	O
of	O
a	O
casual	O
date	O
.	O
“	O
let	O
's	O
figure	O
it	O
out	O
as	O
we	O
go	O
along	O
”	O
agendas	O
have	O
even	O
less	O
place	O
in	O
health-tech	O
than	O
they	O
did	O
in	O
the	O
bygone	O
multiple	O
high	O
silos	O
era	O
.	O
“	O
it	O
is	O
often	O
the	O
case	O
that	O
a	O
pharma	O
company	O
is	O
having	O
discussions	O
with	O
potential	O
partners	O
without	O
a	O
clear	O
image	O
of	O
their	O
to-be	O
state	O
and-or	O
services	O
they	O
would	O
like	O
to	O
provide	O
by	O
using	O
digital	O
health	O
technologies	O
,	O
”	O
deloitte	ORG
's	O
nagakawa	O
notes	O
.	O
disband	O
the	O
digital	O
team	O
.	O
at	O
daiichi	ORG
sankyo	ORG
,	O
takeda	ORG
,	O
astellas	O
,	O
and	O
otsuka	O
,	O
there	O
's	O
no	O
such	O
thing	O
as	O
a	O
digital	O
team	O
.	O
otsuka	O
,	O
in	O
fact	O
,	O
has	O
spun	O
off	O
otsuka	O
digital	O
health	O
as	O
a	O
joint	O
venture	O
with	O
ibm	ORG
japan	ORG
.	O
and	O
while	O
the	O
inner	O
structural	O
workings	O
of	O
most	O
pharma	O
companies	O
are	O
sufficiently	O
opaque	O
as	O
to	O
prevent	O
overarching	O
statements	O
about	O
the	O
prevalence	O
of	O
such	O
units	O
,	O
it	O
's	O
fair	O
to	O
say	O
many	O
non-japanese-based	O
entities	O
have	O
n't	O
eliminated	O
them	O
.	O
see	O
also	O
:	O
the	O
fda	ORG
,	O
astellas	O
,	O
and	O
accenture	ORG
use	O
innovation	O
competitions	O
to	O
help	O
address	O
business	O
challenges	O
the	O
problem	O
seems	O
to	O
have	O
something	O
to	O
do	O
with	O
internal	O
politics	O
.	O
rather	O
than	O
impressing	O
the	O
need	O
to	O
change	O
with	O
the	O
times	O
upon	O
long-established	O
groups	O
and	O
divisions	O
,	O
many	O
companies	O
have	O
taken	O
the	O
easy	O
way	O
out	O
:	O
they	O
've	O
assembled	O
distinct	O
digital	O
teams	O
,	O
feisty	O
bands	O
of	O
upstarts	O
charged	O
with	O
imposing	O
their	O
digital	O
will	O
.	O
in	O
doing	O
so	O
,	O
they	O
've	O
essentially	O
made	O
digital	O
transformation	O
an	O
optional	O
activity	O
.	O
oliver	O
,	O
for	O
one	O
,	O
doubts	O
“	O
digital	O
dna	O
”	O
can	O
readily	O
be	O
embedded	O
into	O
a	O
company	O
's	O
genetic	O
sequence	O
.	O
“	O
[	O
digital	O
and	O
health-tech	O
]	O
are	O
things	O
that	O
were	O
traditionally	O
outside	O
our	O
core	O
,	O
but	O
now	O
they	O
're	O
as	O
essential	O
as	O
anything	O
in	O
our	O
core	O
,	O
”	O
he	O
explains	O
.	O
“	O
it	O
takes	O
intentionality	O
.	O
it	O
takes	O
intense	O
focus	O
.	O
you	O
ca	O
n't	O
just	O
say	O
to	O
a	O
few	O
people	O
,	O
‘	O
ok	O
,	O
go	O
tell	O
everybody	O
to	O
do	O
this	O
.	O
'	O
”	O
villetelle	O
agrees	O
.	O
“	O
digital	O
and	O
digital	O
health	O
does	O
n't	O
work	O
if	O
it	O
's	O
led	O
by	O
a	O
remnant	O
of	O
digital	O
natives	O
.	O
you	O
need	O
to	O
bring	O
everyone	O
on	O
the	O
journey	O
,	O
which	O
maybe	O
is	O
n't	O
so	O
common	O
in	O
this	O
industry.	O
”	O
start	O
early	O
.	O
in	O
his	O
time	O
at	O
partners	O
healthcare	O
,	O
kvedar	O
has	O
worked	O
with	O
companies	O
at	O
the	O
beginning	O
of	O
their	O
digital	O
transformation	O
and	O
ones	O
well	O
into	O
their	O
metamorphosis	O
.	O
what	O
separates	O
the	O
successful	O
from	O
the	O
less	O
successful	O
,	O
he	O
believes	O
,	O
is	O
a	O
depth	O
of	O
vision	O
.	O
for	O
the	O
collaboration	O
with	O
daiichi	ORG
sankyo	ORG
,	O
kvedar	O
and	O
his	O
team	O
were	O
brought	O
in	O
early	O
,	O
which	O
allowed	O
the	O
brands	O
to	O
align	O
philosophically	O
and	O
mechanically	O
.	O
“	O
i	O
do	O
n't	O
know	O
that	O
this	O
is	O
exclusive	O
to	O
companies	O
such	O
as	O
daiichi	ORG
sankyo	ORG
,	O
but	O
the	O
ideal	O
situation	O
in	O
pharma	O
is	O
doing	O
digital	O
as	O
much	O
more	O
than	O
a	O
late	O
add-on	O
,	O
”	O
kvedar	O
explains	O
.	O
“	O
you	O
want	O
the	O
company	O
to	O
come	O
in	O
thinking	O
,	O
‘	O
we	O
have	O
a	O
molecule	O
and	O
want	O
to	O
build	O
some	O
kind	O
of	O
digital	O
wraparound	O
or	O
something	O
that	O
adds	O
value	O
to	O
it	O
.	O
'	O
it	O
's	O
when	O
you	O
start	O
planning	O
midway	O
through	O
that	O
you	O
get	O
in	O
trouble.	O
”	O
see	O
also	O
:	O
how	O
a	O
startup	O
is	O
educating	O
kids	O
with	O
diabetes	O
with	O
a	O
teddy	O
bear	O
early	O
digital	O
planning	O
for	O
and	O
around	O
new	O
drugs	O
and	O
other	O
pharma	O
initiatives	O
should	O
also	O
help	O
the	O
industry	O
evolve	O
toward	O
what	O
might	O
come	O
next	O
.	O
“	O
we	O
think	O
that	O
someday	O
pharma	O
companies	O
will	O
be	O
in	O
the	O
software	O
business	O
,	O
either	O
in	O
addition	O
to	O
the	O
molecule	O
business	O
or	O
in	O
place	O
of	O
it	O
,	O
”	O
kvedar	O
continues	O
.	O
“	O
digital	O
tools	O
can	O
have	O
remarkable	O
therapeutic	O
effects	O
on	O
their	O
own.	O
”	O
pick	O
your	O
spots	O
.	O
villetelle	O
believes	O
takeda	ORG
's	O
successes	O
in	O
the	O
digital	O
realm	O
have	O
everything	O
to	O
do	O
with	O
an	O
approach	O
that	O
is	O
as	O
relentless	O
as	O
it	O
is	O
selective	O
.	O
for	O
example	O
,	O
takeda	ORG
in	O
mid-november	O
was	O
running	O
40	O
health-tech	O
experiments	O
across	O
geographies	O
,	O
brands	O
,	O
and	O
therapeutic	O
areas	O
.	O
some	O
are	O
destined	O
to	O
“	O
fail	O
fast	O
,	O
”	O
as	O
villetelle	O
puts	O
it	O
,	O
while	O
others	O
could	O
morph	O
into	O
something	O
entirely	O
different	O
than	O
first	O
envisioned	O
.	O
ultimately	O
,	O
though	O
,	O
it	O
's	O
not	O
just	O
about	O
the	O
success	O
of	O
a	O
given	O
project	O
.	O
an	O
important	O
side	O
benefit	O
comes	O
in	O
the	O
form	O
of	O
encouraging	O
people	O
at	O
all	O
levels	O
of	O
the	O
organization	O
to	O
prioritize	O
digital	O
thinking	O
and	O
empowering	O
them	O
to	O
translate	O
those	O
thoughts	O
into	O
action	O
.	O
see	O
also	O
:	O
uber	ORG
partners	O
with	O
startup	O
to	O
take	O
patients	O
to	O
the	O
doctor	O
“	O
small	O
,	O
lean	O
teams	O
exploring	O
new	O
areas	O
—	O
that	O
's	O
what	O
commitment	O
to	O
experimentation	O
looks	O
like	O
,	O
”	O
he	O
adds	O
.	O
“	O
i	O
do	O
n't	O
believe	O
there	O
's	O
such	O
a	O
thing	O
as	O
‘	O
digital	O
culture	O
'	O
or	O
‘	O
digital	O
mindset	O
.	O
'	O
you	O
learn	O
by	O
doing.	O
”	O
takeda	ORG
's	O
ibdata	O
program	O
satisfies	O
just	O
about	O
every	O
criteria	O
health-tech	O
leaders	O
at	O
the	O
japanese	O
companies	O
recommend	O
.	O
it	O
was	O
developed	O
in	O
partnership	O
with	O
two	O
important	O
allies	O
,	O
vanderbilt	ORG
university	ORG
medical	ORG
center	ORG
and	O
texas	O
digestive	O
disease	O
consultants	O
.	O
its	O
development	O
coincided	O
with	O
takeda	ORG
's	O
growth	O
within	O
the	O
ibd	O
category	O
.	O
it	O
developed	O
organically	O
,	O
rather	O
than	O
under	O
the	O
thumb	O
of	O
a	O
digital	O
leader	O
or	O
squadron	O
.	O
and	O
it	O
lends	O
itself	O
easily	O
to	O
an	O
elevator	O
pitch	O
:	O
patients	O
can	O
track	O
their	O
symptoms	O
and	O
lifestyle	O
factors	O
using	O
wearable	O
watch	O
technology	O
.	O
villetelle	O
has	O
high	O
hopes	O
for	O
this	O
and	O
other	O
digital	O
experiments	O
,	O
whether	O
efforts	O
to	O
show	O
the	O
mode	O
of	O
action	O
for	O
takeda	ORG
products	O
using	O
virtual	O
reality	O
or	O
a	O
program	O
alongside	O
wechat	O
in	O
china	O
to	O
bolster	O
patient	O
education	O
about	O
chronic	O
disease	O
.	O
he	O
believes	O
the	O
company	O
's	O
work	O
will	O
foster	O
a	O
sense	O
of	O
adventure	O
.	O
“	O
i	O
was	O
listening	O
to	O
entrepreneur	O
elon	PERS
musk	O
give	O
an	O
interview	O
recently	O
and	O
he	O
said	O
something	O
that	O
stuck	O
with	O
me	O
,	O
”	O
villetelle	O
says	O
.	O
“	O
it	O
was	O
something	O
along	O
the	O
lines	O
of	O
,	O
‘	O
life	O
needs	O
to	O
be	O
about	O
more	O
than	O
solving	O
problems	O
every	O
day	O
.	O
'	O
we	O
need	O
to	O
be	O
excited	O
about	O
the	O
future	O
.	O
[	O
digital	O
health	O
]	O
gets	O
us	O
to	O
that	O
place.	O
”	O
oliver	O
,	O
on	O
the	O
other	O
hand	O
,	O
recalls	O
a	O
business-magazine	O
article	O
from	O
years	O
ago	O
that	O
likened	O
the	O
pharma	O
industry	O
to	O
the	O
steel	O
industry	O
.	O
“	O
that	O
's	O
very	O
sobering	O
.	O
that	O
's	O
not	O
the	O
comparison	O
we	O
want	O
,	O
”	O
he	O
recalls	O
.	O
“	O
the	O
point	O
was	O
the	O
last	O
real	O
shakeup	O
in	O
pharma	O
was	O
when	O
the	O
fda	ORG
was	O
formed	O
,	O
130	O
years	O
ago	O
,	O
and	O
now	O
there	O
's	O
very	O
real	O
disruption	O
.	O
you	O
can	O
go	O
two	O
ways	O
when	O
that	O
happens	O
:	O
disrupt	O
yourself	O
or	O
be	O
disrupted	O
by	O
external	O
forces	O
.	O
having	O
the	O
courage	O
to	O
disrupt	O
themselves	O
is	O
what	O
's	O
going	O
to	O
make	O
or	O
break	O
a	O
lot	O
of	O
companies	O
in	O
the	O
next	O
decade.	O
”	O
from	O
the	O
january	O
2017	O
issue	O
of	O
mmm	O
»	O
medical	O
marketing	O
&	O
media	O
return	O
to	O
top	O
correlation	O
between	O
pik3ca	O
mutations	O
in	O
cell-free	O
dna	O
and	O
everolimus	O
efficacy	O
in	O
hr+	O
,	O
her2−	O
advanced	O
breast	O
cancer	O
:	O
results	O
from	O
bolero-2	O
free	O
1department	O
of	O
medicine	O
,	O
memorial	ORG
sloan	ORG
kettering	ORG
cancer	ORG
center	ORG
,	O
new	O
york	O
,	O
ny	O
10065	O
,	O
usa	O
2oncology	O
precision	O
medicine	O
,	O
novartis	ORG
pharmaceuticals	ORG
corporation	ORG
,	O
east	O
hanover	O
,	O
nj	O
07936	O
,	O
usa	O
3global	O
medical	O
affairs	O
,	O
novartis	ORG
pharma	ORG
ag	ORG
,	O
basel	O
ch-4002	O
,	O
switzerland	O
4department	O
of	O
breast	O
medical	O
oncology	O
,	O
the	ORG
university	ORG
of	O
texas	ORG
md	ORG
anderson	ORG
cancer	ORG
center	ORG
,	O
houston	O
,	O
tx	O
77030	O
,	O
usa	O
correspondence	O
:	O
dr	O
me	O
moynahan	PERS
,	O
e-mail	O
:	O
moynaham	O
@	O
mskcc.org	O
advance	O
online	O
publication	O
9	O
february	O
2017	O
presented	O
as	O
poster	O
at	O
the	O
2016	O
american	ORG
society	ORG
of	ORG
clinical	ORG
oncology	ORG
(	O
asco	O
)	O
annual	O
meeting	O
;	O
3–7	O
june	O
2016	O
;	O
chicago	O
,	O
il	O
,	O
usa	O
.	O
abstract	O
background	O
:	O
the	O
current	O
analysis	O
was	O
performed	O
to	O
evaluate	O
the	O
impact	O
of	O
pik3ca	O
hotspot	O
mutations	O
on	O
everolimus	O
efficacy	O
in	O
bolero-2	O
participants	O
,	O
using	O
cell-free	O
dna	O
(	O
cfdna	O
)	O
from	O
plasma	O
samples	O
collected	O
at	O
the	O
time	O
of	O
patient	O
randomisation	O
.	O
methods	O
:	O
pik3ca	O
h1047r	O
,	O
e545k	O
,	O
and	O
e542k	O
mutations	O
in	O
plasma-derived	O
cfdna	O
were	O
analysed	O
by	O
droplet	O
digital	O
pcr	O
(	O
ddpcr	O
)	O
.	O
median	O
pfs	O
was	O
estimated	O
for	O
patient	O
subgroups	O
defined	O
by	O
pik3ca	O
mutations	O
in	O
each	O
treatment	O
arm	O
.	O
results	O
:	O
among	O
550	O
patients	O
included	O
in	O
cfdna	O
analysis	O
,	O
median	O
pfs	O
in	O
everolimus	O
vs	O
placebo	O
arms	O
was	O
similar	O
in	O
patients	O
with	O
tumours	O
that	O
had	O
wild-type	O
or	O
mutant	O
pik3ca	O
(	O
hazard	O
ratio	O
(	O
hr	O
)	O
,	O
0.43	O
and	O
0.37	O
,	O
respectively	O
)	O
.	O
everolimus	O
also	O
prolonged	O
median	O
pfs	O
in	O
patients	O
with	O
pik3ca	O
h1047r	O
(	O
hr	O
,	O
0.37	O
)	O
and	O
e545k/e542k	O
mutations	O
(	O
hr=0.30	O
)	O
with	O
a	O
similar	O
magnitude	O
.	O
conclusions	O
:	O
mutation	O
analysis	O
of	O
plasma-derived	O
cfdna	O
by	O
ddpcr	O
suggests	O
that	O
pfs	O
benefit	O
of	O
everolimus	O
was	O
maintained	O
irrespective	O
of	O
pik3ca	O
genotypes	O
,	O
consistent	O
with	O
the	O
previous	O
analysis	O
of	O
archival	O
tumour	O
dna	O
by	O
next-generation	O
sequencing	O
.	O
keywords	O
:	O
bolero-2	O
;	O
pik3ca	O
;	O
cfdna	O
;	O
everolimus	O
;	O
hr+	O
breast	O
cancer	O
aberrant	O
signalling	O
through	O
the	O
pi3k/akt/mtor	O
pathway	O
has	O
been	O
implicated	O
in	O
tumorigenesis	O
,	O
progression	O
,	O
and	O
therapeutic	O
resistance	O
in	O
various	O
cancers	O
(	O
rodon	O
et	O
al	O
,	O
2013	O
;	O
thorpe	O
et	O
al	O
,	O
2015	O
)	O
.	O
pik3ca	O
mutations	O
result	O
in	O
constitutive	O
activation	O
of	O
p110α	O
,	O
which	O
in	O
turn	O
activates	O
akt1	O
and	O
its	O
downstream	O
target	O
mtor	O
.	O
somatic	O
pik3ca	O
mutations	O
are	O
frequent	O
in	O
human	O
breast	O
cancer	O
,	O
occurring	O
in	O
up	O
to	O
45	O
%	O
of	O
luminal	O
a	O
tumours	O
(	O
cancer	ORG
genome	ORG
atlas	ORG
network	ORG
,	O
2012	O
)	O
;	O
the	O
majority	O
are	O
missense	O
mutations	O
clustering	O
in	O
the	O
helical	O
(	O
e524k	O
and	O
e545k	O
)	O
and	O
catalytic	O
(	O
h1047r	O
)	O
domains	O
(	O
kalinsky	PERS
et	O
al	O
,	O
2009	O
)	O
.	O
in	O
the	O
phase	O
3	O
bolero-2	O
trial	O
,	O
everolimus	O
plus	O
exemestane	O
prolonged	O
the	O
progression-free	O
survival	O
(	O
pfs	O
)	O
vs	O
placebo	O
plus	O
exemestane	O
(	O
median	O
pfs	O
,	O
7.8	O
vs	O
3.2	O
months	O
;	O
hazard	O
ratio	O
(	O
hr	O
)	O
,	O
0.45	O
;	O
p	O
<	O
0.0001	O
)	O
in	O
patients	O
with	O
hormone	O
receptor	O
positive	O
(	O
hr+	O
)	O
,	O
human	O
epidermal	O
growth	O
factor	O
receptor-2	O
negative	O
(	O
her2−	O
)	O
metastatic	O
breast	O
cancer	O
(	O
mbc	O
)	O
progressing	O
after	O
a	O
non-steroidal	O
aromatase	O
inhibitor	O
(	O
nsai	O
)	O
(	O
yardley	O
et	O
al	O
,	O
2013	O
)	O
.	O
an	O
exploratory	O
analysis	O
of	O
predominantly	O
primary	O
tumour	O
samples	O
from	O
roughly	O
40	O
%	O
of	O
the	O
bolero-2	O
trial	O
population	O
suggested	O
that	O
the	O
pfs	O
benefit	O
from	O
everolimus	O
was	O
largely	O
maintained	O
irrespective	O
of	O
pik3ca	O
genotype	O
(	O
hortobagyi	PERS
et	O
al	O
,	O
2016	O
)	O
.	O
however	O
,	O
given	O
that	O
differences	O
between	O
primary	O
and	O
mbc	O
may	O
arise	O
,	O
we	O
performed	O
an	O
analysis	O
of	O
pik3ca	O
hotspot	O
(	O
hs	O
)	O
mutations	O
by	O
droplet	O
digital	O
pcr	O
(	O
ddpcr	O
)	O
using	O
cell-free	O
dna	O
(	O
cfdna	O
)	O
from	O
plasma	O
samples	O
collected	O
at	O
the	O
time	O
of	O
patient	O
randomisation	O
and	O
evaluated	O
their	O
impact	O
on	O
everolimus	O
efficacy	O
in	O
76	O
%	O
of	O
the	O
bolero-2	O
participants	O
.	O
materials	O
and	O
methods	O
patients	O
and	O
cfdna	O
analysis	O
bolero-2	O
study	O
design	O
has	O
been	O
described	O
previously	O
(	O
baselga	O
et	O
al	O
,	O
2012	O
)	O
.	O
briefly	O
,	O
patients	O
with	O
hr+	O
,	O
her2−	O
mbc	O
recurring/progressing	O
on/after	O
nsai	O
were	O
randomised	O
2	O
:	O
1	O
to	O
everolimus	O
plus	O
exemestane	O
or	O
placebo	O
plus	O
exemestane	O
.	O
plasma	O
collection	O
,	O
cfdna	O
extraction	O
,	O
and	O
quantification	O
and	O
analysis	O
by	O
ddpcr	O
for	O
detection	O
were	O
performed	O
as	O
described	O
previously	O
(	O
chandarlapaty	PERS
et	O
al	O
,	O
2016	O
)	O
.	O
pik3ca	O
mutations	O
in	O
cfdna	O
were	O
detected	O
by	O
ddpcr	O
in	O
singleplex	O
assays	O
using	O
inventoried	O
assays	O
for	O
pik3ca	O
h1047r	O
(	O
dhsacp2000077	O
)	O
,	O
e545k	O
(	O
dhsacp2000075	O
)	O
,	O
and	O
e542k	O
(	O
dhsacp2000073	O
)	O
(	O
biorad	O
,	O
hercules	O
,	O
ca	O
,	O
usa	O
)	O
on	O
a	O
biorad	O
qx200	O
droplet	O
digital	O
pcr	O
system	O
.	O
each	O
assay	O
run	O
included	O
mutation	O
positive	O
template	O
,	O
wild-type	O
template	O
,	O
and	O
no	O
template	O
controls	O
.	O
the	O
fractional	O
abundance	O
for	O
the	O
pik3ca	O
mutation	O
was	O
calculated	O
from	O
the	O
number	O
of	O
fam-positive	O
events	O
(	O
mutation	O
positive	O
)	O
over	O
total	O
positive	O
events	O
(	O
both	O
fam	O
and	O
hex	O
positive	O
for	O
mutation	O
and	O
wild	O
type	O
,	O
respectively	O
)	O
using	O
quantasoft	O
version	O
1.7.4.0917	O
(	O
biorad	O
)	O
.	O
mutation	O
analyses	O
were	O
performed	O
on	O
anonymised	O
samples	O
.	O
written	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
patients	O
included	O
in	O
the	O
study	O
.	O
the	O
study	O
was	O
undertaken	O
in	O
accordance	O
with	O
the	O
good	O
clinical	O
practice	O
guidelines	O
and	O
the	O
declaration	O
of	O
helsinki	O
.	O
the	O
study	O
protocol	O
was	O
approved	O
by	O
an	O
independent	O
ethics	O
committee	O
or	O
institutional	O
review	O
board	O
at	O
each	O
site	O
.	O
statistical	O
analysis	O
median	O
pfs	O
was	O
estimated	O
by	O
kaplan–meier	O
method	O
in	O
patient	O
subgroups	O
defined	O
by	O
pik3ca	O
mutations	O
in	O
each	O
treatment	O
arm	O
.	O
hazard	O
ratios	O
with	O
95	O
%	O
confidence	O
intervals	O
(	O
cis	O
)	O
were	O
calculated	O
using	O
cox	O
proportional	O
hazards	O
model	O
for	O
treatment	O
vs	O
placebo	O
arm	O
in	O
the	O
wild-type	O
and	O
mutant	O
subgroups	O
.	O
multivariate	O
analysis	O
was	O
performed	O
to	O
adjust	O
for	O
the	O
potential	O
effects	O
of	O
prior	O
hormonal	O
therapy	O
,	O
visceral	O
disease	O
,	O
and	O
eastern	ORG
cooperative	ORG
oncology	ORG
group	ORG
status	O
.	O
results	O
pik3ca	O
mutation	O
frequency	O
of	O
the	O
724	O
patients	O
in	O
bolero-2	O
,	O
550	O
patients	O
(	O
76	O
%	O
)	O
underwent	O
pik3ca	O
cfdna	O
analysis	O
.	O
the	O
baseline	O
characteristics	O
and	O
clinical	O
outcomes	O
were	O
similar	O
between	O
the	O
cfdna	O
and	O
overall	O
population	O
(	O
supplementary	O
table	O
1	O
)	O
.	O
pik3ca	O
hs	O
mutations	O
were	O
identified	O
in	O
238	O
patients	O
(	O
43.3	O
%	O
)	O
;	O
the	O
most	O
prevalent	O
was	O
h1047r	O
(	O
25.1	O
%	O
)	O
,	O
followed	O
by	O
e545k	O
(	O
11.1	O
%	O
)	O
and	O
e542k	O
(	O
7.1	O
%	O
)	O
.	O
four	O
patients	O
had	O
multiple	O
hs	O
mutations	O
;	O
three	O
,	O
of	O
which	O
,	O
were	O
dual	O
helical	O
mutations	O
.	O
prevalence	O
of	O
total	O
and	O
domain-specific	O
pik3ca	O
mutations	O
was	O
higher	O
in	O
the	O
everolimus	O
arm	O
(	O
47.3	O
%	O
)	O
than	O
the	O
placebo	O
arm	O
(	O
35.8	O
%	O
;	O
table	O
1	O
)	O
.	O
full	O
table	O
concordance	O
between	O
mutations	O
detected	O
in	O
cfdna	O
and	O
archival	O
tumour	O
samples	O
plasma-derived	O
cfdna	O
samples	O
were	O
available	O
in	O
247	O
of	O
the	O
302	O
patients	O
who	O
underwent	O
mutation	O
analysis	O
on	O
archival	O
tumour	O
samples	O
(	O
198	O
primary	O
;	O
49	O
metastatic	O
)	O
by	O
next-generation	O
sequencing	O
(	O
ngs	O
)	O
(	O
hortobagyi	PERS
et	O
al	O
,	O
2016	O
)	O
.	O
the	O
overall	O
concordance	O
in	O
pik3ca	O
mutation	O
status	O
between	O
archival	O
tumour	O
and	O
cfdna	O
sample	O
pairs	O
was	O
70.4	O
%	O
,	O
with	O
a	O
higher	O
concordance	O
(	O
81.6	O
%	O
)	O
for	O
metastatic	O
lesions	O
.	O
for	O
concordant	O
samples	O
,	O
the	O
cfdna	O
mutant	O
fractional	O
abundance	O
was	O
generally	O
higher	O
than	O
in	O
the	O
discordant	O
samples	O
where	O
mutations	O
were	O
detected	O
only	O
by	O
ddpcr	O
in	O
cfdna	O
(	O
supplementary	O
figure	O
1	O
)	O
.	O
correlation	O
between	O
pik3ca	O
genotypes	O
and	O
everolimus	O
efficacy	O
clinical	O
benefit	O
with	O
everolimus	O
as	O
measured	O
by	O
pfs	O
was	O
similar	O
in	O
patients	O
with	O
tumours	O
that	O
had	O
wild-type	O
or	O
mutant	O
pik3ca	O
(	O
hr	O
,	O
0.43	O
(	O
95	O
%	O
ci	O
,	O
0.34–0.56	O
)	O
and	O
0.37	O
(	O
95	O
%	O
ci	O
,	O
0.27–0.51	O
)	O
,	O
respectively	O
)	O
(	O
table	O
2	O
;	O
figure	O
1a	O
)	O
.	O
a	O
multivariate	O
analysis	O
yielded	O
similar	O
results	O
(	O
hrs	O
for	O
pfs	O
:	O
pik3ca	O
wild-type	O
hr	O
,	O
0.39	O
(	O
95	O
%	O
ci	O
,	O
0.30–0.51	O
)	O
;	O
pik3ca-mutant	O
hr	O
,	O
0.35	O
(	O
95	O
%	O
ci	O
,	O
0.25–0.49	O
)	O
)	O
(	O
supplementary	O
table	O
3	O
)	O
.	O
kaplan-meier	O
plot	O
of	O
progression-free	O
survival	O
by	O
pik3ca	O
mutation	O
status	O
.	O
(	O
a	O
)	O
pik3ca	O
wild-type	O
vs	O
hotspot	O
mutations	O
.	O
(	O
b	O
)	O
pik3ca	O
wild-type	O
vs	O
domain-specific	O
hotspot	O
mutations	O
.	O
full	O
table	O
to	O
examine	O
the	O
role	O
of	O
domain-specific	O
mutations	O
in	O
pik3ca	O
on	O
everolimus	O
efficacy	O
,	O
patients	O
were	O
categorised	O
by	O
mutation	O
site	O
,	O
h1047r	O
in	O
the	O
catalytic	O
domain	O
,	O
and	O
e545k	O
and	O
e542k	O
in	O
the	O
helical	O
domain	O
.	O
everolimus	O
prolonged	O
median	O
pfs	O
vs	O
placebo	O
in	O
patients	O
with	O
pik3ca	O
h1047r	O
mutation	O
(	O
hr	O
,	O
0.37	O
;	O
95	O
%	O
ci	O
,	O
0.24–0.56	O
)	O
and	O
e545k/e542k	O
mutations	O
(	O
hr	O
,	O
0.30	O
;	O
95	O
%	O
ci	O
,	O
0.18–0.51	O
)	O
with	O
a	O
similar	O
magnitude	O
(	O
table	O
2	O
;	O
figure	O
1b	O
)	O
.	O
these	O
data	O
suggest	O
that	O
pfs	O
benefit	O
of	O
everolimus	O
was	O
maintained	O
irrespective	O
of	O
pik3ca	O
genotypes	O
.	O
in	O
the	O
placebo	O
arm	O
,	O
patients	O
with	O
e545k/e542k	O
mutation	O
had	O
shorter	O
pfs	O
and	O
overall	O
survival	O
than	O
those	O
with	O
wild-type	O
pik3ca	O
(	O
supplementary	O
table	O
2	O
)	O
,	O
suggesting	O
that	O
pik3ca	O
mutations	O
in	O
the	O
helical	O
domain	O
might	O
play	O
a	O
role	O
in	O
resistance	O
to	O
hormone	O
therapy	O
.	O
however	O
,	O
this	O
analysis	O
by	O
mutation	O
site	O
involved	O
small	O
numbers	O
and	O
was	O
highly	O
exploratory	O
.	O
discussion	O
the	O
advent	O
of	O
cfdna	O
analyses	O
has	O
facilitated	O
the	O
analysis	O
of	O
large	O
clinical	O
trial	O
populations	O
through	O
minimally	O
invasive	O
technologies	O
.	O
we	O
recently	O
determined	O
the	O
feasibility	O
for	O
detection	O
of	O
esr1	O
mutations	O
in	O
cfdna	O
by	O
ddpcr	O
on	O
stored	O
plasma	O
samples	O
from	O
the	O
bolero-2	O
clinical	O
trial	O
(	O
chandarlapaty	PERS
et	O
al	O
,	O
2016	O
)	O
.	O
notably	O
,	O
collection	O
of	O
these	O
plasma	O
samples	O
began	O
in	O
mid-2009	O
at	O
trial	O
enrolment	O
in	O
the	O
absence	O
of	O
a	O
plan	O
for	O
subsequent	O
cfdna	O
analysis	O
.	O
thus	O
,	O
data	O
from	O
large	O
,	O
mature	O
clinical	O
trials	O
can	O
be	O
extended	O
through	O
the	O
use	O
of	O
this	O
emerging	O
technology	O
.	O
in	O
this	O
report	O
,	O
we	O
assessed	O
the	O
impact	O
of	O
three	O
most	O
prevalent	O
pik3ca-activating	O
mutations	O
on	O
everolimus	O
efficacy	O
in	O
>	O
75	O
%	O
of	O
the	O
bolero-2	O
trial	O
population	O
,	O
thus	O
enabling	O
a	O
robust	O
mutation	O
analysis	O
that	O
demonstrates	O
everolimus	O
efficacy	O
regardless	O
of	O
pik3ca	O
genotypes	O
.	O
in	O
the	O
bolero-2	O
analysis	O
,	O
patients	O
with	O
tumours	O
harbouring	O
hs	O
mutations	O
in	O
both	O
helical	O
and	O
catalytic	O
domains	O
of	O
pik3ca	O
benefit	O
from	O
the	O
addition	O
of	O
everolimus	O
.	O
interestingly	O
,	O
in	O
the	O
placebo	O
arm	O
,	O
there	O
is	O
a	O
suggestion	O
of	O
inferior	O
clinical	O
outcome	O
in	O
the	O
small	O
group	O
harbouring	O
e545k/e542k	O
mutations	O
.	O
this	O
is	O
in	O
contrast	O
to	O
a	O
favourable	O
prognosis	O
associated	O
with	O
these	O
mutations	O
in	O
early-stage	O
cancer	O
(	O
kalinsky	PERS
et	O
al	O
,	O
2009	O
;	O
sabine	O
et	O
al	O
,	O
2014	O
)	O
,	O
no	O
effect	O
on	O
prognosis	O
in	O
patients	O
with	O
mbc	O
undergoing	O
first-line	O
hormonal	O
therapy	O
with	O
tamoxifen	O
and	O
an	O
improved	O
outcome	O
in	O
patients	O
with	O
mbc	O
with	O
first-line	O
aromatase	O
inhibitor	O
therapy	O
(	O
ramirez-ardila	O
et	O
al	O
,	O
2013	O
)	O
.	O
from	O
a	O
biologic	O
perspective	O
,	O
mutation	O
site-specific	O
differences	O
are	O
noted	O
for	O
interacting	O
proteins	O
(	O
zhao	O
and	O
vogt	O
,	O
2008	O
;	O
hao	O
et	O
al	O
,	O
2013	O
)	O
,	O
oncogenic	O
potency	O
and	O
behaviour	O
(	O
bader	O
et	O
al	O
,	O
2006	O
;	O
pang	O
et	O
al	O
,	O
2009	O
)	O
,	O
and	O
the	O
phosphoproteome	O
(	O
wu	O
et	O
al	O
,	O
2014	O
;	O
zahari	O
et	O
al	O
,	O
2015	O
)	O
that	O
may	O
be	O
clinically	O
important	O
and	O
deserve	O
further	O
analysis	O
in	O
clinical	O
studies	O
and	O
preclinical	O
modelling	O
.	O
approximately	O
,	O
70	O
%	O
concordance	O
for	O
pik3ca	O
genotype	O
by	O
pik3ca	O
analysis	O
of	O
archival	O
tumour	O
dna	O
by	O
ngs	O
and	O
contemporaneous	O
plasma-derived	O
cfdna	O
by	O
ddpcr	O
is	O
similar	O
to	O
that	O
reported	O
for	O
beaming	O
of	O
cfdna	O
and	O
sequencing	O
of	O
archival	O
tumour	O
(	O
higgins	PERS
et	O
al	O
,	O
2012	O
)	O
.	O
there	O
are	O
several	O
potential	O
biologic	O
and	O
technical	O
reasons	O
for	O
this	O
degree	O
of	O
discordance	O
.	O
ddpcr	O
of	O
plasma	O
cfdna	O
is	O
more	O
sensitive	O
for	O
mutation	O
detection	O
than	O
tumour	O
sequencing	O
(	O
guttery	PERS
et	O
al	O
,	O
2015	O
;	O
schiavon	O
et	O
al	O
,	O
2015	O
;	O
chu	O
et	O
al	O
,	O
2016	O
)	O
with	O
mutant	O
allele	O
fraction	O
(	O
maf	O
)	O
<	O
1–3	O
%	O
not	O
detected	O
by	O
ngs	O
(	O
guttery	PERS
et	O
al	O
,	O
2015	O
)	O
.	O
when	O
both	O
concurrent	O
biopsy	O
and	O
plasma	O
collection	O
are	O
performed	O
and	O
the	O
material	O
is	O
analysed	O
by	O
the	O
same	O
highly	O
sensitive	O
methodology	O
,	O
concordance	O
is	O
quite	O
high	O
(	O
higgins	PERS
et	O
al	O
,	O
2012	O
)	O
.	O
in	O
breast	O
cancer	O
,	O
pik3ca	O
mutation	O
is	O
thought	O
to	O
be	O
truncal	O
,	O
identified	O
in	O
dcis	O
,	O
primary	O
breast	O
cancer	O
,	O
and	O
selected	O
for	O
in	O
metastatic	O
tumour	O
(	O
kalinsky	PERS
et	O
al	O
,	O
2011	O
)	O
.	O
however	O
,	O
compelling	O
evidence	O
from	O
tumour	O
genome	O
sequencing	O
highlights	O
that	O
reliance	O
on	O
a	O
single	O
analysis	O
of	O
the	O
primary	O
tumour	O
may	O
not	O
be	O
suitable	O
for	O
guiding	O
therapy	O
in	O
patients	O
with	O
metastatic	O
disease	O
.	O
genomic	O
heterogeneity	O
in	O
multifocal	O
primary	O
tumours	O
identifies	O
pik3ca	O
mutations	O
occurring	O
in	O
~44	O
%	O
of	O
patients	O
,	O
but	O
in	O
only	O
half	O
is	O
the	O
mutation	O
identified	O
in	O
all	O
tumours	O
(	O
desmedt	O
et	O
al	O
,	O
2015	O
)	O
.	O
even	O
in	O
metastatic	O
disease	O
,	O
emergence	O
of	O
a	O
pik3ca	O
e545k	O
mutation	O
during	O
progression	O
has	O
been	O
reported	O
by	O
serial	O
cfdna	O
analysis	O
(	O
guttery	PERS
et	O
al	O
,	O
2015	O
)	O
.	O
conversely	O
,	O
absence	O
of	O
an	O
h1047r	O
mutation	O
in	O
hepatic	O
metastasis	O
and	O
cfdna	O
is	O
reported	O
,	O
when	O
present	O
in	O
the	O
primary	O
tumour	O
at	O
a	O
high	O
maf	O
of	O
40	O
%	O
(	O
butler	O
et	O
al	O
,	O
2015	O
)	O
.	O
in	O
larger	O
data	O
sets	O
of	O
paired	O
samples	O
,	O
both	O
the	O
loss	O
and	O
gain	O
of	O
pik3ca	O
mutation	O
in	O
metastatic	O
progression	O
is	O
observed	O
(	O
dupont	PERS
jensen	PERS
et	O
al	O
,	O
2011	O
;	O
arthur	O
et	O
al	O
,	O
2014	O
;	O
markou	O
et	O
al	O
,	O
2014	O
)	O
.	O
thus	O
,	O
although	O
selection	O
for	O
a	O
pik3ca-activating	O
mutation	O
is	O
expected	O
,	O
more	O
dominant	O
subclonal	O
populations	O
may	O
give	O
rise	O
to	O
the	O
metastatic	O
tumour	O
.	O
scientists	O
gear	O
up	O
to	O
run	O
for	O
office	O
in	O
a	O
world	O
of	O
“	O
alternate	O
facts	O
”	O
greetings	O
,	O
daily	O
readers	O
.	O
this	O
is	O
sy	O
taking	O
over	O
for	O
cliff	O
.	O
it	O
’	O
s	O
2017	O
and	O
we	O
live	O
in	O
a	O
world	O
of	O
“	O
alternate	O
facts	O
”	O
and	O
fake	O
news	O
.	O
the	O
nascent	O
trump	PERS
administration	O
has	O
wasted	O
little	O
time	O
in	O
challenging	O
well-established	O
science	O
,	O
including	O
the	O
reality	O
of	O
man-made	O
climate	O
change	O
and	O
the	O
safety	O
of	O
vaccines	O
.	O
the	O
president	O
’	O
s	O
decision	O
to	O
impose	O
a	O
gag	O
order	O
on	O
numerous	O
federal	O
agencies	O
,	O
including	O
the	O
u.s.	ORG
department	ORG
of	ORG
agriculture	ORG
and	ORG
environmental	ORG
protection	ORG
agency	ORG
,	O
stunned	O
many	O
observers	O
and	O
cut	O
off	O
vital	O
lines	O
of	O
communication	O
with	O
journalists	O
.	O
(	O
the	O
epa	O
has	O
also	O
been	O
ordered	O
to	O
freeze	O
all	O
grants	O
and	O
contracts	O
until	O
further	O
notice	O
.	O
)	O
at	O
times	O
,	O
it	O
can	O
seem	O
like	O
objective	O
truth	O
itself	O
is	O
under	O
assault	O
.	O
but	O
one	O
group	O
isn	O
’	O
t	O
ready	O
to	O
let	O
reality	O
slip	O
away	O
without	O
a	O
fight	O
.	O
the	O
atlantic	O
has	O
a	O
fascinating	O
piece	O
out	O
on	O
314	O
action	ORG
,	O
a	O
newly	O
formed	O
nonprofit	O
that	O
’	O
s	O
attempting	O
to	O
promote	O
science	O
to	O
the	O
public	O
and	O
elected	O
officials	O
alike	O
(	O
the	O
“	O
314	O
”	O
is	O
a	O
reference	O
to	O
pi	O
)	O
.	O
“	O
314	O
action	ORG
is	O
concerned	O
that	O
stem	O
education	O
in	O
the	O
united	LOC
states	LOC
is	O
falling	O
further	O
and	O
further	O
behind	O
the	O
rest	O
of	O
the	O
world	O
,	O
that	O
our	O
political	O
leaders	O
continue	O
to	O
deny	O
scientific	O
facts	O
and	O
that	O
congress	ORG
fails	O
to	O
fully	O
fund	O
scientific	O
research	O
so	O
we	O
can	O
solve	O
pressing	O
environmental	O
issues	O
like	O
climate	O
change	O
and	O
social	O
problems	O
like	O
gun	O
violence	O
,	O
”	O
says	O
the	O
group	O
on	O
its	O
website	O
.	O
one	O
of	O
314	O
action	ORG
’	O
s	O
biggest	O
goals	O
is	O
to	O
get	O
stem	O
leaders	O
into	O
elected	O
office	O
so	O
that	O
they	O
can	O
change	O
the	O
course	O
of	O
the	O
debate	O
from	O
the	O
inside	O
.	O
“	O
a	O
lot	O
of	O
scientists	O
traditionally	O
feel	O
that	O
science	O
is	O
above	O
politics	O
but	O
we	O
're	O
seeing	O
that	O
politics	O
is	O
not	O
above	O
getting	O
involved	O
in	O
science	O
,	O
”	O
said	O
shaughnessy	PERS
naughton	PERS
,	O
the	O
group	O
’	O
s	O
founder	O
,	O
in	O
an	O
interview	O
with	O
the	O
atlantic	O
.	O
“	O
we	O
're	O
losing	O
,	O
and	O
the	O
only	O
way	O
to	O
stop	O
that	O
is	O
to	O
get	O
more	O
people	O
with	O
scientific	O
backgrounds	O
at	O
the	O
table.	O
”	O
congress	ORG
is	O
overwhelmingly	O
filled	O
with	O
lawyers	O
and	O
business	O
people	O
.	O
the	O
closest	O
thing	O
there	O
is	O
to	O
a	O
scientific	O
contingent	O
is	O
the	O
smattering	O
of	O
physicians	O
in	O
the	O
house	ORG
and	O
senate	ORG
.	O
but	O
even	O
many	O
of	O
these	O
individuals	O
have	O
professed	O
some	O
controversial	O
views	O
on	O
scientific	O
issues	O
,	O
including	O
on	O
climate	O
change	O
and	O
vaccine	O
safety	O
.	O
314	O
action	ORG
’	O
s	O
science-driven	O
goal	O
may	O
be	O
noble	O
.	O
but	O
achieving	O
it	O
will	O
be	O
an	O
uphill	O
battle	O
.	O
and	O
as	O
the	O
scientists-turned-politicians	O
who	O
get	O
an	O
assist	O
from	O
the	O
group	O
will	O
soon	O
learn	O
,	O
it	O
’	O
s	O
one	O
thing	O
to	O
have	O
the	O
facts	O
–	O
convincing	O
constituents	O
and	O
the	O
public	O
at	O
large	O
that	O
they	O
’	O
re	O
right	O
is	O
another	O
matter	O
entirely	O
.	O
read	O
on	O
for	O
the	O
day	O
’	O
s	O
news	O
.	O
sy	PERS
mukherjee	PERS
@	O
the_sy_guy	O
sayak.mukherjee	O
@	O
fortune.com	O
digital	O
health	O
shark	O
tank-funded	O
smartphone	O
breathalyzer	O
slammed	O
by	O
ftc	O
for	O
false	O
claims	O
.	O
breathometer	ORG
,	O
the	O
digital	O
startup	O
that	O
wowed	O
shark	O
tank	O
investors	O
like	O
mark	PERS
cuban	PERS
with	O
its	O
smartphone-connected	O
breathalyzer	O
accessories	O
,	O
has	O
reached	O
a	O
settlement	O
with	O
the	O
federal	ORG
trade	ORG
commission	ORG
over	O
inaccurate	O
marketing	O
claims	O
.	O
the	O
company	O
had	O
advertised	O
its	O
products	O
as	O
comparable	O
to	O
those	O
used	O
by	O
law	O
enforcement	O
and	O
said	O
they	O
'd	O
undergone	O
government-grade	O
testing	O
;	O
the	O
ftc	O
alleged	O
that	O
neither	O
of	O
these	O
claims	O
were	O
actually	O
true	O
and	O
that	O
the	O
devices	O
often	O
underrepresented	O
blood	O
alcohol	O
levels	O
.	O
breathometer	ORG
will	O
have	O
to	O
issue	O
full	O
refunds	O
to	O
customers	O
who	O
bought	O
the	O
product	O
and	O
the	O
company	O
is	O
barred	O
from	O
making	O
similar	O
claims	O
in	O
the	O
future	O
absent	O
rigorous	O
testing	O
.	O
(	O
fortune	O
)	O
big	O
pharmas	O
band	O
together	O
to	O
give	O
health	O
care	O
providers	O
easy	O
digital	O
access	O
to	O
drug	O
info	O
.	O
a	O
consortium	O
of	O
six	O
pharmaceutical	O
giants	O
-	O
allergan	ORG
,	O
astrazeneca	ORG
,	O
biogen	ORG
,	O
glaxosmithkline	ORG
,	O
novartis	ORG
,	O
and	O
pfizer	ORG
-	O
are	O
joining	O
forces	O
with	O
life	O
sciences	O
it	O
firm	O
veeva	ORG
systems	ORG
to	O
create	O
a	O
group	O
called	O
align	O
biopharma	O
.	O
its	O
purpose	O
?	O
providing	O
doctors	O
and	O
health	O
care	O
providers	O
with	O
a	O
simple	O
way	O
to	O
digitally	O
access	O
information	O
about	O
drugs	O
.	O
this	O
is	O
a	O
hotly	O
sought	O
solution	O
in	O
physicians	O
'	O
offices	O
as	O
the	O
number	O
of	O
in-person	O
sales	O
rep	O
visits	O
dwindle	O
and	O
the	O
number	O
of	O
available	O
medicines	O
continues	O
to	O
balloon	O
.	O
doctors	O
must	O
often	O
maintain	O
scores	O
of	O
logins	O
for	O
various	O
pharmaceutical	O
companies	O
'	O
informational	O
websites	O
for	O
health	O
care	O
providers	O
.	O
align	O
wants	O
to	O
bring	O
that	O
number	O
down	O
to	O
a	O
single	O
login	O
that	O
opens	O
up	O
data	O
on	O
thousands	O
of	O
drugs	O
.	O
(	O
fiercepharma	O
)	O
indications	O
novartis	ORG
unveils	O
ambitious	O
cancer	O
immunotherapy	O
,	O
late-stage	O
pipeline	O
plans	O
.	O
pharma	ORG
giant	O
novartis	ORG
is	O
building	O
itself	O
quite	O
the	O
experimental	O
drug	O
pipeline	O
.	O
and	O
during	O
its	O
fourth	O
quarter	O
earnings	O
call	O
this	O
morning	O
,	O
the	O
company	O
asserted	O
its	O
belief	O
that	O
it	O
has	O
no	O
less	O
than	O
13	O
potential	O
blockbuster	O
medicines	O
in	O
late-stage	O
trials	O
.	O
and	O
one	O
new	O
addition	O
to	O
the	O
list	O
is	O
particularly	O
intriguing	O
:	O
ctl019	O
,	O
its	O
chimeric	O
antigen	O
receptor	O
t-cell	O
(	O
car-t	O
)	O
therapy	O
.	O
as	O
daily	O
readers	O
know	O
,	O
car-t	O
is	O
one	O
of	O
the	O
most	O
closely-watched	O
new	O
technologies	O
in	O
cancer	O
therapeutics	O
.	O
it	O
involves	O
extracting	O
killer	O
immune	O
t-cells	O
and	O
turning	O
them	O
into	O
cancer-targeting	O
machines	O
before	O
pumping	O
them	O
back	O
into	O
a	O
patient	O
's	O
body	O
.	O
novartis	ORG
,	O
kite	ORG
pharma	ORG
,	O
and	O
a	O
number	O
of	O
other	O
drug	O
makers	O
are	O
in	O
a	O
race	O
to	O
get	O
the	O
first	O
approved	O
car-t	O
therapy	O
on	O
the	O
market	O
.	O
and	O
novartis	ORG
'	O
update	O
today	O
shows	O
that	O
it	O
thinks	O
the	O
drugs	O
have	O
massive	O
market	O
potential	O
.	O
shkreli	PERS
hits	O
back	O
hard	O
at	O
phrma	O
over	O
drug	O
pricing	O
hypocrisy	O
.	O
biopharma	O
's	O
drug	O
pricing	O
black	O
sheep	O
is	O
on	O
a	O
mission	O
to	O
show	O
that	O
he	O
's	O
just	O
one	O
of	O
the	O
flock	O
.	O
martin	PERS
shkreli	PERS
,	O
who	O
in	O
some	O
ways	O
helped	O
nationalize	O
the	O
drug	O
price	O
hike	O
uproar	O
,	O
has	O
launched	O
a	O
new	O
website	O
called	O
``	O
pharma	ORG
skeletons	O
''	O
that	O
outlines	O
numerous	O
pharmaceutical	O
research	O
and	O
manufacturers	O
of	O
america	LOC
(	O
phrma	O
)	O
member	O
companies	O
that	O
have	O
indulged	O
in	O
extravagant	O
price	O
increases	O
.	O
shkreli	PERS
felt	O
compelled	O
to	O
hit	O
back	O
at	O
phrma	O
(	O
which	O
kicked	O
out	O
both	O
him	O
and	O
his	O
former	O
company	O
turing	ORG
after	O
the	O
5,000	O
%	O
price	O
hike	O
that	O
put	O
shkreli	PERS
on	O
the	O
map	O
)	O
because	O
its	O
president	O
and	O
ceo	O
,	O
stephen	PERS
ubl	PERS
,	O
called	O
out	O
shkreli	PERS
as	O
unrepresentative	O
of	O
the	O
industry	O
while	O
discussing	O
a	O
massive	O
new	O
phrma	O
pr	O
campaign	O
meant	O
to	O
win	O
over	O
hearts	O
and	O
minds	O
.	O
(	O
fortune	O
)	O
could	O
gilead	O
's	O
hepatitis	O
c	O
superstars	O
have	O
a	O
safety	O
problem	O
?	O
a	O
new	O
report	O
published	O
by	O
the	O
institute	ORG
for	ORG
safe	ORG
medication	ORG
practices	ORG
today	O
raises	O
safety	O
concerns	O
about	O
nine	O
antiviral	O
drugs	O
that	O
are	O
used	O
to	O
treat	O
hepatitis	O
c	O
-	O
including	O
gilead	O
's	O
game-changing	O
hep	O
c	O
cures	O
sovaldi	O
and	O
harvoni	O
.	O
the	O
report	O
is	O
far	O
from	O
conclusive	O
and	O
the	O
number	O
of	O
patients	O
experiencing	O
the	O
adverse	O
events	O
is	O
small	O
(	O
the	O
report	O
also	O
states	O
that	O
it	O
's	O
unclear	O
if	O
it	O
's	O
the	O
drugs	O
themselves	O
that	O
are	O
causing	O
the	O
side	O
effects	O
)	O
.	O
but	O
the	O
safety	O
issues	O
that	O
are	O
present	O
are	O
quite	O
serious	O
,	O
including	O
liver	O
failure	O
.	O
(	O
new	ORG
york	ORG
times	ORG
)	O
the	O
big	O
picture	O
arizona	LOC
children	O
at	O
risk	O
of	O
coverage	O
loss	O
under	O
obamacare	O
repeal	O
.	O
the	O
obamacare	O
repeal	O
drama	O
has	O
mostly	O
focused	O
on	O
what	O
nixing	O
the	O
health	O
law	O
will	O
mean	O
for	O
adults	O
who	O
buy	O
coverage	O
on	O
the	O
individual	O
insurance	O
marketplace	O
(	O
and	O
the	O
working	O
poor	O
who	O
might	O
lose	O
their	O
insurance	O
if	O
the	O
medicaid	ORG
expansion	O
is	O
rolled	O
back	O
)	O
.	O
but	O
in	O
at	O
least	O
one	O
state	O
,	O
children	O
's	O
health	O
care	O
is	O
at	O
stake	O
,	O
too	O
.	O
that	O
's	O
because	O
arizona	LOC
's	O
kidscare	O
-	O
the	O
state	O
's	O
version	O
of	O
the	O
children	O
's	O
health	O
insurance	O
program	O
(	O
chip	O
)	O
,	O
which	O
covers	O
kids	O
from	O
families	O
who	O
are	O
n't	O
quite	O
poor	O
enough	O
to	O
qualify	O
for	O
medicaid	ORG
-	O
is	O
funded	O
by	O
obamacare	O
.	O
the	O
program	O
was	O
frozen	O
by	O
arizona	LOC
lawmakers	O
in	O
2010	O
but	O
reinstated	O
with	O
the	O
passage	O
of	O
the	O
health	O
law	O
through	O
at	O
least	O
the	O
end	O
of	O
2017	O
.	O
its	O
future	O
is	O
now	O
decidedly	O
uncertain	O
.	O
(	O
npr	ORG
)	O
required	O
reading	O
why	O
trump	PERS
ditching	O
the	O
tpp	O
could	O
hit	O
drug	O
makers	O
where	O
it	O
hurts	O
,	O
by	O
sy	PERS
mukherjee	PERS
big	ORG
investors	ORG
are	O
betting	O
president	O
trump	PERS
wo	O
n't	O
be	O
able	O
to	O
dump	O
obamacare	O
,	O
by	O
reuters	ORG
apple	ORG
and	O
fitbit	ORG
dominated	O
holiday	O
sales	O
of	O
wearables	O
,	O
by	O
aaron	PERS
pressman	PERS
the	O
dow	ORG
just	O
hit	O
20,000	O
for	O
the	O
first	O
time	O
in	O
history	O
,	O
by	O
lucinda	PERS
shen	PERS
[	O
ceo_attribution	O
author=	O
''	O
produced	O
by	O
sy	PERS
mukherjee	PERS
''	O
email=	O
''	O
sayak.mukherjee	O
@	O
fortune.com	O
''	O
twitter=	O
''	O
the_sy_guy	O
''	O
]	O
find	O
past	O
coverage	O
.	O
sign	O
up	O
for	O
other	O
fortune	O
newsletters	O
.	O
why	O
the	O
trump	PERS
drug	O
rally	O
won	O
’	O
t	O
last	O
the	O
stock	O
market	PERS
has	O
been	O
a	O
lousy	O
prognosticator	O
of	O
late	O
.	O
prior	O
to	O
the	O
election	O
,	O
mr.	O
market	PERS
seemed	O
utterly	O
convinced	O
of	O
a	O
clinton	PERS
win	O
.	O
(	O
it	O
did	O
n't	O
happen	O
.	O
)	O
then	O
,	O
as	O
the	O
outcome	O
looked	O
clear	O
,	O
it	O
predicted	O
panic	O
--	O
then	O
galloped	O
giddily	O
into	O
euphoria	O
.	O
(	O
hapless	O
traders	O
trying	O
to	O
chase	O
these	O
ups	O
and	O
downs	O
no	O
doubt	O
mistimed	O
them	O
--	O
because	O
,	O
well	O
,	O
it	O
's	O
a	O
sucker	O
's	O
game	O
to	O
try	O
to	O
time	O
the	O
market	PERS
.	O
but	O
then	O
you	O
knew	O
that	O
...	O
)	O
that	O
said	O
,	O
the	O
market	PERS
has	O
seemed	O
to	O
send	O
a	O
more	O
consistent	O
message	O
regarding	O
the	O
pharma	O
and	O
biotech	O
industries	O
.	O
after	O
the	O
news	O
of	O
trump	PERS
's	O
victory	O
,	O
stocks	O
of	O
drug	O
makers	O
shot	O
up	O
--	O
a	O
sharp	O
reversal	O
from	O
the	O
previous	O
few	O
months	O
of	O
mostly	O
steady	O
decline	O
when	O
,	O
to	O
many	O
,	O
a	O
clinton	PERS
presidency	O
seemed	O
inevitable	O
.	O
shareholders	O
were	O
also	O
buoyed	O
by	O
the	O
defeat	O
of	O
prop	O
61	O
,	O
the	O
california	LOC
ballot	O
initiative	O
that	O
promised	O
to	O
lower	O
drug	O
prices	O
by	O
pegging	O
what	O
state	O
agencies	O
paid	O
to	O
prices	O
negotiated	O
by	O
the	O
u.s.	ORG
department	ORG
of	ORG
veterans	ORG
affairs	ORG
--	O
an	O
effort	O
the	O
drug	O
industry	O
reportedly	O
spent	O
$	O
109	O
million	O
to	O
defeat	O
.	O
and	O
on	O
first	O
glance	O
,	O
the	O
recent	O
enthusiasm	O
makes	O
sense	O
:	O
clinton	PERS
signaled	O
that	O
she	O
would	O
come	O
down	O
hard	O
on	O
drug	O
company	O
``	O
price	O
gouging	O
''	O
in	O
september	O
,	O
which	O
sent	O
stocks	O
reeling	O
.	O
(	O
favorite	O
hyperbolic	O
headline	O
:	O
``	O
clinton	PERS
delivers	O
poison	O
pill	O
to	O
biotech	O
etfs	O
``	O
)	O
.	O
trump	PERS
,	O
for	O
his	O
part	O
,	O
has	O
said	O
little	O
on	O
the	O
matter	O
.	O
clinton	PERS
looked	O
as	O
if	O
she	O
would	O
continue	O
a	O
cautious	O
regulatory	O
approach	O
at	O
the	O
fda	ORG
.	O
trump	PERS
has	O
said	O
he	O
wants	O
to	O
cut	O
``	O
the	O
red	O
tape	O
at	O
the	O
fda	ORG
,	O
''	O
claiming	O
``	O
there	O
are	O
over	O
4,000	O
drugs	O
awaiting	O
approval	O
,	O
and	O
we	O
especially	O
want	O
to	O
speed	O
the	O
approval	O
of	O
life-saving	O
medications	O
.	O
''	O
(	O
no	O
,	O
the	O
``	O
4,000	O
''	O
drug	O
backlog	O
does	O
n't	O
refer	O
to	O
what	O
you	O
think	O
--	O
and	O
is	O
n't	O
true	O
in	O
any	O
case	O
.	O
)	O
clinton	PERS
would	O
largely	O
keep	O
obamacare	O
;	O
and	O
trump	PERS
,	O
well	O
,	O
i	O
wrote	O
about	O
this	O
on	O
nov.	O
9	O
.	O
which	O
brings	O
me	O
to	O
whether	O
our	O
friend	O
mr.	O
market	PERS
is	O
right	O
or	O
wrong	O
on	O
pharma	O
's	O
future	O
in	O
the	O
trump	PERS
era	O
.	O
the	O
answer	O
is	O
neither	O
.	O
(	O
psst	O
--	O
it	O
does	O
n't	O
know	O
.	O
)	O
the	O
confusion	O
does	O
n't	O
just	O
center	O
over	O
what	O
happens	O
(	O
and	O
when	O
)	O
to	O
the	O
aca	O
--	O
or	O
on	O
any	O
prospective	O
new	O
drug-pricing	O
regulation	O
,	O
for	O
that	O
matter	O
.	O
trump	PERS
has	O
said	O
he	O
favors	O
introducing	O
more	O
competition	O
into	O
the	O
healthcare	O
marketplace	O
,	O
including	O
letting	O
medicare	ORG
negotiate	O
on	O
drug	O
prices	O
.	O
and	O
market	PERS
competition	O
will	O
do	O
more	O
to	O
lower	O
prices	O
than	O
anything	O
.	O
a	O
case	O
in	O
point	O
:	O
gilead	O
's	O
steep	O
stock	O
drop	O
in	O
october	O
had	O
nothing	O
to	O
do	O
with	O
any	O
political	O
rhetoric	O
on	O
sky-high	O
drug	O
costs	O
,	O
but	O
rather	O
with	O
the	O
fact	O
that	O
its	O
$	O
80,000	O
or	O
so	O
hep	O
c	O
combination	O
therapy	O
(	O
harvoni	O
)	O
might	O
face	O
pricing	O
pressure	O
from	O
rivals	O
j	O
&	O
j	O
and	O
abbvie	ORG
--	O
adding	O
another	O
challenge	O
to	O
a	O
company	O
already	O
facing	O
a	O
drop	O
in	O
its	O
hcv	O
drug	O
sales	O
.	O
nor	O
will	O
a	O
change	O
at	O
the	O
helm	O
at	O
fda	ORG
do	O
much	O
to	O
alter	O
the	O
pharma	O
horizon	O
.	O
the	O
drags	O
on	O
the	O
industry	O
today	O
revolve	O
around	O
a	O
paucity	O
of	O
innovation	O
and	O
the	O
expensive	O
,	O
late-stage	O
failures	O
of	O
drugs	O
that	O
continue	O
to	O
plague	O
it	O
.	O
those	O
are	O
two	O
problems	O
that	O
drug	O
makers	O
will	O
have	O
to	O
fix	O
on	O
their	O
own	O
.	O
more	O
news	O
below	O
.	O
clifton	PERS
leaf	PERS
@	O
cliftonleaf	O
clifton.leaf	O
@	O
fortune.com	O
digital	O
health	O
the	O
nih	O
is	O
funding	O
a	O
study	O
of	O
an	O
artificial	O
pancreas	O
.	O
in	O
late	O
september	O
,	O
the	O
food	ORG
and	ORG
drug	ORG
administration	ORG
green	O
lighted	O
the	O
first-ever	O
``	O
artificial	O
pancreas	O
,	O
''	O
medtronic	ORG
's	O
minimed	O
670g	O
.	O
now	O
,	O
the	O
national	ORG
institutes	ORG
of	ORG
health	ORG
(	O
nih	O
)	O
funded	O
international	O
diabetes	O
closed	O
loop	O
trial	O
is	O
enlisting	O
dexcom	O
,	O
tandem	O
diabetes	O
care	O
,	O
and	O
the	O
digital	O
health	O
firm	O
typezero	ORG
technologies	ORG
to	O
create	O
a	O
``	O
closed-loop	O
''	O
insulin	O
delivery	O
system	O
to	O
treat	O
type	O
1	O
diabetes	O
.	O
the	O
experimental	O
system	O
will	O
incorporate	O
a	O
glucose	O
sensor	O
made	O
by	O
dexcom	O
,	O
an	O
insulin	O
pump	O
from	O
tandem	O
,	O
and	O
a	O
smartphone	O
app	O
developed	O
by	O
typezero	ORG
.	O
with	O
an	O
artificial	O
pancreas	O
,	O
insulin	O
levels	O
can	O
be	O
adjusted	O
continuously	O
in	O
response	O
to	O
changes	O
in	O
blood	O
sugar	O
,	O
which	O
are	O
monitored	O
by	O
the	O
system	O
.	O
and	O
the	O
device	O
will	O
also	O
give	O
users	O
the	O
option	O
to	O
manually	O
administer	O
higher	O
doses	O
,	O
such	O
as	O
before	O
meals	O
.	O
(	O
fiercepharma	O
,	O
fortune	O
)	O
google	ORG
honors	O
insulin	O
pioneer	O
frederick	PERS
banting	PERS
.	O
google	ORG
regularly	O
pays	O
respects	O
to	O
scientific	O
luminaries	O
.	O
and	O
on	O
monday	O
,	O
the	O
company	O
's	O
search	O
engine	O
homepage	O
has	O
a	O
``	O
doodle	O
''	O
featuring	O
sir	O
frederick	PERS
banting	PERS
,	O
a	O
nobel	O
laureate	O
in	O
medicine	O
who	O
was	O
the	O
first	O
person	O
to	O
use	O
insulin	O
in	O
humans	O
.	O
banting	PERS
was	O
able	O
to	O
isolate	O
insulin	O
from	O
the	O
pancreases	O
of	O
dogs	O
and	O
calves	O
alongside	O
his	O
partners	O
dr.	O
charles	PERS
best	PERS
(	O
with	O
whom	O
banting	PERS
would	O
eventually	O
share	O
his	O
nobel	O
prize	O
money	O
)	O
and	O
j.j.r	O
.	O
macleod	O
,	O
with	O
whom	O
he	O
shared	O
the	O
prize	O
itself	O
.	O
himss	ORG
health	O
it	O
conference	O
will	O
feature	O
ibm	ORG
chief	O
and	O
former	O
house	ORG
speaker	O
boehner	PERS
.	O
the	O
healthcare	ORG
information	ORG
and	ORG
management	ORG
systems	ORG
society	ORG
(	O
himss	ORG
)	O
annual	O
meeting	O
is	O
arguably	O
the	O
most	O
important	O
health	O
it	O
conference	O
to	O
take	O
place	O
each	O
year	O
.	O
in	O
2017	O
,	O
it	O
's	O
going	O
to	O
feature	O
an	O
all-star	O
roster	O
of	O
keynote	O
speakers	O
including	O
ibm	ORG
ceo	O
ginni	PERS
rometty	PERS
,	O
former	O
house	ORG
speaker	O
john	PERS
boehner	PERS
,	O
and	O
shark	O
tank	O
investors	O
robert	PERS
herjavec	PERS
and	O
kevin	PERS
o'leary	PERS
.	O
after	O
stepping	O
down	O
as	O
speaker	O
,	O
boehner	PERS
joined	O
the	O
board	O
of	O
tobacco	O
giant	O
reynolds	ORG
american	ORG
and	O
the	O
d.c.	LOC
law	O
firm	O
squire	ORG
patton	ORG
boggs	ORG
.	O
himss	ORG
2017	O
will	O
run	O
from	O
february	O
19-23	O
,	O
2017	O
,	O
in	O
florida	LOC
and	O
will	O
focus	O
on	O
a	O
host	O
of	O
topics	O
including	O
interoperability	O
,	O
cybersecurity	O
,	O
health	O
data	O
analytics	O
,	O
and	O
more	O
.	O
(	O
healthcare	O
it	O
news	O
)	O
fda	ORG
proposes	O
studying	O
a	O
key	O
issue	O
in	O
pharma	O
's	O
digital	O
marketing	O
.	O
the	O
regulations	O
surrounding	O
drug	O
marketing	O
have	O
n't	O
exactly	O
kept	O
up	O
with	O
the	O
digital	O
age	O
.	O
since	O
2009	O
,	O
biopharma	O
firms	O
have	O
had	O
trouble	O
promoting	O
their	O
products	O
on	O
platforms	O
like	O
twitter	ORG
because	O
u.s.	LOC
rules	O
require	O
all	O
drug	O
ads	O
to	O
present	O
comprehensive	O
(	O
and	O
lengthy	O
)	O
safety	O
and	O
side	O
effect	O
information	O
.	O
companies	O
figured	O
that	O
including	O
an	O
outside	O
link	O
to	O
safety	O
information	O
in	O
social	O
media	O
drug	O
ads	O
would	O
suffice	O
;	O
the	O
fda	ORG
disagreed	O
.	O
but	O
the	O
agency	O
in	O
now	O
proposing	O
a	O
study	O
to	O
see	O
whether	O
or	O
not	O
these	O
links	O
can	O
be	O
just	O
as	O
effective	O
for	O
giving	O
patients	O
the	O
information	O
they	O
need	O
.	O
and	O
if	O
regulators	O
eventually	O
conclude	O
that	O
drug	O
makers	O
can	O
use	O
this	O
tactic	O
in	O
their	O
social	O
media	O
marketing	O
,	O
it	O
could	O
open	O
up	O
an	O
entirely	O
new	O
horizon	O
in	O
digital	O
medicine	O
promotion	O
.	O
(	O
fiercepharma	O
)	O
indications	O
ptc	ORG
therapeutics	ORG
can	O
keep	O
its	O
controversial	O
duchenne	O
drug	O
on	O
the	O
market	PERS
.	O
ptc	ORG
therapeutics	ORG
got	O
a	O
massive	O
break	O
on	O
friday	O
when	O
european	O
regulators	O
decided	O
to	O
allow	O
translarna	ORG
,	O
the	O
company	O
's	O
controversial	O
treatment	O
for	O
duchenne	O
muscular	O
dystrophy	O
,	O
a	O
devastating	O
genetic	O
disorder	O
that	O
leads	O
to	O
loss	O
of	O
motor	O
function	O
,	O
to	O
remain	O
on	O
the	O
market	PERS
.	O
many	O
analysts	O
had	O
expected	O
the	O
drug	O
's	O
marketing	O
approval	O
to	O
be	O
revoked	O
given	O
its	O
checkered	O
efficacy	O
.	O
but	O
the	O
advisory	O
body	O
to	O
the	O
european	ORG
medicines	ORG
agency	ORG
is	O
recommending	O
that	O
sales	O
be	O
allowed	O
to	O
continue	O
as	O
long	O
as	O
ptc	ORG
can	O
prove	O
significant	O
efficacy	O
through	O
a	O
pair	O
of	O
larger	O
studies	O
(	O
which	O
wo	O
n't	O
conclude	O
until	O
2021	O
)	O
.	O
ptc	ORG
shares	O
soared	O
more	O
than	O
88	O
%	O
in	O
friday	O
trading	O
and	O
is	O
up	O
about	O
another	O
9	O
%	O
in	O
early	O
monday	O
trading	O
.	O
(	O
fortune	O
)	O
novartis	ORG
may	O
snap	O
up	O
generic	O
drug	O
maker	O
amneal	ORG
for	O
$	O
8	O
billion	O
.	O
sources	O
tell	O
bloomberg	ORG
that	O
pharma	O
giant	O
novartis	ORG
may	O
be	O
close	O
to	O
hammering	O
out	O
a	O
deal	O
for	O
the	O
closely	O
held	O
u.s.	LOC
generics	O
firm	O
amneal	ORG
pharmaceuticals	ORG
,	O
which	O
could	O
be	O
valued	O
at	O
as	O
much	O
as	O
$	O
8	O
billion	O
.	O
the	O
company	O
makes	O
generic	O
treatments	O
for	O
conditions	O
like	O
herpes	O
and	O
epilepsy	O
,	O
and	O
novartis	ORG
'	O
generic	O
drug	O
unit	O
sandoz	ORG
could	O
get	O
a	O
boost	O
from	O
an	O
acquisition	O
--	O
especially	O
in	O
light	O
of	O
teva	O
's	O
$	O
40.5	O
billion	O
buyout	O
of	O
allergan	O
's	O
generic	O
drug	O
portfolio	O
.	O
still	O
,	O
as	O
bloomberg	ORG
notes	O
,	O
the	O
deal	O
could	O
come	O
at	O
a	O
difficult	O
time	O
for	O
the	O
generic	O
industry	O
given	O
ongoing	O
justice	ORG
department	ORG
investigations	O
into	O
potential	O
widescale	O
price	O
fixing	O
and	O
collusion	O
on	O
copycat	O
medicines	O
.	O
(	O
bloomberg	ORG
,	O
fortune	O
)	O
fda	ORG
rejects	O
dynavax	ORG
's	O
hepatitis	O
b	O
vaccine	O
(	O
again	O
)	O
.	O
shares	O
of	O
dynavax	ORG
plummeted	O
63	O
%	O
in	O
early	O
monday	O
trading	O
after	O
the	O
company	O
announced	O
that	O
the	O
food	ORG
and	ORG
drug	ORG
administration	ORG
had	O
,	O
once	O
again	O
,	O
declined	O
to	O
approve	O
its	O
hepatitis	O
b	O
vaccine	O
heplisav-b	O
.	O
dynavax	ORG
's	O
stock	O
has	O
been	O
on	O
a	O
bit	O
of	O
a	O
roller	O
coaster	O
this	O
year	O
;	O
shares	O
flew	O
in	O
early	O
2016	O
on	O
the	O
strength	O
of	O
late-stage	O
clinical	O
trials	O
demonstrating	O
heplisav-b	O
's	O
efficacy	O
.	O
but	O
the	O
firm	O
is	O
now	O
in	O
dire	O
straits	O
with	O
the	O
latest	O
fda	ORG
setback	O
--	O
and	O
ceo	O
eddie	PERS
gray	PERS
says	O
that	O
the	O
embattled	O
biotech	O
will	O
need	O
a	O
partner	O
to	O
help	O
get	O
the	O
experimental	O
treatment	O
to	O
market	PERS
.	O
``	O
[	O
t	O
]	O
he	O
time	O
and	O
resources	O
that	O
will	O
be	O
required	O
to	O
gain	O
approval	O
leads	O
us	O
to	O
consider	O
that	O
we	O
may	O
not	O
be	O
able	O
to	O
advance	O
this	O
program	O
on	O
our	O
own	O
and	O
we	O
are	O
moving	O
swiftly	O
to	O
identify	O
a	O
potential	O
pharmaceutical	O
or	O
financial	O
partner	O
,	O
''	O
he	O
said	O
in	O
a	O
statement	O
.	O
(	O
endpoints	O
)	O
the	O
big	O
picture	O
president-elect	O
trump	PERS
may	O
keep	O
some	O
major	O
parts	O
of	O
obamacare	O
.	O
in	O
a	O
seemingly	O
stunning	O
reversal	O
,	O
president-elect	O
donald	PERS
trump	PERS
told	O
both	O
the	O
wall	ORG
street	ORG
journal	ORG
and	O
60	O
minutes	O
that	O
he	O
's	O
open	O
to	O
keeping	O
some	O
of	O
obamacare	O
's	O
most	O
popular	O
provisions	O
,	O
including	O
guaranteed	O
insurance	O
coverage	O
for	O
americans	O
with	O
pre-existing	O
conditions	O
and	O
allowing	O
young	O
people	O
to	O
remain	O
on	O
their	O
parents	O
'	O
health	O
policies	O
up	O
until	O
the	O
age	O
of	O
26	O
.	O
it	O
's	O
unclear	O
how	O
that	O
would	O
work	O
in	O
tandem	O
with	O
trump	PERS
's	O
and	O
the	O
congressional	O
gop	ORG
's	O
promises	O
to	O
dismantle	O
the	O
law	O
,	O
including	O
repeal	O
of	O
its	O
mandate	O
requiring	O
americans	O
to	O
purchase	O
insurance	O
.	O
that	O
provision	O
is	O
meant	O
to	O
prevent	O
adverse	O
selection	O
in	O
the	O
market	PERS
,	O
since	O
otherwise	O
consumers	O
could	O
simply	O
wait	O
until	O
they	O
got	O
sick	O
to	O
buy	O
coverage	O
.	O
and	O
trump	PERS
's	O
transition	O
website	O
endorses	O
the	O
use	O
of	O
high-risk	O
pools	O
for	O
people	O
with	O
pre-existing	O
conditions	O
,	O
which	O
would	O
n't	O
be	O
necessary	O
with	O
guaranteed	O
issue	O
(	O
although	O
it	O
's	O
possible	O
that	O
's	O
what	O
trump	PERS
is	O
referring	O
to	O
when	O
he	O
says	O
he	O
likes	O
the	O
pre-existing	O
condition	O
provision	O
)	O
.	O
trump	PERS
said	O
that	O
his	O
oval	ORG
office	ORG
sit	O
down	O
with	O
president	O
obama	PERS
helped	O
convince	O
him	O
to	O
consider	O
keeping	O
those	O
parts	O
of	O
the	O
law	O
.	O
(	O
fortune	O
)	O
there	O
are	O
new	O
bird	O
flu	O
outbreaks	O
in	O
germany	LOC
,	O
switzerland	LOC
,	O
and	O
austria	LOC
.	O
europe	LOC
's	O
bird	O
flu	O
problem	O
got	O
worse	O
over	O
the	O
weekend	O
as	O
germany	LOC
,	O
switzerland	LOC
,	O
and	O
austria	LOC
all	O
announced	O
new	O
outbreaks	O
of	O
h5n8	O
,	O
a	O
dangerous	O
and	O
severe	O
bird	O
flu	O
strain	O
that	O
's	O
also	O
popped	O
up	O
in	O
the	LOC
netherlands	LOC
,	O
denmark	LOC
,	O
hungary	LOC
,	O
and	O
poland	LOC
,	O
in	O
poultry	O
.	O
regulators	O
and	O
food	O
safety	O
officials	O
announced	O
that	O
they	O
would	O
be	O
culling	O
tens	O
of	O
thousands	O
of	O
chickens	O
at	O
affected	O
farms	O
and	O
set	O
up	O
a	O
safety	O
radius	O
of	O
1.2	O
square	O
miles	O
surrounding	O
the	O
affected	O
regions	O
.	O
(	O
fortune	O
)	O
trump	PERS
's	O
win	O
is	O
fueling	O
a	O
huge	O
demand	O
for	O
iuds	O
and	O
donations	O
to	O
planned	ORG
parenthood	ORG
.	O
trump	PERS
's	O
election	O
last	O
week	O
helped	O
fuel	O
a	O
massive	O
surge	O
in	O
obamacare	O
enrollment	O
on	O
wednesday	O
.	O
it	O
's	O
also	O
leading	O
to	O
substantial	O
donations	O
to	O
planned	ORG
parenthood	ORG
and	O
huge	O
demand	O
for	O
iuds	O
out	O
of	O
fear	O
that	O
a	O
republican	O
congress	ORG
will	O
de-fund	O
the	O
family	O
planning	O
services	O
provider	O
over	O
abortion	O
procedures	O
.	O
the	O
planned	ORG
parenthood	ORG
federation	ORG
of	ORG
america	ORG
has	O
received	O
more	O
than	O
80,000	O
new	O
donations	O
from	O
across	O
the	O
country	O
following	O
trump	PERS
's	O
victory	O
,	O
and	O
several	O
local	O
planned	ORG
parenthood	ORG
affiliates	O
have	O
reported	O
big	O
spikes	O
in	O
appointment	O
requests	O
for	O
long-acting	O
contraceptives	O
such	O
as	O
iuds	O
.	O
(	O
fortune	O
)	O
required	O
reading	O
5	O
tech	O
gadgets	O
that	O
help	O
me	O
manage	O
my	O
life	O
,	O
by	O
greg	PERS
spencer	PERS
it	O
's	O
time	O
to	O
get	O
real	O
about	O
artificial	O
intelligence	O
,	O
by	O
adam	PERS
lashinsky	PERS
trump	PERS
and	O
the	O
supreme	ORG
court	ORG
:	O
5	O
big	O
questions	O
,	O
by	O
jeff	PERS
john	PERS
roberts	PERS
pfizer	ORG
's	O
celebrex	O
shown	O
to	O
be	O
as	O
safe	O
as	O
other	O
painkillers	O
,	O
by	O
reuters	ORG
[	O
ceo_attribution	O
author=	O
''	O
produced	O
by	O
sy	PERS
mukherjee	PERS
''	O
email=	O
''	O
sayak.mukherjee	O
@	O
fortune.com	O
''	O
twitter=	O
''	O
the_sy_guy	O
''	O
]	O
find	O
past	O
coverage	O
.	O
sign	O
up	O
for	O
other	O
fortune	O
newsletters	O
.	O
getting	O
real	O
about	O
addiction—finally	O
the	O
u.s	O
.	O
surgeon	O
general	O
released	O
a	O
remarkable	O
report	O
yesterday	O
,	O
entitled	O
facing	O
addiction	O
in	O
america	LOC
.	O
it	O
's	O
hard	O
to	O
believe	O
that	O
this	O
is	O
that	O
office	O
's	O
first-ever	O
comprehensive	O
study	O
of	O
substance	O
misuse	O
in	O
the	O
u.s.	LOC
--	O
but	O
what	O
the	O
government	O
lacks	O
in	O
response	O
time	O
it	O
has	O
made	O
up	O
for	O
in	O
thoroughness	O
.	O
the	O
report	O
is	O
powerful	O
,	O
candid	O
,	O
and	O
surprisingly	O
well	O
written	O
.	O
(	O
i	O
read	O
about	O
200	O
pages	O
of	O
it	O
last	O
night	O
,	O
though	O
admittedly	O
a	O
good	O
chunk	O
was	O
in	O
the	O
form	O
of	O
tables	O
.	O
)	O
in	O
case	O
it	O
was	O
n't	O
obvious	O
from	O
the	O
headlines	O
greeting	O
us	O
everyday	O
:	O
``	O
the	O
united	ORG
states	LOC
has	O
a	O
serious	O
substance	O
misuse	O
problem	O
.	O
''	O
and	O
that	O
misuse	O
--	O
66.7	O
million	O
americans	O
acknowledge	O
binge	O
drinking	O
in	O
the	O
past	O
month	O
;	O
more	O
than	O
27	O
million	O
americans	O
currently	O
use	O
illicit	O
drugs	O
or	O
misuse	O
prescription	O
meds	O
like	O
painkillers	O
--	O
has	O
a	O
profound	O
cost	O
for	O
the	O
nation	O
.	O
but	O
the	O
sg	O
's	O
report	O
does	O
n't	O
just	O
make	O
a	O
definitive	O
case	O
about	O
the	O
reality	O
and	O
stakes	O
of	O
the	O
crisis	O
,	O
it	O
offers	O
a	O
smart	O
and	O
sober	O
plan	O
forward	O
.	O
technology	O
plays	O
a	O
big	O
role	O
in	O
that	O
.	O
chapter	O
4	O
of	O
the	O
report	O
,	O
which	O
delves	O
into	O
tools	O
that	O
are	O
available	O
for	O
early	O
intervention	O
and	O
treatment	O
--	O
has	O
a	O
good	O
(	O
but	O
too	O
brief	O
)	O
section	O
on	O
how	O
emerging	O
technologies	O
,	O
from	O
telemedicine	O
to	O
web-based	O
cognitive	O
behavioral	O
training	O
,	O
can	O
offer	O
inexpensive	O
and	O
timely	O
help	O
for	O
millions	O
.	O
to	O
the	O
extent	O
that	O
these	O
new	O
approaches	O
catch	O
on	O
,	O
you	O
can	O
thank	O
in	O
large	O
part	O
a	O
slew	O
of	O
new	O
entrepreneurs	O
and	O
the	O
venture	O
capitalists	O
backing	O
them	O
.	O
in	O
recent	O
months	O
,	O
several	O
innovative	O
startups	O
have	O
launched	O
with	O
the	O
aim	O
of	O
convincing	O
potential	O
customers	O
that	O
they	O
need	O
to	O
change	O
their	O
own	O
destructive	O
behaviors	O
(	O
in	O
theory	O
--	O
one	O
would	O
think	O
--	O
not	O
an	O
easy	O
sell	O
)	O
.	O
michael	PERS
laskoff	PERS
's	O
new	O
digital	O
health	O
offering	O
,	O
annum	O
health	O
--	O
which	O
provides	O
a	O
new	O
home-based	O
treatment	O
platform	O
for	O
heavy	O
drinkers	O
--	O
recently	O
raised	O
$	O
5	O
million	O
in	O
funding	O
.	O
former	O
wall	O
streeter	PERS
lauren	PERS
stahl	PERS
has	O
set	O
up	O
sparkite	O
,	O
an	O
``	O
aftercare	O
platform	O
''	O
built	O
specifically	O
for	O
mobile	O
devices	O
which	O
she	O
calls	O
``	O
addiction	O
support	O
in	O
the	O
pocket	O
.	O
''	O
pear	ORG
therapeutics	ORG
says	O
it	O
's	O
``	O
the	O
first	O
prescription	O
digital	O
therapy	O
designed	O
to	O
treat	O
opiate	O
dependence	O
.	O
''	O
and	O
venrock	O
-backed	O
lyra	O
health	O
,	O
cofounded	O
by	O
former	O
facebook	ORG
and	O
genentech	ORG
cfo	O
david	PERS
ebersman	PERS
,	O
works	O
with	O
employers	O
and	O
insurance	O
providers	O
to	O
coordinate	O
care	O
(	O
and	O
improve	O
outcomes	O
)	O
for	O
employees	O
with	O
regard	O
to	O
behavioral	O
health	O
issues	O
.	O
you	O
can	O
also	O
throw	O
into	O
the	O
mix	O
workit	O
health	O
,	O
mystrength	O
,	O
and	O
the	O
rock	O
health-backed	O
lantern	O
,	O
which	O
received	O
a	O
$	O
4	O
million	O
grant	O
from	O
the	O
national	ORG
institute	ORG
of	ORG
mental	ORG
health	ORG
.	O
private	O
insurers	O
are	O
becoming	O
much	O
more	O
aggressive	O
about	O
trying	O
to	O
stem	O
this	O
epidemic	O
as	O
well	O
--	O
see	O
,	O
for	O
example	O
,	O
sy	O
's	O
write-up	O
of	O
cigna	ORG
's	O
latest	O
effort	O
below	O
.	O
the	O
surgeon	O
general	O
calls	O
our	O
response	O
to	O
this	O
public	O
health	O
crisis	O
``	O
a	O
moral	O
test	O
for	O
america	LOC
.	O
''	O
he	O
is	O
right	O
.	O
read	O
on	O
for	O
more	O
.	O
and	O
please	O
be	O
sure	O
and	O
email	O
me	O
with	O
any	O
news	O
,	O
feedback	O
,	O
or	O
a	O
general	O
hello	O
.	O
i	O
would	O
love	O
to	O
hear	O
from	O
you	O
!	O
clifton	PERS
leaf	PERS
@	O
cliftonleaf	O
clifton.leaf	O
@	O
fortune.com	O
digital	O
health	O
intel	ORG
and	O
the	O
broad	ORG
institute	ORG
strike	O
a	O
5-year	O
genomic	O
data	O
collaboration	O
.	O
tech	O
giant	O
intel	ORG
and	O
the	O
broad	ORG
institute	ORG
of	ORG
mit	ORG
and	ORG
harvard	ORG
are	O
teaming	O
up	O
for	O
a	O
5-year	O
,	O
$	O
25	O
million	O
partnership	O
that	O
aims	O
to	O
make	O
it	O
easier	O
to	O
sift	O
through	O
the	O
mountains	O
of	O
genomic	O
data	O
which	O
are	O
piling	O
up	O
in	O
labs	O
and	O
academic	O
institutes	O
throughout	O
the	O
world	O
.	O
the	O
hope	O
is	O
that	O
the	O
new	O
intel-broad	ORG
center	ORG
for	ORG
genomic	ORG
data	ORG
engineering	ORG
will	O
be	O
able	O
to	O
create	O
a	O
data	O
``	O
superhighway	O
''	O
that	O
will	O
make	O
it	O
far	O
easier	O
for	O
scientists	O
to	O
access	O
information	O
in	O
disparate	O
cloud	O
networks	O
,	O
including	O
in	O
both	O
the	O
private	O
and	O
public	O
spheres	O
.	O
``	O
the	O
size	O
of	O
genomic	O
datasets	O
doubles	O
about	O
every	O
eight	O
months	O
and	O
,	O
as	O
it	O
does	O
,	O
the	O
challenge	O
of	O
acquiring	O
,	O
processing	O
,	O
storing	O
,	O
and	O
analyzing	O
this	O
information	O
increases	O
as	O
well	O
,	O
''	O
said	O
eric	PERS
banks	PERS
,	O
director	O
of	O
the	O
data	ORG
sciences	ORG
and	ORG
data	ORG
engineering	ORG
group	O
at	O
the	O
broad	ORG
institute	ORG
,	O
in	O
a	O
statement	O
.	O
``	O
working	O
with	O
intel	ORG
,	O
we	O
plan	O
to	O
build	O
out	O
solutions	O
that	O
can	O
work	O
across	O
different	O
infrastructures	O
to	O
facilitate	O
efficient	O
processing	O
of	O
these	O
growing	O
data	O
sets	O
,	O
and	O
then	O
make	O
these	O
tools	O
openly	O
available	O
for	O
researchers	O
worldwide	O
.	O
''	O
e-cigarettes	O
may	O
yellow	O
teeth	O
just	O
as	O
much	O
as	O
the	O
real	O
things	O
.	O
electronic	O
cigarettes	O
were	O
meant	O
to	O
be	O
one	O
of	O
the	O
earlier	O
examples	O
of	O
how	O
the	O
digital	O
health	O
revolution	O
could	O
extend	O
into	O
the	O
consumer	O
public	O
health	O
sphere	O
.	O
the	O
products	O
were	O
largely	O
hawked	O
as	O
healthier	O
alternatives	O
to	O
traditional	O
cigarettes	O
and	O
even	O
as	O
a	O
step	O
in	O
smoking	O
cessation	O
,	O
since	O
they	O
do	O
n't	O
have	O
some	O
of	O
the	O
more	O
obvious	O
carcinogens	O
in	O
cigarettes	O
.	O
but	O
new	O
research	O
has	O
brought	O
e-cigs	O
'	O
effect	O
on	O
health	O
into	O
question	O
--	O
including	O
suggestions	O
that	O
they	O
may	O
actually	O
be	O
encouraging	O
teens	O
who	O
may	O
otherwise	O
have	O
never	O
used	O
nicotine	O
products	O
at	O
all	O
to	O
smoke	O
.	O
and	O
a	O
new	O
study	O
on	O
3d	O
human	O
jaw	O
models	O
suggests	O
that	O
the	O
inflammation	O
and	O
irritation	O
caused	O
by	O
electronic	O
cigarette	O
vapor	O
may	O
be	O
just	O
as	O
deleterious	O
for	O
tooth	O
and	O
gum	O
tissue	O
health	O
.	O
(	O
fortune	O
)	O
trump	PERS
's	O
plans	O
to	O
scrap	O
obamacare	O
are	O
messing	O
with	O
his	O
in-law	O
's	O
$	O
2.7	O
billion	O
high-tech	O
insurance	O
startup	O
.	O
as	O
president	O
barack	PERS
obama	PERS
painfully	O
found	O
out	O
over	O
the	O
course	O
of	O
his	O
two	O
terms	O
,	O
major	O
policy	O
overhauls	O
inherently	O
demand	O
tradeoffs	O
.	O
and	O
president-elect	O
donald	PERS
trump	PERS
's	O
pledge	O
to	O
repeal	O
(	O
or	O
significantly	O
dismantle	O
)	O
obamacare	O
is	O
no	O
different	O
.	O
in	O
fact	O
,	O
it	O
's	O
already	O
having	O
an	O
effect	O
on	O
one	O
of	O
his	O
relatives	O
'	O
business	O
:	O
oscar	PERS
health	PERS
,	O
the	O
app-oriented	O
individual	O
insurance	O
company	O
that	O
was	O
co-founded	O
by	O
joshua	PERS
kushner	PERS
,	O
brother	O
of	O
trump	PERS
's	O
son-in-law	O
jared	PERS
kushner	PERS
.	O
oscar	PERS
has	O
set	O
out	O
to	O
streamline	O
healthcare	O
through	O
a	O
combination	O
of	O
its	O
insurance	O
plans	O
and	O
digital	O
offerings	O
that	O
can	O
make	O
it	O
easier	O
to	O
connect	O
with	O
the	O
hugely	O
disparate	O
american	O
health	O
system	O
.	O
the	O
firm	O
has	O
faced	O
some	O
financial	O
troubles	O
since	O
its	O
inception	O
but	O
still	O
recently	O
nabbed	O
a	O
$	O
2.7	O
billion	O
valuation	O
.	O
but	O
now	O
,	O
as	O
kushner	PERS
and	O
his	O
oscar	PERS
co-founder	O
and	O
ceo	O
mario	PERS
schlosser	PERS
write	O
in	O
a	O
lengthy	O
blog	O
post	O
,	O
the	O
future	O
is	O
a	O
bit	O
more	O
uncertain	O
.	O
scrapping	O
obamacare	O
's	O
statewide	O
marketplaces	O
,	O
where	O
oscar	PERS
does	O
much	O
of	O
its	O
business	O
,	O
would	O
be	O
a	O
big	O
disruption	O
,	O
and	O
the	O
company	O
believes	O
that	O
the	O
problems	O
which	O
have	O
dogged	O
the	O
health	O
law	O
in	O
its	O
nascent	O
years	O
are	O
simply	O
the	O
growing	O
pains	O
of	O
a	O
new	O
and	O
relatively	O
uncharted	O
market	O
.	O
the	O
pair	O
still	O
sounded	O
an	O
optimistic	O
note	O
,	O
arguing	O
that	O
some	O
of	O
the	O
potential	O
changes	O
coming	O
under	O
trump	PERS
and	O
gop-controlled	O
congress	ORG
could	O
be	O
good	O
for	O
all	O
consumers	O
.	O
(	O
fortune	O
)	O
indications	O
this	O
could	O
become	O
j	O
&	O
j	O
's	O
next	O
blockbuster	O
drug	O
.	O
johnson	ORG
&	ORG
johnson	ORG
has	O
submitted	O
an	O
anti-inflammatory	O
medication	O
that	O
it	O
believes	O
could	O
become	O
a	O
massive	O
sales	O
driver	O
for	O
food	ORG
and	ORG
drug	ORG
administration	ORG
approval	O
.	O
the	O
treatment	O
,	O
guselkumab	O
,	O
is	O
being	O
tested	O
out	O
in	O
conditions	O
like	O
severe	O
plaque	O
psoriasis	O
.	O
so	O
why	O
is	O
j	O
&	O
j	O
so	O
bullish	O
about	O
its	O
prospects	O
?	O
in	O
late-stage	O
trials	O
,	O
the	O
experimental	O
therapy	O
beat	O
out	O
abbvie	O
's	O
humira	O
,	O
the	O
best-selling	O
medicine	O
in	O
the	O
world	O
,	O
significantly	O
in	O
a	O
head-to-head	O
match	O
up	O
.	O
furthermore	O
,	O
guselkumab	O
has	O
shown	O
a	O
lower	O
propensity	O
for	O
producing	O
the	O
kinds	O
of	O
harmful	O
side	O
effects	O
that	O
some	O
of	O
its	O
rivals	O
'	O
own	O
candidates	O
have	O
shown	O
in	O
clinical	O
studies	O
.	O
(	O
endpoints	O
)	O
glaxosmithkline	ORG
is	O
consolidating	O
r	O
&	O
d	O
with	O
``	O
smart	O
labs	O
''	O
in	O
philly	O
.	O
british	O
pharma	O
giant	O
glaxosmithkline	ORG
,	O
which	O
is	O
planning	O
to	O
shift	O
40	O
%	O
of	O
its	O
worldwide	O
phama	O
r	O
&	O
d	O
workers	O
to	O
philadelphia	LOC
by	O
2018	O
,	O
is	O
pumping	O
$	O
250	O
million	O
to	O
create	O
what	O
the	O
company	O
calls	O
a	O
new	O
,	O
smarter	O
type	O
of	O
laboratory	O
work	O
space	O
.	O
the	O
``	O
smart	O
space	O
''	O
will	O
be	O
designed	O
to	O
encourage	O
collaboration	O
among	O
glaxo	ORG
scientists	O
and	O
to	O
boost	O
safety	O
measures	O
by	O
harnessing	O
technology	O
.	O
for	O
instance	O
,	O
the	O
changing	O
room	O
in	O
the	O
space	O
can	O
notify	O
researchers	O
if	O
they	O
have	O
put	O
on	O
their	O
protective	O
gear	O
properly	O
or	O
need	O
to	O
adjust	O
it	O
.	O
the	O
consolidation	O
of	O
work	O
spaces	O
,	O
powered	O
by	O
new	O
tech	O
,	O
is	O
n't	O
unique	O
to	O
pharma	O
companies	O
;	O
ge	ORG
healthcare	ORG
and	O
johns	ORG
hopkins	ORG
recently	O
announced	O
a	O
``	O
digital	O
command	O
center	O
''	O
that	O
oversees	O
the	O
entirety	O
of	O
hospital	O
operations	O
and	O
can	O
proactively	O
sense	O
inefficiencies	O
or	O
problems	O
like	O
a	O
shortage	O
of	O
available	O
hospital	O
beds	O
.	O
(	O
biopharma	O
dive	O
)	O
amgen	ORG
and	O
novartis	ORG
migraine	O
drug	O
could	O
be	O
first-to-market	O
in	O
a	O
crowded	O
field	O
.	O
amgen	ORG
and	O
novartis	ORG
announced	O
new	O
late-stage	O
trial	O
data	O
this	O
week	O
finding	O
that	O
their	O
experimental	O
migraine	O
treatment	O
erenumab	O
successfully	O
reduced	O
the	O
number	O
of	O
monthly	O
migraine	O
episodes	O
experienced	O
by	O
patients	O
by	O
about	O
40	O
%	O
.	O
those	O
numbers	O
set	O
the	O
companies	O
up	O
for	O
marketing	O
approval	O
applications	O
in	O
the	O
u.s.	LOC
and	O
europe	LOC
by	O
next	O
year	O
,	O
which	O
in	O
turn	O
means	O
amgen	ORG
and	O
novartis	ORG
could	O
be	O
sailing	O
towards	O
a	O
first-to-market	O
advantage	O
among	O
next-gen	O
migraine	O
drugs	O
.	O
but	O
a	O
number	O
of	O
other	O
companies	O
are	O
also	O
actively	O
exploring	O
the	O
space	O
with	O
their	O
own	O
investigational	O
products	O
,	O
including	O
pharma	O
giants	O
eli	ORG
lilly	ORG
and	O
allergan	ORG
.	O
the	O
big	O
picture	O
cigna	ORG
announces	O
new	O
steps	O
to	O
help	O
stop	O
its	O
customers	O
from	O
using	O
opioids	O
.	O
on	O
the	O
same	O
day	O
that	O
u.s	O
.	O
surgeon	O
general	O
vivek	PERS
murthy	PERS
's	O
released	O
an	O
update	O
on	O
the	O
state	O
of	O
the	O
opioid	O
addiction	O
crisis	O
in	O
america	LOC
,	O
health	O
insurer	O
cigna	ORG
announced	O
more	O
details	O
surrounding	O
its	O
ambitious	O
plan	O
to	O
curb	O
its	O
customers	O
'	O
use	O
of	O
opioid	O
addiction	O
by	O
25	O
%	O
in	O
three	O
years	O
.	O
the	O
company	O
said	O
that	O
its	O
asking	O
the	O
medical	O
care	O
providers	O
under	O
its	O
collaborative	O
care	O
umbrella	O
(	O
which	O
resemble	O
accountable	O
care	O
organizations	O
whose	O
mission	O
is	O
to	O
coordinate	O
medical	O
treatment	O
to	O
boost	O
outcomes	O
and	O
cut	O
costs	O
)	O
to	O
sign	O
a	O
pledge	O
to	O
promote	O
non-opioid	O
pain	O
therapy	O
alternatives	O
and	O
watch	O
out	O
for	O
patients	O
who	O
are	O
at	O
risk	O
for	O
abuse	O
and	O
addiction	O
.	O
for	O
its	O
part	O
,	O
cigna	ORG
will	O
help	O
teach	O
these	O
providers	O
new	O
centers	ORG
for	ORG
disease	ORG
control	ORG
guidelines	O
on	O
how	O
to	O
safely	O
prescribe	O
opioids	O
and	O
alert	O
facilities	O
when	O
their	O
prescribing	O
practices	O
run	O
afoul	O
of	O
those	O
guidelines	O
.	O
and	O
the	O
insurance	O
giant	O
believes	O
this	O
could	O
have	O
a	O
wide-ranging	O
effect	O
beyond	O
its	O
own	O
plan	O
holders	O
.	O
``	O
the	O
resources	O
we	O
share	O
with	O
our	O
provider	O
partners	O
will	O
benefit	O
all	O
of	O
their	O
patients	O
,	O
not	O
just	O
those	O
who	O
are	O
cigna	ORG
customers	O
,	O
''	O
said	O
cigna	ORG
vp	O
dr.	O
dick	PERS
salmon	PERS
in	O
a	O
statement	O
.	O
``	O
cigna	ORG
is	O
committed	O
to	O
reducing	O
the	O
burden	O
of	O
substance	O
use	O
disorders	O
for	O
all	O
americans	O
.	O
''	O
(	O
fortune	O
)	O
u.s.	LOC
still	O
among	O
most	O
unhealthy	O
countries	O
in	O
the	O
world	O
.	O
a	O
new	O
study	O
in	O
the	O
journal	O
health	ORG
affairs	ORG
finds	O
that	O
the	O
united	ORG
states	LOC
continues	O
to	O
lag	O
significantly	O
behind	O
other	O
developed	O
countries	O
like	O
germany	LOC
and	O
australia	LOC
when	O
it	O
comes	O
to	O
public	O
health	O
.	O
and	O
the	O
survey	O
points	O
to	O
a	O
likely	O
culprit	O
:	O
the	O
sky	O
high	O
cost	O
of	O
medical	O
care	O
in	O
america	LOC
.	O
in	O
fact	O
,	O
33	O
%	O
of	O
surveyed	O
adults	O
said	O
they	O
'd	O
either	O
not	O
seek	O
out	O
a	O
doctor	O
or	O
fill	O
a	O
recommended	O
prescription	O
because	O
of	O
cost	O
concerns	O
.	O
that	O
's	O
compared	O
to	O
just	O
7	O
%	O
of	O
u.k.	LOC
adults	O
who	O
said	O
they	O
avoid	O
medical	O
care	O
for	O
financial	O
reasons	O
.	O
(	O
fortune	O
)	O
obamacare	O
repeal	O
without	O
replacement	O
could	O
wreak	O
further	O
havoc	O
on	O
marketplaces	O
.	O
healthcare	O
experts	O
are	O
warning	O
that	O
president-elect	O
donald	PERS
trump	PERS
's	O
obamacare	O
repeal	O
ambitions	O
are	O
easier	O
said	O
than	O
done	O
,	O
and	O
that	O
a	O
haphazard	O
repeal	O
without	O
a	O
robust	O
replacement	O
plan	O
would	O
likely	O
wreak	O
havoc	O
on	O
an	O
individual	O
insurance	O
market	O
that	O
's	O
already	O
been	O
on	O
a	O
roller	O
coaster	O
.	O
there	O
's	O
a	O
simple	O
timing	O
reason	O
for	O
this	O
:	O
insurers	O
must	O
prospectively	O
set	O
their	O
premiums	O
before	O
open	O
enrollment	O
begins	O
in	O
the	O
fall	O
based	O
on	O
the	O
costs	O
they	O
incur	O
in	O
the	O
previous	O
year	O
.	O
but	O
that	O
will	O
be	O
considerably	O
harder	O
to	O
do	O
for	O
2018	O
insurance	O
rates	O
if	O
they	O
do	O
n't	O
know	O
exactly	O
what	O
's	O
coming	O
down	O
the	O
pike	O
,	O
policy-wise	O
.	O
``	O
i	O
would	O
not	O
be	O
surprised	O
by	O
a	O
stampede	O
to	O
exit	O
the	O
market	O
for	O
fear	O
of	O
uncertainty	O
and	O
the	O
strong	O
potential	O
for	O
adverse	O
selection	O
,	O
''	O
said	O
mike	PERS
kreidler	PERS
,	O
washington	LOC
state	O
's	O
insurance	O
commissioner	O
,	O
during	O
an	O
event	O
on	O
wednesday	O
.	O
(	O
modern	O
healthcare	O
)	O
required	O
reading	O
this	O
startup	O
suggests	O
the	O
best	O
wines	O
for	O
your	O
dna	O
,	O
by	O
rebecca	PERS
robbins	PERS
donald	PERS
trump	PERS
has	O
made	O
his	O
pick	O
for	O
attorney	O
general	O
,	O
by	O
associated	ORG
press	ORG
how	O
united	ORG
's	O
oscar	PERS
munoz	PERS
bounced	O
back	O
after	O
a	O
heart	O
transplant	O
,	O
by	O
shawn	PERS
tully	PERS
koch	PERS
industries	ORG
pours	O
$	O
2.5	O
billion	O
into	O
business	O
software	O
maker	O
infor	ORG
,	O
by	O
barb	PERS
darrow	PERS
[	O
ceo_attribution	O
author=	O
''	O
produced	O
by	O
sy	PERS
mukherjee	PERS
''	O
email=	O
''	O
sayak.mukherjee	O
@	O
fortune.com	O
''	O
twitter=	O
''	O
the_sy_guy	O
''	O
]	O
find	O
past	O
coverage	O
.	O
sign	O
up	O
for	O
other	O
fortune	O
newsletters	O
.	O
mia	O
in	O
the	O
medical	O
revolution	ORG
:	O
a	O
sense	O
of	O
urgency	O
there	O
was	O
a	O
moment	O
yesterday	O
when	O
vice	O
president	O
joe	PERS
biden	PERS
’	O
s	O
words	O
got	O
caught	O
in	O
his	O
throat	O
.	O
he	O
was	O
addressing	O
an	O
intimate	O
crowd	O
at	O
the	O
startup	O
health	ORG
café	ORG
in	O
san	LOC
francisco	LOC
about	O
the	O
white	ORG
house	ORG
cancer	O
moonshot	O
—the	O
widely	O
praised	O
initiative	O
he	O
had	O
begun	O
leading	O
just	O
a	O
year	O
ago	O
and	O
that	O
,	O
only	O
days	O
from	O
now	O
,	O
was	O
slated	O
to	O
lose	O
its	O
potent	O
“	O
white	ORG
house	ORG
”	O
prefix—when	O
he	O
began	O
talking	O
about	O
his	O
eldest	O
son	O
.	O
beau	PERS
biden	PERS
had	O
been	O
the	O
state	O
of	O
delaware	LOC
’	O
s	O
attorney	O
general	O
and	O
a	O
decorated	O
veteran	O
who	O
had	O
served	O
in	O
iraq	LOC
.	O
in	O
2013	O
,	O
a	O
few	O
years	O
after	O
returning	O
from	O
the	O
war	O
,	O
the	O
forty-four	O
year	O
old	O
was	O
diagnosed	O
with	O
stage	O
4	O
glioblastoma	O
,	O
a	O
diagnosis	O
that	O
the	O
vice	O
president	O
said	O
his	O
entire	O
family	O
“	O
knew	O
was	O
the	O
equivalent	O
of	O
a	O
death	O
sentence.	O
”	O
so	O
joe	PERS
,	O
the	O
dad	O
,	O
set	O
out	O
to	O
learn	O
everything	O
he	O
could	O
about	O
the	O
disease	O
during	O
his	O
son	O
’	O
s	O
year-and-a-half	O
fight	O
to	O
survive	O
.	O
“	O
the	O
most	O
important	O
thing	O
i	O
learned	O
,	O
”	O
he	O
recounted	O
,	O
“	O
was	O
that	O
we	O
’	O
ve	O
reached—you	O
all	O
have	O
reached	O
in	O
science—an	O
inflection	O
point	O
in	O
cancer….i	O
found	O
myself	O
realizing	O
that	O
maybe	O
,	O
although	O
we	O
couldn	O
’	O
t	O
save	O
our	O
son	O
,	O
that	O
maybe	O
we	O
could…	O
''	O
that	O
’	O
s	O
when	O
the	O
words	O
disappeared	O
for	O
a	O
long	O
moment	O
and	O
a	O
father	O
’	O
s	O
grief	O
took	O
over	O
.	O
in	O
a	O
day	O
in	O
which	O
investors	O
and	O
entrepreneurs	O
young	O
and	O
old	O
shared	O
business	O
cards	O
and	O
elevator	O
pitches	O
,	O
in	O
which	O
the	O
notion	O
of	O
healthcare	O
as	O
deal-making	O
and	O
commerce	O
reigned	O
supreme	O
,	O
biden	PERS
’	O
s	O
seconds-long	O
flash	O
of	O
wordlessness	O
was	O
a	O
rare	O
moment	O
of	O
clarity	O
.	O
we	O
don	O
’	O
t	O
just	O
need	O
innovation	O
.	O
or	O
investment	O
.	O
or	O
a	O
clever	O
new	O
strategy	O
.	O
we	O
need	O
a	O
change	O
in	O
the	O
circadian	O
rhythm	O
of	O
medical	O
science	O
:	O
we	O
need	O
speed	O
.	O
“	O
my	O
absolute	O
conviction	O
is	O
that	O
we	O
have	O
to	O
inject	O
an	O
overwhelming	O
sense	O
of	O
urgency	O
into	O
this	O
fight	O
,	O
”	O
biden	PERS
told	O
the	O
shoulder-to-shoulder	O
gathering	O
on	O
monday	O
afternoon	O
.	O
these	O
,	O
in	O
my	O
view	O
,	O
ought	O
to	O
be	O
the	O
guiding	O
words	O
of	O
the	O
healthcare	O
revolution	ORG
.	O
more	O
news	O
below	O
.	O
[	O
ceo_attribution	O
author=	O
''	O
clifton	PERS
leaf	PERS
''	O
email=	O
''	O
clifton.leaf	O
@	O
fortune.com	O
''	O
twitter=	O
''	O
cliftonleaf	O
''	O
]	O
digital	O
health	O
this	O
company	O
is	O
launching	O
an	O
ai-powered	O
``	O
digital	O
doctor	O
.	O
''	O
digital	O
health	O
firm	O
healthtap	ORG
today	O
announced	O
that	O
it	O
's	O
launching	O
dr	O
.	O
a.i.	O
,	O
which	O
the	O
company	O
describes	O
as	O
``	O
a	O
personal	O
artificial	O
intelligence-powered	O
'physician	O
'	O
that	O
helps	O
route	O
users	O
to	O
doctor-recommended	O
insights	O
and	O
care	O
immediately	O
.	O
''	O
healthtap	ORG
founder	O
and	O
ceo	O
ron	PERS
gutman	PERS
gave	O
me	O
a	O
personal	O
demonstration	O
of	O
how	O
the	O
tech	O
works	O
before	O
the	O
holidays	O
.	O
it	O
's	O
basically	O
a	O
far	O
more	O
advanced	O
(	O
and	O
guided	O
)	O
version	O
of	O
webmd	O
;	O
but	O
rather	O
than	O
have	O
users	O
try	O
to	O
play	O
a	O
guessing	O
game	O
matching	O
their	O
symptoms	O
with	O
thousands	O
of	O
possible	O
medical	O
conditions	O
,	O
the	O
dr.	O
a.i	O
.	O
platform	O
asks	O
a	O
series	O
of	O
directed	O
questions	O
about	O
what	O
kinds	O
of	O
symptoms	O
the	O
patient	O
is	O
experiencing	O
(	O
for	O
example	O
,	O
light-headedness	O
,	O
pain	O
in	O
a	O
certain	O
region	O
of	O
the	O
body	O
,	O
trouble	O
sleeping	O
,	O
etc	O
.	O
)	O
.	O
it	O
then	O
uses	O
real-world	O
patient	O
question	O
data	O
compiled	O
from	O
more	O
than	O
100,000	O
physicians	O
over	O
six	O
years	O
in	O
order	O
to	O
compile	O
a	O
list	O
of	O
possible	O
conditions	O
that	O
may	O
be	O
afflicting	O
the	O
patient	O
,	O
and	O
then	O
ranks	O
them	O
in	O
order	O
of	O
seriousness	O
from	O
low	O
risk	O
to	O
advising	O
an	O
emergency	O
room	O
visit	O
.	O
and	O
the	O
software	O
,	O
which	O
is	O
connected	O
to	O
healthtap	ORG
's	O
broader	O
digital	O
connection	O
services	O
to	O
physicians	O
and	O
medical	O
experts	O
,	O
can	O
even	O
connect	O
users	O
to	O
doctors	O
and	O
specialists	O
right	O
from	O
the	O
app	O
.	O
st.	ORG
jude	ORG
updates	O
heart	O
device	O
after	O
cyber	O
security	O
concerns	O
.	O
last	O
year	O
,	O
st.	ORG
jude	ORG
medical	ORG
and	O
acquirer	O
abbott	ORG
laboratories	ORG
was	O
hit	O
with	O
a	O
federal	O
government	O
probe	O
into	O
claims	O
that	O
st.	ORG
jude	ORG
's	O
popular	O
heart	O
devices	O
had	O
security	O
vulnerabilities	O
that	O
made	O
them	O
vulnerable	O
to	O
life-threatening	O
hacking	O
.	O
on	O
monday	O
,	O
abbott	ORG
announced	O
that	O
it	O
's	O
taken	O
steps	O
to	O
update	O
the	O
devices	O
'	O
cyber	O
security	O
features	O
.	O
the	O
updates	O
will	O
be	O
automatically	O
applied	O
to	O
the	O
products	O
;	O
but	O
the	O
department	ORG
of	ORG
homeland	ORG
security	ORG
's	O
industrial	O
control	O
systems	O
cyber	O
emergency	O
response	O
team	O
(	O
ics-cert	O
)	O
says	O
that	O
there	O
are	O
still	O
some	O
lingering	O
concerns	O
.	O
``	O
st.	ORG
jude	ORG
medical	ORG
is	O
continuing	O
to	O
work	O
with	O
ics-cert	O
and	O
the	O
fda	ORG
to	O
address	O
additional	O
security	O
issues	O
that	O
have	O
been	O
identified	O
,	O
''	O
said	O
the	O
agency	O
in	O
a	O
statement	O
.	O
(	O
fortune	ORG
)	O
ge	ORG
's	O
hiring	O
practices	O
in	O
saudi	O
it	O
services	O
unit	O
wins	O
it	O
an	O
ace	ORG
.	O
general	ORG
electric	ORG
has	O
been	O
awarded	O
the	O
state	ORG
department	ORG
's	O
prestigious	O
global	O
2016	O
award	O
for	O
corporate	O
excellence	O
(	O
ace	ORG
)	O
for	O
its	O
efforts	O
to	O
recruit	O
a	O
diverse	O
workforce	O
,	O
especially	O
in	O
its	O
it	O
services	O
sectors	O
,	O
in	O
countries	O
like	O
saudi	LOC
arabia	LOC
.	O
for	O
instance	O
,	O
ge	ORG
has	O
an	O
all-women	O
business	O
process	O
&	O
it	O
services	O
center	O
in	O
riyadh	LOC
that	O
employs	O
more	O
than	O
1,000	O
women	O
and	O
has	O
a	O
goal	O
of	O
eventually	O
getting	O
to	O
3,000	O
female	O
hires	O
.	O
ge	ORG
ceo	O
jeff	PERS
immelt	PERS
,	O
who	O
's	O
made	O
workforce	O
diversification	O
a	O
priority	O
for	O
the	O
company	O
,	O
argues	O
that	O
the	O
hiring	O
tactic	O
is	O
ultimately	O
a	O
win	O
for	O
everybody	O
.	O
``	O
the	O
all-women	O
business	O
process	O
center	O
is	O
an	O
innovative	O
solution	O
that	O
enabled	O
us	O
not	O
only	O
to	O
provide	O
career	O
opportunities	O
for	O
the	O
well-educated	O
and	O
talented	O
saudi	O
females	O
but	O
also	O
to	O
build	O
in-country	O
capabilities	O
that	O
’	O
ll	O
have	O
lasting	O
impact	O
,	O
in	O
what	O
is	O
an	O
important	O
market	O
going	O
through	O
transformative	O
changes	O
,	O
''	O
he	O
said	O
in	O
a	O
statement	O
.	O
as	O
cliff	O
's	O
written	O
before	O
,	O
digital	O
health	O
firms	O
in	O
general	O
could	O
use	O
a	O
whole	O
lot	O
more	O
female	O
talent	O
.	O
(	O
healthcare	O
it	O
news	O
)	O
indications	O
teva	ORG
ceo	O
explains	O
why	O
the	O
company	O
's	O
sales	O
guidance	O
was	O
off	O
by	O
$	O
1	O
billion	O
.	O
drug	O
giant	O
teva	ORG
had	O
to	O
make	O
a	O
pretty	O
serious	O
revision	O
to	O
its	O
2017	O
guidance	O
last	O
week	O
,	O
cutting	O
more	O
than	O
$	O
1	O
billion	O
off	O
of	O
its	O
sales	O
forecast	O
for	O
the	O
year	O
.	O
at	O
the	O
ongoing	O
j.p.	ORG
morgan	ORG
healthcare	ORG
conference	O
in	O
san	LOC
francisco	LOC
,	O
ceo	O
erez	PERS
vigodman	PERS
offered	O
an	O
explanation	O
:	O
the	O
snafu	O
can	O
be	O
traced	O
to	O
a	O
hot	O
hand	O
fallacy	O
of	O
sorts	O
where	O
teva	ORG
projected	O
new	O
product	O
sales	O
to	O
keep	O
up	O
the	O
robust	O
pace	O
of	O
the	O
past	O
five	O
years	O
.	O
but	O
that	O
did	O
n't	O
happen	O
in	O
2016	O
,	O
leading	O
to	O
inflated	O
expectations	O
in	O
the	O
initial	O
july	O
sales	O
forecast	O
.	O
in	O
fact	O
,	O
new	O
launches	O
added	O
just	O
$	O
140	O
million	O
to	O
teva	ORG
's	O
coffers	O
last	O
year	O
.	O
``	O
[	O
teva	ORG
will	O
]	O
do	O
everything	O
in	O
our	O
power	O
to	O
make	O
sure	O
that	O
something	O
like	O
that	O
does	O
not	O
happen	O
again	O
,	O
''	O
said	O
vigodman	PERS
at	O
jpm	O
.	O
still	O
,	O
the	O
sheer	O
scope	O
of	O
the	O
guidance	O
revision	O
has	O
some	O
analysts	O
questioning	O
whether	O
teva	ORG
's	O
personnel	O
is	O
suited	O
to	O
the	O
task	O
of	O
properly	O
accounting	O
for	O
and	O
projecting	O
the	O
drug	O
maker	O
's	O
business	O
.	O
(	O
fiercepharma	O
)	O
more	O
details	O
emerge	O
about	O
moderna	O
's	O
pipeline	O
strategy	O
.	O
moderna	O
therapeutics	O
has	O
no	O
shortage	O
of	O
cash	O
.	O
in	O
fact	O
,	O
at	O
$	O
5	O
billion	O
,	O
it	O
's	O
the	O
most	O
highly	O
valued	O
private	O
biotech	O
in	O
the	O
country	O
.	O
but	O
the	O
secretive	O
firm	O
,	O
which	O
is	O
building	O
out	O
a	O
highly	O
experimental	O
messenger	O
rna	O
(	O
mrna	O
)	O
drug	O
platform	O
,	O
has	O
plenty	O
of	O
skeptics	O
,	O
including	O
stat	O
's	O
damian	PERS
garde	PERS
.	O
garde	PERS
and	O
others	O
have	O
pointed	O
to	O
key	O
personnel	O
departures	O
and	O
a	O
lack	O
of	O
evidence	O
about	O
exactly	O
how	O
effective	O
moderna	O
's	O
pipeline	O
prospects	O
might	O
be	O
.	O
at	O
the	O
j.p.	ORG
morgan	ORG
healthcare	ORG
conference	O
,	O
the	O
firm	O
pulled	O
back	O
the	O
curtains	O
on	O
its	O
strategy	O
a	O
bit	O
,	O
revealing	O
that	O
it	O
's	O
concentrating	O
on	O
five	O
clinical	O
vaccines	O
programs	O
as	O
a	O
way	O
of	O
introducing	O
its	O
platform	O
to	O
the	O
market	O
.	O
but	O
that	O
decision	O
is	O
also	O
raising	O
some	O
eyebrows	O
since	O
vaccines	O
are	O
inherently	O
a	O
low-margin	O
business	O
.	O
moderna	O
,	O
for	O
its	O
part	O
,	O
argues	O
that	O
it	O
's	O
playing	O
the	O
long	O
game	O
by	O
demonstrating	O
that	O
mrna	O
is	O
a	O
feasible	O
drug	O
delivery	O
method	O
that	O
can	O
be	O
used	O
to	O
make	O
a	O
wide	O
variety	O
of	O
treatments	O
.	O
(	O
endpoints	O
)	O
kite	ORG
plots	O
big	O
moves	O
into	O
asian	O
markets	O
as	O
pioneering	O
car-t	O
drug	O
nears	O
an	O
fda	ORG
filing	O
.	O
kite	ORG
pharma	ORG
,	O
which	O
is	O
locked	O
in	O
a	O
race	O
with	O
pharma	O
giant	O
novartis	ORG
to	O
be	O
the	O
first	O
company	O
with	O
an	O
approved	O
car-t	O
therapy	O
on	O
the	O
market	O
,	O
is	O
partnering	O
with	O
japan	LOC
's	O
daiichi	ORG
sankyo	O
in	O
a	O
$	O
250	O
million	O
deal	O
that	O
will	O
net	O
kite	ORG
$	O
50	O
million	O
in	O
upfront	O
cash	O
.	O
car-t	O
is	O
a	O
hot	O
new	O
space	O
in	O
cancer	O
treatment	O
which	O
involves	O
modifying	O
a	O
patient	O
's	O
immune	O
t-cells	O
to	O
target	O
cancers	O
before	O
infusing	O
the	O
re-engineered	O
cells	O
back	O
into	O
the	O
body	O
.	O
it	O
's	O
shown	O
particular	O
promise	O
in	O
blood	O
cancers	O
like	O
non-hodgkin	O
lymphoma	O
,	O
which	O
kite	ORG
is	O
targeting	O
for	O
its	O
first	O
car-t	O
approval	O
.	O
the	O
daiichi	ORG
partnership	O
will	O
give	O
kite	ORG
access	O
to	O
the	O
japanese	O
market	O
as	O
well	O
as	O
the	O
firm	O
's	O
manufacturing	O
assets	O
(	O
car-t	O
drugs	O
are	O
particularly	O
hard	O
to	O
scale	O
thanks	O
to	O
their	O
highly	O
personalized	O
nature	O
)	O
.	O
(	O
reuters	ORG
)	O
the	O
big	O
picture	O
the	O
global	O
cost	O
of	O
smoking	O
is	O
$	O
1	O
trillion	O
per	O
year	O
.	O
here	O
's	O
a	O
whopper	O
of	O
a	O
stat	O
:	O
a	O
new	O
study	O
by	O
the	O
national	ORG
cancer	ORG
institute	ORG
(	O
nci	ORG
)	O
finds	O
that	O
the	O
cost	O
of	O
smoking	O
to	O
the	O
global	O
economy	O
is	O
more	O
than	O
$	O
1	O
trillion	O
per	O
year	O
,	O
easily	O
dwarfing	O
the	O
approximately	O
$	O
269	O
billion	O
in	O
tobacco	O
taxes	O
collected	O
between	O
2013	O
and	O
2014	O
.	O
and	O
continued	O
smoking	O
growth	O
in	O
poorer	O
nations	O
will	O
contribute	O
to	O
millions	O
of	O
more	O
tobacco-related	O
deaths	O
by	O
2030	O
.	O
``	O
the	O
number	O
of	O
tobacco-related	O
deaths	O
is	O
projected	O
to	O
increase	O
from	O
about	O
6	O
million	O
deaths	O
annually	O
to	O
about	O
8	O
million	O
annually	O
by	O
2030	O
,	O
with	O
more	O
than	O
80	O
%	O
of	O
these	O
occurring	O
in	O
lmics	O
(	O
low-	O
and	O
middle-income	O
countries	O
)	O
,	O
''	O
wrote	O
the	O
study	O
authors	O
.	O
the	O
$	O
1	O
trillion-plus	O
figure	O
is	O
a	O
combination	O
of	O
preventable	O
smoking-related	O
health	O
care	O
costs	O
and	O
lost	O
productivity	O
.	O
(	O
fortune	ORG
)	O
unitedhealth	ORG
continues	O
its	O
health	O
services	O
buyout	O
spree	O
.	O
health	O
care	O
giant	O
unitedhealth	ORG
group	ORG
is	O
continuing	O
the	O
buying	O
spree	O
for	O
its	O
optum	ORG
health	O
services	O
unit	O
,	O
snapping	O
up	O
the	O
major	O
surgical	O
care	O
provider	O
surgical	ORG
care	ORG
affiliates	ORG
for	O
$	O
2.3	O
billion	O
.	O
it	O
's	O
the	O
latest	O
in	O
a	O
series	O
of	O
horizontal	O
buyouts	O
in	O
the	O
health	O
care	O
field	O
for	O
unitedhealth	ORG
group	ORG
,	O
which	O
already	O
contains	O
the	O
insurance	O
giant	O
unitedhealth	ORG
and	O
a	O
burgeoning	O
roster	O
of	O
actual	O
primary	O
care	O
and	O
ambulatory	O
service	O
providers	O
.	O
(	O
wall	ORG
street	ORG
journal	ORG
)	O
digital	O
disrupters	O
take	O
big	O
pharma	O
‘	O
beyond	O
the	O
pill	O
’	O
after	O
maggie	PERS
philyaw	PERS
developed	O
type	O
2	O
diabetes	O
,	O
she	O
found	O
solace	O
not	O
in	O
the	O
medicines	O
of	O
the	O
pharmaceutical	O
industry	O
,	O
but	O
the	O
technology	O
of	O
silicon	LOC
valley	LOC
.	O
two	O
years	O
ago	O
,	O
her	O
then	O
employer	O
in	O
north	LOC
carolina	LOC
signed	O
ms	O
philyaw	PERS
up	O
to	O
a	O
programme	O
run	O
by	O
livongo	O
health	O
,	O
a	O
california-based	O
start-up	O
,	O
which	O
gave	O
her	O
a	O
device	O
,	O
smaller	O
than	O
an	O
iphone	O
and	O
fitted	O
with	O
a	O
cellular	O
chip	O
,	O
that	O
keeps	O
track	O
of	O
her	O
blood	O
sugar	O
levels	O
.	O
using	O
the	O
latest	O
advances	O
in	O
cloud	O
computing	O
,	O
the	O
drop	O
of	O
blood	O
she	O
draws	O
each	O
day	O
is	O
instantly	O
analysed	O
,	O
and	O
a	O
text	O
telling	O
her	O
what	O
to	O
do	O
—	O
“	O
drink	O
two	O
glasses	O
of	O
water	O
and	O
walk	O
for	O
15	O
minutes	O
”	O
—	O
is	O
sent	O
if	O
her	O
readings	O
place	O
her	O
in	O
the	O
danger	O
zone	O
.	O
at	O
the	O
press	O
of	O
a	O
button	O
she	O
can	O
also	O
access	O
further	O
help	O
over	O
the	O
telephone	O
from	O
her	O
“	O
coach	O
”	O
,	O
a	O
highly	O
qualified	O
dietitian	O
who	O
has	O
managed	O
her	O
own	O
diabetes	O
for	O
more	O
than	O
40	O
years	O
.	O
for	O
the	O
titans	ORG
of	O
big	O
pharma	O
,	O
ms	O
philyaw	PERS
represents	O
omen	O
and	O
opportunity	O
,	O
as	O
a	O
disruptive	O
breed	O
of	O
digital	O
innovator	O
becomes	O
the	O
access	O
point	O
to	O
healthcare	O
for	O
hundreds	O
of	O
thousands	O
of	O
patients	O
and	O
threatens	O
to	O
undermine	O
the	O
industry	O
’	O
s	O
decades-old	O
business	O
model	O
.	O
big	O
pharma	O
has	O
long	O
focused	O
on	O
the	O
lucrative	O
business	O
of	O
drug	O
development	O
,	O
supported	ORG
by	ORG
armies	ORG
of	O
sales	O
people	O
deployed	O
to	O
persuade	O
physicians	O
to	O
choose	O
its	O
medicines	O
.	O
but	O
emerging	O
digital	O
technologies	O
are	O
reshaping	O
the	O
landscape	O
.	O
a	O
new	O
generation	O
of	O
companies	O
is	O
using	O
big	O
data	O
,	O
sensors	O
and	O
artificial	O
intelligence	O
to	O
provide	O
precise	O
real-time	O
monitoring	O
of	O
patients	O
,	O
especially	O
those	O
suffering	O
from	O
conditions	O
such	O
as	O
diabetes	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
which	O
are	O
imposing	O
a	O
daunting	O
burden	O
on	O
overstretched	O
health	O
budgets	O
.	O
as	O
a	O
result	O
of	O
the	O
products	O
and	O
services	O
these	ORG
companies	ORG
are	O
developing	O
,	O
a	O
patient	O
’	O
s	O
primary	O
point	O
of	O
contact	O
with	O
the	O
health	O
system	O
can	O
sometimes	O
now	O
be	O
a	O
remote	O
monitoring	O
centre	O
,	O
or	O
disembodied	O
voice	O
on	O
the	O
telephone	O
,	O
instead	O
of	O
a	O
doctor	O
’	O
s	O
office	O
.	O
“	O
rather	O
than	O
buying	O
a	O
pill	O
,	O
[	O
insurers	O
or	O
employers	O
]	O
might	O
buy	O
an	O
overall	O
solution	O
for	O
diabetes	O
,	O
”	O
says	O
tom	PERS
main	PERS
,	O
a	O
partner	O
in	O
7wire	ORG
ventures	ORG
,	O
a	O
venture	O
capital	O
fund	O
that	O
led	O
the	O
first	O
round	O
of	O
investment	O
in	O
livongo	O
.	O
“	O
and	O
that	O
’	O
s	O
a	O
very	O
different	O
framework	O
for	O
pharma.	O
”	O
now	O
retired	O
from	O
her	O
job	O
as	O
a	O
registered	O
nurse	O
,	O
ms	O
philyaw	PERS
pays	O
$	O
50	O
a	O
month	O
for	O
livongo	O
’	O
s	O
service	O
and	O
lives	O
free	O
of	O
medication	O
.	O
she	O
counts	O
her	O
coach	O
toby	PERS
smithson	PERS
,	O
whom	O
she	O
has	O
never	O
met	O
but	O
who	O
has	O
offered	O
practical	O
and	O
psychological	O
support	O
,	O
as	O
her	O
most	O
frequent	O
point	O
of	O
contact	O
with	O
the	O
health	O
system	O
.	O
“	O
i	O
have	O
a	O
good	O
relationship	O
with	O
my	O
physician	O
but	O
i	O
feel	O
i	O
speak	O
with	O
[	O
ms	O
smithson	PERS
]	O
more	O
often	O
,	O
”	O
she	O
says	O
.	O
“	O
having	O
a	O
coach	O
has	O
contributed	O
to	O
fewer	O
doctor	O
visits	O
and	O
less	O
money	O
spent	O
that	O
way	O
.	O
i	O
feel	O
that	O
she	O
really	O
cares	O
if	O
i	O
make	O
it	O
or	O
meet	O
my	O
goals	O
[	O
on	O
diet	O
and	O
exercise	O
]	O
”	O
,	O
she	O
adds	O
.	O
investment	O
opportunity	O
glen	PERS
tullman	PERS
,	O
chief	O
executive	O
of	O
livongo	O
,	O
says	O
as	O
recently	O
as	O
three	O
years	O
ago	O
the	O
technology	O
underpinning	O
his	O
company	O
did	O
not	O
exist	O
.	O
but	O
corporate	O
america	LOC
,	O
which	O
is	O
a	O
major	O
provider	O
of	O
health	O
insurance	O
,	O
is	O
taking	O
notice	O
.	O
more	O
than	O
half	O
the	O
companies	O
in	O
the	O
fortune	O
100	O
are	O
working	O
with	O
livongo	O
and	O
it	O
is	O
eyeing	O
expansion	O
into	O
europe	LOC
,	O
asia	LOC
and	O
canada	LOC
.	O
investors	O
are	O
starting	O
to	O
bet	O
heavily	O
on	O
the	O
potential	O
of	O
technological	O
innovation	O
to	O
transform	O
the	O
way	O
healthcare	O
is	O
delivered	O
.	O
according	O
to	O
rock	ORG
health	ORG
,	O
a	O
venture	O
fund	O
dedicated	O
to	O
digital	O
health	O
,	O
a	O
total	O
of	O
$	O
4.2bn	O
was	O
invested	O
in	O
the	O
sector	O
last	O
year	O
,	O
with	O
companies	O
in	O
the	O
analytics	O
and	O
big	O
data	O
category	O
attracting	O
$	O
341m	O
over	O
22	O
deals	O
,	O
more	O
than	O
doubled	O
from	O
2015	O
.	O
however	O
the	O
pharma	O
industry	O
will	O
have	O
to	O
grapple	O
with	O
its	O
own	O
entrenched	O
culture	O
if	O
it	O
is	O
to	O
take	O
advantage	O
of	O
the	O
expansion	O
in	O
digital	O
technologies	O
.	O
stefan	PERS
biesdorf	PERS
,	O
who	O
leads	O
mckinsey	O
’	O
s	O
digital	O
pharma	O
and	O
medical	O
technology	O
work	O
in	O
europe	LOC
,	O
says	O
the	O
margins	O
achieved	O
by	O
a	O
digital	O
health	O
business	O
are	O
small	O
compared	O
with	O
those	O
associated	O
with	O
a	O
blockbuster	ORG
drug	O
,	O
making	O
it	O
harder	O
to	O
build	O
a	O
commercial	O
case	O
for	O
investment	O
.	O
moreover	O
,	O
the	O
never-ending	O
cycle	O
of	O
tweaks	O
and	O
upgrades	O
through	O
which	O
a	O
digital	O
device	O
passes	O
is	O
foreign	O
to	O
an	O
industry	O
that	O
will	O
wait	O
more	O
than	O
a	O
decade	O
to	O
get	O
a	O
drug	O
from	O
bench	O
to	O
bedside	O
—	O
but	O
expects	O
to	O
make	O
no	O
further	O
changes	O
once	O
it	O
has	O
secured	O
regulatory	O
approval	O
.	O
nor	O
is	O
the	O
industry	O
well	O
placed	O
to	O
exploit	O
a	O
new	O
healthcare	O
universe	O
that	O
requires	O
an	O
ability	O
to	O
build	O
lasting	O
bonds	O
with	O
consumers	O
.	O
he	O
cites	O
as	O
an	O
example	O
mysugr	ORG
,	O
a	O
vienna-based	O
company	O
that	O
uses	O
a	O
similar	O
blend	O
of	O
technology	O
,	O
combined	O
with	O
on-demand	O
support	O
,	O
to	O
collect	O
data	O
directly	O
from	O
consumers	O
.	O
“	O
it	O
only	O
has	O
50	O
employees	O
but	O
it	O
has	O
much	O
,	O
much	O
,	O
more	O
in-depth	O
understanding	O
of	O
patient	O
behaviour	O
in	O
diabetes	O
than	O
probably	O
some	O
of	O
the	ORG
largest	ORG
diabetes	ORG
companies	ORG
,	O
or	ORG
insulin	ORG
producers	ORG
,	O
in	O
the	O
world	O
,	O
”	O
says	O
mr	O
biesdorf	O
.	O
joe	PERS
jimenez	PERS
,	O
chief	O
executive	O
of	O
novartis	ORG
,	O
the	O
swiss	O
drugmaker	O
that	O
is	O
widely	O
seen	O
as	O
the	O
leader	O
among	O
big	O
pharma	ORG
companies	ORG
on	O
digital	O
health	O
,	O
concedes	O
that	O
the	O
industry	O
has	O
been	O
“	O
slow	O
to	O
adopt	O
some	O
of	O
the	O
digital	O
technologies	O
,	O
compared	O
to	O
other	O
industries	O
”	O
and	O
recognises	O
“	O
a	O
risk	O
that	O
some	O
of	O
these	O
digital	O
start-ups	O
‘	O
own	O
’	O
the	O
relationship	O
with	O
the	O
physician	O
and	O
the	O
patient	O
and	O
they	O
distance	O
the	O
pharmaceutical	O
company	O
from	O
that	O
”	O
.	O
however	O
,	O
mr	O
jimenez	PERS
,	O
a	O
former	O
heinz	ORG
executive	O
whose	O
background	O
is	O
in	O
the	O
fast	O
moving	O
world	O
of	O
retail	O
,	O
says	O
the	O
industry	O
is	O
adopting	O
digital	O
technologies	O
“	O
at	O
an	O
accelerated	O
rate	O
”	O
,	O
and	O
argues	O
that	O
they	O
can	O
boast	O
a	O
base	O
of	O
knowledge	O
the	O
digital	O
minnows	O
can	O
not	O
rival	O
.	O
“	O
i	O
do	O
believe	O
that	O
large	O
pharma	ORG
companies	ORG
have	O
an	O
advantage	O
,	O
not	O
on	O
the	O
agility	O
side	O
but	O
definitely	O
on	O
what	O
they	O
know	O
about	O
disease	O
states	O
,	O
about	O
patients	O
,	O
about	O
the	O
entire	O
healthcare	O
system	O
,	O
and	O
many	O
of	O
the	O
start-ups	O
don	O
’	O
t	O
have	O
that	O
experience	O
,	O
”	O
he	O
says	O
.	O
mr	O
jimenez	PERS
adds	O
that	O
the	O
digital	O
exemplars	O
are	O
“	O
definitely	O
either	O
potential	O
competitors	O
or	O
they	O
will	O
become	O
partners	O
”	O
.	O
a	O
flurry	O
of	O
deals	O
in	O
recent	O
years	O
shows	O
that	O
some	O
pharma	O
groups	O
are	O
racing	O
to	O
boost	O
digital	O
capability	O
,	O
by	O
buying	O
companies	O
that	O
offer	O
ready-made	O
expertise	O
,	O
or	O
entering	O
into	O
partnerships	O
as	O
they	O
seek	O
to	O
offer	O
services	O
“	O
beyond	O
the	O
pill	O
”	O
.	O
teva	ORG
pharmaceuticals	ORG
showed	O
the	O
way	O
in	O
2015	O
when	O
it	O
announced	O
it	O
was	O
buying	O
gecko	O
health	O
innovations	O
for	O
an	O
undisclosed	O
sum	O
.	O
the	O
lure	O
was	O
gecko	O
’	O
s	O
main	O
product	O
,	O
caretrx	O
,	O
a	O
platform	O
to	O
help	O
chronic	O
sufferers	O
from	O
respiratory	O
disease	O
,	O
which	O
combines	O
a	O
sensor	O
device	O
that	O
connects	O
to	O
most	O
inhalers	O
with	O
a	O
data	O
analytics	O
function	O
.	O
meanwhile	O
,	O
the	O
french	O
drugmaker	O
sanofi	ORG
recently	O
joined	O
forces	O
with	O
verily	ORG
life	O
sciences	O
to	O
work	O
on	O
devices	O
and	O
patient	O
support	O
for	O
diabetics	O
,	O
and	O
pfizer	ORG
is	O
working	O
with	O
ibm	ORG
watson	O
as	O
part	O
of	O
its	O
work	O
on	O
immuno-oncology	O
,	O
using	O
its	O
expertise	O
in	O
data	O
analytics	O
to	O
identify	O
new	O
drug	O
targets	O
.	O
erik	PERS
nordkamp	PERS
,	O
the	O
uk	LOC
head	O
of	O
pfizer	ORG
,	O
says	O
the	O
future	O
of	O
healthcare	O
will	O
involve	O
“	O
a	O
convergence	O
of	O
technologies	O
to	O
come	O
to	O
better	O
solutions	O
”	O
.	O
“	O
both	O
locally	O
and	O
globally	O
we	O
are	O
.	O
.	O
.	O
having	O
discussions	O
with	O
some	O
of	O
these	ORG
companies	ORG
to	O
say	O
,	O
‘	O
what	O
could	O
that	O
future	O
look	O
like	O
?	O
’	O
,	O
”	O
he	O
says	O
.	O
reaching	O
the	O
patients	O
it	O
is	O
still	O
early	O
days	O
for	O
big	O
pharma	O
’	O
s	O
digital	O
push	O
.	O
even	O
novartis	ORG
,	O
whose	O
investment	O
in	O
cutting-edge	O
technology	O
is	O
informing	O
everything	O
it	O
does	O
,	O
has	O
yet	O
to	O
bring	O
any	O
digitally	O
enabled	O
products	O
to	O
the	O
mass	O
market	O
.	O
one	O
promising	O
programme	O
centres	O
on	O
its	O
heart	O
disease	O
drug	O
entresto	O
,	O
which	O
has	O
been	O
found	O
to	O
reduce	O
hospitalisation	O
and	O
cardiovascular	O
death	O
by	O
20	O
per	O
cent	O
.	O
it	O
has	O
formed	O
a	O
joint	O
venture	O
with	O
sanitas	ORG
,	O
a	ORG
swiss	ORG
health	ORG
insurer	ORG
,	O
to	O
offer	O
remote	O
monitoring	O
and	O
coaching	O
for	O
patients	O
with	O
advanced	O
heart	O
failure	O
.	O
yet	O
progress	O
is	O
slow	O
.	O
a	O
pilot	O
project	O
features	O
only	O
50	O
patients	O
and	O
will	O
be	O
extended	O
only	O
gradually	O
in	O
the	O
coming	O
months	O
.	O
livongo	O
,	O
by	O
comparison	O
,	O
has	O
35,000	O
“	O
members	O
”	O
,	O
as	O
it	O
terms	O
its	O
users	O
.	O
mr	O
jimenez	PERS
points	O
to	O
other	O
novartis	ORG
initiatives	O
such	O
as	O
the	O
breezhaler	O
,	O
a	O
wireless	O
enabled	O
asthma	O
inhaler	O
,	O
and	O
a	O
“	O
smart	O
”	O
contact	O
lens	O
that	O
can	O
detect	O
blood	O
glucose	O
levels	O
through	O
tears	O
,	O
obviating	O
the	O
need	O
to	O
draw	O
blood	O
,	O
which	O
will	O
be	O
“	O
much	O
less	O
labour-intensive	O
and	O
much	O
easier	O
to	O
roll	O
out	O
very	O
quickly	O
”	O
.	O
however	O
,	O
last	O
year	O
trials	O
of	O
the	O
diabetic	O
lens	O
were	O
postponed	O
with	O
no	O
firm	O
replacement	O
date	O
and	O
novartis	ORG
is	O
widely	O
thought	O
to	O
be	O
considering	O
the	O
sale	O
of	O
alcon	ORG
,	O
its	ORG
eyecare	ORG
unit	ORG
.	O
(	O
the	O
company	O
says	O
it	O
is	O
“	O
reviewing	O
strategic	O
options	O
for	O
the	O
alcon	ORG
division	ORG
to	O
maximise	O
shareholder	O
value	O
”	O
.	O
)	O
the	O
imperative	O
to	O
develop	O
a	O
capability	O
in	O
this	O
field	O
is	O
becoming	O
stronger	O
as	O
health	O
systems	O
demand	O
hard	O
evidence	O
that	O
a	O
drug	O
is	O
effective	O
and	O
will	O
ease	O
strain	O
on	O
the	O
budget	O
—	O
for	O
example	O
by	O
reducing	O
hospital	O
stays	O
.	O
mr	O
jimenez	PERS
says	O
the	O
prospect	O
of	O
these	O
new	O
payment	O
structures	O
makes	O
big	O
pharma	O
“	O
quite	O
nervous	O
.	O
they	O
say	O
,	O
‘	O
if	O
i	O
’	O
m	O
going	O
to	O
be	O
paid	O
on	O
the	O
outcome	O
of	O
a	O
patient	O
’	O
s	O
health	O
,	O
then	O
i	O
want	O
to	O
be	O
able	O
to	O
control	O
patient	O
adherence	O
,	O
for	O
example	O
,	O
because	O
if	O
that	O
patient	O
doesn	O
’	O
t	O
take	O
their	O
medicine	O
,	O
then	O
that	O
means	O
i	O
won	O
’	O
t	O
get	O
paid	O
’	O
.	O
”	O
he	O
estimates	O
that	O
about	O
25	O
per	O
cent	O
of	O
all	O
health	O
spending	O
,	O
including	O
on	O
pharmaceuticals	O
,	O
“	O
is	O
not	O
contributing	O
towards	O
a	O
positive	O
patient	O
outcome	O
”	O
.	O
lars	PERS
fruergaard	PERS
jorgensen	PERS
,	O
chief	O
executive	O
of	O
novo	ORG
nordisk	ORG
,	O
the	O
world	O
’	O
s	O
biggest	O
insulin	O
maker	O
,	O
suggests	O
this	O
is	O
the	O
missing	O
piece	O
for	O
all	O
drugmakers	O
.	O
“	O
we	O
have	O
spent	O
more	O
than	O
90	O
years	O
refining	O
the	O
molecules	O
,	O
yet	O
we	O
have	O
less	O
than	O
10	O
per	O
cent	O
of	O
our	O
patients	O
in	O
a	O
level	O
of	O
control	O
that	O
would	O
eliminate	O
the	O
risk	O
of	O
late-stage	O
complications	O
and	O
that	O
’	O
s	O
not	O
good	O
enough.	O
”	O
it	O
has	O
teamed	O
up	O
with	O
glooko	ORG
,	O
a	O
silicon	LOC
valley	LOC
company	O
that	O
helps	O
patients	O
manage	O
diabetes	O
,	O
to	O
develop	O
an	O
app	O
that	O
will	O
allow	O
sufferers	O
continuously	O
to	O
monitor	O
their	O
blood	O
glucose	O
levels	O
.	O
through	ORG
another	ORG
partnership	ORG
,	O
with	O
ibm	ORG
watson	O
,	O
it	O
will	O
gather	O
data	O
about	O
the	O
impact	O
of	O
its	O
insulin	O
,	O
and	O
patient	O
compliance	O
,	O
that	O
will	O
provide	O
“	O
an	O
increased	O
comfort	O
level	O
”	O
that	O
it	O
can	O
balance	O
the	O
risks	O
and	O
rewards	O
in	O
future	O
outcomes-based	O
contracts	O
.	O
patients	O
who	O
have	O
better	O
knowledge	O
about	O
their	O
health	O
will	O
“	O
also	O
treat	O
[	O
themselves	O
]	O
better	O
,	O
which	O
would	O
lead	O
to	O
higher	O
use	O
of	O
high	O
quality	O
insulin	O
from	O
novo	ORG
nordisk	ORG
”	O
,	O
he	O
adds	O
.	O
one	O
of	O
the	O
biggest	O
problems	O
for	O
the	O
industry	O
,	O
however	O
,	O
is	O
whether	O
an	O
app	O
produced	O
by	O
a	O
pharmaceutical	O
company	O
—	O
and	O
related	O
to	O
a	O
single	O
branded	O
medicine	O
—	O
would	O
generate	O
the	O
same	O
degree	O
of	O
loyalty	O
from	O
patients	O
and	O
their	O
doctors	O
as	O
those	O
produced	O
by	O
an	O
independent	O
start-up	O
.	O
in	O
north	LOC
carolina	LOC
,	O
ms	O
philyaw	PERS
expresses	O
just	O
such	O
reservations	O
.	O
“	O
personally	O
i	O
probably	O
would	O
prefer	O
a	O
more	O
neutral	O
ground	O
that	O
wasn	O
’	O
t	O
connected	O
to	O
a	O
drug	O
,	O
”	O
she	O
says	O
.	O
at	O
livongo	O
,	O
mr	O
tullman	PERS
is	O
planning	O
to	O
extend	O
its	O
service	O
to	O
cover	O
at	O
least	O
two	O
more	O
conditions	O
by	O
the	O
end	O
of	O
the	O
year	O
.	O
in	O
a	O
comparison	O
that	O
may	O
resonate	O
in	O
the	O
boardrooms	O
of	O
pharma	ORG
companies	ORG
,	O
as	O
they	O
frame	O
their	O
response	O
to	O
the	O
digital	O
revolution	ORG
,	O
he	O
likens	O
the	O
impact	O
of	O
these	O
health	O
technologies	O
to	O
that	O
of	O
uber	O
,	O
which	O
created	O
a	O
whole	O
new	O
market	O
.	O
“	O
everybody	O
said	O
it	O
’	O
s	O
going	O
to	O
take	O
the	O
place	O
of	O
the	O
traditional	O
taxi	O
but	O
actually	O
in	O
the	O
us	LOC
people	O
are	O
using	O
uber	O
who	O
would	O
have	O
never	O
used	O
a	O
taxi	O
before.	O
”	O
he	O
adds	O
:	O
“	O
all	O
of	O
a	O
sudden	O
we	O
can	O
keep	O
people	O
healthier	O
.	O
”	O
digital	O
disrupters	O
take	O
big	O
pharma	O
beyond	O
the	O
pill	O
after	O
maggie	PERS
philyaw	PERS
developed	O
type	O
2	O
diabetes	O
,	O
she	O
found	O
solace	O
not	O
in	O
the	O
medicines	O
of	O
the	O
pharmaceutical	O
industry	O
,	O
but	O
the	O
technology	O
of	O
silicon	LOC
valley	LOC
.	O
two	O
years	O
ago	O
,	O
her	O
then	O
employer	O
in	O
north	LOC
carolina	LOC
signed	O
ms	O
philyaw	PERS
up	O
to	O
a	O
programme	O
run	O
by	O
livongo	O
health	O
,	O
a	O
california-based	O
start-up	O
,	O
which	O
gave	O
her	O
a	O
device	O
,	O
smaller	O
than	O
an	O
iphone	O
and	O
fitted	O
with	O
a	O
cellular	O
chip	O
,	O
that	O
keeps	O
track	O
of	O
her	O
blood	O
sugar	O
levels	O
.	O
using	O
the	O
latest	O
advances	O
in	O
cloud	O
computing	O
,	O
the	O
drop	O
of	O
blood	O
she	O
draws	O
each	O
day	O
is	O
instantly	O
analysed	O
,	O
and	O
a	O
text	O
telling	O
her	O
what	O
to	O
do	O
—	O
“	O
drink	O
two	O
glasses	O
of	O
water	O
and	O
walk	O
for	O
15	O
minutes	O
”	O
—	O
is	O
sent	O
if	O
her	O
readings	O
place	O
her	O
in	O
the	O
danger	O
zone	O
.	O
at	O
the	O
press	O
of	O
a	O
button	O
she	O
can	O
also	O
access	O
further	O
help	O
over	O
the	O
telephone	O
from	O
her	O
“	O
coach	O
”	O
,	O
a	O
highly	O
qualified	O
dietitian	O
who	O
has	O
managed	O
her	O
own	O
diabetes	O
for	O
more	O
than	O
40	O
years	O
.	O
for	O
the	O
titans	O
of	O
big	O
pharma	O
,	O
ms	O
philyaw	PERS
represents	O
omen	O
and	O
opportunity	O
,	O
as	O
a	O
disruptive	O
breed	O
of	O
digital	O
innovator	O
becomes	O
the	O
access	O
point	O
to	O
healthcare	O
for	O
hundreds	O
of	O
thousands	O
of	O
patients	O
and	O
threatens	O
to	O
undermine	O
the	O
industry	O
’	O
s	O
decades-old	O
business	O
model	O
.	O
big	O
pharma	O
has	O
long	O
focused	O
on	O
the	O
lucrative	O
business	O
of	O
drug	O
development	O
,	O
supported	O
by	O
armies	O
of	O
sales	O
people	O
deployed	O
to	O
persuade	O
physicians	O
to	O
choose	O
its	O
medicines	O
.	O
but	O
emerging	O
digital	O
technologies	O
are	O
reshaping	O
the	O
landscape	O
.	O
a	O
new	O
generation	O
of	O
companies	O
is	O
using	O
big	O
data	O
,	O
sensors	O
and	O
artificial	O
intelligence	O
to	O
provide	O
precise	O
real-time	O
monitoring	O
of	O
patients	O
,	O
especially	O
those	O
suffering	O
from	O
conditions	O
such	O
as	O
diabetes	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
which	O
are	O
imposing	O
a	O
daunting	O
burden	O
on	O
overstretched	O
health	O
budgets	O
.	O
as	O
a	O
result	O
of	O
the	O
products	O
and	O
services	O
these	O
companies	O
are	O
developing	O
,	O
a	O
patient	O
’	O
s	O
primary	O
point	O
of	O
contact	O
with	O
the	O
health	O
system	O
can	O
sometimes	O
now	O
be	O
a	O
remote	O
monitoring	O
centre	O
,	O
or	O
disembodied	O
voice	O
on	O
the	O
telephone	O
,	O
instead	O
of	O
a	O
doctor	O
’	O
s	O
office	O
.	O
“	O
rather	O
than	O
buying	O
a	O
pill	O
,	O
[	O
insurers	O
or	O
employers	O
]	O
might	O
buy	O
an	O
overall	O
solution	O
for	O
diabetes	O
,	O
”	O
says	O
tom	PERS
main	PERS
,	O
a	O
partner	O
in	O
7wire	ORG
ventures	ORG
,	O
a	O
venture	O
capital	O
fund	O
that	O
led	O
the	O
first	O
round	O
of	O
investment	O
in	O
livongo	O
.	O
“	O
and	O
that	O
’	O
s	O
a	O
very	O
different	O
framework	O
for	O
pharma.	O
”	O
now	O
retired	O
from	O
her	O
job	O
as	O
a	O
registered	O
nurse	O
,	O
ms	O
philyaw	PERS
pays	O
$	O
50	O
a	O
month	O
for	O
livongo	O
’	O
s	O
service	O
and	O
lives	O
free	O
of	O
medication	O
.	O
she	O
counts	O
her	O
coach	O
toby	PERS
smithson	PERS
,	O
whom	O
she	O
has	O
never	O
met	O
but	O
who	O
has	O
offered	O
practical	O
and	O
psychological	O
support	O
,	O
as	O
her	O
most	O
frequent	O
point	O
of	O
contact	O
with	O
the	O
health	O
system	O
.	O
“	O
i	O
have	O
a	O
good	O
relationship	O
with	O
my	O
physician	O
but	O
i	O
feel	O
i	O
speak	O
with	O
[	O
ms	O
smithson	PERS
]	O
more	O
often	O
,	O
”	O
she	O
says	O
.	O
“	O
having	O
a	O
coach	O
has	O
contributed	O
to	O
fewer	O
doctor	O
visits	O
and	O
less	O
money	O
spent	O
that	O
way	O
.	O
i	O
feel	O
that	O
she	O
really	O
cares	O
if	O
i	O
make	O
it	O
or	O
meet	O
my	O
goals	O
[	O
on	O
diet	O
and	O
exercise	O
]	O
”	O
,	O
she	O
adds	O
.	O
***	O
glen	PERS
tullman	PERS
,	O
chief	O
executive	O
of	O
livongo	O
,	O
says	O
as	O
recently	O
as	O
three	O
years	O
ago	O
the	O
technology	O
underpinning	O
his	O
company	O
did	O
not	O
exist	O
.	O
but	O
corporate	O
america	LOC
,	O
which	O
is	O
a	O
major	O
provider	O
of	O
health	O
insurance	O
,	O
is	O
taking	O
notice	O
.	O
more	O
than	O
half	O
the	O
companies	O
in	O
the	O
fortune	O
100	O
are	O
working	O
with	O
livongo	O
and	O
it	O
is	O
eyeing	O
expansion	O
into	O
europe	LOC
,	O
asia	LOC
and	O
canada	LOC
.	O
investors	O
are	O
starting	O
to	O
bet	O
heavily	O
on	O
the	O
potential	O
of	O
technological	O
innovation	O
to	O
transform	O
the	O
way	O
healthcare	O
is	O
delivered	O
.	O
according	O
to	O
rock	ORG
health	ORG
,	O
a	O
venture	O
fund	O
dedicated	O
to	O
digital	O
health	O
,	O
a	O
total	O
of	O
$	O
4.2bn	O
was	O
invested	O
in	O
the	O
sector	O
last	O
year	O
,	O
with	O
companies	O
in	O
the	O
analytics	O
and	O
big	O
data	O
category	O
attracting	O
$	O
341m	O
over	O
22	O
deals	O
,	O
more	O
than	O
doubled	O
from	O
2015	O
.	O
however	O
the	O
pharma	O
industry	O
will	O
have	O
to	O
grapple	O
with	O
its	O
own	O
entrenched	O
culture	O
if	O
it	O
is	O
to	O
take	O
advantage	O
of	O
the	O
expansion	O
in	O
digital	O
technologies	O
.	O
stefan	PERS
biesdorf	PERS
,	O
who	O
leads	O
mckinsey	ORG
’	O
s	O
digital	O
pharma	O
and	O
medical	O
technology	O
work	O
in	O
europe	LOC
,	O
says	O
the	O
margins	O
achieved	O
by	O
a	O
digital	O
health	O
business	O
are	O
small	O
compared	O
with	O
those	O
associated	O
with	O
a	O
blockbuster	O
drug	O
,	O
making	O
it	O
harder	O
to	O
build	O
a	O
commercial	O
case	O
for	O
investment	O
.	O
moreover	O
,	O
the	O
never-ending	O
cycle	O
of	O
tweaks	O
and	O
upgrades	O
through	O
which	O
a	O
digital	O
device	O
passes	O
is	O
foreign	O
to	O
an	O
industry	O
that	O
will	O
wait	O
more	O
than	O
a	O
decade	O
to	O
get	O
a	O
drug	O
from	O
bench	O
to	O
bedside	O
—	O
but	O
expects	O
to	O
make	O
no	O
further	O
changes	O
once	O
it	O
has	O
secured	O
regulatory	O
approval	O
.	O
nor	O
is	O
the	O
industry	O
well	O
placed	O
to	O
exploit	O
a	O
new	O
healthcare	O
universe	O
that	O
requires	O
an	O
ability	O
to	O
build	O
lasting	O
bonds	O
with	O
consumers	O
.	O
he	O
cites	O
as	O
an	O
example	O
mysugr	ORG
,	O
a	O
vienna-based	O
company	O
that	O
uses	O
a	O
similar	O
blend	O
of	O
technology	O
,	O
combined	O
with	O
on-demand	O
support	O
,	O
to	O
collect	O
data	O
directly	O
from	O
consumers	O
.	O
“	O
it	O
only	O
has	O
50	O
employees	O
but	O
it	O
has	O
much	O
,	O
much	O
,	O
more	O
in-depth	O
understanding	O
of	O
patient	O
behaviour	O
in	O
diabetes	O
than	O
probably	O
some	O
of	O
the	O
largest	O
diabetes	O
companies	O
,	O
or	O
insulin	O
producers	O
,	O
in	O
the	O
world	O
,	O
”	O
says	O
mr	O
biesdorf	O
.	O
joe	ORG
jimenez	ORG
,	O
chief	O
executive	O
of	O
novartis	ORG
,	O
the	O
swiss	O
drugmaker	O
that	O
is	O
widely	O
seen	O
as	O
the	O
leader	O
among	O
big	O
pharma	O
companies	O
on	O
digital	O
health	O
,	O
concedes	O
that	O
the	O
industry	O
has	O
been	O
“	O
slow	O
to	O
adopt	O
some	O
of	O
the	O
digital	O
technologies	O
,	O
compared	O
to	O
other	O
industries	O
”	O
and	O
recognises	O
“	O
a	O
risk	O
that	O
some	O
of	O
these	O
digital	O
start-ups	O
‘	O
own	O
’	O
the	O
relationship	O
with	O
the	O
physician	O
and	O
the	O
patient	O
and	O
they	O
distance	O
the	O
pharmaceutical	O
company	O
from	O
that	O
”	O
.	O
however	O
,	O
mr	O
jimenez	PERS
,	O
a	O
former	O
heinz	ORG
executive	O
whose	O
background	O
is	O
in	O
the	O
fast	O
moving	O
world	O
of	O
retail	O
,	O
says	O
the	O
industry	O
is	O
adopting	O
digital	O
technologies	O
“	O
at	O
an	O
accelerated	O
rate	O
”	O
,	O
and	O
argues	O
that	O
they	O
can	O
boast	O
a	O
base	O
of	O
knowledge	O
the	O
digital	O
minnows	O
can	O
not	O
rival	O
.	O
“	O
i	O
do	O
believe	O
that	O
large	O
pharma	O
companies	O
have	O
an	O
advantage	O
,	O
not	O
on	O
the	O
agility	O
side	O
but	O
definitely	O
on	O
what	O
they	O
know	O
about	O
disease	O
states	O
,	O
about	O
patients	O
,	O
about	O
the	O
entire	O
healthcare	O
system	O
,	O
and	O
many	O
of	O
the	O
start-ups	O
don	O
’	O
t	O
have	O
that	O
experience	O
,	O
”	O
he	O
says	O
.	O
mr	O
jimenez	PERS
adds	O
that	O
the	O
digital	O
exemplars	O
are	O
“	O
definitely	O
either	O
potential	O
competitors	O
or	O
they	O
will	O
become	O
partners	O
”	O
.	O
a	O
flurry	O
of	O
deals	O
in	O
recent	O
years	O
shows	O
that	O
some	O
pharma	O
groups	O
are	O
racing	O
to	O
boost	O
digital	O
capability	O
,	O
by	O
buying	O
companies	O
that	O
offer	O
ready-made	O
expertise	O
,	O
or	O
entering	O
into	O
partnerships	O
as	O
they	O
seek	O
to	O
offer	O
services	O
“	O
beyond	O
the	O
pill	O
”	O
.	O
teva	ORG
pharmaceuticals	ORG
showed	O
the	O
way	O
in	O
2015	O
when	O
it	O
announced	O
it	O
was	O
buying	O
gecko	O
health	O
innovations	O
for	O
an	O
undisclosed	O
sum	O
.	O
the	O
lure	O
was	O
gecko	O
’	O
s	O
main	O
product	O
,	O
caretrx	O
,	O
a	O
platform	O
to	O
help	O
chronic	O
sufferers	O
from	O
respiratory	O
disease	O
,	O
which	O
combines	O
a	O
sensor	O
device	O
that	O
connects	O
to	O
most	O
inhalers	O
with	O
a	O
data	O
analytics	O
function	O
.	O
meanwhile	O
,	O
the	O
french	O
drugmaker	O
sanofi	ORG
recently	O
joined	O
forces	O
with	O
verily	ORG
life	ORG
sciences	ORG
to	O
work	O
on	O
devices	O
and	O
patient	O
support	O
for	O
diabetics	O
,	O
and	O
pfizer	ORG
is	O
working	O
with	O
ibm	ORG
watson	O
as	O
part	O
of	O
its	O
work	O
on	O
immuno-oncology	O
,	O
using	O
its	O
expertise	O
in	O
data	O
analytics	O
to	O
identify	O
new	O
drug	O
targets	O
.	O
erik	PERS
nordkamp	PERS
,	O
the	O
uk	LOC
head	O
of	O
pfizer	ORG
,	O
says	O
the	O
future	O
of	O
healthcare	O
will	O
involve	O
“	O
a	O
convergence	O
of	O
technologies	O
to	O
come	O
to	O
better	O
solutions	O
”	O
.	O
“	O
both	O
locally	O
and	O
globally	O
we	O
are	O
.	O
.	O
.	O
having	O
discussions	O
with	O
some	O
of	O
these	O
companies	O
to	O
say	O
,	O
‘	O
what	O
could	O
that	O
future	O
look	O
like	O
?	O
’	O
,	O
”	O
he	O
says	O
.	O
***	O
it	O
is	O
still	O
early	O
days	O
for	O
big	O
pharma	O
’	O
s	O
digital	O
push	O
.	O
even	O
novartis	ORG
,	O
which	O
says	O
it	O
investment	O
in	O
cutting-edge	O
technology	O
is	O
informing	O
everything	O
it	O
does	O
,	O
has	O
yet	O
to	O
bring	O
any	O
digitally	O
enabled	O
products	O
to	O
the	O
mass	O
market	O
.	O
one	O
promising	O
programme	O
centres	O
on	O
its	O
heart	O
disease	O
drug	O
entresto	O
,	O
which	O
has	O
been	O
found	O
to	O
reduce	O
hospitalisation	O
and	O
cardiovascular	O
death	O
by	O
20	O
per	O
cent	O
.	O
it	O
has	O
formed	O
a	O
joint	O
venture	O
with	O
sanitas	ORG
,	O
a	O
swiss	O
health	O
insurer	O
,	O
to	O
offer	O
remote	O
monitoring	O
and	O
coaching	O
for	O
patients	O
with	O
advanced	O
heart	O
failure	O
.	O
yet	O
progress	O
is	O
slow	O
.	O
a	O
pilot	O
project	O
features	O
only	O
50	O
patients	O
and	O
will	O
be	O
extended	O
only	O
gradually	O
in	O
the	O
coming	O
months	O
.	O
livongo	O
,	O
by	O
comparison	O
,	O
has	O
35,000	O
“	O
members	O
”	O
,	O
as	O
it	O
terms	O
its	O
users	O
.	O
mr	O
jimenez	PERS
points	O
to	O
other	O
novartis	ORG
initiatives	O
such	O
as	O
the	O
breezhaler	O
,	O
a	O
wireless	O
enabled	O
asthma	O
inhaler	O
,	O
and	O
a	O
“	O
smart	O
”	O
contact	O
lens	O
that	O
can	O
detect	O
blood	O
glucose	O
levels	O
through	O
tears	O
,	O
obviating	O
the	O
need	O
to	O
draw	O
blood	O
,	O
which	O
will	O
be	O
“	O
much	O
less	O
labour-intensive	O
and	O
much	O
easier	O
to	O
roll	O
out	O
very	O
quickly	O
”	O
.	O
however	O
,	O
last	O
year	O
trials	O
of	O
the	O
diabetic	O
lens	O
were	O
postponed	O
with	O
no	O
firm	O
replacement	O
date	O
and	O
novartis	ORG
is	O
widely	O
thought	O
to	O
be	O
considering	O
the	O
sale	O
of	O
alcon	ORG
,	O
its	O
eyecare	O
unit	O
.	O
(	O
the	O
company	O
says	O
it	O
is	O
“	O
reviewing	O
strategic	O
options	O
for	O
the	O
alcon	ORG
division	O
to	O
maximise	O
shareholder	O
value	O
”	O
.	O
)	O
the	O
imperative	O
to	O
develop	O
a	O
capability	O
in	O
this	O
field	O
is	O
becoming	O
stronger	O
as	O
health	O
systems	O
demand	O
hard	O
evidence	O
that	O
a	O
drug	O
is	O
effective	O
and	O
will	O
ease	O
strain	O
on	O
the	O
budget	O
—	O
for	O
example	O
by	O
reducing	O
hospital	O
stays	O
.	O
mr	O
jimenez	PERS
says	O
the	O
prospect	O
of	O
these	O
new	O
payment	O
structures	O
makes	O
big	O
pharma	O
“	O
quite	O
nervous	O
.	O
they	O
say	O
,	O
‘	O
if	O
i	O
’	O
m	O
going	O
to	O
be	O
paid	O
on	O
the	O
outcome	O
of	O
a	O
patient	O
’	O
s	O
health	O
,	O
then	O
i	O
want	O
to	O
be	O
able	O
to	O
control	O
patient	O
adherence	O
,	O
for	O
example	O
,	O
because	O
if	O
that	O
patient	O
doesn	O
’	O
t	O
take	O
their	O
medicine	O
,	O
then	O
that	O
means	O
i	O
won	O
’	O
t	O
get	O
paid	O
’	O
.	O
”	O
he	O
estimates	O
that	O
about	O
25	O
per	O
cent	O
of	O
all	O
health	O
spending	O
,	O
including	O
on	O
pharmaceuticals	O
,	O
“	O
is	O
not	O
contributing	O
towards	O
a	O
positive	O
patient	O
outcome	O
”	O
.	O
lars	PERS
fruergaard	PERS
jorgensen	PERS
,	O
chief	O
executive	O
of	O
novo	ORG
nordisk	ORG
,	O
the	O
world	O
’	O
s	O
biggest	O
insulin	O
maker	O
,	O
suggests	O
this	O
is	O
the	O
missing	O
piece	O
for	O
all	O
drugmakers	O
.	O
“	O
we	O
have	O
spent	O
more	O
than	O
90	O
years	O
refining	O
the	O
molecules	O
,	O
yet	O
we	O
have	O
less	O
than	O
10	O
per	O
cent	O
of	O
our	O
patients	O
in	O
a	O
level	O
of	O
control	O
that	O
would	O
eliminate	O
the	O
risk	O
of	O
late-stage	O
complications	O
and	O
that	O
’	O
s	O
not	O
good	O
enough.	O
”	O
it	O
has	O
teamed	O
up	O
with	O
glooko	O
,	O
a	O
silicon	LOC
valley	LOC
company	O
that	O
helps	O
patients	O
manage	O
diabetes	O
,	O
to	O
develop	O
an	O
app	O
that	O
will	O
allow	O
sufferers	O
continuously	O
to	O
monitor	O
their	O
blood	O
glucose	O
levels	O
.	O
through	O
another	O
partnership	O
,	O
with	O
ibm	ORG
watson	O
,	O
it	O
will	O
gather	O
data	O
about	O
the	O
impact	O
of	O
its	O
insulin	O
,	O
and	O
patient	O
compliance	O
,	O
that	O
will	O
provide	O
“	O
an	O
increased	O
comfort	O
level	O
”	O
that	O
it	O
can	O
balance	O
the	O
risks	O
and	O
rewards	O
in	O
future	O
outcomes-based	O
contracts	O
.	O
patients	O
who	O
have	O
better	O
knowledge	O
about	O
their	O
health	O
will	O
“	O
also	O
treat	O
[	O
themselves	O
]	O
better	O
,	O
which	O
would	O
lead	O
to	O
higher	O
use	O
of	O
high	O
quality	O
insulin	O
from	O
novo	ORG
nordisk	ORG
”	O
,	O
he	O
adds	O
.	O
one	O
of	O
the	O
biggest	O
problems	O
for	O
the	O
industry	O
,	O
however	O
,	O
is	O
whether	O
an	O
app	O
produced	O
by	O
a	O
pharmaceutical	O
company	O
—	O
and	O
related	O
to	O
a	O
single	O
branded	O
medicine	O
—	O
would	O
generate	O
the	O
same	O
degree	O
of	O
loyalty	O
from	O
patients	O
and	O
their	O
doctors	O
as	O
those	O
produced	O
by	O
an	O
independent	O
start-up	O
.	O
in	O
north	LOC
carolina	LOC
,	O
ms	O
philyaw	PERS
expresses	O
just	O
such	O
reservations	O
.	O
“	O
personally	O
i	O
probably	O
would	O
prefer	O
a	O
more	O
neutral	O
ground	O
that	O
wasn	O
’	O
t	O
connected	O
to	O
a	O
drug	O
,	O
”	O
she	O
says	O
.	O
at	O
livongo	O
,	O
mr	O
tullman	PERS
is	O
planning	O
to	O
extend	O
its	O
service	O
to	O
cover	O
at	O
least	O
two	O
more	O
conditions	O
by	O
the	O
end	O
of	O
the	O
year	O
.	O
in	O
a	O
comparison	O
that	O
may	O
resonate	O
in	O
the	O
boardrooms	O
of	O
pharma	O
companies	O
,	O
as	O
they	O
frame	O
their	O
response	O
to	O
the	O
digital	O
revolution	O
,	O
he	O
likens	O
the	O
impact	O
of	O
these	O
health	O
technologies	O
to	O
that	O
of	O
uber	O
,	O
which	O
created	O
a	O
whole	O
new	O
market	O
.	O
“	O
everybody	O
said	O
it	O
’	O
s	O
going	O
to	O
take	O
the	O
place	O
of	O
the	O
traditional	O
taxi	O
but	O
actually	O
in	O
the	O
us	LOC
people	O
are	O
using	O
uber	O
who	O
would	O
have	O
never	O
used	O
a	O
taxi	O
before.	O
”	O
he	O
adds	O
:	O
“	O
all	O
of	O
a	O
sudden	O
we	O
can	O
keep	O
people	O
healthier.	O
”	O
while	O
some	O
pharmaceutical	O
industry	O
executives	O
remain	O
uncertain	O
how	O
to	O
respond	O
to	O
the	O
digital	O
health	O
revolution	O
,	O
the	O
danger	O
that	O
tech	O
groups	O
may	O
steal	O
a	O
march	O
by	O
collecting	O
valuable	O
data	O
on	O
their	O
patients	O
serves	O
as	O
a	O
powerful	O
spur	O
to	O
action	O
.	O
andrew	PERS
baum	PERS
,	O
head	O
of	O
global	O
healthcare	O
at	O
citigroup	ORG
,	O
says	O
the	O
industry	O
is	O
well	O
aware	O
that	O
companies	O
such	O
as	O
google	ORG
,	O
baiduand	O
yahooare	O
investing	O
heavily	O
in	O
artificial	O
intelligence	O
and	O
machine	O
learning	O
to	O
gain	O
insights	O
into	O
patient	O
behaviour	O
and	O
responses	O
to	O
disease	O
.	O
“	O
the	O
industry	O
is	O
not	O
quite	O
sure	O
how	O
to	O
engage	O
,	O
because	O
[	O
digital	O
health	O
]	O
is	O
not	O
really	O
their	O
core	O
competence	O
.	O
but	O
on	O
the	O
other	O
hand	O
,	O
they	O
don	O
’	O
t	O
want	O
someone	O
else	O
to	O
control	O
the	O
data	O
,	O
”	O
he	O
says.stefan	O
biesdorf	O
,	O
a	O
,	O
principal	O
at	O
mckinsey	ORG
,	O
adds	O
:	O
“	O
in	O
digital	O
health	O
the	O
winners	O
are	O
going	O
to	O
be	O
the	O
companies	O
that	O
sit	O
on	O
the	O
largest	O
amount	O
of	O
patient-level	O
,	O
granular	O
data	O
.	O
.	O
.	O
a	O
lot	O
of	O
players	O
are	O
taking	O
and	O
building	O
a	O
position	O
in	O
the	O
market.	O
”	O
ibm	ORG
,	O
for	O
example	O
,	O
has	O
recently	O
acquired	O
,	O
for	O
several	O
billion	O
dollars	O
,	O
four	O
companies	O
—	O
truven	O
,	O
explorys	O
,	O
mergeand	O
phytel—	O
that	O
between	O
them	O
own	O
large	O
amounts	O
of	O
health	O
data	O
.	O
some	O
pharma	O
companies	O
are	O
partnering	O
with	O
the	O
major	O
tech	O
groups	O
.	O
novartisis	O
working	O
with	O
google	ORG
healthon	O
a	O
smart	O
contact	O
lens	O
.	O
“	O
the	O
data	O
are	O
key	O
to	O
assessing	O
the	O
patient	O
’	O
s	O
compliance	O
[	O
and	O
]	O
adherence	O
,	O
”	O
says	O
joe	ORG
jimenez	ORG
,	O
the	O
swiss	O
drug	O
company	O
’	O
s	O
chief	O
executive	O
.	O
“	O
whoever	O
owns	O
that	O
data	O
,	O
or	O
has	O
access	O
to	O
that	O
data	O
,	O
is	O
going	O
to	O
have	O
the	O
power	O
in	O
the	O
system.	O
”	O
however	O
,	O
the	O
data	O
that	O
exist	O
in	O
a	O
real-world	O
setting	O
,	O
or	O
in	O
health	O
medical	O
records	O
,	O
are	O
stirring	O
“	O
sensitive	O
”	O
issues	O
about	O
who	O
has	O
ultimate	O
ownership	O
,	O
he	O
says	O
.	O
“	O
is	O
it	O
the	O
patients	O
,	O
or	O
if	O
the	O
patient	O
waives	O
their	O
right	O
,	O
can	O
a	O
company	O
own	O
the	O
data	O
itself	O
?	O
”	O
the	O
investments	O
we	O
’	O
re	O
making—and	O
not	O
making—in	O
digital	O
health	O
more	O
digital	O
health	O
deals	O
--	O
296	O
--	O
were	O
done	O
last	O
year	O
than	O
ever	O
,	O
though	O
the	O
average	O
deal	O
size	O
(	O
$	O
13.8	O
million	O
)	O
was	O
smaller	O
than	O
it	O
was	O
in	O
either	O
2015	O
or	O
2014	O
.	O
startups	O
devoted	O
to	O
genomics	O
and	O
sequencing	O
got	O
the	O
lion	O
's	O
share	O
of	O
the	O
investment	O
(	O
$	O
410	O
million	O
)	O
,	O
followed	O
by	O
analytics	O
and	O
``	O
big	O
data	O
''	O
companies	O
(	O
$	O
341	O
million	O
)	O
.	O
and	O
of	O
the	O
17	O
digital	O
health	O
concerns	O
that	O
have	O
gone	O
public	O
since	O
2012	O
,	O
10	O
are	O
trading	O
at	O
above	O
their	O
ipo	O
price	O
and	O
seven	O
below	O
.	O
all	O
this	O
and	O
more	O
i	O
learned	O
from	O
rock	ORG
health	ORG
's	O
impressive	O
2016	O
year	O
end	O
funding	O
report	O
:	O
a	O
reality	O
check	O
for	O
digital	O
health	O
,	O
compiled	O
by	O
rock	ORG
health	ORG
founder	O
and	O
industry	O
veteran	O
halle	PERS
tecco	PERS
(	O
with	O
help	O
from	O
colleagues	O
)	O
.	O
data	O
grazers	O
will	O
find	O
plenty	O
to	O
chew	O
on	O
here	O
.	O
and	O
whether	O
you	O
come	O
away	O
feeling	O
as	O
if	O
this	O
has	O
been	O
a	O
standout	O
year	O
in	O
venture	O
funding	O
or	O
a	O
disappointment	O
is	O
likely	O
to	O
reflect	O
whether	O
you	O
're	O
more	O
excited	O
about	O
dollars	O
(	O
the	O
$	O
4.2	O
billion	O
invested	O
in	O
2016	O
is	O
down	O
about	O
$	O
400	O
million	O
from	O
the	O
previous	O
year	O
's	O
tally	O
)	O
or	O
participation	O
:	O
``	O
four	O
hundred	O
and	O
fifty-one	O
unique	O
investors	O
made	O
bets	O
in	O
digital	O
health	O
this	O
year	O
,	O
''	O
the	O
rock	ORG
health	ORG
team	O
reveals	O
,	O
of	O
whom	O
237	O
investors	O
put	O
down	O
their	O
first	O
stakes	O
in	O
the	O
field	O
.	O
(	O
i	O
'm	O
a	O
participation	O
guy	O
,	O
so	O
count	O
me	O
as	O
an	O
optimist	O
.	O
)	O
but	O
one	O
set	O
of	O
statistics	O
in	O
the	O
report	O
was	O
particularly	O
sobering	O
--	O
and	O
that	O
's	O
the	O
number	O
of	O
women	O
ceos	O
in	O
this	O
burgeoning	O
space	O
.	O
just	O
9	O
%	O
of	O
digital	O
health	O
companies	O
had	O
a	O
female	O
boss	O
compared	O
with	O
11	O
%	O
the	O
year	O
before	O
.	O
(	O
rock	ORG
health	ORG
counts	O
only	O
u.s.	LOC
deals	O
and	O
those	O
that	O
are	O
worth	O
more	O
than	O
$	O
2	O
million	O
,	O
so	O
that	O
limits	O
the	O
universe	O
a	O
bit	O
.	O
)	O
that	O
9	O
%	O
share	O
is	O
better	O
than	O
that	O
for	O
the	O
corporate	O
giants	O
--	O
the	O
fortune	ORG
500	O
has	O
but	O
25	O
women	O
ceos	O
(	O
5	O
%	O
)	O
--	O
but	O
not	O
much	O
better	O
.	O
given	O
that	O
women	O
have	O
long	O
held	O
a	O
higher	O
share	O
of	O
top	O
management	O
jobs	O
in	O
healthcare	O
than	O
they	O
have	O
in	O
other	O
industries	O
(	O
one	O
in	O
five	O
hospital	O
ceos	O
are	O
women	O
,	O
for	O
instance	O
)	O
,	O
i	O
had	O
thought	O
--	O
and	O
hoped	O
--	O
that	O
the	O
digihealth	O
arena	O
would	O
be	O
more	O
equitable	O
in	O
gender	O
representation	O
than	O
the	O
rest	O
of	O
the	O
techosphere	O
.	O
i	O
was	O
wrong	O
.	O
so	O
why	O
have	O
n't	O
we	O
done	O
better	O
?	O
klick	O
health	O
's	O
diljot	O
chhina	O
offers	O
some	O
very	O
informed	O
perspective	O
here	O
--	O
in	O
a	O
piece	O
last	O
january	O
for	O
who	O
else	O
?	O
rock	ORG
health	ORG
.	O
what	O
else	O
is	O
in	O
the	O
ether	O
today	O
?	O
sy	O
has	O
some	O
fascinating	O
news	O
below	O
--	O
including	O
one	O
report	O
on	O
how	O
insane	O
biopharma	O
m	O
&	O
a	O
valuations	O
have	O
gotten	O
.	O
one	O
fact	O
:	O
the	O
median	O
buyout	O
in	O
2016	O
was	O
39	O
times	O
sales	O
revenue	O
,	O
double	O
the	O
level	O
in	O
2015	O
,	O
according	O
to	O
an	O
analysis	O
by	O
novasecta	ORG
.	O
hmm	O
...	O
did	O
i	O
say	O
i	O
was	O
an	O
optimist	O
?	O
clifton	PERS
leaf	PERS
@	O
cliftonleaf	O
clifton.leaf	O
@	O
fortune.com	O
digital	O
health	O
activating	O
your	O
medication	O
with	O
...	O
light	O
?	O
researchers	O
at	O
the	O
university	ORG
of	ORG
north	ORG
carolina	ORG
at	ORG
chapel	ORG
hills	ORG
are	O
working	O
on	O
an	O
experimental	O
tech	O
that	O
's	O
,	O
well	O
,	O
just	O
downright	O
cool	O
:	O
using	O
long-wavelength	O
light	O
to	O
activate	O
medicines	O
at	O
very	O
specific	O
sites	O
.	O
the	O
technique	O
involves	O
binding	O
a	O
drug	O
and	O
a	O
phosphorescent	O
molecule	O
to	O
vitamin	O
b12	O
and	O
then	O
loading	O
this	O
package	O
into	O
red	O
blood	O
cells	O
that	O
circulate	O
throughout	O
the	O
body	O
.	O
since	O
the	O
light-sensitive	O
molecule	O
can	O
better	O
capture	O
long-wavelength	O
light	O
,	O
it	O
can	O
harness	O
the	O
energy	O
of	O
that	O
light	O
to	O
break	O
apart	O
the	O
energy	O
bond	O
and	O
activate	O
the	O
medicine	O
.	O
as	O
lead	O
researcher	O
david	PERS
lawrence	PERS
points	O
out	O
,	O
that	O
has	O
a	O
lot	O
of	O
implications	O
beyond	O
just	O
the	O
``	O
wow	O
''	O
factor	O
.	O
``	O
[	O
the	O
]	O
benefits	O
could	O
include	O
avoiding	O
surgery	O
and	O
the	O
risk	O
of	O
infection	O
,	O
making	O
anesthesia	O
unnecessary	O
and	O
allowing	O
people	O
to	O
treat	O
themselves	O
by	O
shining	O
a	O
light	O
on	O
a	O
problem	O
area	O
,	O
such	O
as	O
an	O
arthritic	O
knee	O
,	O
''	O
he	O
said	O
.	O
(	O
fortune	ORG
)	O
a	O
government	O
subcontractor	O
left	O
special	O
ops	ORG
medical	O
data	O
exposed	O
.	O
it	O
's	O
hard	O
enough	O
for	O
the	O
health	O
industry	O
to	O
grapple	O
with	O
the	O
reality	O
of	O
hacking	O
and	O
data	O
breaches	O
without	O
giving	O
would-be	O
cyber	O
criminals	O
more	O
ammunition	O
.	O
that	O
appears	O
to	O
be	O
what	O
happened	O
at	O
potomac	ORG
healthcare	ORG
,	O
a	O
defense	ORG
department	ORG
subcontractor	O
that	O
exposed	O
11	O
gigabytes	O
of	O
sensitive	O
data	O
(	O
including	O
social	O
security	O
numbers	O
and	O
salaries	O
for	O
special	O
ops	ORG
workers	O
)	O
through	O
an	O
unsecured	O
remote	O
synchronization	O
service	O
,	O
according	O
to	O
white	O
hat	O
hacker	O
chris	PERS
vickery	PERS
.	O
``	O
let	O
's	O
hope	O
i	O
was	O
the	O
only	O
outsider	O
to	O
come	O
across	O
this	O
gem	O
,	O
''	O
said	O
vickery	PERS
on	O
his	O
blog	O
,	O
noting	O
that	O
it	O
took	O
potomac	ORG
more	O
than	O
an	O
hour	O
and	O
a	O
half	O
to	O
fix	O
the	O
issue	O
after	O
he	O
alerted	O
the	O
firm	O
.	O
``	O
let	O
's	O
really	O
hope	O
that	O
no	O
hostile	O
entities	O
found	O
it	O
.	O
loose	O
backups	O
sink	O
ships	O
.	O
''	O
potomac	ORG
,	O
for	O
its	O
part	O
,	O
says	O
that	O
it	O
addressed	O
the	O
exposure	O
in	O
a	O
timely	O
manner	O
.	O
``	O
upon	O
learning	O
of	O
the	O
allegation	O
,	O
we	O
immediately	O
initiated	O
an	O
internal	O
review	O
and	O
brought	O
in	O
an	O
external	O
forensic	O
it	O
firm	O
for	O
additional	O
support	O
,	O
''	O
the	O
company	O
said	O
.	O
(	O
healthcare	O
it	O
news	O
)	O
your	O
fitbit	ORG
is	O
getting	O
a	O
social	O
feed	O
.	O
fitbit	ORG
announced	O
a	O
slew	O
of	O
major	O
software	O
updates	O
at	O
the	O
ongoing	O
consumer	O
electronics	O
show	O
(	O
ces	O
)	O
in	O
las	LOC
vegas	LOC
,	O
including	O
a	O
social	O
media	O
feed	O
on	O
its	O
main	O
app	O
meant	O
to	O
keep	O
users	O
motivated	O
.	O
the	O
company	O
is	O
also	O
revamping	O
its	O
personalized	O
workout	O
recommendation	O
service	O
--	O
all	O
part	O
of	O
an	O
effort	O
to	O
get	O
the	O
company	O
's	O
17	O
million	O
customer-strong	O
user	O
base	O
to	O
be	O
more	O
engaged	O
with	O
their	O
fitness	O
trackers	O
.	O
``	O
the	O
new	O
news	O
feed	O
in	O
the	O
fitbit	ORG
app	O
will	O
allow	O
users	O
to	O
post	O
pictures	O
and	O
brag	O
about	O
their	O
fitness	O
activity	O
to	O
friends	O
along	O
with	O
notices	O
about	O
sponsored	O
fitness	O
events	O
and	O
tips	O
from	O
the	O
company	O
,	O
''	O
writes	O
my	O
colleague	O
aaron	PERS
pressman	PERS
.	O
fitbit	ORG
has	O
n't	O
announced	O
any	O
new	O
devices	O
as	O
part	O
of	O
its	O
ces	O
update	O
.	O
(	O
fortune	ORG
)	O
indications	O
another	O
pharma	O
vet	O
heads	O
into	O
biotech	O
.	O
in	O
what	O
's	O
becoming	O
an	O
increasingly	O
popular	O
trend	O
,	O
a	O
major	O
pharma	O
veteran	O
is	O
taking	O
his	O
industry	O
experience	O
over	O
to	O
a	O
biotech-focused	O
venture	O
capital	O
firm	O
.	O
this	O
time	O
,	O
it	O
's	O
former	O
novartis	ORG
pharmaceuticals	O
unit	O
head	O
david	PERS
epstein	PERS
,	O
who	O
will	O
be	O
heading	O
over	O
to	O
cambridge	LOC
,	O
massachusetts-based	O
flagship	O
pioneering	O
.	O
as	O
the	O
wall	ORG
street	ORG
journal	ORG
notes	O
,	O
pharma	O
bigwigs	O
like	O
former	O
sanofi	ORG
ceo	O
chris	PERS
viehbacher	PERS
and	O
former	O
astrazeneca	ORG
chief	O
medical	O
officer	O
briggs	PERS
morrison	PERS
have	O
made	O
similar	O
moves	O
into	O
the	O
biotech	O
sphere	O
,	O
where	O
companies	O
tend	O
to	O
run	O
leaner	O
,	O
take	O
bigger	O
risks	O
,	O
and	O
get	O
a	O
significantly	O
higher	O
return	O
on	O
their	O
r	O
&	O
d	O
investments	O
compared	O
with	O
traditional	O
pharma	O
companies	O
.	O
(	O
wall	ORG
street	ORG
journal	ORG
)	O
biopharma	O
m	O
&	O
a	O
valuations	O
are	O
out	O
of	O
control	O
.	O
what	O
's	O
a	O
reasonable	O
premium	O
for	O
acquiring	O
a	O
company	O
or	O
an	O
asset	O
?	O
25	O
%	O
?	O
30	O
%	O
?	O
well	O
,	O
in	O
the	O
world	O
of	O
2016	O
biopharma	O
m	O
&	O
a	O
,	O
the	O
median	O
payout	O
for	O
a	O
deal	O
was	O
39	O
times	O
sales	O
revenue	O
,	O
according	O
to	O
a	O
new	O
analysis	O
by	O
consulting	O
firm	O
novasecta	ORG
.	O
astonishingly	O
,	O
that	O
's	O
actually	O
double	O
the	O
median	O
valuation	O
in	O
2015	O
,	O
when	O
deals	O
paid	O
out	O
19	O
times	O
revenue	O
.	O
there	O
's	O
no	O
shortage	O
of	O
examples	O
.	O
just	O
consider	O
allergan	O
's	O
$	O
1.7	O
billion	O
deal	O
for	O
the	O
liver	O
disease	O
drug	O
maker	O
tobira	ORG
therapeutics	ORG
,	O
which	O
pegged	O
the	O
biotech	O
at	O
19	O
times	O
its	O
market	O
value	O
for	O
the	O
$	O
50	O
million	O
upfront	O
cash	O
component	O
alone	O
(	O
and	O
the	O
company	O
does	O
n't	O
even	O
have	O
any	O
approved	O
products	O
on	O
the	O
market	O
)	O
.	O
the	O
question	O
is	O
:	O
is	O
the	O
trend	O
sustainable	O
?	O
or	O
will	O
this	O
level	O
of	O
inflation	O
keep	O
would-be	O
buyers	O
on	O
the	O
sidelines	O
until	O
things	O
cool	O
down	O
?	O
joe	PERS
biden	PERS
will	O
have	O
cancer	O
drug	O
prices	O
in	O
his	O
crosshairs	O
after	O
leaving	O
office	O
.	O
vice	O
president	O
joe	PERS
biden	PERS
told	O
the	O
washington	ORG
post	ORG
that	O
he	O
will	O
be	O
launching	O
a	O
nonprofit	O
after	O
leaving	O
office	O
later	O
this	O
month	O
in	O
order	O
to	O
tackle	O
a	O
wide	O
array	O
of	O
issues	O
related	O
to	O
cancer	O
,	O
including	O
the	O
sky	O
high	O
costs	O
of	O
cancer	O
treatments	O
.	O
``	O
i	O
'm	O
going	O
to	O
begin	O
a	O
national	O
conversation	O
and	O
get	O
congress	ORG
and	O
advocacy	O
groups	O
in	O
to	O
make	O
sure	O
these	O
treatments	O
are	O
accessible	O
for	O
everyone	O
,	O
including	O
these	O
vulnerable	O
underserved	O
populations	O
,	O
and	O
that	O
we	O
have	O
a	O
more	O
rational	O
way	O
of	O
paying	O
for	O
them	O
while	O
promoting	O
innovation	O
,	O
''	O
biden	PERS
said	O
in	O
an	O
interview	O
with	O
the	O
post	O
,	O
adding	O
that	O
pharmaceutical	O
companies	O
are	O
aware	O
that	O
their	O
prices	O
are	O
unsustainable	O
.	O
the	O
new	O
organization	O
will	O
also	O
concentrate	O
on	O
many	O
of	O
the	O
issues	O
that	O
biden	PERS
has	O
tackled	O
as	O
head	O
of	O
the	O
white	ORG
house	ORG
's	O
cancer	O
moonshot	O
program	O
,	O
including	O
promoting	O
data-sharing	O
and	O
getting	O
more	O
people	O
into	O
clinical	O
trials	O
.	O
(	O
washington	ORG
post	ORG
)	O
the	O
big	ORG
picture	ORG
wide-ranging	ORG
panel	O
of	O
experts	O
announces	O
new	O
peanut	O
allergy	O
prevention	O
guidelines	O
.	O
a	O
group	O
of	O
organizations	O
including	O
the	O
american	ORG
academy	ORG
of	ORG
pediatrics	ORG
,	O
the	O
american	ORG
academy	ORG
of	ORG
family	ORG
physicians	ORG
,	O
the	O
american	ORG
academy	ORG
of	ORG
allergy	ORG
,	O
asthma	O
&	O
immunology	O
,	O
have	O
released	O
a	O
new	O
set	O
of	O
guidelines	O
on	O
how	O
to	O
best	O
prevent	O
peanut	O
allergies	O
in	O
children	O
.	O
the	O
group	O
's	O
new	O
recommendations	O
are	O
based	O
on	O
a	O
recent	O
gold	O
standard	O
trial	O
finding	O
that	O
introducing	O
peanuts	O
into	O
infants	O
'	O
diets	O
can	O
actually	O
prevent	O
them	O
from	O
developing	O
an	O
allergy	O
,	O
especially	O
in	O
children	O
who	O
are	O
at	O
the	O
highest	O
risk	O
of	O
peanut	O
allergy	O
(	O
such	O
as	O
those	O
with	O
asthma	O
,	O
eczema	O
,	O
or	O
an	O
egg	O
allergy	O
)	O
.	O
public	O
health	O
officials	O
say	O
the	O
guidelines	O
are	O
meant	O
to	O
provide	O
a	O
unified	O
source	O
of	O
information	O
for	O
health	O
care	O
providers	O
and	O
parents	O
.	O
(	O
cnn	ORG
)	O
obamacare	O
repeal	O
battle	O
continues	O
to	O
be	O
fluid	O
,	O
contentious	O
.	O
on	O
wednesday	O
,	O
the	O
newly-inducted	O
,	O
gop-controlled	O
senate	ORG
fired	O
the	O
opening	O
legislative	O
shots	O
of	O
the	O
obamacare	O
repeal	O
wars	O
,	O
voting	O
51-48	O
on	O
a	O
procedural	O
motion	O
to	O
start	O
debate	O
on	O
a	O
budget	O
resolution	O
that	O
will	O
then	O
be	O
used	O
to	O
dismantle	O
the	O
health	O
law	O
.	O
notably	O
,	O
the	O
only	O
senator	O
to	O
break	O
with	O
his	O
part	O
was	O
republican	O
rand	PERS
paul	PERS
,	O
who	O
has	O
also	O
previously	O
warned	O
against	O
repealing	O
the	O
affordable	O
care	O
act	O
without	O
establishing	O
a	O
replacement	O
.	O
debate	O
over	O
the	O
budget	O
resolution	O
began	O
today	O
and	O
will	O
stretch	O
into	O
next	O
week	O
,	O
after	O
which	O
democrats	O
can	O
add	O
troublesome	O
amendments	O
to	O
the	O
bill	O
.	O
if	O
it	O
passes	O
,	O
various	O
congressional	O
committees	O
will	O
then	O
begin	O
constructing	O
a	O
budget	O
reconciliation	O
bill	O
that	O
can	O
take	O
apart	O
obamacare	O
and	O
only	O
require	O
a	O
simple	O
majority	O
vote	O
to	O
pass	O
.	O
required	O
reading	O
ibm	ORG
brain	ORG
trust	ORG
predicts	O
that	O
'superhero	O
vision	O
'	O
is	O
on	O
the	O
way	O
,	O
by	O
barb	PERS
darrow	PERS
4	O
digital	O
tools	O
to	O
help	O
you	O
keep	O
those	O
new	O
year	O
's	O
resolutions	O
,	O
by	O
joseph	PERS
riley	PERS
google	ORG
's	O
ceo	O
thought	PERS
gmail	PERS
was	O
a	O
joke	O
during	O
his	O
job	O
interview	O
,	O
by	O
madeline	PERS
farber	PERS
this	O
guru	O
thinks	O
artificial	O
intelligence	O
will	O
unleash	O
human	O
creativity	O
,	O
by	O
adam	PERS
lashinsky	PERS
[	O
ceo_attribution	O
author=	O
''	O
produced	O
by	O
sy	PERS
mukherjee	PERS
''	O
email=	O
''	O
sayak.mukherjee	O
@	O
fortune.com	O
''	O
twitter=	O
''	O
the_sy_guy	O
''	O
]	O
find	O
past	O
coverage	O
.	O
sign	O
up	O
for	O
other	O
fortune	ORG
newsletters	O
.	O
term	O
sheet	O
—	O
wednesday	O
,	O
november	O
1	O
et	O
cetera	O
money	O
in	O
the	O
bank	O
:	O
yesterday	O
's	O
term	O
sheet	O
included	O
a	O
last-minute	O
deal	O
announcement	O
that	O
deserves	O
a	O
little	O
extra	O
attention	O
today	O
:	O
battery	ORG
ventures	ORG
,	O
andreessen	ORG
horowitz	ORG
and	ORG
ribbit	ORG
capital	ORG
invested	O
$	O
28	O
million	O
in	O
cross	ORG
river	ORG
bank	ORG
.	O
as	O
the	O
company	O
's	O
name	O
suggests	O
,	O
cross	ORG
river	ORG
is	O
n't	O
a	O
hot	O
fintech	O
startup	O
working	O
out	O
of	O
a	O
wework	O
in	O
soma	O
.	O
it	O
's	O
a	O
boring	O
old	O
fdic-insured	O
,	O
deposit-taking	O
community	O
bank	O
.	O
it	O
is	O
eight	O
years	O
old	O
and	O
has	O
a	O
single	O
branch	O
in	O
teaneck	LOC
,	O
new	LOC
jersey	LOC
.	O
so	O
why	O
would	O
three	O
venture	O
firms	O
throw	O
so	O
much	O
money	O
at	O
a	O
bank	O
?	O
well	O
,	O
they	O
think	O
cross	ORG
river	ORG
can	O
become	O
the	O
next	O
bank	ORG
of	ORG
america	ORG
.	O
as	O
wsj	O
and	O
others	O
reported	O
yesterday	O
,	O
the	O
bank	O
is	O
doing	O
some	O
interesting	O
partnerships	O
with	O
companies	O
like	O
stripe	ORG
and	O
mastercard	ORG
,	O
as	O
well	O
as	O
online	O
lenders	O
.	O
but	O
there	O
's	O
one	O
key	O
element	O
that	O
was	O
n't	O
reported	O
in	O
yesterday	O
's	O
announcement	O
:	O
cross	ORG
river	ORG
is	O
stealthily	O
building	O
a	O
brand-new	O
``	O
next	O
generation	O
''	O
consumer	O
bank	O
.	O
it	O
's	O
called	O
almond	ORG
bank	ORG
,	O
and	O
its	O
run	O
by	O
ben	PERS
weiss	PERS
,	O
who	O
was	O
most	O
recently	O
entrepreneur-in-residence	O
at	O
two	ORG
sigma	ORG
ventures	ORG
.	O
prior	O
to	O
that	O
he	O
did	O
business	O
development	O
at	O
opera	ORG
solutions	ORG
and	O
stocktwits	O
.	O
a	O
cross	ORG
river	ORG
rep	O
declined	O
to	O
share	O
any	O
more	O
information	O
about	O
almond	ORG
bank	ORG
,	O
but	O
from	O
what	O
i	O
understand	O
,	O
it	O
's	O
meant	O
to	O
be	O
an	O
innovative	O
``	O
bank	O
within	O
a	O
bank	O
.	O
''	O
based	O
in	O
new	LOC
york	LOC
,	O
the	O
division	O
has	O
been	O
in	O
the	O
works	O
for	O
about	O
a	O
year	O
.	O
linkedin	ORG
lists	O
around	O
ten	O
employees	O
.	O
one	O
source	O
described	O
almond	ORG
as	O
``	O
if	O
bbva	ORG
had	O
incubated	O
simple	O
instead	O
of	O
buying	O
it	O
.	O
''	O
you	O
remember	O
simple	O
:	O
it	O
was	O
meant	O
to	O
be	O
a	O
new	O
kind	O
of	O
bank	O
with	O
no	O
branches	O
and	O
no	O
atm	O
fees	O
.	O
it	O
even	O
marketed	O
itself	O
as	O
an	O
``	O
anti-bank	O
.	O
''	O
but	O
it	O
was	O
plagued	O
by	O
outages	O
and	O
glitches	O
,	O
which	O
led	O
to	O
lots	O
of	O
toldja-sos	O
.	O
(	O
``	O
this	O
is	O
what	O
happens	O
when	O
your	O
bank	O
is	O
an	O
app	O
!	O
''	O
)	O
when	O
it	O
comes	O
to	O
money	O
,	O
trust	O
will	O
always	O
trump	PERS
good	O
ux	O
.	O
simple	O
eventually	O
sold	O
to	O
bbva	ORG
in	O
2014	O
,	O
and	O
it	O
has	O
stayed	O
quiet	O
since	O
.	O
from	O
the	O
looks	O
of	O
it	O
,	O
almond	ORG
aims	O
to	O
pick	O
up	O
where	O
simple	O
left	O
off	O
.	O
white	ORG
house	ORG
to	O
sand	O
hill	O
road	O
:	O
president	O
obama	PERS
has	O
hinted	O
he	O
would	O
like	O
to	O
dabble	O
in	O
venture	O
capital	O
once	O
he	O
's	O
out	O
of	O
office	O
.	O
many	O
bold-faced	O
names	O
on	O
his	O
staff	O
have	O
already	O
taken	O
jobs	O
at	O
startups	O
or	O
tech	O
giants	O
,	O
including	O
david	PERS
plouffe	PERS
,	O
lisa	PERS
jackson	PERS
,	O
eric	ORG
holder	ORG
,	O
ryan	PERS
metcalf	PERS
,	O
nick	PERS
shapiro	PERS
,	O
and	O
demetrios	PERS
marantis	PERS
.	O
here	O
's	O
one	O
more	O
to	O
add	O
to	O
the	O
list	ORG
joining	O
a	O
venture	O
firm	O
:	O
jay	PERS
tansey	PERS
,	O
former	O
presidential	O
appointee	O
and	O
policy	O
advisor	O
at	O
the	O
u.s.	ORG
small	ORG
business	ORG
administration	ORG
,	O
has	O
joined	O
north	ORG
atlantic	ORG
capital	ORG
,	O
a	O
portland	LOC
,	O
maine-based	O
venture	O
firm	O
focused	O
on	O
late-stage	O
technology	O
companies	O
,	O
as	O
a	O
principal	O
.	O
for	O
your	O
health	O
:	O
fortune	ORG
's	O
inaugural	O
brainstorm	O
health	O
conference	O
is	O
underway	O
.	O
follow	O
along	O
with	O
the	O
livestream	O
,	O
if	O
that	O
's	O
your	O
thing	O
,	O
right	O
here	O
.	O
some	O
coverage	O
from	O
last	O
night	O
's	O
kick-off	O
:	O
we	O
've	O
been	O
treating	O
appendicitis	O
wrong	O
.	O
arianna	O
does	O
n't	O
love	O
vr	O
,	O
does	O
love	O
rest	O
.	O
maria	PERS
shriver	PERS
talks	O
alzheimer	O
's	O
.	O
how	O
to	O
stop	O
pandemics	O
.	O
meditating	O
with	O
deepak	PERS
chopra	PERS
.	O
shrinking	O
drug	O
development	O
cycles	O
.	O
replacing	O
doctors	O
with	O
3d	O
printing	O
and	O
ai	O
.	O
the	O
latest	O
from	O
fortune.com	ORG
...	O
[	O
ts_bullet_primary	O
]	O
herbalife	ORG
's	O
ceo	O
steps	O
down	O
.	O
[	O
ts_bullet_primary	O
]	O
a	O
tepid	O
response	O
for	O
yum	O
's	O
chinese	O
ipo	O
.	O
[	O
ts_bullet_primary	O
]	O
what	O
it	O
takes	O
to	O
become	O
a	O
youtube	ORG
star	O
.	O
[	O
ts_bullet_primary	O
]	O
ousted	O
barclays	ORG
ceo	O
's	O
next	O
act	O
is	O
in	O
fintech	O
.	O
[	O
ts_bullet_primary	O
]	O
the	O
insider	O
trading	O
app	O
.	O
[	O
ts_bullet_primary	O
]	O
more	O
potential	O
chip	O
industry	O
consolidation	O
.	O
[	O
ts_bullet_primary	O
]	O
why	O
mark	PERS
carney	PERS
staying	O
on	O
for	O
brexit	O
matters	O
.	O
[	O
ts_bullet_primary	O
]	O
uber	ORG
partners	O
with	O
lyft	ORG
's	O
major	O
investor	O
.	O
[	O
ts_bullet_primary	O
]	O
alibaba	O
earnings	O
beat	O
.	O
[	O
ts_bullet_primary	O
]	O
chipotle	ORG
may	O
oust	O
founder	O
.	O
[	O
ts_bullet_primary	O
]	O
the	O
russian	O
bank	O
with	O
ties	O
to	O
trump	PERS
.	O
[	O
ts_bullet_primary	O
]	O
volvo	ORG
's	O
built-in	O
refrigerators	O
.	O
...	O
and	O
elsewhere	O
female	O
ceos	O
get	O
blamed	O
more	O
than	O
their	O
male	O
counterparts	O
.	O
how	O
the	O
internet	O
is	O
loosening	O
our	O
grip	O
on	O
the	O
truth	O
.	O
prenups	O
for	O
ideas	O
.	O
venture	O
deals	O
[	O
ts_bullet_primary	O
]	O
voyager	ORG
labs	ORG
,	O
an	O
israeli	O
artificial	O
intelligence	O
company	O
,	O
has	O
emerged	O
from	O
stealth	O
mode	O
with	O
$	O
100	O
million	O
in	O
funding	O
.	O
investors	O
include	O
ocapac	ORG
holding	ORG
company	ORG
,	O
horizons	ORG
ventures	ORG
,	O
and	O
angels	O
ronald	PERS
cohen	PERS
and	O
lloyd	PERS
dorfman	PERS
.	O
[	O
ts_bullet_primary	O
]	O
biohaven	O
,	O
a	O
new	O
haven	O
,	O
conn.-based	O
biopharmaceutical	O
company	O
,	O
has	O
raised	O
$	O
80	O
million	O
in	O
funding	O
.	O
venrock	O
led	O
the	O
round	O
,	O
and	O
was	O
joined	O
by	O
ra	ORG
capital	ORG
management	ORG
,	O
vivo	ORG
capital	ORG
,	O
aisling	O
capital	O
,	O
rock	ORG
springs	ORG
capital	ORG
,	O
john	PERS
w.	PERS
childs	PERS
,	O
knoll	ORG
capital	ORG
management	ORG
,	O
osage	ORG
university	ORG
partners	ORG
,	O
aperture	ORG
venture	ORG
partners	ORG
,	O
connecticut	LOC
innovations	O
,	O
greg	ORG
bailey	ORG
and	ORG
litmore	ORG
capital	ORG
.	O
[	O
ts_bullet_primary	O
]	O
rokid	ORG
,	O
a	O
san	O
francisco-based	O
artificial	O
intelligence	O
and	O
robotics	O
smart	O
home	O
company	O
,	O
has	O
raised	O
more	O
than	O
$	O
50	O
million	O
in	O
series	O
b	O
funding	O
at	O
a	O
post-money	O
valuation	O
of	O
$	O
450	O
million	O
.	O
advantech	O
led	O
the	O
round	O
,	O
and	O
was	O
joined	O
by	O
existing	O
investors	O
idg	ORG
capital	ORG
partners	ORG
and	ORG
walden	ORG
international	ORG
.	O
note	O
:	O
a	O
prior	O
edition	O
of	O
term	O
sheet	O
overstated	O
the	O
amount	O
raised	O
by	O
rokid	ORG
.	O
[	O
ts_bullet_primary	O
]	O
turnstone	ORG
biologics	ORG
,	O
an	O
ottawa-based	O
biotech	O
company	O
that	O
develops	O
viral	O
immunotherapies	O
to	O
treat	O
cancer	O
,	O
has	O
raised	O
$	O
41.4	O
million	O
in	O
series	O
b	O
funding	O
.	O
orbimed	O
led	O
the	O
round	O
and	O
was	O
joined	O
by	O
f-prime	ORG
capital	ORG
partners	ORG
,	O
facit	ORG
and	ORG
versant	ORG
ventures	ORG
.	O
[	O
ts_bullet_primary	O
]	O
miragen	ORG
,	O
a	O
boulder-based	O
biotech	O
company	O
,	O
has	O
raised	O
$	O
40	O
million	O
in	O
funding	O
from	O
investors	O
including	O
fidelity	ORG
management	ORG
and	ORG
research	ORG
company	ORG
,	O
brace	ORG
pharma	ORG
capital	ORG
,	O
atlas	ORG
venture	ORG
,	O
boulder	ORG
ventures	ORG
,	O
jafco	ORG
,	O
mp	ORG
healthcare	ORG
venture	ORG
management	ORG
,	O
mrl	ORG
ventures	ORG
,	O
and	O
remeditex	ORG
ventures	ORG
.	O
miragen	ORG
also	O
announced	O
has	O
agreed	O
to	O
merge	O
with	O
signal	ORG
genetics	ORG
,	O
a	O
carlsbad	O
,	O
calif.-based	O
molecular	O
diagnostic	O
company	O
.	O
[	O
ts_bullet_primary	O
]	O
paktor	O
,	O
a	O
singapore-based	O
tinder-like	O
dating	O
app	O
,	O
has	O
raised	O
$	O
32.5	O
million	O
k2	O
global	ORG
and	O
mnc	ORG
media	ORG
group	ORG
led	O
the	O
round	O
.	O
[	O
ts_bullet_primary	O
]	O
classy	O
,	O
a	O
san	O
diego-based	O
crowdfunding	O
platform	O
for	O
social	O
enterprises	O
,	O
has	O
raised	O
$	O
30	O
million	O
in	O
series	O
c	O
funding	O
.	O
jmi	O
equity	O
led	O
the	O
round	O
and	O
was	O
joined	O
by	O
bullpen	ORG
capital	ORG
,	O
galileo	ORG
partners	ORG
,	O
mithril	ORG
capital	ORG
management	ORG
,	O
and	O
salesforce	ORG
ventures	ORG
.	O
[	O
ts_bullet_primary	O
]	O
concertohealth	O
,	O
an	O
irvine	O
,	O
calif.-based	O
provider	O
of	O
healthcare	O
services	O
for	O
seniors	O
,	O
has	O
raised	O
$	O
30	O
million	O
in	O
a	O
round	O
led	O
by	O
aboretum	O
and	O
deerfield	ORG
management	ORG
company	ORG
.	O
[	O
ts_bullet_primary	O
]	O
axonify	ORG
,	O
an	O
ontario-based	O
company	O
that	O
builds	O
gamified	O
training	O
platforms	O
for	O
employees	O
,	O
has	O
raised	O
$	O
27	O
million	O
in	O
series	O
c	O
funding	O
.	O
jmi	O
equity	O
led	O
the	O
round	O
and	O
was	O
joined	O
by	O
bdc	ORG
it	O
venture	ORG
fund	ORG
,	O
bdc	ORG
capital	ORG
's	O
vc	O
arm	O
.	O
[	O
ts_bullet_primary	O
]	O
relayr	ORG
,	O
a	O
berlin-based	O
startup	O
creating	O
internet	O
of	O
things	O
technology	O
for	O
industrial	O
customers	O
,	O
has	O
raised	O
$	O
23	O
million	O
in	O
funding	O
.	O
munich	O
re/hsb	O
ventures	O
led	O
the	O
round	O
,	O
and	O
was	O
joined	O
by	O
kleiner	PERS
perkins	PERS
caufield	PERS
&	O
byers	O
,	O
and	O
munich	ORG
venture	ORG
partners	ORG
.	O
[	O
ts_bullet_primary	O
]	O
ubiome	ORG
,	O
a	O
san	O
francisco-based	O
consumer	O
microbial	O
sequencing	O
company	O
,	O
has	O
raised	O
$	O
22	O
million	O
in	O
series	O
b	O
funding	O
,	O
according	O
to	O
techcrunch	ORG
.	O
8vc	O
led	O
the	O
round	O
,	O
and	O
was	O
joined	O
by	O
slow	O
ventures	O
,	O
startx	ORG
,	O
and	O
angel	O
investors	O
.	O
read	O
more	O
.	O
[	O
ts_bullet_primary	O
]	O
atlas	PERS
informatics	PERS
,	O
a	O
seattle-based	O
digital	O
content	O
organization	O
company	O
founded	O
by	O
napster	ORG
cofounder	O
jordan	PERS
ritter	PERS
,	O
has	O
raised	O
$	O
20.7	O
million	O
in	O
funding	O
.	O
investors	O
include	O
microsoft	ORG
,	O
nathan	PERS
myhrvold	PERS
,	O
and	O
aspect	ORG
ventures	ORG
.	O
the	O
company	O
also	O
announced	O
the	O
launch	O
atlas	PERS
recall	PERS
,	O
a	O
new	O
product	O
that	O
allows	O
consumers	O
to	O
build	O
a	O
cross-platform	O
searchable	O
index	O
of	O
their	O
digital	O
activity	O
.	O
[	O
ts_bullet_primary	O
]	O
interana	O
,	O
a	O
redwood	LOC
city	LOC
,	O
calif.-based	O
behavioral	O
analytics	O
company	O
,	O
has	O
raised	O
$	O
18	O
million	O
in	O
funding	O
in	O
a	O
round	O
led	O
by	O
vertex	ORG
ventures	ORG
led	O
the	O
round	O
,	O
with	O
participation	O
from	O
battery	ORG
ventures	ORG
,	O
data	O
collective	O
,	O
allen	ORG
company	ORG
,	O
fuel	ORG
capital	ORG
,	O
and	O
index	ORG
ventures	ORG
.	O
[	O
ts_bullet_primary	O
]	O
teforia	O
,	O
a	O
mountain	O
view	O
,	O
calif.-based	O
smart	O
tea	O
infuser	O
and	O
app	O
,	O
has	O
raised	O
$	O
12	O
million	O
in	O
series	O
a	O
funding	O
.	O
translink	ORG
capital	ORG
led	O
the	O
round	O
,	O
and	O
was	O
joined	O
by	O
upfront	ORG
ventures	ORG
,	O
lemnos	ORG
labs	ORG
,	O
mousse	ORG
partners	ORG
,	O
and	O
correlation	ORG
ventures	ORG
.	O
[	O
ts_bullet_primary	O
]	O
valimail	O
,	O
a	O
san	O
francisco-based	O
automated	O
email	O
authentication	O
service	O
,	O
has	O
raised	O
$	O
12	O
million	O
in	O
series	O
a	O
funding	O
.	O
shasta	ORG
ventures	ORG
led	O
the	O
round	O
,	O
and	O
was	O
joined	O
by	O
flybridge	ORG
capital	ORG
and	O
bloomberg	ORG
beta	ORG
.	O
[	O
ts_bullet_primary	O
]	O
spongecell	ORG
,	O
a	O
new	LOC
york	LOC
city-based	O
ad	O
tech	O
company	O
,	O
has	O
raised	O
$	O
10.5	O
million	O
in	O
a	O
combination	O
of	O
equity	O
and	O
debt	O
financing	O
.	O
existing	O
investor	O
safeguard	ORG
scientifics	O
participated	O
,	O
and	O
was	O
joined	O
by	O
venture	O
debt	O
company	O
pivotal	ORG
capital	ORG
.	O
[	O
ts_bullet_primary	O
]	O
ando	O
,	O
david	PERS
chang	PERS
's	O
new	LOC
york	LOC
city-based	O
delivery-only	O
restaurant	O
,	O
has	O
raised	O
$	O
7	O
million	O
in	O
series	O
a	O
funding	O
.	O
forerunner	O
led	O
the	O
round	O
,	O
and	O
was	O
joined	O
by	O
boxgroup	O
,	O
wildcat	ORG
venture	ORG
partners	ORG
,	O
and	O
angel	O
investors	O
including	O
jimmy	PERS
fallon	PERS
,	O
aziz	PERS
ansari	PERS
,	O
and	O
william	PERS
lauder	PERS
.	O
[	O
ts_bullet_primary	O
]	O
genos	ORG
research	ORG
,	O
a	O
san	O
francisco-based	O
consumer	O
genome	O
sequencing	O
startup	O
,	O
has	O
raised	O
$	O
6	O
million	O
in	O
funding	O
from	O
nantworks	O
,	O
a	O
los	O
angeles-based	O
network	O
of	O
digital	O
healthcare	O
and	O
media	O
companies	O
founded	O
by	O
billionaire	O
pharma	O
executive	O
patrick	PERS
soon-shiong	O
.	O
[	O
ts_bullet_primary	O
]	O
airpr	ORG
,	O
a	O
san	O
francisco-based	O
analytics	O
company	O
that	O
measures	O
the	O
impact	O
of	O
pr	O
efforts	O
,	O
has	O
raised	O
$	O
5	O
million	O
in	O
series	O
b	O
funding	O
.	O
storm	ORG
ventures	ORG
led	O
the	O
round	O
,	O
with	O
participation	O
from	O
salesforce	ORG
ventures	ORG
,	O
mohr	ORG
davidow	ORG
,	O
and	O
correlation	ORG
ventures	ORG
.	O
[	O
ts_bullet_primary	O
]	O
fleetsmith	ORG
,	O
a	O
san	O
francisco-based	O
startup	O
that	O
makes	O
computer	O
management	O
tools	O
for	O
small	O
and	O
medium	O
businesses	O
,	O
has	O
raised	O
$	O
3.1	O
million	O
in	O
seed	O
funding	O
.	O
index	ORG
ventures	ORG
and	O
harrison	PERS
metal	PERS
led	O
the	O
round	O
,	O
and	O
was	O
joined	O
by	O
angel	O
investors	O
including	O
dropbox	ORG
co-founder	O
arash	PERS
ferdowsi	PERS
.	O
[	O
ts_bullet_primary	O
]	O
peerwell	O
,	O
a	O
san	O
francisco-based	O
mobile	O
platforms	O
for	O
patients	O
preparing	O
for	O
and	O
recovering	O
from	O
surgery	O
,	O
has	O
raised	O
$	O
2.1	O
million	O
in	O
seed	O
funding	O
in	O
a	O
round	O
led	O
by	O
xseed	ORG
capital	ORG
.	O
[	O
ts_bullet_primary	O
]	O
avizia	O
,	O
a	O
reston	O
,	O
va.-based	O
a	O
telehealth	O
company	O
,	O
has	O
closed	O
its	O
series	O
a	O
rounding	O
,	O
adding	O
$	O
6	O
million	O
to	O
the	O
$	O
11	O
million	O
it	O
raised	O
in	O
july	O
for	O
a	O
total	O
of	O
$	O
17	O
million	O
.	O
healthquest	ORG
capital	ORG
led	O
the	O
round	O
,	O
and	O
was	O
joined	O
by	O
newyork-presbyterian	O
.	O
private	O
equity	O
deals	O
[	O
ts_bullet_primary	O
]	O
salt	O
creek	O
capital	O
has	O
acquired	O
extranomical	ORG
adventures	ORG
,	O
a	O
san	O
francisco-based	O
tour	O
company	O
.	O
financial	O
terms	O
were	O
not	O
disclosed	O
.	O
[	O
ts_bullet_primary	O
]	O
bridgepoint	ORG
development	ORG
partners	ORG
has	O
acquired	O
inspiring	ORG
learning	ORG
,	O
a	O
u.k.-based	O
educational	O
tour	O
company	O
.	O
[	O
ts_bullet_primary	O
]	O
lnc	ORG
partners	ORG
has	O
invested	O
an	O
undisclosed	O
amount	O
in	O
outsolve	O
,	O
a	O
consulting	O
firm	O
for	O
federal	O
contractors	O
.	O
[	O
ts_bullet_primary	O
]	O
peak	O
rock	O
capital	O
has	O
acquired	O
lew	O
's	O
fishing	O
,	O
a	O
springfield	LOC
,	O
miss.-based	O
fishing	O
gear	O
supplier	O
.	O
[	O
ts_bullet_primary	O
]	O
bertram	ORG
capital	ORG
has	O
invested	O
in	O
trademark	ORG
games	ORG
holdings	ORG
,	O
a	O
lorain	O
,	O
ohio-based	O
wholesale	O
distributor	O
.	O
[	O
ts_bullet_primary	O
]	O
jmi	O
equity	O
has	O
invested	O
in	O
automotivemastermind	O
,	O
a	O
new	LOC
york	LOC
city-based	O
predictive	O
analytics	O
and	O
marketing	O
automation	O
software	O
provider	O
for	O
the	O
automotive	O
industry	O
.	O
[	O
ts_bullet_primary	O
]	O
strattam	O
capital	O
has	O
agreed	O
to	O
invest	O
in	O
contegix	O
,	O
a	O
saint	O
louis-based	O
it	O
hosting	O
company	O
.	O
other	O
deals	O
[	O
ts_bullet_primary	O
]	O
broadcom	ORG
,	O
a	O
singapore-based	O
chipmaker	O
,	O
said	O
it	O
would	O
acquire	O
network	O
gear	O
maker	O
brocade	ORG
for	O
$	O
5.5	O
billion	O
in	O
cash	O
,	O
or	O
$	O
12.75	O
per	O
share	O
,	O
46.7	O
%	O
above	O
brocade	ORG
's	O
friday	O
close	O
.	O
read	O
more	O
at	O
fortune	ORG
.	O
[	O
ts_bullet_primary	O
]	O
valeant	ORG
pharmaceuticals	ORG
international	ORG
is	O
in	O
talks	O
to	O
sell	O
salix	ORG
pharmaceuticals	ORG
,	O
its	O
stomach	O
drug	O
business	O
,	O
to	O
the	O
japanese	O
pharmaceutical	O
giant	O
takeda	ORG
for	O
around	O
$	O
10	O
billion	O
,	O
the	O
wall	ORG
street	ORG
journal	ORG
reports	O
.	O
valeant	O
acquired	O
salix	ORG
less	O
than	O
two	O
years	O
ago	O
for	O
about	O
$	O
11	O
billion	O
.	O
read	O
more	O
.	O
[	O
ts_bullet_primary	O
]	O
angie	O
's	O
list	ORG
,	O
an	O
indianapolis-based	O
publicly	O
traded	O
local	O
services	O
marketplace	O
and	O
review	O
site	O
,	O
said	O
it	O
is	O
exploring	O
'strategic	O
options	O
'	O
after	O
reporting	O
a	O
loss	O
for	O
a	O
third	O
quarter	O
.	O
last	O
year	O
,	O
it	O
rejected	O
an	O
unsolicited	O
$	O
512	O
million	O
buyout	O
offer	O
from	O
iac/interactive	ORG
corp	ORG
.	ORG
ipos	ORG
gds	ORG
holdings	ORG
,	O
a	O
china-based	O
provider	O
of	O
data	O
centers	O
,	O
has	O
priced	O
its	O
ipo	O
below	O
the	O
expected	O
range	O
of	O
$	O
12	O
to	O
$	O
15	O
at	O
$	O
10	O
per	O
share	O
.	O
the	O
company	O
will	O
raise	O
$	O
192.5	O
million	O
.	O
credit	ORG
suisse	ORG
,	O
j.p.	ORG
morgan	ORG
,	O
citigroup	ORG
global	ORG
markets	ORG
inc.	ORG
,	O
rbc	O
capital	O
markets	O
,	O
llc	O
and	O
china	ORG
renaissance	ORG
securities	ORG
are	O
joint	O
book-running	O
managers	O
.	O
shareholders	O
include	O
st	O
telemedia	O
(	O
45.1	O
%	O
pre-ipo	O
stake	O
)	O
,	O
sb	ORG
china	ORG
venture	ORG
capital	ORG
(	O
18.1	O
%	O
)	O
and	O
ping	O
an	O
insurance	O
(	O
9.9	O
%	O
)	O
exits	O
[	O
ts_bullet_primary	O
]	O
fulcrum	ORG
equity	ORG
partners	ORG
and	ORG
level	ORG
capital	ORG
partners	ORG
have	O
recapitalized	O
careplus	ORG
medical	ORG
corporation	ORG
,	O
a	O
senior	O
credit	O
company	O
.	O
[	O
ts_bullet_primary	O
]	O
wasena	ORG
capital	ORG
management	ORG
and	ORG
millpond	ORG
equity	ORG
partners	ORG
have	O
recapitalized	O
science	O
first	O
,	O
a	O
yulee	O
,	O
fla.-based-based	O
designer	O
,	O
manufacturer	O
,	O
and	O
distributor	O
of	O
science	O
education	O
equipment	O
and	O
supplies	O
.	O
[	O
ts_bullet_primary	O
]	O
audax	O
private	O
equity	O
has	O
acquired	O
mobileum	O
,	O
a	O
san	LOC
jose	LOC
,	O
calif.-based	O
mobile	O
financial	O
services	O
startup	O
,	O
whose	O
backers	O
include	O
dcm	ORG
ventures	ORG
,	O
shelter	ORG
capital	ORG
partners	ORG
,	O
and	O
t-mobile	ORG
.	O
financial	O
terms	O
were	O
not	O
disclosed	O
.	O
[	O
ts_bullet_primary	O
]	O
spotify	ORG
has	O
acquired	O
preact	O
,	O
a	O
san	O
francisco-based	O
cloud	O
service	O
that	O
helps	O
companies	O
acquire	O
and	O
retain	O
customers	O
.	O
preact	O
has	O
raised	O
$	O
12.3	O
million	O
from	O
investors	O
including	O
trinity	ORG
ventures	ORG
,	O
root	ORG
ventures	ORG
,	O
atlas	ORG
venture	ORG
,	O
bee	ORG
partners	ORG
,	O
boldstart	ORG
ventures	ORG
,	O
karlin	ORG
ventures	ORG
,	O
harmony	ORG
partners	ORG
and	O
launchpad	ORG
la	ORG
.	O
firms	O
+	O
funds	ORG
kensington	ORG
capital	ORG
partners	ORG
,	O
the	O
manager	O
of	O
bc	ORG
tech	ORG
fund	ORG
,	O
has	O
invested	O
in	O
vanedge	O
capital	O
ii	O
,	O
a	O
vancouver-based	O
venture	O
capital	O
fund	O
focused	O
on	O
technology	O
companies	O
in	O
cloud	O
and	O
infrastructure	O
,	O
saas	O
,	O
cybersecurity	O
and	O
digital	O
media	O
.	O
new	O
jobs	O
[	O
ts_bullet_primary	O
]	O
daniel	PERS
schultz	PERS
has	O
joined	O
webster	ORG
capital	ORG
as	O
vice	O
president	O
of	O
business	O
development	O
,	O
while	O
alicia	PERS
alexander	PERS
has	O
been	O
promoted	O
to	O
vice	O
president	O
of	O
the	O
consumer	O
group	O
at	O
the	O
private	O
equity	O
firm	O
.	O
schultz	O
was	O
previously	O
director	O
of	O
business	O
development	O
at	O
capstone	ORG
partners	ORG
.	O
[	O
ts_bullet_primary	O
]	O
michael	PERS
drai	PERS
and	O
kim	PERS
vender	PERS
moffat	PERS
have	O
both	O
been	O
promoted	O
to	O
managing	O
director	O
at	O
sterling	ORG
capital	ORG
.	O
moffat	PERS
joined	O
the	O
private	O
equity	O
firm	O
in	O
1999	O
,	O
and	O
drai	O
in	O
2008	O
.	O
[	O
ts_bullet_primary	O
]	O
robbie	PERS
radant	PERS
has	O
joined	O
matrix	ORG
capital	ORG
markets	ORG
group	ORG
as	O
a	O
director	O
,	O
where	O
he	O
'll	O
head	O
the	O
firm	O
's	O
new	O
dallas	LOC
office	O
.	O
he	O
was	O
previously	O
vice	O
president	O
of	O
mergers	O
and	O
acquisitions	O
at	O
7-eleven	ORG
.	O
share	O
today	O
's	O
term	O
sheet	O
http	O
:	O
//fortune.com/newsletter/termsheet	O
term	O
sheet	O
is	O
produced	O
by	O
laura	PERS
entis	PERS
.	O
submit	O
deal	O
items	O
here	O
.	O
term	O
sheet	O
—	O
tuesday	O
,	O
december	O
13	O
open	O
mic	O
we	O
've	O
covered	O
a	O
lot	O
of	O
ground	O
since	O
our	O
last	O
feedback	O
column	O
.	O
here	O
is	O
a	O
selection	O
of	O
your	O
responses	O
:	O
on	O
the	O
tech	O
industry	O
's	O
disappointed	O
reaction	O
to	O
the	O
election	O
:	O
jesse	O
writes	O
:	O
as	O
a	O
society	O
,	O
this	O
is	O
what	O
happens	O
when	O
you	O
do	O
n't	O
teach	O
future	O
generations	O
how	O
to	O
lose	O
.	O
when	O
you	O
give	O
everyone	O
a	O
trophy	O
for	O
participating	O
and	O
do	O
not	O
declare	O
a	O
winner/loser	O
-	O
you	O
are	O
depriving	O
them	O
of	O
the	O
ability	O
to	O
process	O
losing	O
that	O
will	O
inevitably	O
come	O
at	O
some	O
stage	O
in	O
life	O
.	O
meredith	O
writes	O
:	O
erin	O
,	O
as	O
a	O
white	O
woman	O
who	O
did	O
n't	O
vote	O
for	O
hillary	O
,	O
i	O
am	O
sick	O
of	O
being	O
scolded	O
by	O
my	O
peers	O
and	O
strangers	O
alike	O
for	O
my	O
``	O
betrayal	O
.	O
''	O
but	O
the	O
chastisement	O
that	O
particularly	O
rankles	O
comes	O
from	O
silicon	LOC
valley	LOC
.	O
as	O
a	O
woman	O
in	O
tech	O
,	O
i	O
would	O
like	O
silicon	LOC
valley	LOC
to	O
shut-up	O
already	O
about	O
the	O
latent	O
sexism	O
in	O
america	LOC
and	O
focus	O
on	O
the	O
latent	O
sexism	O
in	O
their	O
companies	O
and	O
board	O
rooms	O
where	O
they	O
have	O
the	O
education	O
to	O
know	O
better	O
and	O
the	O
resources	O
to	O
do	O
better	O
.	O
all	O
politics	O
are	O
local	O
and	O
until	O
they	O
stop	O
celebrating	O
hillary	O
,	O
sheryl	O
,	O
marissa	O
and	O
meg	O
while	O
promoting	O
man	O
after	O
man	O
after	O
man	O
their	O
actions	O
speak	O
louder	O
than	O
their	O
words	O
.	O
good	O
for	O
peter	PERS
thiel	PERS
to	O
brave	O
the	O
sting	O
of	O
the	O
hypocrites	O
to	O
stand	O
up	O
for	O
what	O
he	O
believes	O
in	O
.	O
on	O
calpers	O
and	O
fee	O
transparency	O
:	O
gene	O
writes	O
:	O
vc	O
fees	O
have	O
always	O
seemed	O
too	O
high	O
to	O
me	O
.	O
portfolio	O
companies	O
create	O
the	O
wealth	O
,	O
and	O
if	O
they	O
do	O
,	O
the	O
team	O
gets	O
about	O
20	O
%	O
.	O
all	O
of	O
them	O
working	O
full	O
time	O
.	O
the	O
vc	O
shows	O
up	O
for	O
board	O
meetings	O
once	O
a	O
quarter	O
.	O
plus	O
they	O
have	O
a	O
diversified	O
portfolio	O
of	O
investments	O
.	O
companies	O
are	O
all-in	O
on	O
one	O
deal	O
.	O
vc	O
success	O
or	O
lack	O
thereof	O
determines	O
whether	O
they	O
can	O
raise	O
their	O
next	O
fund	O
,	O
and	O
stay	O
on	O
the	O
gravy	O
train	O
.	O
on	O
whether	O
theranos	O
is	O
disproportionally	O
criticized	O
because	O
elizabeth	PERS
holmes	PERS
is	O
a	O
woman	O
:	O
kevin	O
writes	O
:	O
if	O
a	O
company	O
is	O
struggling	O
,	O
a	O
female	O
ceo	O
is	O
more	O
likely	O
to	O
be	O
the	O
sole	O
target	O
of	O
the	O
blame	O
compared	O
to	O
their	O
male	O
counterparts	O
.	O
maybe	O
male	O
ceos	O
should	O
be	O
held	O
more	O
accountable	O
or	O
maybe	O
public	O
scrutiny	O
should	O
ease	O
up	O
on	O
female	O
ceos	O
themselves	O
.	O
i	O
'm	O
not	O
personally	O
sure	O
what	O
is	O
best	O
,	O
but	O
gender	O
dynamics	O
are	O
certainly	O
at	O
play	O
in	O
how	O
a	O
company	O
is	O
evaluated	O
.	O
on	O
snapchat	O
's	O
ipo	O
:	O
josh	O
writes	O
:	O
i	O
think	O
people	O
misunderstand	O
how	O
much	O
snapchat	O
has	O
or	O
has	O
n't	O
cycled	O
through	O
execs	O
.	O
a	O
lot	O
of	O
the	O
core	O
folks	O
including	O
imran	O
khan	O
,	O
nick	O
bell	O
,	O
their	O
general	O
counsel	O
,	O
and	O
timothy	PERS
sehn	PERS
,	O
their	O
vp	O
of	O
engineering	O
,	O
have	O
been	O
very	O
stable	O
for	O
several	O
years	O
now	O
.	O
we	O
get	O
caught	O
up	O
in	O
the	O
myth	O
(	O
emily	PERS
white	PERS
,	O
mike	PERS
randall	PERS
came	O
and	O
left	O
quickly	O
)	O
but	O
it	O
's	O
a	O
lot	O
more	O
stable	O
than	O
people	O
give	O
snapchat	O
credit	O
for	O
.	O
on	O
the	O
``	O
pipeline	O
problem	O
''	O
for	O
women	O
on	O
startup	O
boards	O
:	O
gerry	O
writes	O
:	O
i	O
think	O
your	O
section	O
on	O
the	O
lack	O
of	O
diversity	O
on	O
startup	O
boards	O
may	O
have	O
reflected	O
your	O
bias	O
,	O
when	O
you	O
stated	O
that	O
men	O
believe	O
it	O
's	O
a	O
pipeline	O
issue	O
,	O
while	O
women	O
know	O
it	O
's	O
unconscious	O
bias	O
.	O
my	O
opinion	O
(	O
as	O
a	O
male	O
)	O
is	O
it	O
's	O
a	O
mix	O
of	O
both	O
,	O
but	O
varies	O
by	O
sector	O
.	O
i	O
certainly	O
do	O
not	O
dismiss	O
unconscious	O
bias	O
as	O
a	O
factor	O
.	O
i	O
'm	O
on	O
the	O
board	O
of	O
a	O
company	O
with	O
strong	O
broadcast	O
media	O
ties	O
.	O
there	O
,	O
we	O
have	O
a	O
female	O
outside	O
board	O
member	O
,	O
in	O
part	O
because	O
the	O
pipeline	O
allowed	O
it	O
.	O
but	O
i	O
'm	O
on	O
the	O
board	O
of	O
a	O
chemical	O
company	O
where	O
the	O
executive	O
pipeline	O
of	O
females	O
is	O
very	O
,	O
very	O
thin	O
.	O
my	O
response	O
:	O
to	O
be	O
clear	O
,	O
the	O
first	ORG
round	ORG
capital	ORG
state	O
of	O
startups	O
survey	O
was	O
focused	O
almost	O
entirely	O
on	O
enterprise	O
and	O
consumer	O
tech	O
startups	O
,	O
where	O
there	O
's	O
plenty	O
of	O
pipeline	O
.	O
on	O
tech	O
replacing	O
jobs	O
:	O
tony	O
writes	O
:	O
technology	O
will	O
eventually	O
replace	O
all	O
current	O
jobs	O
.	O
if	O
people	O
still	O
want	O
to	O
do	O
what	O
a	O
machine	O
can	O
do	O
(	O
like	O
driving	O
)	O
,	O
then	O
people	O
have	O
not	O
kept	O
pace	O
.	O
machines	O
taking	O
non-engaging	O
jobs	O
should	O
be	O
a	O
relief	O
,	O
not	O
a	O
negative	O
.	O
who	O
really	O
misses	O
washing	O
dishes	O
or	O
calculating	O
the	O
same	O
numbers	O
over	O
and	O
over	O
because	O
an	O
assumption	O
changes	O
?	O
adam	O
writes	O
:	O
i	O
think	O
the	O
less-explored	O
issue	O
is	O
about	O
the	O
amorality	O
of	O
the	O
social	O
cost	O
of	O
change	O
-	O
whether	O
tech	O
or	O
economic	O
-	O
as	O
they	O
both	O
have	O
significant	O
political	O
consequences	O
.	O
the	O
challenge	O
for	O
innovation	O
is	O
exacerbated	O
by	O
the	O
lack	O
of	O
acknowledgement	O
of	O
the	O
outcomes	O
.	O
which	O
engineers	O
-	O
it	O
and	O
financial	O
-	O
are	O
generally	O
not	O
the	O
most	O
sensitive	O
to	O
or	O
even	O
aware	O
of	O
!	O
separately	O
i	O
have	O
been	O
surprised	O
at	O
how	O
little	O
coverage	O
there	O
has	O
been	O
on	O
students	O
'	O
ability	O
to	O
assess	O
information	O
credibility	O
online	O
.	O
without	O
question	O
it	O
would	O
seem	O
that	O
there	O
will	O
be	O
a	O
legitimate	O
focus	O
to	O
regulate	O
.	O
perhaps	O
it	O
is	O
not	O
scold/self-loathe	O
but	O
practicality	O
that	O
should	O
prevail	O
?	O
vlad	O
says	O
:	O
it	O
sounds	O
like	O
you	O
have	O
n't	O
read	O
the	O
second	O
machine	O
age	O
or	O
rise	O
of	O
the	O
robots	O
.	O
you	O
're	O
much	O
too	O
quick	O
to	O
dismiss	O
the	O
possibility	O
that	O
it	O
truly	O
might	O
be	O
different	O
this	O
time	O
.	O
consider	O
again	O
.	O
consider	O
it	O
reconsidered	O
,	O
vlad	O
!	O
luke	O
writes	O
:	O
i	O
appreciated	O
your	O
commentary	O
and	O
insight	O
with	O
regards	O
to	O
this	O
topic	O
.	O
i	O
truly	O
believe	O
that	O
those	O
working	O
in	O
tech	O
(	O
both	O
those	O
at	O
the	O
bottom	O
and	O
those	O
at	O
the	O
top	O
)	O
do	O
n't	O
understand	O
when	O
they	O
realize	O
that	O
a	O
lot	O
of	O
people	O
look	O
at	O
startups	O
with	O
a	O
mixture	O
of	O
skepticism	O
and	O
fear	O
.	O
i	O
have	O
been	O
repeatedly	O
woken	O
up	O
to	O
that	O
fact	O
when	O
i	O
've	O
chatted	O
with	O
people	O
outside	O
of	O
the	O
bay	O
area	O
and	O
especially	O
those	O
outside	O
of	O
california	LOC
.	O
i	O
have	O
taken	O
for	O
granted	O
that	O
most	O
people	O
hold	O
my	O
views	O
and	O
that	O
the	O
west	O
coast	O
pov	O
is	O
very	O
clearly	O
the	O
view	O
which	O
should	O
be	O
championed	O
above	O
all	O
others	O
.	O
it	O
's	O
led	O
to	O
a	O
barrier	O
in	O
understanding	O
and	O
relating	O
to	O
a	O
significant	O
amount	O
of	O
people	O
and	O
increasing	O
separation	O
with	O
this	O
small	O
geographic	O
region	O
and	O
others	O
.	O
jason	O
writes	O
:	O
we	O
're	O
turning	O
into	O
luddites	O
.	O
and	O
one	O
poor	O
word	O
choice	O
on	O
my	O
part	O
,	O
from	O
yesterday	O
's	O
edition	O
:	O
when	O
referencing	O
the	O
paydays	O
of	O
private	O
equity	O
's	O
bigwigs	O
,	O
i	O
said	O
``	O
salary	O
''	O
when	O
i	O
should	O
have	O
said	O
``	O
pay	O
.	O
''	O
steve	PERS
schwarzman	PERS
makes	O
a	O
$	O
350,000	O
salary	O
,	O
for	O
example	O
,	O
but	O
he	O
took	O
home	O
$	O
800	O
million	O
last	O
year	O
from	O
carried	O
interest	O
,	O
personal	O
investment	O
profits	O
,	O
and	O
mostly	O
,	O
dividends	O
and	O
distributions	O
,	O
according	O
to	O
the	O
new	O
york	O
times	O
estimate	O
.	O
some	O
of	O
you	O
took	O
issue	O
with	O
that	O
.	O
ray	O
writes	O
:	O
so	O
someone	O
invests	O
their	O
own	O
money	O
...	O
and	O
then	O
has	O
a	O
good	O
year	O
investing	O
.	O
and	O
so	O
makes	O
a	O
lot	O
of	O
money	O
.	O
great	O
point	O
.	O
the	O
latest	O
from	O
fortune	O
...	O
[	O
ts_bullet_primary	O
]	O
4	O
stocks	O
that	O
could	O
ride	O
china	LOC
's	O
global	O
construction	O
boom	O
[	O
ts_bullet_primary	O
]	O
entrepreneurs	O
take	O
on	O
depression	O
[	O
ts_bullet_primary	O
]	O
fortune	O
's	O
most	O
powerful	O
women	O
podcast	O
interview	O
is	O
with	O
ginni	O
rometty	O
,	O
chairman	O
and	O
ceo	O
of	O
ibm	ORG
.	O
[	O
ts_bullet_primary	O
]	O
salesforce	ORG
believes	O
messaging	O
is	O
the	O
future	O
of	O
crm	O
[	O
ts_bullet_primary	O
]	O
why	O
on	O
earth	O
are	O
ceos	O
joining	O
trump	PERS
's	O
cabinet	O
?	O
[	O
ts_bullet_primary	O
]	O
google	ORG
,	O
diversity	O
and	O
the	O
bottom	O
line	O
[	O
ts_bullet_primary	O
]	O
bill	PERS
gates	PERS
talked	O
with	O
donald	PERS
trump	PERS
[	O
ts_bullet_primary	O
]	O
rex	O
tillerson	O
's	O
mixed	O
record	O
[	O
ts_bullet_primary	O
]	O
why	O
vcs	O
are	O
giving	O
up	O
on	O
on-demand	O
...	O
and	O
elsewhere	O
what	O
will	O
you	O
do	O
with	O
your	O
extra	O
second	O
this	O
year	O
?	O
the	O
home	O
office	O
is	O
dying	O
.	O
tecent	O
seeks	O
hollywood	LOC
deals	O
.	O
automation	O
can	O
create	O
more	O
jobs	O
.	O
romney	O
got	O
played	O
-	O
is	O
carly	O
next	O
on	O
the	O
humiliation	O
list	O
?	O
goodbye	O
,	O
net	O
neutrality	O
.	O
venture	O
deals	O
[	O
ts_bullet_primary	O
]	O
jetsmarter	O
,	O
a	O
fort	O
lauderdale	O
,	O
fla.-based	O
service	O
for	O
renting	O
private	O
and	O
shared	O
chartered	O
jets	O
,	O
raised	O
$	O
105	O
million	O
in	O
series	O
c	O
funding	O
from	O
the	O
saudi	O
royal	O
family	O
,	O
jay	O
z	O
,	O
and	O
other	O
investors	O
.	O
the	O
company	O
is	O
now	O
valued	O
at	O
$	O
1.5	O
billion	O
.	O
[	O
ts_bullet_primary	O
]	O
iterable	O
,	O
a	O
san	O
francisco-based	O
marketing	O
software	O
company	O
,	O
raised	O
$	O
23	O
million	O
in	O
series	O
b	O
funding	O
.	O
index	ORG
ventures	ORG
led	O
the	O
round	O
,	O
with	O
participation	O
from	O
crv	O
and	O
other	O
existing	O
investors	O
.	O
[	O
ts_bullet_primary	O
]	O
nasuni	O
,	O
a	O
natick	O
,	O
mass.-based	O
cloud	O
storage	O
company	O
,	O
raised	O
$	O
17.5	O
million	O
in	O
series	O
e	O
funding	O
from	O
sigma	ORG
prime	ORG
ventures	ORG
.	O
[	O
ts_bullet_primary	O
]	O
applepie	O
,	O
a	O
seattle-based	O
online	O
seller	O
of	O
u.s.-made	O
products	O
,	O
raised	O
$	O
16.5	O
million	O
in	O
series	O
b	O
funding	O
.	O
qed	O
investors	O
and	O
fifth	ORG
third	ORG
capital	ORG
led	O
the	O
round	O
,	O
with	O
participation	O
from	O
colchis	ORG
capital	ORG
management	ORG
and	O
existing	O
investors	O
signia	ORG
venture	ORG
partners	ORG
,	O
freestyle	ORG
capital	ORG
,	O
and	O
ron	PERS
suber	PERS
.	O
[	O
ts_bullet_primary	O
]	O
truecaller	O
,	O
a	O
stockholm-based	O
developer	O
of	O
mobile	O
services	O
including	O
caller-id	O
and	O
spam	O
protection	O
,	O
raised	O
100	O
million	O
swedish	O
krona	O
(	O
$	O
10.9	O
million	O
)	O
from	O
zenith	ORG
venture	ORG
capital	ORG
,	O
according	O
to	O
tech.eu	O
.	O
read	O
more	O
.	O
[	O
ts_bullet_primary	O
]	O
boatsetter	O
,	O
a	O
miami-based	O
peer-to-peer	O
boat	O
rental	O
marketplace	O
,	O
raised	O
$	O
13	O
million	O
in	O
series	O
a	O
funding	O
.	O
investors	O
include	O
great	ORG
oaks	ORG
venture	ORG
capital	ORG
,	O
stanford	ORG
university	ORG
daper	ORG
fund	ORG
,	O
zg	ORG
ventures	ORG
,	O
peninsula	ORG
ventures	ORG
,	O
and	O
several	O
angel	O
investors	O
.	O
[	O
ts_bullet_primary	O
]	O
lygos	O
,	O
a	O
berkeley	O
,	O
calif.-based	O
biotech	O
specialty	O
chemicals	O
company	O
,	O
raised	O
$	O
13	O
million	O
in	O
series	O
a	O
funding	O
.	O
ia	ORG
ventures	ORG
and	ORG
os	ORG
fund	ORG
led	O
the	O
round	O
,	O
with	O
participation	O
from	O
first	ORG
round	ORG
capital	ORG
,	O
the	O
y	ORG
combinator	ORG
continuity	ORG
fund	ORG
,	O
50	O
years	O
,	O
vast	O
ventures	O
,	O
and	O
angel	O
investors	O
.	O
[	O
ts_bullet_primary	O
]	O
socure	O
,	O
a	O
new	O
york	O
city-based	O
digital	O
verification	O
company	O
,	O
raised	O
$	O
13	O
million	O
in	O
funding	O
.	O
flint	ORG
capital	ORG
led	O
the	O
round	O
,	O
and	O
was	O
joined	O
by	O
santander	O
innoventures	O
and	O
two	O
sigma	ORG
ventures	ORG
.	O
[	O
ts_bullet_primary	O
]	O
clear	O
labs	O
,	O
a	O
menlo	O
park	O
,	O
calif.-based	O
provider	O
of	O
food	O
analytics	O
for	O
retailers	O
and	O
manufacturers	O
,	O
raised	O
$	O
13	O
million	O
in	O
series	O
b	O
funding	O
.	O
wing	O
vc	O
led	O
the	O
round	O
,	O
with	O
participation	O
from	O
gv	O
,	O
tencent	O
,	O
khosla	ORG
ventures	ORG
,	O
and	O
felicis	ORG
ventures	ORG
.	O
[	O
ts_bullet_primary	O
]	O
signal	O
media	O
,	O
a	O
u.k.	LOC
ai-powered	O
information	O
intelligence	O
company	O
,	O
raised	O
?	O
5.8	O
million	O
(	O
$	O
7.3	O
million	O
)	O
in	O
funding	O
from	O
mmc	ORG
ventures	ORG
,	O
hearst	ORG
ventures	ORG
,	O
frontline	ORG
ventures	ORG
,	O
reed	ORG
elsevier	ORG
ventures	ORG
and	O
local	ORG
globe	ORG
.	O
[	O
ts_bullet_primary	O
]	O
lola	O
,	O
a	O
new	O
york	O
city-based	O
maker	O
of	O
organic	O
tampons	O
and	O
pads	O
,	O
raised	O
$	O
7	O
million	O
in	O
series	O
a	O
funding	O
.	O
spark	ORG
capital	ORG
led	O
the	O
round	O
,	O
and	O
was	O
joined	O
by	O
angel	O
investors	O
including	O
lena	PERS
dunham	PERS
.	O
[	O
ts_bullet_primary	O
]	O
solvvy	O
,	O
a	O
palo	LOC
alto	LOC
,	O
calif.-based	O
startup	O
that	O
makes	O
machine-learning	O
software	O
to	O
help	O
companies	O
manage	O
customer	O
service	O
,	O
raised	O
$	O
4.5	O
million	O
in	O
seed	O
funding	O
.	O
true	ORG
ventures	ORG
led	O
the	O
round	O
,	O
with	O
participation	O
from	O
pear	ORG
ventures	ORG
(	O
formerly	O
pejman	ORG
mar	ORG
ventures	ORG
)	O
,	O
carnegie	ORG
mellon	ORG
university	ORG
,	O
signatures	ORG
capital	ORG
,	O
investment	ORG
group	ORG
of	O
santa	O
barbara	O
,	O
and	O
angel	O
investors	O
including	O
dan	PERS
rose	PERS
and	O
hamid	O
barkhordar	O
.	O
[	O
ts_bullet_primary	O
]	O
supportpay	O
,	O
a	O
sacramento-based	O
app	O
for	O
managing	O
child	O
support	O
payments	O
and	O
expenses	O
,	O
raised	O
$	O
4.1	O
million	O
in	O
series	O
a	O
funding	O
.	O
fenway	ORG
summer	ORG
ventures	ORG
led	O
the	O
round	O
,	O
and	O
was	O
joined	O
by	O
moneta	ORG
ventures	ORG
and	ORG
continental	ORG
advisors	ORG
.	O
[	O
ts_bullet_primary	O
]	O
jumpcrew	O
,	O
a	O
nashville	LOC
,	O
tenn.-based	O
social	O
media	O
marketing	O
company	O
,	O
raised	O
$	O
3.3	O
million	O
in	O
seed	O
funding	O
.	O
david	PERS
pachter	PERS
led	O
the	O
round	O
,	O
with	O
participation	O
from	O
jim	PERS
caden	PERS
,	O
bob	PERS
pasker	PERS
,	O
and	O
david	PERS
steinhardt	PERS
.	O
[	O
ts_bullet_primary	O
]	O
plato	O
,	O
a	O
san	LOC
jose	LOC
,	O
calif.-based	O
gaming	O
app	O
,	O
raised	O
$	O
3	O
million	O
in	O
seed	O
funding	O
from	O
unnamed	O
angel	O
investors	O
.	O
[	O
ts_bullet_primary	O
]	O
breezometer	O
,	O
an	O
israeli	O
air	O
quality	O
analytics	O
provider	O
,	O
raised	O
$	O
3	O
million	O
in	O
series	O
a	O
funding	O
.	O
phi	ORG
square	ORG
holdings	ORG
led	O
the	O
round	O
,	O
and	O
was	O
joined	O
by	O
entr	O
?	O
e	O
capital	O
,	O
launchpad	O
digital	O
health	O
and	O
seedil	O
.	O
[	O
ts_bullet_primary	O
]	O
skupos	O
,	O
a	O
san	O
francisco-based	O
provider	O
of	O
retail	O
distribution	O
software	O
for	O
the	O
convenience	O
store	O
industry	O
,	O
raised	O
$	O
2.4	O
million	O
in	O
seed	O
funding	O
.	O
dynamo	ORG
fund	ORG
led	O
the	O
round	O
with	O
participation	O
from	O
toba	ORG
capital	ORG
.	O
[	O
ts_bullet_primary	O
]	O
privacy	O
,	O
a	O
new	O
york	O
city-based	O
developer	O
of	O
payments	O
privacy	O
software	O
,	O
raised	O
$	O
2.2	O
million	O
in	O
seed	O
funding	O
.	O
index	ORG
ventures	ORG
led	O
the	O
round	O
,	O
with	O
participation	O
from	O
rocketship.vc	O
and	O
angel	O
investors	O
.	O
[	O
ts_bullet_primary	O
]	O
codecheck	O
,	O
a	O
switzerland-based	O
developer	O
of	O
a	O
smartphone	O
app	O
that	O
provides	O
product	O
descriptions	O
and	O
ingredients	O
when	O
consumers	O
scan	O
items	O
as	O
they	O
shop	O
,	O
raised	O
$	O
1.3	O
million	O
in	O
funding	O
from	O
polytech	O
ecosystem	O
,	O
among	O
other	O
investors	O
.	O
[	O
ts_bullet_primary	O
]	O
maropost	O
,	O
a	O
toronto-based	O
developer	O
of	O
email	O
and	O
digital	O
marketing	O
automation	O
software	O
,	O
has	O
secured	O
an	O
undisclosed	O
amount	O
of	O
funding	O
from	O
elephant	O
and	O
highland	ORG
europe	ORG
.	O
private	O
equity	O
deals	O
[	O
ts_bullet_primary	O
]	O
rs	O
energy	O
group	O
,	O
backed	O
by	O
warburg	O
pincus	O
,	O
has	O
acquired	O
navport	O
,	O
a	O
provider	O
of	O
data	O
analytics	O
software	O
for	O
the	O
oil	O
and	O
gas	O
industry	O
.	O
financial	O
terms	O
were	O
not	O
disclosed	O
.	O
[	O
ts_bullet_primary	O
]	O
ranch	O
creek	O
partners	O
has	O
acquired	O
a	O
majority	O
stake	O
in	O
apposite	ORG
technologies	ORG
,	O
a	O
los	O
angeles-based	O
a	O
maker	O
of	O
network	O
simulation	O
products	O
.	O
financial	O
terms	O
were	O
not	O
disclosed	O
.	O
[	O
ts_bullet_primary	O
]	O
altamont	O
capital	O
partners	O
has	O
acquired	O
maxi	ORG
canada	ORG
,	O
a	O
st-lin-laurentides	O
,	O
qc.-based	O
manufacturer	O
of	O
frozen	O
poultry	O
products	O
.	O
financial	O
terms	O
were	O
not	O
disclosed	O
.	O
[	O
ts_bullet_primary	O
]	O
contegix	O
,	O
a	O
saint	O
louis	O
,	O
miss.-based	O
cloud	O
computing	O
company	O
backed	O
by	O
strattam	ORG
capital	ORG
,	O
has	O
acquired	O
admo.net	O
web	ORG
services	ORG
,	O
a	O
kansas	LOC
city	LOC
cloud	O
and	O
managed	O
services	O
provider	O
.	O
[	O
ts_bullet_primary	O
]	O
equistone	O
partners	O
europe	LOC
,	O
a	O
european	O
mid-market	O
private	O
equity	O
firm	O
,	O
has	O
acquired	O
group	O
of	O
butchers	O
,	O
a	O
dutch	O
producer	O
of	O
meat	O
products	O
.	O
[	O
ts_bullet_primary	O
]	O
finalsite	O
,	O
an	O
east	LOC
hartford	LOC
,	O
conn.-based	O
developer	O
of	O
educational	O
software	O
backed	O
by	O
bridge	ORG
growth	ORG
partners	ORG
,	O
has	O
acquired	O
school	O
website	O
,	O
a	O
saas-based	O
cms	O
software	O
provider	O
to	O
schools	O
in	O
the	O
uk	LOC
.	O
[	O
ts_bullet_primary	O
]	O
h.i.g	O
.	O
capital	O
,	O
a	O
miami-based	O
private	O
equity	O
firm	O
,	O
has	O
agreed	O
to	O
buy	O
lionbridge	ORG
technologies	ORG
,	O
inc.	O
(	O
nasdaq	O
:	O
liox	O
)	O
for	O
around	O
$	O
369	O
million	O
.	O
lionbridge	O
shareholders	O
will	O
receive	O
$	O
5.75	O
in	O
cash	O
per	O
share	O
,	O
a	O
3.2	O
%	O
premium	O
over	O
the	O
company	O
's	O
friday	O
close	O
.	O
[	O
ts_bullet_primary	O
]	O
pace	ORG
holdings	ORG
corp.	ORG
(	O
nasdaq	O
:	O
pace	O
)	O
,	O
a	O
blank-check	O
company	O
backed	O
by	O
private	O
equity	O
firm	O
tpg	ORG
,	O
has	O
agreed	O
to	O
buy	O
playa	ORG
hotels	ORG
&	ORG
resorts	ORG
b.v	ORG
.	O
,	O
an	O
amsterdam-based	O
owner	O
,	O
operator	O
,	O
and	O
developer	O
of	O
resorts	O
.	O
the	O
combined	O
company	O
will	O
be	O
publicly	O
listed	O
with	O
an	O
estimated	O
enterprise	O
value	O
of	O
around	O
$	O
1.75	O
billion	O
.	O
it	O
will	O
retain	O
the	O
playa	ORG
name	O
.	O
other	O
deals	O
[	O
ts_bullet_primary	O
]	O
anheuser-busch	ORG
inbev	ORG
(	O
enxtbr	O
:	O
abi	O
)	O
has	O
agreed	O
to	O
sell	O
five	O
of	O
its	O
european	O
beer	O
brands	O
to	O
asahi	ORG
group	ORG
holdings	ORG
(	O
tse:2502	O
)	O
for	O
eur7.3	O
billion	O
(	O
$	O
7.8	O
billion	O
)	O
.	O
read	O
more	O
at	O
fortune	O
.	O
[	O
ts_bullet_primary	O
]	O
google	ORG
(	O
nasdaqgs	O
:	O
googl	O
)	O
has	O
acquired	O
cronologics	O
,	O
a	O
san	O
mateo	O
,	O
calif.-based	O
developer	O
of	O
a	O
software	O
platform	O
for	O
smart	O
watches	O
.	O
financial	O
terms	O
were	O
not	O
disclosed	O
,	O
but	O
cronologics	O
co-founders	O
lan	O
rcohe	O
,	O
leor	O
stern	O
,	O
and	O
john	O
lagerling	O
,	O
all	O
ex-google	O
employees	O
,	O
will	O
rejoin	O
the	O
company	O
working	O
under	O
its	O
android	O
wear	O
division	O
.	O
read	O
more	O
at	O
fortune	O
.	O
[	O
ts_bullet_primary	O
]	O
bow	O
street	O
,	O
a	O
new	O
york	O
city-based	O
hedge	O
fund	O
,	O
has	O
offered	O
to	O
buy	O
northstar	ORG
realty	ORG
europe	ORG
corp	ORG
(	O
nyse	O
:	O
nre	O
)	O
for	O
$	O
13	O
per	O
share	O
,	O
in	O
a	O
deal	O
valued	O
at	O
about	O
$	O
728	O
million	O
,	O
according	O
to	O
reuters	O
.	O
read	O
more	O
.	O
[	O
ts_bullet_primary	O
]	O
cloudflare	O
,	O
a	O
san	O
francisco-based	O
internet	O
performance	O
and	O
security	O
company	O
,	O
has	O
acquired	O
eager	O
platform	O
,	O
a	O
cambridge	LOC
,	O
mass.-based	O
service	O
for	O
building	O
web	O
applications	O
.	O
financial	O
terms	O
were	O
not	O
disclosed	O
.	O
[	O
ts_bullet_primary	O
]	O
first	O
republic	O
bank	O
,	O
a	O
san	O
francisco-based	O
bank	O
,	O
has	O
acquired	O
gradifi	O
,	O
a	O
boston-based	O
student	O
loan	O
repayment	O
company	O
.	O
financial	O
terms	O
were	O
not	O
disclosed	O
.	O
ipos	O
no	O
ipo	O
news	O
today	O
.	O
exits	O
[	O
ts_bullet_primary	O
]	O
kkr	ORG
(	O
nyse	O
:	O
kkr	ORG
)	O
and	O
ksl	ORG
capital	ORG
partners	ORG
,	O
a	O
denver-based	O
private	O
equity	O
firm	O
,	O
have	O
agreed	O
to	O
sell	O
apple	ORG
leisure	ORG
group	ORG
,	O
a	O
newtown	O
square	O
,	O
penn.-based	O
tour	O
operator	O
,	O
to	O
bain	ORG
capital	ORG
private	ORG
equity	ORG
.	O
financial	O
terms	O
were	O
not	O
disclosed	O
.	O
[	O
ts_bullet_primary	O
]	O
california	LOC
cryobank	O
has	O
agreed	O
to	O
acquire	O
donor	ORG
egg	ORG
bank	ORG
usa	ORG
,	O
a	O
rockville	O
,	O
md.-based	O
provider	O
of	O
frozen	O
donor	O
sperm	O
and	O
eggs	O
,	O
from	O
longitude	ORG
capital	ORG
and	O
novaquest	ORG
capital	ORG
management	ORG
.	O
firms	O
+	O
funds	O
[	O
ts_bullet_primary	O
]	O
apple	ORG
(	O
nasdq	O
:	O
aapl	O
)	O
is	O
considering	O
investing	O
up	O
to	O
$	O
1	O
billion	O
in	O
softbank	ORG
's	O
upcoming	O
$	O
100	O
billion	O
vision	O
fund	O
.	O
read	O
more	O
at	O
fortune	O
.	O
new	O
jobs	O
[	O
ts_bullet_primary	O
]	O
matthew	O
g.	O
harrison	O
and	O
seth	PERS
r.	PERS
pearson	PERS
have	O
been	O
promoted	O
to	O
partners	O
at	O
wellspring	ORG
capital	ORG
management	ORG
,	O
a	O
new	O
york	O
city-based	O
private	O
equity	O
firm	O
.	O
both	O
were	O
previously	O
principals	O
at	O
the	O
firm	O
.	O
[	O
ts_bullet_primary	O
]	O
peter	O
flint	ORG
is	O
joining	O
nfx	O
guild	O
,	O
a	O
palo	LOC
alto	LOC
,	O
calif.-based	O
early-stage	O
venture	O
capital	O
fund	O
and	O
accelerator	O
program	O
for	O
startups	O
,	O
as	O
managing	O
partner	O
.	O
flint	ORG
co-founded	O
trulia	O
,	O
a	O
san	O
francisco-based	O
real	O
estate	O
website	O
.	O
[	O
ts_bullet_primary	O
]	O
jacob	O
mullins	O
has	O
joined	O
shasta	ORG
ventures	ORG
,	O
a	O
san	O
francisco-based	O
venture	O
capital	O
firm	O
,	O
as	O
a	O
principal	O
to	O
lead	O
a	O
new	O
program	O
focused	O
on	O
augmented	O
reality	O
and	O
virtual	O
reality	O
,	O
according	O
to	O
the	O
wall	O
street	O
journal	O
.	O
mullins	O
co-founded	O
exitround	O
,	O
a	O
san	O
francisco-based	O
mergers	O
and	O
acquisitions	O
marketplace	O
.	O
read	O
more	O
.	O
[	O
ts_bullet_primary	O
]	O
leonardo	O
dicaprio	O
has	O
joined	O
the	O
advisory	O
board	O
of	O
data	ORG
point	ORG
capital	ORG
,	O
a	O
boston-based	O
venture	O
capital	O
firm	O
.	O
share	O
today	O
's	O
term	O
sheet	O
http	O
:	O
//fortune.com/newsletter/termsheet	O
term	O
sheet	O
is	O
produced	O
by	O
laura	PERS
entis	PERS
and	O
kia	ORG
kokalitcheva	O
.	O
submit	O
deal	O
items	O
here	O
.	O
why	O
trump	PERS
and	O
congress	ORG
should	O
keep	O
women	O
in	O
mind	O
when	O
retooling	O
obamacare	O
as	O
president-elect	O
donald	PERS
trump	PERS
and	O
the	O
republican-led	O
congress	ORG
weigh	O
changes	O
to	O
the	O
affordable	O
care	O
act	O
,	O
two	O
women	O
's	O
health	O
practitioners	O
have	O
some	O
advice	O
for	O
how	O
washington	LOC
should	O
proceed	O
as	O
they	O
consider	O
reshaping	O
the	O
landmark	O
public	O
health	O
program	O
.	O
president	O
barack	PERS
obama	PERS
's	O
signature	O
legislation	O
has	O
been	O
coming	O
apart	O
at	O
the	O
seams	O
as	O
health	O
insurers	O
bolt	O
public	O
exchanges	O
and	O
insurance	O
costs	O
surge	O
for	O
many	O
of	O
obamacare	O
's	O
20	O
million	O
users	O
.	O
yet	O
molly	PERS
maloof	PERS
,	O
a	O
physician	O
,	O
technologist	O
and	O
a	O
wellness	O
expert	O
,	O
told	O
cnbc	ORG
something	O
that	O
the	O
gop	ORG
appears	O
to	O
be	O
figuring	O
out	O
on	O
its	O
own	O
:	O
repealing	O
and	O
replacing	O
obamacare	O
may	O
be	O
easier	O
said	O
than	O
done	O
.	O
``	O
i	O
'm	O
really	O
concerned	O
that	O
reversing	O
it	O
will	O
make	O
the	O
problem	O
worse	O
.	O
i	O
do	O
n't	O
know	O
if	O
trump	PERS
totally	O
understands	O
the	O
weight	O
of	O
this	O
problem	O
,	O
''	O
maloof	O
told	O
cnbc	ORG
recently	O
.	O
as	O
congress	ORG
and	O
the	O
president-elect	O
move	O
to	O
reshape	O
the	O
legislation	O
,	O
the	O
physician	O
said	O
she	O
'd	O
like	O
to	O
see	O
more	O
discussion	O
around	O
family	O
planning	O
and	O
women	O
's	O
health	O
care	O
,	O
which	O
could	O
take	O
a	O
hit	O
under	O
reform	O
.	O
still	O
,	O
even	O
house	ORG
speaker	O
paul	PERS
ryan	PERS
acknowledged	O
the	O
challenges	O
obamacare	O
reform	O
presents	O
.	O
he	O
told	O
cnbc	ORG
this	O
week	O
that	O
a	O
``	O
reasonable	O
''	O
transition	O
period	O
was	O
necessary	O
,	O
as	O
to	O
ensure	O
the	O
government	O
was	O
``	O
not	O
pulling	O
the	O
rug	O
out	O
from	O
under	O
people	O
midstream	O
.	O
''	O
``	O
most	O
key	O
stakeholders	O
at	O
the	O
helm	O
of	O
insurance	O
companies	O
,	O
hospitals	O
,	O
government—even	O
digital	O
health	O
companies—are	O
men	O
.	O
''	O
-katherine	O
ryder	PERS
,	O
ceo	O
and	O
founder	O
,	O
maven	ORG
maloof	ORG
told	O
cnbc	ORG
that	O
the	O
u.s.	LOC
health-care	O
system	O
was	O
``	O
very	O
paternalistic	O
''	O
—	O
a	O
reflection	O
of	O
data	O
showing	O
that	O
women	O
's	O
health	O
costs	O
are	O
often	O
higher	O
than	O
men	O
's	O
.	O
a	O
2014	O
study	O
by	O
mercer	O
showed	O
that	O
women	O
pay	O
more	O
than	O
their	O
male	O
counterparts	O
for	O
health	O
benefits	O
—	O
primarily	O
because	O
they	O
tend	O
to	O
utilize	O
those	O
services	O
more	O
.	O
``	O
before	O
the	O
aca	O
,	O
women	O
paid	O
$	O
1	O
billion	O
more	O
than	O
men	O
each	O
year	O
for	O
identical	O
health	O
plans	O
in	O
the	O
individual	O
market	O
.	O
this	O
is	O
not	O
right	O
,	O
''	O
maloof	O
said	O
.	O
maloof	O
and	O
katherine	PERS
ryder	PERS
,	O
the	O
founder	O
of	O
maven	ORG
,	O
a	O
digital	O
app	O
targeted	O
toward	O
women	O
that	O
connects	O
them	O
with	O
health-care	O
providers	O
,	O
said	O
they	O
would	O
like	O
to	O
see	O
broader	O
changes	O
in	O
the	O
health-care	O
industry	O
under	O
trump	PERS
.	O
``	O
women	O
make	O
the	O
disproportionate	O
number	O
of	O
health-care	O
decisions	O
in	O
the	O
u.s.	LOC
,	O
''	O
ryder	PERS
told	O
cnbc	ORG
.	O
``	O
so	O
we	O
wanted	O
to	O
design	O
a	O
product	O
with	O
the	O
female	O
patient	O
in	O
mind	O
.	O
''	O
a	O
similar	O
philosophy	O
motivated	O
ryder	PERS
in	O
2014	O
when	O
she	O
created	O
maven	ORG
,	O
a	O
digital	O
clinic	O
that	O
seeks	O
to	O
provide	O
women	O
with	O
affordable	O
and	O
readily	O
available	O
health	O
care	O
.	O
the	O
idea	O
occurred	O
to	O
ryder	PERS
after	O
she	O
turned	O
30	O
and	O
she	O
witnessed	O
her	O
friends	O
having	O
children	O
.	O
``	O
i	O
realized	O
that	O
there	O
was	O
n't	O
as	O
much	O
support	O
as	O
there	O
could	O
,	O
or	O
should	O
,	O
be	O
around	O
this	O
moment	O
in	O
a	O
woman	O
's	O
life	O
,	O
''	O
ryder	PERS
said	O
.	O
``	O
right	O
now	O
our	O
health-care	O
system	O
is	O
really	O
inconvenient	O
,	O
and	O
there	O
are	O
gaps	O
in	O
women	O
's	O
care	O
''	O
—	O
which	O
could	O
be	O
exacerbated	O
if	O
obamacare	O
reform	O
is	O
n't	O
executed	O
properly	O
.	O
the	O
playing	O
field	O
is	O
even	O
more	O
uncertain	O
,	O
with	O
trump	PERS
planning	O
to	O
nominate	O
georgia	PERS
gop	PERS
representative	O
tom	PERS
price	PERS
as	O
health	ORG
and	ORG
human	ORG
services	ORG
secretary	O
.	O
price	PERS
,	O
himself	O
a	O
physician	O
,	O
has	O
previously	O
argued	O
in	O
favor	O
of	O
reducing	O
the	O
government	O
's	O
role	O
in	O
health	O
care	O
,	O
something	O
that	O
makes	O
both	O
maloof	O
and	O
ryder	PERS
somewhat	O
uneasy	O
.	O
|	O
``	O
health	O
care	O
is	O
a	O
heavily	O
regulated	O
industry	O
,	O
which	O
has	O
contributed	O
to	O
the	O
slow	O
pace	O
of	O
change	O
,	O
but	O
it	O
's	O
also	O
been	O
a	O
sector	O
historically	O
dominated	O
by	O
men	O
,	O
''	O
ryder	PERS
added	O
.	O
``	O
most	O
key	O
stakeholders	O
at	O
the	O
helm	O
of	O
insurance	O
companies	O
,	O
hospitals	O
,	O
government	O
—	O
even	O
digital	O
health	O
companies	O
—	O
are	O
men	O
.	O
''	O
maloof	O
's	O
advice	O
to	O
trump	PERS
would	O
be	O
to	O
find	O
a	O
good	O
solution	O
to	O
fixing	O
the	O
health-care	O
system	O
before	O
repealing	O
obamacare	O
,	O
acknowledging	O
republican	O
opposition	O
but	O
arguing	O
that	O
the	O
u.s.	LOC
ca	O
n't	O
go	O
backward	O
.	O
``	O
a	O
lot	O
of	O
women	O
voted	O
for	O
trump	PERS
because	O
they	O
thought	O
[	O
former	O
secretary	O
of	O
state	O
hillary	PERS
clinton	PERS
]	O
was	O
n't	O
a	O
better	O
choice	O
,	O
''	O
says	O
maloof	O
.	O
in	O
light	O
of	O
trump	PERS
's	O
focus	O
on	O
the	O
economy	O
,	O
women	O
would	O
like	O
to	O
see	O
how	O
trump	PERS
plans	O
to	O
help	O
women	O
play	O
a	O
bigger	O
role	O
in	O
the	O
economy	O
and	O
achieve	O
parity	O
,	O
maloof	O
argued	O
.	O
back	O
in	O
september	O
,	O
then-candidate	O
trump	PERS
announced	O
his	O
plan	O
to	O
provide	O
six	O
weeks	O
of	O
paid	O
maternity	O
leave	O
,	O
a	O
proposal	O
ryder	PERS
endorsed	O
.	O
she	O
told	O
cnbc	ORG
she	O
's	O
optimistic	O
about	O
the	O
future	O
of	O
paid	O
maternity	O
leave	O
.	O
``	O
business	O
leaders	O
are	O
finally	O
recognizing	O
the	O
importance	O
of	O
supporting	O
women	O
in	O
the	O
workplace	O
because	O
it	O
makes	O
for	O
better	O
companies	O
,	O
''	O
she	O
added	O
.	O
maloof	O
agreed	O
.	O
``	O
we	O
need	O
far	O
more	O
women	O
leaders	O
in	O
government	O
…	O
and	O
to	O
recognize	O
that	O
the	O
economics	O
of	O
caring	O
for	O
children	O
are	O
better	O
.	O
it	O
's	O
better	O
to	O
have	O
children	O
that	O
are	O
happier	O
and	O
more	O
nourished	O
and	O
well	O
loved	O
,	O
''	O
she	O
said	O
.	O
brainstorm	ORG
health	ORG
daily	ORG
:	O
june	O
21	O
,	O
2017	O
good	O
morning	O
,	O
dailies	O
.	O
a	O
quick	O
note	O
today	O
.	O
i	O
'm	O
in	O
palo	LOC
alto	LOC
for	O
a	O
meeting	O
of	O
the	O
board	ORG
of	ORG
fellows	ORG
at	O
stanford	PERS
medicine	PERS
--	O
an	O
institution	O
that	O
,	O
in	O
my	O
view	O
,	O
is	O
brilliantly	O
forging	O
a	O
path	O
to	O
become	O
a	O
true	O
leader	O
in	O
the	O
digital	O
health	PERS
revolution	O
.	O
and	O
a	O
case	O
in	O
point	O
:	O
just	O
yesterday	O
it	O
released	O
a	O
special	O
report	O
,	O
entitled	O
``	O
harnessing	O
the	O
power	O
of	O
data	O
in	O
health	PERS
,	O
''	O
that	O
is	O
one	O
of	O
the	O
smartest	O
and	O
most	O
comprehensive	O
takes	O
on	O
the	O
subject	O
i	O
've	O
seen	O
.	O
this	O
white	O
paper	O
is	O
no	O
light	O
effort	O
,	O
mind	O
you	O
.	O
in	O
order	O
to	O
produce	O
it	O
,	O
writes	O
lloyd	PERS
minor	PERS
,	O
dean	PERS
of	O
the	O
stanford	ORG
university	ORG
school	ORG
of	ORG
medicine	ORG
,	O
the	O
team	O
of	O
authors	O
did	O
a	O
deep-dive	O
``	O
analysis	O
of	O
existing	O
health	PERS
care	O
research	O
and	O
open-source	O
data	O
,	O
combined	O
with	O
insights	O
from	O
stanford	ORG
faculty	O
and	O
external	O
health	PERS
care	O
experts	O
.	O
''	O
and	O
trust	O
me	O
,	O
it	O
shows	O
:	O
you	O
can	O
see	O
the	O
months	O
of	O
work	O
and	O
deep	O
thinking	O
that	O
went	O
into	O
creating	O
this	O
report	O
.	O
it	O
is	O
well	O
worth	O
the	O
read	O
!	O
i	O
'll	O
save	O
some	O
of	O
my	O
own	O
takeaways	O
for	O
later	O
.	O
but	O
in	O
the	O
coming	O
days	O
,	O
i	O
'm	O
hoping	O
that	O
i	O
can	O
convince	O
dean	PERS
minor	PERS
to	O
write	O
an	O
essay	O
for	O
the	O
daily	ORG
taking	O
us	O
through	O
the	O
report	O
--	O
and	O
sharing	O
the	O
lessons	O
and	O
insights	O
that	O
surprised	O
him	O
most	O
from	O
the	O
research	O
.	O
until	O
then	O
,	O
dive	O
in	O
yourself	O
.	O
clifton	PERS
leaf	PERS
,	O
editor	O
in	O
chief	O
,	O
fortune	O
@	O
cliftonleaf	O
clifton.leaf	O
@	O
fortune.com	O
digital	O
health	PERS
theranos	ORG
,	O
walgreens	ORG
reach	O
tentative	O
settlement	O
deal	O
on	O
breach	O
of	O
contract	O
case	O
.	O
the	O
wall	ORG
street	ORG
journal	ORG
reports	O
that	O
embattled	O
blood	O
testing	O
firm	O
theranos	ORG
is	O
close	O
to	O
settling	O
what	O
may	O
have	O
been	O
its	O
most	O
contentious	O
lawsuit	O
,	O
with	O
former	O
partner	O
walgreens	ORG
,	O
for	O
about	O
$	O
30	O
million	O
.	O
that	O
's	O
more	O
than	O
$	O
100	O
million	O
less	O
than	O
the	O
investment	O
that	O
walgreens	ORG
put	O
into	O
the	O
company	O
(	O
the	O
pharmacy	O
chain	O
hawked	O
theranos	ORG
tests	O
at	O
about	O
40	O
of	O
its	O
``	O
wellness	ORG
centers	ORG
''	O
before	O
news	O
broke	O
that	O
the	O
company	O
's	O
proprietary	O
blood	O
testing	O
technology	O
did	O
n't	O
really	O
work	O
as	O
planned	O
and	O
produced	O
faulty	O
results	O
)	O
.	O
(	O
wall	ORG
street	ORG
journal	ORG
)	O
oscar	PERS
health	PERS
to	O
expand	O
obamacare	O
offerings	O
in	O
uncertain	O
times	O
for	O
health	PERS
law	O
.	O
digital	O
health	PERS
insurance	O
upstart	O
oscar	PERS
health	PERS
,	O
which	O
recently	O
teamed	O
up	O
with	O
the	O
famed	O
cleveland	ORG
clinic	ORG
,	O
announced	O
wednesday	O
that	O
it	O
will	O
be	O
expanding	O
its	O
offerings	O
in	O
obamacare	O
markets	O
in	O
five	O
states	O
:	O
ohio	LOC
,	O
texas	LOC
,	O
new	LOC
jersey	LOC
,	O
tennessee	LOC
,	O
and	O
california	LOC
.	O
``	O
why	O
seek	O
to	O
expand	O
in	O
a	O
time	O
of	O
uncertainty	O
?	O
we	O
're	O
confident	O
that	O
when	O
the	O
dust	O
settles	O
,	O
the	O
market	O
for	O
health	PERS
insurance	O
will	O
stabilize	O
in	O
time	O
for	O
2018	O
.	O
for	O
all	O
of	O
the	O
political	O
noise	O
,	O
there	O
are	O
simply	O
too	O
many	O
lives	O
at	O
stake	O
for	O
representatives	O
in	O
washington	LOC
,	O
d.c.	LOC
not	O
to	O
do	O
what	O
's	O
right	O
for	O
the	O
people	O
,	O
''	O
wrote	O
ceo	O
mario	PERS
schlosser	PERS
in	O
a	O
blog	O
post	O
on	O
the	O
company	O
's	O
website	O
.	O
indications	O
the	O
curious	O
case	O
of	O
mylan	ORG
's	O
tax	O
rate	O
and	O
coal	O
companies	O
.	O
reuters	ORG
is	O
out	O
with	O
a	O
truly	O
extraordinary	O
report	O
about	O
epipen	ORG
maker	O
mylan	ORG
pharmaceuticals	ORG
unique	O
tax	O
practices	O
.	O
the	O
firm	O
's	O
been	O
able	O
to	O
secure	O
a	O
bargain	O
bin	O
effective	O
tax	O
rate	O
through	O
--	O
wait	O
for	O
it	O
--	O
ownership	O
stakes	O
in	O
coal	O
refining	O
plants	O
,	O
of	O
all	O
things	O
(	O
mylan	ORG
is	O
one	O
of	O
the	O
largest	O
generic	O
drug	O
makers	O
on	O
the	O
planet	O
)	O
.	O
``	O
since	O
2011	O
,	O
mylan	ORG
has	O
bought	O
99	O
percent	O
stakes	O
in	O
five	O
companies	O
across	O
the	O
u.s.	LOC
that	O
own	O
plants	O
which	O
process	O
coal	O
to	O
reduce	O
smog-causing	O
emissions	O
.	O
it	O
then	O
sells	O
the	O
coal	O
at	O
a	O
loss	O
to	O
power	O
plants	O
to	O
generate	O
the	O
real	O
benefit	O
for	O
the	O
drug	O
company	O
:	O
credits	O
that	O
allow	O
mylan	ORG
to	O
lower	O
its	O
own	O
tax	O
bill	O
,	O
''	O
writes	O
reuters	ORG
.	O
(	O
reuters	ORG
)	O
trump	PERS
's	O
draft	O
executive	O
order	O
on	O
drug	O
pricing	O
could	O
be	O
a	O
boon	O
to	O
the	O
industry	O
.	O
in	O
another	O
bit	O
of	O
breaking	O
news	O
this	O
morning	O
,	O
the	O
new	ORG
york	ORG
times	ORG
has	O
reportedly	O
obtained	O
copies	O
of	O
a	O
draft	O
drug	O
pricing	O
executive	O
order	O
being	O
prepped	O
by	O
the	O
white	ORG
house	ORG
.	O
and	O
critics	O
are	O
already	O
pouncing	O
on	O
what	O
they	O
see	O
as	O
a	O
giveaway	O
to	O
the	O
biopharma	O
industry	O
that	O
wo	O
n't	O
do	O
much	O
to	O
lower	O
the	O
high	O
drug	O
prices	O
(	O
and	O
price	O
increases	O
)	O
that	O
president	O
donald	PERS
trump	PERS
has	O
frequently	O
lambasted	O
.	O
one	O
proposed	O
element	O
purportedly	O
scales	O
back	O
a	O
program	O
meant	O
to	O
assist	O
hospitals	O
that	O
serve	O
low-income	O
patients	O
,	O
part	O
of	O
a	O
series	O
of	O
initiatives	O
aiming	O
to	O
ease	O
biopharma	O
regulations	O
.	O
(	O
new	ORG
york	ORG
times	ORG
)	O
the	O
big	O
picture	O
the	O
house	ORG
health	PERS
care	O
bill	O
has	O
gotten	O
even	O
more	O
unpopular	O
ahead	O
of	O
a	O
planned	O
senate	ORG
vote	O
.	O
the	O
house-passed	O
american	PERS
health	PERS
care	O
act	O
has	O
become	O
significantly	O
more	O
unpopular	O
as	O
the	O
senate	ORG
prepares	O
to	O
unveil	O
its	O
own	O
health	PERS
care	O
legislation	O
(	O
and	O
reportedly	O
vote	O
on	O
it	O
next	O
week	O
)	O
.	O
the	O
ahca	O
was	O
never	O
particularly	O
popular	O
in	O
opinion	O
polls	O
;	O
but	O
now	O
,	O
according	O
to	O
a	O
morning	O
consult/politico	O
survey	O
,	O
a	O
full	O
50	O
%	O
of	O
respondents	O
disapprove	O
of	O
the	O
legislation	O
and	O
just	O
35	O
%	O
approve	O
.	O
(	O
morning	O
consult	O
)	O
required	O
reading	O
this	O
grocery	O
store	O
's	O
unusual	O
business	O
model	O
is	O
powered	O
by	O
wasted	O
food	O
,	O
by	O
beth	PERS
kowitt	PERS
every	O
event	O
that	O
led	O
to	O
uber	ORG
ceo	O
travis	PERS
kalanick	PERS
's	O
resignation	O
,	O
by	O
katie	PERS
reilly	PERS
stephen	PERS
hawking	PERS
:	O
'i	O
am	O
convinced	O
humans	O
need	O
to	O
leave	O
earth	O
'	O
,	O
by	O
lisa	PERS
marie	PERS
segarra	PERS
walmart	ORG
strikes	O
back	O
at	O
amazon	ORG
,	O
by	O
barb	PERS
darrow	PERS
[	O
ceo_attribution	O
author=	O
''	O
produced	O
by	O
sy	PERS
mukherjee	PERS
''	O
email=	O
''	O
sayak.mukherjee	O
@	O
fortune.com	O
''	O
twitter=	O
''	O
the_sy_guy	O
''	O
]	O
find	O
past	O
coverage	O
.	O
sign	O
up	O
for	O
other	O
fortune	O
newsletters	O
.	O
brainstorm	ORG
health	ORG
daily	ORG
:	O
july	O
31	O
,	O
2017	O
happy	O
monday	O
,	O
my	O
fellow	O
dailies	O
.	O
in	O
friday	O
's	O
newsletter	O
,	O
i	O
asked	O
,	O
``	O
why	O
do	O
n't	O
we	O
have	O
a	O
shark	O
tank	O
for	O
healthcare	O
startups	O
?	O
''	O
a	O
few	O
in-the-know	O
readers	O
pointed	O
out	O
that	O
the	O
question	O
was	O
based	O
on	O
a	O
faulty	O
assumption	O
:	O
it	O
turns	O
out	O
there	O
are	O
shark	O
tank	O
-like	O
contests	O
for	O
healthcare	O
startups	O
.	O
plenty	O
of	O
them	O
.	O
for	O
three	O
years	O
,	O
for	O
instance	O
,	O
prime	ORG
health	ORG
--	O
a	O
``	O
digital	O
health	ORG
innovation	ORG
ecosystem	O
''	O
based	O
in	O
colorado	LOC
--	O
has	O
sponsored	O
a	O
``	O
digital	O
health	O
challenge	O
,	O
''	O
says	O
prime	ORG
health	ORG
ceo	O
steve	PERS
adams	PERS
.	O
the	O
contest	O
is	O
open	O
to	O
any	O
early-stage	O
health-tech	O
startup	O
with	O
a	O
product	O
at	O
least	O
in	O
beta	O
stage	O
.	O
finalists	O
get	O
to	O
pitch	O
their	O
offerings	O
in	O
front	O
of	O
a	O
live	O
audience	O
and	O
potential	O
investors	O
(	O
this	O
year	O
's	O
event	O
is	O
being	O
held	O
at	O
a	O
big	O
denver	LOC
convention	O
center	O
on	O
oct.	O
19	O
)	O
.	O
winners	O
get	O
a	O
share	O
of	O
a	O
$	O
150,000	O
prize	O
--	O
and	O
more	O
importantly	O
,	O
are	O
offered	O
the	O
opportunity	O
to	O
work	O
with	O
a	O
large	O
colorado	LOC
healthcare	O
system	O
,	O
payer	O
,	O
or	O
provider	O
network	O
on	O
building	O
a	O
pilot	O
project	O
.	O
since	O
it	O
was	O
launched	O
in	O
2014	O
,	O
the	O
prime	ORG
health	ORG
challenge	O
has	O
connected	O
46	O
companies	O
to	O
investors	O
and	O
major	O
healthcare	O
organizations	O
.	O
``	O
i	O
have	O
been	O
founder	O
and	O
ceo	O
of	O
several	O
digital	O
health	O
companies	O
,	O
''	O
says	O
adams	PERS
,	O
``	O
and	O
can	O
tell	O
you	O
from	O
experience	O
that	O
there	O
is	O
huge	O
value	O
for	O
early-stage	O
companies	O
to	O
have	O
access	O
to	O
customers	O
with	O
a	O
desire	O
to	O
pilot	O
these	O
solutions	O
.	O
''	O
dan	PERS
wasserman	PERS
,	O
founder	O
and	O
ceo	O
of	O
mammoth	ORG
health	ORG
innovation	ORG
in	O
ontario	LOC
,	O
canada	LOC
,	O
calls	O
attention	O
to	O
several	O
other	O
health-related	O
shark	O
tanks	O
which	O
,	O
unfortunately	O
,	O
``	O
are	O
not	O
nearly	O
as	O
visible	O
as	O
the	O
tv	O
show	O
.	O
''	O
two	O
worthy	O
talent	O
showcases	O
,	O
he	O
says	O
,	O
are	O
the	O
cedars-sinai	O
accelerator	O
,	O
in	O
partnership	O
with	O
techstars	O
;	O
and	O
healthkick	O
,	O
sponsored	O
by	O
the	O
well-regarded	O
mars	O
innovation	O
hub	O
in	O
toronto	LOC
.	O
wasserman	PERS
,	O
who	O
helped	O
create	O
ontario	LOC
's	O
healthcare	O
ecosphere	O
,	O
which	O
focuses	O
on	O
bringing	O
innovative	O
,	O
problem-solving	O
ideas	O
to	O
hospitals	O
,	O
says	O
several	O
other	O
cities	O
(	O
including	O
baltimore	LOC
,	O
boston	LOC
,	O
chicago	LOC
,	O
washington	O
,	O
dc	O
,	O
and	O
san	LOC
francisco	LOC
)	O
have	O
their	O
own	O
health-tech	O
bake-offs	O
,	O
too	O
.	O
throw	O
in	O
entrepreneur-nurturing	O
programs	O
like	O
johnson	ORG
&	ORG
johnson	ORG
's	O
celebrated	O
jlabs	O
and	O
the	O
illumina	O
accelerator	O
and	O
there	O
are	O
yet	O
more	O
places	O
for	O
med	O
startups	O
to	O
show	O
off	O
their	O
ingenuity	O
and	O
find	O
avenues	O
for	O
commercialization	O
.	O
``	O
bottom	O
line	O
,	O
''	O
says	O
wasserman	PERS
,	O
``	O
they	O
are	O
all	O
'health	O
shark	O
tanks	O
.	O
'	O
''	O
agreed	O
.	O
thank	O
you	O
dan	PERS
and	O
steve	PERS
--	O
and	O
to	O
all	O
of	O
you	O
faithful	O
brainstorm	ORG
health	ORG
daily	ORG
readers	O
--	O
for	O
your	O
great	O
contributions	O
to	O
this	O
newsletter	O
community	O
.	O
keep	O
those	O
emails	O
coming	O
,	O
please	O
!	O
sy	O
's	O
got	O
the	O
news	O
below	O
.	O
clifton	PERS
leaf	PERS
,	O
editor	O
in	O
chief	O
,	O
fortune	O
@	O
cliftonleaf	O
clifton.leaf	O
@	O
fortune.com	O
digital	O
health	O
merck	ORG
:	O
notpetya	O
cyberattack	O
affected	O
r	O
&	O
d	O
,	O
manufacturing	O
.	O
during	O
its	O
recent	O
second	O
quarter	O
2017	O
earnings	O
call	O
,	O
pharma	ORG
giant	O
merck	ORG
revealed	O
that	O
last	O
month	O
's	O
notpetya	O
cyberattack	O
did	O
indeed	O
hamper	O
the	O
drug	O
maker	O
's	O
r	O
&	O
d	O
,	O
manufacturing	O
,	O
and	O
sales	O
operations	O
--	O
but	O
it	O
's	O
unclear	O
to	O
exactly	O
what	O
extent	O
.	O
``	O
the	O
company	O
is	O
in	O
the	O
process	O
of	O
restoring	O
its	O
manufacturing	O
operations	O
.	O
to	O
date	O
,	O
merck	ORG
has	O
largely	O
restored	O
its	O
packaging	O
operations	O
and	O
has	O
partially	O
restored	O
its	O
formulation	O
operations	O
.	O
the	O
company	O
is	O
in	O
the	O
process	O
of	O
restoring	O
its	O
active	O
pharmaceutical	O
ingredient	O
operations	O
but	O
is	O
not	O
yet	O
producing	O
bulk	O
product	O
.	O
the	O
company	O
's	O
external	O
manufacturing	O
was	O
not	O
impacted	O
,	O
''	O
the	O
firm	O
said	O
,	O
adding	O
that	O
it	O
's	O
``	O
confident	O
''	O
that	O
key	O
portfolio	O
products	O
will	O
maintain	O
a	O
continuous	O
supply	O
.	O
pharma	ORG
companies	O
turn	O
to	O
pandora	ORG
for	O
targeted	O
ads	O
.	O
pandora	ORG
,	O
the	O
music	O
streaming	O
and	O
radio	O
service	O
which	O
creates	O
personally	O
tailored	O
stations	O
for	O
its	O
listeners	O
,	O
is	O
ramping	O
up	O
its	O
presence	O
in	O
the	O
targeted	O
pharmaceutical	O
advertising	O
game	O
with	O
the	O
help	O
of	O
a	O
collaborative	O
agreement	O
with	O
patient	O
data	O
mining	O
company	O
crossix	ORG
,	O
which	O
compiles	O
anonymized	O
patient	O
health	O
information	O
.	O
pandora	ORG
's	O
lee	PERS
ann	PERS
longinotti	PERS
,	O
who	O
runs	O
the	O
firm	O
's	O
health	O
care	O
efforts	O
,	O
tells	O
fiercepharma	O
that	O
pandora	ORG
is	O
a	O
data	O
company	O
at	O
heart	O
,	O
and	O
its	O
ability	O
to	O
reach	O
highly	O
specific	O
population	O
segments	O
can	O
help	O
drug	O
makers	O
run	O
disease	O
awareness	O
campaigns	O
and	O
also	O
attempt	O
to	O
lure	O
them	O
away	O
from	O
competitors	O
.	O
(	O
fiercepharma	O
)	O
indications	O
johnson	ORG
&	ORG
johnson	ORG
rheumatoid	O
arthritis	O
drug	O
may	O
be	O
in	O
trouble	O
.	O
mere	O
days	O
before	O
a	O
critical	O
meeting	O
of	O
expert	O
advisers	O
to	O
the	O
food	ORG
and	ORG
drug	ORG
administration	ORG
(	O
fda	ORG
)	O
,	O
staff	O
reviewers	O
at	O
the	O
agency	O
are	O
raising	O
red	O
flags	O
over	O
johnson	ORG
&	ORG
johnson	ORG
's	O
experimental	O
rheumatoid	O
arthritis	O
treatment	O
sirukumab	O
,	O
which	O
the	O
company	O
has	O
long	O
hoped	O
may	O
eventually	O
become	O
a	O
$	O
1	O
billion-plus	O
sales	O
drug	O
.	O
the	O
reviewers	O
point	O
out	O
a	O
spike	O
in	O
patient	O
deaths	O
among	O
clinical	O
trial	O
participants	O
taking	O
the	O
therapy	O
compared	O
with	O
those	O
on	O
a	O
placebo	O
.	O
for	O
its	O
part	O
,	O
j	O
&	O
j	O
says	O
that	O
's	O
it	O
is	O
still	O
confident	O
of	O
the	O
treatment	O
's	O
risk-benefit	O
profile	O
.	O
but	O
recently	O
,	O
partner	O
glaxosmithkline	ORG
pulled	O
out	O
of	O
its	O
partnership	O
with	O
j	O
&	O
j	O
on	O
the	O
drug	O
.	O
(	O
reuters	ORG
)	O
the	O
big	O
picture	O
trump	PERS
threatens	O
to	O
end	O
obamacare	O
insurer	O
payments	O
that	O
keep	O
market	O
stable	O
.	O
after	O
last	O
week	O
's	O
dramatic	O
collapse	O
of	O
the	O
senate	ORG
gop	ORG
's	O
plan	O
to	O
repeal	O
parts	O
of	O
obamacare	O
,	O
the	O
big	O
question	O
was	O
:	O
how	O
would	O
president	O
donald	PERS
trump	PERS
react	O
?	O
the	O
answer	O
appears	O
to	O
be	O
threatening	O
the	O
law	O
's	O
marketplaces	O
.	O
in	O
a	O
series	O
of	O
tweets	O
over	O
the	O
weekend	O
,	O
trump	PERS
implied	O
he	O
would	O
cut	O
off	O
what	O
he	O
calls	O
insurance	O
company	O
``	O
bailouts	O
''	O
under	O
obamacare	O
(	O
he	O
also	O
appeared	O
to	O
threaten	O
lawmakers	O
'	O
health	O
care	O
coverage	O
)	O
.	O
these	O
payments	O
are	O
made	O
to	O
insurance	O
companies	O
in	O
exchange	O
for	O
them	O
lowering	O
the	O
deductibles	O
and	O
out-of-pocket	O
costs	O
paid	O
by	O
low-income	O
americans	O
;	O
without	O
them	O
,	O
insurers	O
would	O
likely	O
exit	O
the	O
markets	O
or	O
be	O
forced	O
to	O
hike	O
premiums	O
significantly	O
.	O
there	O
's	O
a	O
chance	O
that	O
lawsuits	O
could	O
eventually	O
force	O
the	O
trump	PERS
administration	O
to	O
make	O
the	O
payments	O
,	O
but	O
with	O
an	O
important	O
premium-setting	O
deadline	O
for	O
2018	O
obamacare	O
rates	O
just	O
weeks	O
away	O
,	O
insurers	O
are	O
already	O
likely	O
to	O
be	O
spooked	O
by	O
the	O
messaging	O
.	O
the	O
department	ORG
of	ORG
health	ORG
and	ORG
human	ORG
services	ORG
has	O
reportedly	O
not	O
made	O
a	O
final	O
decision	O
on	O
the	O
insurer	O
payments	O
.	O
(	O
fortune	O
)	O
poll	O
:	O
majority	O
want	O
congress	ORG
to	O
move	O
on	O
from	O
health	O
reform	O
.	O
while	O
obamacare	O
repeal	O
continues	O
to	O
exist	O
in	O
a	O
zombie-like	O
state	O
,	O
americans	O
appear	O
ready	O
to	O
move	O
on	O
to	O
something	O
else	O
,	O
according	O
to	O
a	O
new	O
reuters/ipsos	O
poll	O
.	O
the	O
survey	O
found	O
that	O
just	O
29	O
%	O
of	O
americans	O
want	O
congress	ORG
to	O
keep	O
working	O
on	O
a	O
new	O
health	O
care	O
bill	O
,	O
and	O
nearly	O
two-thirds	O
of	O
respondents	O
said	O
they	O
either	O
want	O
to	O
preserve	O
obamacare	O
as	O
is	O
or	O
shore	O
up	O
its	O
problem	O
areas	O
.	O
a	O
bipartisan	O
group	O
of	O
lawmaker	O
recently	O
met	O
to	O
begin	O
proposing	O
certain	O
fixes	O
to	O
the	O
health	O
law	O
.	O
(	O
reuters	ORG
)	O
required	O
reading	O
how	O
a	O
moment	O
of	O
doubt	O
changed	O
foursquare	O
,	O
by	O
polina	PERS
marinova	PERS
bitcoin	PERS
just	O
avoided	O
a	O
massive	O
breakup	O
,	O
but	O
it	O
's	O
getting	O
a	O
little	O
one	O
instead	O
,	O
by	O
david	PERS
z.	PERS
morris	PERS
charter	PERS
says	O
it	O
has	O
'no	O
interest	O
'	O
in	O
buying	O
sprint	ORG
,	O
by	O
reuters	ORG
end	O
of	O
an	O
era	O
:	O
richard	PERS
branson	PERS
surrenders	PERS
control	PERS
of	O
virgin	ORG
atlantic	ORG
,	O
by	O
natasha	PERS
bach	PERS
[	O
ceo_attribution	O
author=	O
''	O
produced	O
by	O
sy	PERS
mukherjee	PERS
''	O
email=	O
''	O
sayak.mukherjee	O
@	O
fortune.com	O
''	O
twitter=	O
''	O
the_sy_guy	O
''	O
]	O
find	O
past	O
coverage	O
.	O
sign	O
up	O
for	O
other	O
fortune	O
newsletters	O
.	O
spry	ORG
health	ORG
pierre-jean	O
“	O
pj	O
”	O
cobut	O
is	O
the	O
co-founder	O
of	O
,	O
a	O
company	O
that	O
offers	O
a	O
clinical-grade	O
wearable	O
and	O
disease	O
management	O
platform	O
that	O
enhances	O
timely	O
care	O
to	O
chronically	O
ill	O
patients	O
with	O
individualized	O
analytics	O
to	O
improve	O
patient	O
outcomes	O
,	O
reduce	O
hospitalization	O
,	O
and	O
decrease	O
spending	O
by	O
healthcare	O
organizations	O
.	O
spry	ORG
health	ORG
,	ORG
inc.	ORG
was	O
formerly	O
known	O
as	O
echo	O
labs	O
,	O
inc.	O
pj	O
co-founded	O
spry	ORG
health	ORG
while	O
earning	O
his	O
mba	O
from	O
the	O
stanford	ORG
graduate	ORG
school	ORG
of	ORG
business	ORG
.	O
his	O
previous	O
experience	O
includes	O
founding	O
a	O
european	O
b2b	O
hardware	O
startup	O
and	O
finance	O
&	O
strategy	O
for	O
proctor	ORG
&	ORG
gamble	ORG
.	O
pj	O
has	O
taken	O
the	O
time	O
to	O
sit	O
down	O
with	O
for	O
a	O
q	O
&	O
a	O
with	O
us	O
.	O
-let	O
’	O
s	O
start	O
by	O
introducing	O
our	O
audience	O
to	O
spry	ORG
health	ORG
.	O
how	O
did	O
you	O
get	O
started	O
?	O
elad	PERS
and	O
i	O
met	O
at	O
stanford	ORG
business	ORG
school	ORG
in	O
2012	O
.	O
we	O
quickly	O
decided	O
we	O
wanted	O
to	O
start	O
a	O
company	O
together	O
-	O
we	O
both	O
wanted	O
to	O
build	O
a	O
large	O
,	O
impactful	O
company	O
in	O
healthcare	O
,	O
had	O
similar	O
values	O
,	O
and	O
different	O
skillsets	O
.	O
we	O
decided	O
to	O
start	O
spry	ORG
health	ORG
based	O
on	O
our	O
personal	O
experience	O
with	O
family	O
members	O
struggling	O
to	O
manage	O
chronic	O
conditions	O
.	O
patients	O
see	O
their	O
doctors	O
a	O
few	O
times	O
a	O
year	O
,	O
for	O
a	O
few	O
minutes	O
at	O
a	O
time	O
.	O
in	O
order	O
for	O
physicians	O
to	O
determine	O
changes	O
in	O
a	O
patient	O
’	O
s	O
condition	O
,	O
they	O
often	O
rely	O
on	O
a	O
mix	O
of	O
current	O
symptoms	O
,	O
intermittent	O
monitoring	O
,	O
and	O
the	O
patient	O
’	O
s	O
own	O
recollection	O
of	O
their	O
health	O
and	O
symptoms	O
since	O
the	O
last	O
visit	O
.	O
this	O
is	O
a	O
partial	O
picture	O
at	O
best	O
.	O
and	O
it	O
often	O
isn	O
’	O
t	O
enough	O
to	O
keep	O
patients	O
out	O
of	O
the	O
hospital	O
or	O
support	O
them	O
in	O
keeping	O
their	O
condition	O
under	O
control	O
.	O
we	O
decided	O
to	O
create	O
a	O
solution	O
that	O
would	O
enable	O
continuous	O
healthcare	O
,	O
enabling	O
the	O
system	O
to	O
make	O
better	O
,	O
more	O
timely	O
decisions	O
and	O
drive	O
better	O
outcomes	O
for	O
people	O
.	O
-	O
how	O
did	O
you	O
initially	O
fund	O
spry	ORG
health	ORG
?	O
why	O
did	O
you	O
go	O
the	O
incubator	O
route	O
?	O
what	O
happened	O
after	O
you	O
left	O
them	O
?	O
we	O
didn	O
’	O
t	O
raise	O
funds	O
until	O
a	O
few	O
months	O
after	O
graduating	O
from	O
stanford	ORG
.	O
the	O
first	O
few	O
months	O
of	O
the	O
project	O
that	O
would	O
become	O
spry	ORG
were	O
dedicated	O
to	O
understanding	O
users	O
,	O
the	O
market	O
,	O
as	O
well	O
as	O
some	O
early	O
technological	O
development	O
and	O
prototyping	O
.	O
we	O
raised	O
a	O
seed	O
round	O
in	O
february	O
2015	O
after	O
some	O
additional	O
validation	O
and	O
traction	O
.	O
we	O
applied	O
and	O
joined	O
startx	O
because	O
we	O
wanted	O
to	O
be	O
part	O
of	O
a	O
strong	O
network	O
of	O
entrepreneurs	O
that	O
help	O
each	O
other	O
out	O
-	O
building	O
a	O
company	O
is	O
always	O
tough	O
but	O
it	O
’	O
s	O
much	O
easier	O
when	O
you	O
have	O
smart	O
,	O
talented	O
people	O
around	O
you	O
who	O
have	O
been	O
through	O
the	O
same	O
challenges	O
.	O
we	O
also	O
loved	O
the	O
fact	O
that	O
startx	O
is	O
a	O
non-profit	O
(	O
with	O
potential	O
investment	O
as	O
part	O
of	O
an	O
institutional	O
capital	O
raise	O
)	O
so	O
they	O
’	O
re	O
really	O
there	O
to	O
help	O
you	O
grow	O
your	O
business	O
.	O
much	O
like	O
stanford	ORG
did	O
a	O
couple	O
of	O
years	O
before	O
,	O
startx	O
really	O
opened	O
a	O
lot	O
of	O
doors	O
for	O
us	O
.	O
we	O
’	O
re	O
now	O
involved	O
as	O
mentors	O
and	O
interviewers	O
just	O
because	O
of	O
how	O
much	O
we	O
love	O
the	O
community	O
and	O
want	O
to	O
be	O
involved	O
supporting	O
the	O
next	O
generations	O
of	O
entrepreneurs	O
.	O
-you	O
’	O
re	O
one	O
of	O
the	O
few	O
early-stage	O
digital	O
health	O
startups	O
with	O
a	O
physician	O
(	O
cmo	O
)	O
on	O
board	O
.	O
what	O
made	O
you	O
decide	O
to	O
hire	O
a	O
physician	O
?	O
how	O
has	O
that	O
influenced	O
the	O
direction	O
of	O
your	O
product	O
?	O
dr.	O
andre	PERS
atoian	PERS
,	O
our	O
cmo	O
,	O
was	O
employee	O
#	O
6	O
or	O
7	O
.	O
it	O
was	O
important	O
for	O
us	O
to	O
add	O
a	O
physician	O
to	O
the	O
team	O
early	O
on	O
because	O
neither	O
elad	PERS
or	O
i	O
have	O
clinical	O
experience	O
.	O
we	O
have	O
seen	O
many	O
silicon	LOC
valley	LOC
digital	O
health	O
companies	O
fail	O
because	O
they	O
are	O
being	O
built	O
and	O
managed	O
like	O
consumer	O
software	O
companies	O
.	O
we	O
realized	O
pretty	O
quickly	O
that	O
the	O
rules	O
in	O
healthcare	O
are	O
completely	O
different	O
and	O
wanted	O
someone	O
on	O
the	O
team	O
with	O
strong	O
experience	O
in	O
the	O
clinical	O
world	O
to	O
shape	O
the	O
product	O
design	O
and	O
avoid	O
common	O
pitfalls	O
.	O
since	O
andre	PERS
came	O
on	O
board	O
,	O
the	O
company	O
has	O
gained	O
a	O
much	O
deeper	O
understanding	O
and	O
appreciation	O
for	O
the	O
difficulties	O
of	O
practicing	O
medicine	O
and	O
an	O
increased	O
focus	O
not	O
only	O
on	O
making	O
patients	O
’	O
lives	O
easier	O
but	O
also	O
physicians	O
’	O
lives	O
easier	O
and	O
more	O
efficient	O
.	O
andre	PERS
helped	O
us	O
realized	O
that	O
improved	O
outcomes	O
for	O
patients	O
and	O
improved	O
efficiency	O
for	O
clinical	O
staff	O
are	O
so	O
strongly	O
intertwined	O
-	O
we	O
would	O
never	O
get	O
the	O
chance	O
to	O
improve	O
patient	O
lives	O
if	O
our	O
solution	O
doesn	O
’	O
t	O
perfectly	O
fit	O
within	O
an	O
existing	O
care	O
delivery	O
model	O
.	O
-how	O
did	O
you	O
recognize	O
the	O
need	O
for	O
loop	O
?	O
elad	PERS
and	O
i	O
have	O
had	O
personal	O
experience	O
in	O
our	O
families	O
with	O
people	O
who	O
suffer	O
from	O
chronic	O
conditions	O
.	O
managing	O
a	O
chronic	O
condition	O
is	O
incredibly	O
complex	O
and	O
stressful	O
and	O
being	O
able	O
to	O
see	O
a	O
physician	O
only	O
3-4	O
times	O
a	O
year	O
is	O
not	O
enough	O
to	O
help	O
patients	O
manage	O
it	O
better	O
.	O
it	O
’	O
s	O
definitely	O
not	O
enough	O
to	O
keep	O
them	O
out	O
of	O
the	O
er	O
or	O
the	O
hospital	O
.	O
we	O
both	O
concluded	O
that	O
in	O
order	O
to	O
be	O
proactive	O
and	O
get	O
ahead	O
of	O
problems	O
before	O
they	O
sent	O
a	O
patient	O
to	O
the	O
hospital	O
,	O
we	O
needed	O
to	O
continuously	O
capture	O
clinical-grade	O
data	O
in	O
the	O
home	O
setting	O
.	O
capturing	O
meaningful	O
data	O
on	O
a	O
day-to-day	O
basis	O
would	O
help	O
us	O
understand	O
a	O
patient	O
’	O
s	O
baseline	O
and	O
alert	O
physicians	O
at	O
the	O
first	O
signs	O
of	O
deviation	O
from	O
that	O
baseline	O
,	O
helping	O
them	O
address	O
problems	O
earlier	O
and	O
improve	O
outcomes	O
for	O
patients	O
.	O
-what	O
can	O
you	O
tell	O
us	O
about	O
your	O
clinical	O
validation	O
trials	O
?	O
as	O
a	O
science	O
and	O
healthcare	O
company	O
,	O
we	O
’	O
ve	O
always	O
put	O
a	O
lot	O
of	O
focus	O
on	O
clinical	O
validation	O
,	O
even	O
with	O
our	O
early	O
prototypes	O
.	O
we	O
started	O
knowing	O
that	O
we	O
had	O
highly	O
complex	O
technical	O
challenges	O
to	O
overcome	O
.	O
that	O
meant	O
it	O
was	O
that	O
much	O
more	O
important	O
to	O
keep	O
on	O
validating	O
extensively	O
and	O
ensure	O
we	O
were	O
pushing	O
the	O
boundaries	O
of	O
what	O
had	O
been	O
done	O
in	O
non-invasive	O
sensing	O
for	O
a	O
remote	O
monitoring	O
application	O
.	O
our	O
latest	O
clinical	O
trial	O
(	O
held	O
in	O
2016	O
)	O
was	O
one	O
of	O
the	O
most	O
extensive	O
conducted	O
in	O
the	O
space	O
with	O
over	O
250	O
participants	O
with	O
very	O
wide	O
demographics	O
and	O
medical	O
conditions	O
.	O
we	O
proved	O
equivalence	O
to	O
outpatient	O
standards	O
of	O
care	O
(	O
e.g	O
.	O
home	O
blood	O
pressure	O
monitor	O
,	O
pulse-oximeter	O
,	O
breath	O
analyzer	O
,	O
etc	O
.	O
)	O
.	O
we	O
currently	O
have	O
an	O
even	O
more	O
extensive	O
trial	O
happening	O
in	O
a	O
large	O
private	O
hospital	O
in	O
los	LOC
angeles	LOC
and	O
an	O
additional	O
trial	O
scheduled	O
at	O
ucsf	O
for	O
later	O
this	O
year	O
.	O
both	O
of	O
these	O
trials	O
are	O
aimed	O
at	O
generating	O
additional	O
clinical	O
evidence	O
.	O
-how	O
do	O
you	O
see	O
this	O
product	O
in	O
the	O
market	O
place	O
?	O
what	O
sets	O
you	O
apart	O
from	O
other	O
players	O
in	O
the	O
space	O
?	O
the	O
idea	O
of	O
remote	O
monitoring	O
isn	O
’	O
t	O
new	O
but	O
the	O
medtech	O
industry	O
has	O
continuously	O
ignored	O
an	O
important	O
parameter	O
-	O
patient	O
satisfaction	O
and	O
user	O
experience	O
.	O
more	O
and	O
more	O
of	O
the	O
care	O
is	O
moving	O
to	O
the	O
home	O
setting	O
because	O
it	O
has	O
been	O
established	O
that	O
patients	O
do	O
better	O
in	O
that	O
familiar	O
setting	O
surrounded	O
by	O
the	O
people	O
who	O
love	O
them	O
.	O
monitoring	O
technology	O
that	O
was	O
built	O
for	O
hospital	O
use	O
(	O
blood	O
pressure	O
monitors	O
,	O
pulse-oximeters	O
,	O
capnometers	O
,	O
scales	O
,	O
spirometers	O
,	O
etc	O
.	O
)	O
was	O
then	O
packaged	O
and	O
delivered	O
to	O
the	O
homes	O
of	O
patients	O
so	O
that	O
they	O
would	O
use	O
them	O
.	O
more	O
often	O
than	O
not	O
,	O
patients	O
don	O
’	O
t	O
use	O
these	O
monitoring	O
tools	O
beyond	O
the	O
first	O
few	O
days	O
of	O
novelty	O
.	O
why	O
?	O
because	O
these	O
devices	O
are	O
complicated	O
,	O
cumbersome	O
,	O
don	O
’	O
t	O
provide	O
useful/understandable	O
feedback	O
,	O
but	O
most	O
of	O
all	O
because	O
they	O
place	O
the	O
burden	O
of	O
monitoring	O
on	O
the	O
patients	O
themselves	O
.	O
loop	O
was	O
designed	O
to	O
address	O
these	O
concerns	O
-	O
one	O
single	O
,	O
small	O
device	O
that	O
is	O
easy	O
to	O
use	O
,	O
non-stigmatizing	O
,	O
and	O
does	O
all	O
of	O
the	O
work	O
passively	O
.	O
in	O
return	O
,	O
patients	O
receive	O
information	O
that	O
gives	O
them	O
peace	O
of	O
mind	O
:	O
they	O
become	O
more	O
aware	O
of	O
their	O
limits	O
on	O
a	O
daily	O
basis	O
and	O
their	O
doctor	O
is	O
connected	O
and	O
will	O
help	O
at	O
the	O
first	O
signs	O
of	O
trouble	O
.	O
-what	O
would	O
your	O
advice	O
be	O
for	O
providers	O
right	O
now	O
,	O
at	O
a	O
time	O
of	O
intense	O
change	O
in	O
healthcare	O
?	O
at	O
a	O
system	O
level	O
,	O
i	O
would	O
encourage	O
providers	O
to	O
take	O
leadership	O
roles	O
and	O
embrace	O
innovation	O
.	O
changes	O
in	O
healthcare	O
are	O
undeniably	O
coming	O
with	O
the	O
increase	O
of	O
data	O
availability	O
,	O
care	O
moving	O
from	O
the	O
traditional	O
setting	O
to	O
the	O
home	O
,	O
and	O
digital	O
therapeutics	O
.	O
in	O
my	O
opinion	O
,	O
more	O
of	O
these	O
changes	O
need	O
to	O
be	O
physician-led	O
because	O
physicians	O
are	O
the	O
most	O
apt	O
at	O
recognizing	O
the	O
value	O
for	O
the	O
patients	O
they	O
see	O
every	O
day	O
.	O
this	O
can	O
obviously	O
mean	O
starting	O
companies	O
around	O
these	O
ideas	O
,	O
but	O
physicians	O
can	O
also	O
have	O
very	O
meaningful	O
impact	O
by	O
recognizing	O
needs	O
in	O
their	O
clinical	O
focus	O
area	O
,	O
looking	O
for	O
innovative	O
solutions	O
,	O
and	O
testing	O
them	O
out	O
.	O
-as	O
providers	O
go	O
forward	O
under	O
the	O
aco	O
program	O
and	O
meaningful	O
use	O
,	O
what	O
do	O
you	O
see	O
as	O
the	O
challenges	O
facing	O
them	O
?	O
transitioning	O
to	O
value	O
is	O
undeniably	O
the	O
right	O
thing	O
to	O
do	O
for	O
patients	O
,	O
but	O
it	O
’	O
s	O
a	O
relatively	O
abstract	O
concept	O
.	O
properly	O
defining	O
value	O
and	O
quality	O
of	O
care	O
is	O
an	O
important	O
challenge	O
.	O
this	O
is	O
obviously	O
critical	O
for	O
physicians	O
because	O
it	O
drives	O
reimbursement	O
but	O
it	O
also	O
will	O
define	O
how	O
innovation	O
is	O
shaped	O
in	O
the	O
space	O
.	O
the	O
more	O
these	O
definitions	O
become	O
crisp	O
and	O
standardized	O
,	O
the	O
more	O
we	O
will	O
see	O
interesting	O
innovation	O
that	O
will	O
benefit	O
both	O
patients	O
and	O
providers	O
.	O
-what	O
advice	O
do	O
you	O
have	O
for	O
young	O
professionals	O
who	O
aspire	O
to	O
work	O
in	O
digital	O
health	O
?	O
a	O
successful	O
digital	O
health	O
product	O
needs	O
to	O
be	O
at	O
a	O
happy	O
middle	O
between	O
the	O
tech	O
industry	O
and	O
traditional	O
healthcare	O
.	O
to	O
people	O
coming	O
from	O
the	O
tech	O
industry	O
,	O
i	O
’	O
d	O
recommend	O
surrounding	O
yourselves	O
with	O
people	O
who	O
know	O
the	O
healthcare	O
system	O
inside	O
and	O
out	O
,	O
physicians	O
in	O
particular	O
.	O
healthcare	O
is	O
a	O
complicated	O
industry	O
that	O
obeys	O
a	O
very	O
different	O
set	O
of	O
rules	O
than	O
the	O
tech	O
industry	O
-	O
“	O
disrupting	O
”	O
and	O
“	O
breaking	O
things	O
”	O
cost	O
millions	O
to	O
organizations	O
when	O
people	O
’	O
s	O
lives	O
are	O
on	O
the	O
line	O
every	O
single	O
day	O
.	O
there	O
are	O
too	O
many	O
great	O
technologies	O
being	O
built	O
in	O
silos	O
for	O
the	O
sake	O
of	O
the	O
technology	O
itself	O
but	O
without	O
completely	O
meeting	O
a	O
tangible	O
need	O
or	O
without	O
appreciating	O
what	O
health	O
systems	O
are	O
capable	O
of	O
handling/integrating	O
.	O
this	O
is	O
a	O
common	O
trap	O
:	O
don	O
’	O
t	O
fall	O
for	O
it	O
.	O
to	O
healthcare	O
professionals	O
interested	O
in	O
digital	O
health	O
,	O
i	O
’	O
d	O
encourage	O
them	O
to	O
challenge	O
the	O
status	O
quo	O
more	O
.	O
decades-old	O
processes	O
are	O
getting	O
in	O
the	O
way	O
of	O
efficient	O
care	O
and	O
there	O
is	O
definitely	O
a	O
better	O
way	O
,	O
usually	O
empowered	O
by	O
technology	O
,	O
that	O
isn	O
’	O
t	O
necessarily	O
complicated	O
to	O
build	O
.	O
use	O
your	O
clinical	O
experience	O
to	O
take	O
a	O
leadership	O
role	O
in	O
how	O
these	O
innovations	O
are	O
shaped	O
and	O
tested	O
in	O
healthcare	O
systems	O
.	O
-what	O
is	O
the	O
biggest	O
trend	O
you	O
’	O
re	O
seeing	O
healthcare	O
systems	O
embrace	O
in	O
terms	O
of	O
it	O
?	O
we	O
see	O
a	O
big	O
trend	O
in	O
health	O
systems	O
embracing	O
different	O
types	O
of	O
telemedicine	O
initiatives	O
.	O
the	O
best	O
care	O
is	O
provided	O
in	O
the	O
home	O
because	O
that	O
’	O
s	O
where	O
patients	O
do	O
better	O
-	O
patients	O
maintain	O
independence	O
and	O
social	O
lives	O
,	O
have	O
the	O
benefit	O
of	O
familiar	O
surroundings	O
and	O
habits	O
,	O
and	O
have	O
lower	O
rates	O
of	O
complications	O
.	O
telemedicine	O
is	O
a	O
great	O
way	O
to	O
bridge	O
the	O
gap	O
between	O
the	O
home	O
and	O
traditional	O
brick	O
and	O
mortar	O
settings	O
,	O
and	O
in	O
a	O
sense	O
,	O
get	O
the	O
best	O
of	O
both	O
worlds	O
.	O
-what	O
is	O
your	O
objective	O
for	O
the	O
next	O
12	O
to	O
18	O
months	O
?	O
in	O
the	O
next	O
year	O
or	O
so	O
,	O
our	O
main	O
objective	O
is	O
to	O
increase	O
the	O
number	O
of	O
patients	O
we	O
work	O
with	O
and	O
the	O
number	O
of	O
partnerships	O
we	O
have	O
with	O
innovative	O
healthcare	O
organizations	O
.	O
the	O
whole	O
company	O
is	O
focused	O
on	O
demonstrating	O
the	O
value	O
of	O
our	O
product	O
in	O
terms	O
of	O
patient	O
satisfaction	O
,	O
improved	O
outcomes	O
,	O
and	O
decreased	O
utilization	O
.	O
we	O
have	O
also	O
submitted	O
with	O
the	O
fda	ORG
and	O
expect	O
clearance	O
for	O
loop	O
as	O
a	O
class	O
ii	O
medical	O
device	O
by	O
the	O
first	O
quarter	O
of	O
2018	O
.	O
#	O
wearables	O
#	O
healthwearables	O
#	O
medicalwearables	O
#	O
telemedicine	O
#	O
telehealth	O
#	O
mhealth	O
#	O
healthit	O
#	O
digitalhealth	O
#	O
valuebasedcare	O
#	O
chronic	O
care	O
and	O
remote	O
patient	O
monitoring	O
pj	O
cobut	O
the	O
morning	O
email	O
wake	O
up	O
to	O
the	O
day	O
's	O
most	O
important	O
news	O
.	O
business	O
wire	O
:	O
neue	O
ghx	ORG
einvoicing-lösung	O
hilft	O
lieferanten	O
im	O
gesundheitswesen	O
bei	O
der	O
einhaltung	O
der	O
eu-richtlinien	O
mitteilung	O
uebermittelt	O
von	O
business	O
wire	O
.	O
fuer	O
den	O
inhalt	O
ist	O
allein	O
das	O
berichtende	O
unternehmen	O
verantwortlich	O
.	O
einfaches	O
,	O
effizientes	O
einvoicing	O
(	O
elektronische	O
rechnungsstellung	O
)	O
erfüllt	O
die	O
anforderungen	O
in	O
ganz	O
europa	O
über	O
eine	O
einzige	O
verbindung	O
brüssel	O
--	O
(	O
business	O
wire	O
)	O
--	O
31.07.2017	O
--	O
global	O
healthcare	O
exchange	O
,	O
llc	O
(	O
ghx	ORG
)	O
kündigte	O
heute	O
eine	O
europaweite	O
einvoicing-lösung	O
an	O
,	O
die	O
lieferanten	O
im	O
gesundheitswesen	O
helfen	O
soll	O
,	O
die	O
bestimmungen	O
für	O
die	O
elektronische	O
rechnungsstellung	O
zu	O
erfüllen	O
.	O
mit	O
dem	O
neuen	O
ghx	ORG
einvoicing	O
können	O
anbieter	O
bestimmungskonforme	O
rechnungen	O
an	O
gesundheitsdienstleister-kunden	O
und	O
regierungen	O
in	O
ganz	O
europa	O
von	O
einer	O
verbindung	O
aus	O
schicken	O
.	O
die	O
ghx-lösung	O
,	O
die	O
mit	O
den	O
ghx	ORG
exchange	ORG
services	ORG
funktioniert	O
,	O
unterstützt	O
die	O
einvoicing-anforderungen	O
an	O
integrität	O
,	O
authentizität	O
,	O
lesbarkeit	O
und	O
archivierung	O
gemäß	O
der	O
mehrwertsteuerrichtlinie	O
2006/112/ed	O
und	O
der	O
richtlinie	O
für	O
elektronische	O
rechnungsstellung	O
2010/45/eu	O
.	O
die	O
lösung	O
bietet	O
zudem	O
ein	O
benutzerfreundliches	O
portal	O
für	O
kunden	O
,	O
um	O
auf	O
rechnungen	O
elektronisch	O
zuzugreifen	O
,	O
selbst	O
für	O
kunden	O
ohne	O
edi-fähigkeiten	O
.	O
``	O
der	PERS
verzicht	PERS
auf	O
papiergestützte	O
rechnungen	O
und	O
manuelle	O
rechnungsstellung	O
wird	O
ein	O
vorteil	O
für	O
sanitätshäuser	O
in	O
ganz	O
europa	O
sein	O
.	O
der	PERS
umgang	PERS
mit	O
der	O
komplexität	O
des	O
europäischen	O
marktes	O
und	O
die	O
einhaltung	O
der	O
verschiedenen	O
bestimmungen	O
der	O
eu-mitgliedsstaaten	O
können	O
eine	O
erhebliche	O
herausforderung	O
darstellen	O
''	O
,	O
so	O
dr.	O
nedzad	PERS
fajic	PERS
,	O
präsident	O
,	O
ghx	ORG
europa	ORG
.	O
``	O
die	O
neue	O
ghx	ORG
einvoicing-lösung	O
mit	O
ihrem	O
einvoicing-portal	O
wird	O
einen	O
besseren	O
einblick	O
in	O
den	O
gesamten	O
order-to-cash-zyklus	O
liefern	O
,	O
die	O
manuelle	O
abwicklung	O
reduzieren	O
und	O
anbietern	O
helfen	O
,	O
ein	O
besseres	O
kundenerlebnis	O
zu	O
bieten	O
.	O
''	O
anzeige	O
bis	O
zum	O
27	O
.	O
november	O
2018	O
müssen	O
alle	O
eu-länder	O
die	O
richtlinie	O
2014/55/eu	O
in	O
ihre	O
jeweilige	O
gesetzgebung	O
aufnehmen	O
.	O
diese	O
verlangt	O
,	O
dass	O
alle	O
an	O
krankenhäuser	O
gesandten	O
rechnungen	O
durch	O
den	O
einsatz	O
von	O
technologie	O
für	O
unternehmenskontrolle	O
und/oder	O
elektronische	O
rechnungsstellung	O
die	O
vorgaben	O
``	O
echtheit	O
der	O
herkunft	O
,	O
inhaltsintegrität	O
und	O
lesbarkeit	O
''	O
erfüllen	O
.	O
ghx	ORG
einvoicing	O
ist	O
so	O
konzipiert	O
,	O
dass	O
es	O
diese	O
vorgaben	O
mit	O
einer	O
einfachen	O
und	O
effizienten	O
lösung	O
erfüllt	O
.	O
elektronische	O
rechnungen	O
werden	O
über	O
die	O
bestehende	O
ghx	ORG
global	ORG
exchange-verbindung	ORG
eines	O
anbieters	O
versandt	O
und	O
geprüft	O
,	O
um	O
zu	O
bestätigen	O
,	O
dass	O
alle	O
pflichtfelder	O
ausgefüllt	O
sind	O
.	O
die	O
elektronische	O
rechnung	O
wird	O
dann	O
an	O
die	O
entsprechenden	O
kunden	O
und	O
zugangspunkte	O
der	O
regierung	O
in	O
ganz	O
europa	O
geliefert	O
,	O
und	O
zwar	O
mit	O
digitalen	O
unterschriften	O
und	O
archivierung	O
,	O
sofern	O
compliance	O
dies	O
erfordert	O
.	O
nicht-edi-fähige	O
kunden	O
können	O
ebenfalls	O
rechnungen	O
über	O
das	O
neue	O
einvoicing-portal	O
erhalten	O
,	O
wo	O
sie	O
rechnungen	O
in	O
pdf-format	O
verwalten	O
und	O
herunterladen	O
sowie	O
per	O
e-mail	O
erhalten	O
können	O
.	O
die	O
neue	O
einvoicing-lösung	O
bietet	O
:	O
die	O
möglichkeit	O
,	O
jede	O
elektronische	O
rechnung	O
in	O
das	O
entsprechende	O
format	O
mit	O
den	O
entsprechenden	O
informationen	O
zu	O
konvertieren	O
,	O
um	O
die	O
eu-länderspezifischen	O
bestimmungen	O
zur	O
rechnungsstellung	O
zu	O
erfüllen	O
;	O
ist	O
kompatibel	O
mit	O
ghx	ORG
global	ORG
exchange	ORG
und	O
anderen	O
ghx-lösungen	O
für	O
den	O
gesamten	O
order-to-cash-zyklus	O
,	O
um	O
eine	O
komplettlösung	O
für	O
die	O
elektronische	O
rechnungsstellung	O
in	O
europa	O
zu	O
bieten	O
;	O
schickt	O
automatisch	O
die	O
bestimmungskonforme	O
rechnung	O
an	O
den	O
entsprechenden	O
zugangspunkt	O
der	O
öffentlichen	O
verwaltung	O
sowie	O
den	O
entsprechenden	O
kunden	O
;	O
ein	O
dediziertes	O
online-portal	O
,	O
das	O
selbst	O
nicht-edi-fähigen	O
kunden	O
ermöglicht	O
,	O
rechnungen	O
aufzurufen	O
und	O
herunterzuladen	O
;	O
stellt	O
anbietern	O
und	O
ihren	O
kunden	O
zugang	O
zu	O
aktuellen	O
und	O
alten	O
rechnungen	O
bereit	O
,	O
alles	O
von	O
einer	O
stelle	O
aus	O
;	O
umfasst	O
tracking-	O
und	O
überwachungsfunktionen	O
.	O
verfügbarkeit	O
ghx	ORG
einvoicing	O
ist	O
jetzt	O
allgemein	O
in	O
ganz	O
europa	O
erhältlich	O
.	O
um	O
mehr	O
zu	O
erfahren	O
,	O
wenden	O
sie	O
sich	O
bitte	O
an	O
marcus	O
schiewe	O
,	O
head	O
of	O
supplier	O
sales	O
,	O
europa	O
,	O
+49	O
(	O
0	O
)	O
211	O
301	O
88	O
300	O
.	O
über	O
ghx	ORG
europa	ORG
global	O
healthcare	O
exchange	O
,	O
llc	O
(	O
ghx	ORG
)	O
mit	O
seinem	O
europäischen	O
hauptsitz	O
in	O
brüssel	O
senkt	O
die	O
kosten	O
im	O
gesundheitswesen	O
mit	O
cloudbasierten	O
technologien	O
und	O
dienstleistungen	O
für	O
das	O
lieferkettenmanagement	O
,	O
um	O
durch	O
die	O
maximierung	O
der	O
automatisierung	O
,	O
der	PERS
effizienz	PERS
und	O
der	O
richtigkeit	O
von	O
geschäftsprozessen	O
für	O
eine	O
bessere	O
patientenversorgung	O
und	O
kosteneinsparung	O
zu	O
sorgen	O
.	O
ghx	ORG
bietet	O
europäischen	O
anbietern	O
und	O
lieferanten	O
im	O
gesundheitswesen	O
ein	O
offenes	O
und	O
neutrales	O
elektronisches	O
handelssystem	O
,	O
das	O
beschaffung	O
und	O
kreditorenbuchhaltung	O
automatisiert	O
sowie	O
weitere	O
lieferkettenbezogene	O
tools	O
und	O
services	O
liefert	O
.	O
weitere	O
informationen	O
finden	O
sie	O
auf	O
www.ghx.com/europe/en	O
und	O
the	O
healthcare	O
hub	O
.	O
die	O
ausgangssprache	O
,	O
in	O
der	PERS
der	PERS
originaltext	PERS
veröffentlicht	O
wird	O
,	O
ist	O
die	O
offizielle	O
und	O
autorisierte	O
version	O
.	O
übersetzungen	O
werden	O
zur	O
besseren	O
verständigung	O
mitgeliefert	O
.	O
nur	O
die	O
sprachversion	O
,	O
die	O
im	O
original	O
veröffentlicht	O
wurde	O
,	O
ist	O
rechtsgültig	O
.	O
gleichen	O
sie	O
deshalb	O
übersetzungen	O
mit	O
der	O
originalen	O
sprachversion	O
der	O
veröffentlichung	O
ab	O
.	O
originalversion	O
auf	O
businesswire.com	O
ansehen	O
:	O
http	O
:	O
//www.businesswire.com/news/home/20170730005005/de/	O
tier	O
one	O
partners	O
paula	PERS
timko	PERS
,	O
508-826-1508	O
ptimko	O
@	O
tieronepr.com	O
the	O
innovators	O
dr.	O
bill	O
byrom	O
at	O
the	O
forefront	O
of	O
eclinical	O
technology	O
title	O
:	O
senior	O
director	O
of	O
product	O
innovation	O
company	O
:	O
icon	O
clinical	O
research	O
education	O
:	O
bsc	O
,	O
mathematics	O
with	O
statistics	O
,	O
university	O
of	O
nottingham	O
;	O
phd	O
,	O
university	O
of	O
strathclyde	O
family	O
:	O
wife	O
,	O
tina	O
;	O
two	O
teenage	O
daughters	O
,	O
charlotte	O
and	O
sophie	O
hobbies	O
:	O
road	O
cycling	O
,	O
walking	O
his	O
dogs	O
with	O
the	O
family	O
,	O
and	O
watching	O
live	O
indie	O
rock	O
music	O
in	O
his	O
hometown	O
of	O
nottingham	O
,	O
england	LOC
bucket	O
list	O
:	O
complete	O
a	O
triathlon	O
awards/honors	O
:	O
pharmavoice	O
100	O
,	O
2008	O
;	O
stevie	O
business	O
award	O
:	O
selling	O
power	O
sales	O
excellence	O
award	O
for	O
innovative	O
sales	O
training	O
program	O
,	O
2006	O
;	O
nottingham	O
girls	O
’	O
and	O
ladies	O
’	O
football	O
league	O
,	O
manager	O
of	O
the	O
season	O
,	O
2011	O
associations	O
:	O
the	O
critical	O
path	O
institute	O
’	O
s	O
epro	O
consortium	O
;	O
eclinical	O
forum	O
;	O
dia	O
study	O
endpoints	O
community	O
;	O
ispor	O
;	O
centre	O
for	O
business	O
intelligence	O
medical	O
adherence	O
consortium	O
social	O
media	O
:	O
tweet	O
at	O
:	O
@	O
billbyrom	O
bill	O
byrom	O
,	O
ph.d.	O
,	O
has	O
spent	O
a	O
significant	O
amount	O
of	O
his	O
professional	O
career	O
working	O
to	O
understand	O
how	O
to	O
better	O
collect	O
clinical	O
trial	O
data	O
from	O
patients	O
.	O
he	O
has	O
written	O
the	O
book	O
on	O
electronic	O
patient	O
reported	O
outcomes	O
(	O
epro	O
)	O
—	O
literally	O
.	O
in	O
addition	O
to	O
writing	O
too	O
many	O
papers	O
and	O
book	O
chapters	O
to	O
count	O
,	O
dr.	O
byrom	O
,	O
along	O
with	O
brian	O
tiplady	O
,	O
wrote	O
epro	O
:	O
electronic	O
solutions	O
for	O
patient-reported	O
data	O
in	O
2010	O
.	O
through	O
his	O
writing	O
and	O
as	O
senior	O
director	O
of	O
product	O
innovation	O
at	O
icon	O
clinical	O
research	O
,	O
dr.	O
byrom	O
has	O
contributed	O
to	O
the	O
overall	O
understanding	O
of	O
epro	O
and	O
its	O
use	O
in	O
clinical	O
trials	O
.	O
in	O
addition	O
to	O
his	O
innovation	O
role	O
at	O
icon	O
,	O
dr.	O
byrom	O
currently	O
serves	O
as	O
the	O
vice	O
director	O
for	O
the	O
epro	O
consortium	O
(	O
critical	O
path	O
institute	O
)	O
where	O
he	O
has	O
led	O
industrywide	O
collaborations	O
to	O
push	O
forward	O
current	O
thinking	O
on	O
the	O
regulatory	O
and	O
scientific	O
areas	O
of	O
electronic	O
clinical	O
outcome	O
assessment	O
(	O
ecoa	O
)	O
.	O
his	O
research	O
includes	O
demonstrating	O
the	O
viability	O
of	O
bring	O
your	O
own	O
device	O
(	O
byod	O
)	O
patient-centric	O
tools	O
,	O
thorough	O
investigation	O
of	O
wearables	O
and	O
their	O
application	O
in	O
21st	O
century	O
research	O
and	O
medicine	O
,	O
and	O
new	O
ways	O
to	O
recruit	O
,	O
motivate	O
,	O
monitor	O
,	O
and	O
interact	O
with	O
patients	O
in	O
clinical	O
trials	O
.	O
in	O
recent	O
years	O
,	O
he	O
has	O
helped	O
to	O
evaluate	O
how	O
patients	O
can	O
be	O
supported	O
in	O
reporting	O
epro	O
data	O
from	O
home	O
.	O
dr.	O
byrom	O
not	O
only	O
researched	O
operational	O
aspects	O
of	O
byod	O
,	O
but	O
also	O
regulatory	O
and	O
scientific	O
aspects	O
championing	O
epro	O
and	O
byod	O
within	O
clinical	O
trials	O
,	O
including	O
cutting	O
edge	O
primary	O
research	O
to	O
support	O
the	O
validity	O
of	O
the	O
approach	O
.	O
he	O
has	O
not	O
only	O
done	O
considerable	O
work	O
to	O
advance	O
the	O
techniques	O
of	O
epro	O
and	O
associated	O
technologies	O
,	O
but	O
dr.	O
byrom	O
has	O
also	O
advocated	O
and	O
facilitated	O
their	O
increased	O
use	O
within	O
clinical	O
studies	O
.	O
colleagues	O
say	O
one	O
of	O
his	O
many	O
strengths	O
is	O
his	O
ability	O
to	O
take	O
scientific	O
and	O
theoretical	O
theories	O
and	O
translate	O
them	O
into	O
practical	O
application	O
.	O
those	O
who	O
have	O
worked	O
with	O
dr.	O
byrom	O
say	O
they	O
admire	O
the	O
way	O
he	O
constantly	O
seeks	O
new	O
ways	O
to	O
improve	O
clinical	O
research	O
,	O
especially	O
in	O
areas	O
using	O
technology	O
.	O
he	O
has	O
excellent	O
communication	O
skills	O
and	O
a	O
strong	O
lead-by-example	O
work	O
ethic	O
.	O
these	O
attributes	O
have	O
enabled	O
him	O
to	O
pull	O
together	O
teams	O
of	O
top	O
thinkers	O
from	O
a	O
variety	O
of	O
biopharma	O
companies	O
,	O
academia	O
,	O
and	O
even	O
competing	O
companies	O
.	O
dr.	O
byrom	O
says	O
one	O
of	O
his	O
goals	O
is	O
to	O
drive	O
innovative	O
approaches	O
within	O
clinical	O
drug	O
development	O
and	O
commercialization	O
,	O
and	O
to	O
operationalize	O
these	O
approaches	O
to	O
enable	O
use	O
at	O
scale	O
within	O
clinical	O
trials	O
and	O
real-world	O
evidence	O
studies	O
.	O
another	O
of	O
his	O
goals	O
is	O
to	O
drive	O
the	O
industry	O
’	O
s	O
adoption	O
and	O
use	O
of	O
wearable	O
devices	O
.	O
as	O
vice	O
director	O
of	O
the	O
epro	O
consortium	O
,	O
he	O
is	O
leading	O
a	O
consensus	O
group	O
that	O
is	O
developing	O
recommendations	O
for	O
evidence	O
needed	O
to	O
support	O
the	O
selection	O
of	O
wearable	O
devices	O
for	O
use	O
in	O
regulatory	O
submission	O
trials	O
and	O
to	O
support	O
endpoints	O
derived	O
from	O
their	O
data	O
.	O
“	O
i	O
’	O
m	O
passionate	O
about	O
leveraging	O
smartphone	O
sensors	O
within	O
patient	O
apps	O
,	O
remote	O
collection	O
of	O
data	O
using	O
wearables	O
and	O
shareables	O
—	O
such	O
as	O
commercial	O
health	O
kiosks	O
—	O
and	O
leveraging	O
existing	O
technology	O
in	O
novel	O
ways	O
,	O
”	O
he	O
says	O
.	O
“	O
currently	O
,	O
i	O
’	O
m	O
looking	O
at	O
how	O
we	O
can	O
use	O
motion-based	O
gaming	O
platforms	O
such	O
as	O
microsoft	ORG
xbox	O
to	O
collect	O
movement	O
and	O
mobility	O
endpoints	O
from	O
the	O
3d	O
coordinates	O
of	O
body	O
joints	O
tracked	O
using	O
the	O
gaming	O
platform	O
during	O
tests	O
conducted	O
by	O
the	O
patient.	O
”	O
he	O
says	O
he	O
has	O
a	O
desire	O
to	O
continually	O
improve	O
how	O
clinical	O
data	O
are	O
collected	O
to	O
see	O
patients	O
benefit	O
from	O
these	O
improvements	O
.	O
his	O
overall	O
goal	O
is	O
to	O
leverage	O
technology	O
in	O
novel	O
ways	O
to	O
make	O
trial	O
participation	O
easier	O
,	O
more	O
engaging	O
,	O
and	O
to	O
provide	O
richer	O
and	O
more	O
informative	O
data	O
that	O
generates	O
deeper	O
insights	O
for	O
researchers	O
and	O
healthcare	O
providers	O
.	O
he	O
wants	O
to	O
be	O
remembered	O
for	O
bringing	O
forward	O
creative	O
eclinical	O
solutions	O
to	O
improve	O
the	O
conduct	O
of	O
clinical	O
trials	O
.	O
dr.	O
byrom	O
is	O
dedicated	O
to	O
delivering	O
the	O
scientific	O
work	O
needed	O
to	O
help	O
drive	O
the	O
increased	O
adoption	O
of	O
wearable	O
,	O
mobile	O
,	O
and	O
telemedicine	O
technology	O
in	O
trials	O
that	O
ultimately	O
helps	O
patients	O
to	O
become	O
partners	O
in	O
research	O
and	O
addresses	O
their	O
medical	O
needs	O
.	O
(	O
pv	O
)	O
dr.	O
susan	O
atkinson	O
practical	O
innovator	O
title	O
:	O
senior	O
vp	O
,	O
global	O
biometrics	O
company	O
:	O
ppd	O
education	O
:	O
bs	O
,	O
ms	O
,	O
phd	O
,	O
university	O
of	O
north	O
carolina	O
,	O
chapel	O
hill	O
family	O
:	O
her	O
husband	O
,	O
their	O
grown	O
children	O
,	O
and	O
rescued	O
german	O
shephard	O
hobbies	O
:	O
crocheting	O
,	O
quilting	O
,	O
yoga	O
,	O
reading	O
bucket	O
list	O
:	O
travel	O
to	O
numerous	O
places	O
she	O
has	O
yet	O
to	O
see	O
—	O
top	O
of	O
the	O
list	O
are	O
australia	LOC
,	O
new	O
zealand	O
,	O
italy	O
,	O
and	O
a	O
safari	O
in	O
africa	O
associations	O
:	O
american	O
statistical	O
association	O
;	O
cdisc	O
;	O
board	O
of	O
directors	O
for	O
local	O
nonprofit	O
,	O
church	O
membership	O
and	O
related	O
ministries	O
social	O
media	O
:	O
for	O
susan	O
atkinson	O
,	O
ph.d.	O
,	O
her	O
job	O
is	O
very	O
much	O
a	O
calling	O
.	O
it	O
’	O
s	O
about	O
doing	O
work	O
that	O
matters	O
to	O
those	O
she	O
collaborates	O
alongside	O
,	O
to	O
the	O
company	O
she	O
innovates	O
for	O
,	O
and	O
to	O
the	O
patients	O
who	O
receive	O
benefits	O
from	O
the	O
drugs	O
they	O
are	O
developing	O
.	O
as	O
senior	O
vp	O
of	O
global	O
biometrics	O
for	O
ppd	O
,	O
dr.	O
atkinson	O
oversees	O
the	O
company	O
’	O
s	O
global	O
patient	O
data	O
acquisition	O
,	O
cleaning	O
,	O
analysis	O
and	O
reporting	O
for	O
all	O
phases	O
of	O
its	O
clinical	O
trial	O
data	O
,	O
leads	O
the	O
clinical	O
supplies	O
and	O
randomization	O
services	O
and	O
plays	O
a	O
strategic	O
role	O
in	O
ppd	O
’	O
s	O
innovation	O
efforts	O
.	O
“	O
real	O
innovation	O
brings	O
value	O
when	O
it	O
’	O
s	O
applied	O
to	O
a	O
practical	O
problem	O
with	O
an	O
enterprise	O
mindset	O
,	O
”	O
she	O
says	O
.	O
“	O
there	O
is	O
an	O
abundance	O
of	O
data	O
in	O
clinical	O
r	O
&	O
d	O
.	O
the	O
tools	O
to	O
acquire	O
and	O
analyze	O
these	O
data	O
sets	O
are	O
becoming	O
more	O
accessible	O
.	O
the	O
ability	O
to	O
warehouse	O
—	O
organize	O
and	O
store	O
data	O
—	O
is	O
increasing	O
.	O
my	O
role	O
in	O
innovation	O
is	O
to	O
connect	O
these	O
tools	O
and	O
approaches	O
to	O
business	O
problems	O
that	O
need	O
solving	O
.	O
and	O
in	O
reverse	O
,	O
it	O
is	O
to	O
take	O
a	O
business	O
problem	O
and	O
look	O
at	O
it	O
from	O
a	O
fresh	O
perspective	O
and	O
see	O
how	O
other	O
solutions	O
can	O
be	O
extrapolated	O
to	O
the	O
problem	O
at	O
hand.	O
”	O
since	O
joining	O
ppd	O
in	O
1991	O
as	O
a	O
senior	O
biostatistician	O
,	O
dr.	O
atkinson	O
has	O
risen	O
through	O
the	O
ranks	O
of	O
the	O
cro	O
to	O
her	O
current	O
leadership	O
role	O
to	O
which	O
she	O
brings	O
vast	O
expertise	O
in	O
statistical	O
analysis	O
,	O
clinical	O
trial	O
design	O
,	O
regulatory	O
submission	O
strategies	O
,	O
and	O
knowledge	O
of	O
eclinical	O
trial	O
technologies	O
.	O
increasingly	O
,	O
dr.	O
atkinson	O
believes	O
traditional	O
boundaries	O
of	O
the	O
clinical	O
trial	O
r	O
&	O
d	O
model	O
are	O
being	O
challenged	O
by	O
a	O
much-needed	O
focus	O
of	O
putting	O
the	O
patient	O
first	O
.	O
to	O
stay	O
relevant	O
,	O
clinical	O
trial	O
protocols	O
must	O
be	O
innovated	O
with	O
the	O
patient	O
’	O
s	O
view	O
in	O
mind	O
and	O
data	O
collection	O
methods	O
must	O
continue	O
to	O
evolve	O
in	O
support	O
.	O
a	O
natural	O
puzzle-solver	O
,	O
dr.	O
atkinson	O
loves	O
the	O
challenge	O
of	O
analyzing	O
a	O
situation	O
,	O
considering	O
options	O
,	O
and	O
putting	O
together	O
new	O
solutions	O
.	O
colleagues	O
describe	O
dr.	O
atkinson	O
as	O
an	O
inspiring	O
leader	O
,	O
incredibly	O
intelligent	O
,	O
ethical	O
,	O
sincere	O
,	O
compassionate	O
,	O
and	O
a	O
visionary	O
leader	O
during	O
times	O
of	O
change	O
.	O
she	O
has	O
a	O
skill	O
for	O
grasping	O
complex	O
concepts	O
and	O
distilling	O
them	O
down	O
to	O
develop	O
creative	O
strategies	O
.	O
she	O
describes	O
success	O
as	O
sustainable	O
business	O
growth	O
amid	O
challenging	O
times	O
.	O
she	O
says	O
many	O
leaders	O
thrive	O
during	O
the	O
good	O
times	O
;	O
it	O
’	O
s	O
those	O
leaders	O
who	O
steer	O
people	O
through	O
the	O
rougher	O
times	O
who	O
really	O
stand	O
out	O
.	O
her	O
colleagues	O
say	O
she	O
has	O
the	O
talent	O
to	O
take	O
the	O
worst	O
situation	O
and	O
reframe	O
it	O
to	O
what	O
it	O
could	O
be	O
.	O
dr.	O
atkinson	O
sets	O
high	O
expectations	O
for	O
her	O
teams	O
and	O
for	O
herself	O
.	O
the	O
environment	O
she	O
creates	O
is	O
fair	O
and	O
respectful	O
,	O
and	O
one	O
in	O
which	O
people	O
come	O
first	O
.	O
this	O
balance	O
breeds	O
motivation	O
and	O
inspires	O
those	O
around	O
her	O
to	O
reach	O
their	O
goals	O
.	O
leadership	O
to	O
dr.	O
atkinson	O
is	O
about	O
encouraging	O
others	O
to	O
do	O
the	O
right	O
thing	O
—	O
with	O
integrity	O
,	O
a	O
high	O
personal	O
standard	O
of	O
quality	O
,	O
deep	O
domain	O
knowledge	O
,	O
and	O
driven	O
by	O
data	O
—	O
for	O
the	O
right	O
reason	O
and	O
at	O
the	O
right	O
time	O
.	O
she	O
encourages	O
her	O
people	O
to	O
draw	O
on	O
situational	O
awareness	O
,	O
collaborative	O
skills	O
,	O
and	O
team	O
dynamics	O
.	O
dr.	O
atkinson	O
particularly	O
enjoys	O
working	O
on	O
the	O
integration	O
of	O
acquisitions	O
,	O
where	O
the	O
skills	O
of	O
collaboration	O
and	O
teamwork	O
are	O
leveraged	O
to	O
build	O
something	O
that	O
is	O
greater	O
than	O
the	O
sum	O
of	O
its	O
parts	O
.	O
when	O
challenges	O
arise	O
,	O
she	O
keeps	O
teams	O
focused	O
on	O
the	O
purpose	O
and	O
vision	O
behind	O
what	O
they	O
are	O
working	O
on	O
.	O
and	O
she	O
helps	O
others	O
to	O
see	O
that	O
a	O
challenge	O
is	O
really	O
an	O
opportunity	O
—	O
to	O
grow	O
personally	O
,	O
question	O
the	O
status	O
quo	O
,	O
and	O
improve	O
operations	O
to	O
benefit	O
patients	O
.	O
collaboration	O
is	O
important	O
to	O
dr.	O
atkinson	O
,	O
who	O
runs	O
a	O
large	O
and	O
diverse	O
global	O
operation	O
by	O
pulling	O
her	O
teams	O
together	O
and	O
aligning	O
their	O
vision	O
on	O
the	O
goal	O
at	O
hand	O
.	O
she	O
would	O
like	O
to	O
be	O
remembered	O
by	O
others	O
who	O
feel	O
that	O
they	O
are	O
better	O
leaders	O
because	O
of	O
her	O
input	O
.	O
her	O
hope	O
is	O
that	O
the	O
teams	O
she	O
has	O
assembled	O
will	O
build	O
on	O
the	O
foundations	O
she	O
has	O
instilled	O
of	O
quality	O
,	O
innovation	O
,	O
and	O
collaboration	O
to	O
soar	O
to	O
new	O
heights	O
,	O
doing	O
even	O
greater	O
things	O
in	O
the	O
areas	O
of	O
research	O
and	O
development	O
.	O
dr.	O
atkinson	O
inspires	O
others	O
by	O
remaining	O
focused	O
and	O
humble	O
amid	O
an	O
intense	O
and	O
often	O
demanding	O
industry	O
.	O
she	O
mentors	O
both	O
officially	O
and	O
unofficially	O
within	O
ppd	O
and	O
the	O
nonprofit	O
organizations	O
she	O
is	O
involved	O
with	O
.	O
colleagues	O
note	O
that	O
dr.	O
atkinson	O
encourages	O
others	O
to	O
reach	O
their	O
full	O
potential	O
by	O
remaining	O
genuine	O
and	O
having	O
a	O
sincere	O
interest	O
in	O
understanding	O
and	O
listening	O
to	O
their	O
concerns	O
.	O
in	O
addition	O
to	O
mentoring	O
others	O
,	O
dr.	O
atkinson	O
helped	O
to	O
develop	O
a	O
leadership	O
training	O
program	O
.	O
“	O
leaders	O
have	O
to	O
share	O
and	O
develop	O
others	O
;	O
otherwise	O
,	O
they	O
are	O
just	O
managers	O
or	O
individual	O
contributors	O
,	O
”	O
she	O
says	O
.	O
“	O
i	O
find	O
that	O
i	O
grow	O
and	O
develop	O
just	O
as	O
much	O
in	O
these	O
mentoring	O
engagements	O
as	O
does	O
the	O
mentee	O
.	O
the	O
more	O
i	O
mentor	O
,	O
the	O
more	O
challenged	O
i	O
am	O
to	O
clarify	O
my	O
thinking	O
and	O
evaluate	O
approaches	O
from	O
different	O
perspectives.	O
”	O
(	O
pv	O
)	O
amber	O
eaton	O
connecting	O
passion	O
and	O
conviction	O
title	O
:	O
vp	O
,	O
group	O
account	O
director	O
company	O
:	O
micromass	O
communications	O
inc.	O
education	O
:	O
ba	O
,	O
public	O
and	O
interpersonal	O
communication	O
,	O
north	O
carolina	O
state	O
university	O
,	O
2001	O
family	O
:	O
husband	O
,	O
eric	O
;	O
two	O
sons	O
,	O
cooper	O
and	O
walker	O
hobbies	O
:	O
spending	O
time	O
with	O
family	O
and	O
friends	O
,	O
reading	O
,	O
traveling	O
social	O
media	O
:	O
tweet	O
at	O
:	O
@	O
amberseaton1	O
an	O
innovator	O
and	O
motivator	O
,	O
amber	O
eaton	O
is	O
propelling	O
micromass	O
to	O
new	O
heights	O
in	O
its	O
efforts	O
to	O
change	O
patient	O
and	O
provider	O
behavior	O
.	O
in	O
her	O
role	O
as	O
vp	O
and	O
group	O
account	O
director	O
at	O
micromass	O
communications	O
,	O
ms.	O
eaton	O
is	O
also	O
cultivating	O
an	O
atmosphere	O
where	O
people	O
matter	O
and	O
she	O
is	O
helping	O
others	O
to	O
re-envision	O
the	O
future	O
and	O
take	O
risks	O
.	O
ms.	O
eaton	O
possesses	O
a	O
strong	O
strategic	O
vision	O
as	O
well	O
as	O
a	O
penchant	O
for	O
the	O
fine	O
details	O
,	O
which	O
have	O
served	O
her	O
well	O
in	O
her	O
role	O
as	O
the	O
main	O
agency	O
point	O
person	O
for	O
very	O
large	O
,	O
exhaustive	O
brand	O
initiatives	O
and	O
specialized	O
projects	O
.	O
an	O
innate	O
passion	O
for	O
helping	O
improve	O
the	O
patient	O
experience	O
helps	O
to	O
keep	O
ms.	O
eaton	O
’	O
s	O
ideas	O
fresh	O
and	O
her	O
interest	O
high	O
.	O
she	O
has	O
created	O
an	O
environment	O
that	O
enables	O
her	O
colleagues	O
to	O
craft	O
solutions	O
that	O
haven	O
’	O
t	O
been	O
used	O
before	O
to	O
solve	O
client	O
challenges	O
.	O
according	O
to	O
ms.	O
eaton	O
,	O
the	O
industry	O
is	O
still	O
tackling	O
real-world	O
barriers	O
around	O
prescription	O
initiation	O
and	O
adherence	O
.	O
to	O
win	O
this	O
battle	O
,	O
she	O
says	O
the	O
industry	O
must	O
address	O
both	O
the	O
clinical	O
and	O
psychosocial	O
needs	O
of	O
patients	O
along	O
the	O
treatment	O
journey	O
and	O
that	O
means	O
bringing	O
together	O
pharma	O
companies	O
and	O
external	O
partners	O
,	O
including	O
nurse	O
educators	O
,	O
healthcare	O
providers	O
,	O
specialty	O
pharmacies	O
,	O
patient	O
assistant	O
teams	O
,	O
and	O
advocacy	O
groups	O
to	O
implement	O
a	O
whole	O
patient	O
approach	O
.	O
this	O
approach	O
supplements	O
conventional	O
efforts	O
with	O
active	O
motivation	O
and	O
skill-building	O
programs	O
to	O
accelerate	O
product	O
awareness	O
and	O
adoption	O
and	O
drive	O
optimal	O
outcomes	O
.	O
ms.	O
eaton	O
is	O
working	O
to	O
ensure	O
that	O
micromass	O
remains	O
relevant	O
and	O
innovative	O
in	O
its	O
thinking	O
,	O
pushes	O
limits	O
,	O
constantly	O
pressure	O
tests	O
ideas	O
,	O
and	O
evolves	O
to	O
not	O
only	O
solve	O
clients	O
’	O
challenges	O
but	O
has	O
a	O
true	O
impact	O
on	O
patient	O
outcomes	O
.	O
her	O
innovative	O
approach	O
to	O
problem	O
solving	O
is	O
taking	O
micromass	O
’	O
behaviorally	O
based	O
solutions	O
to	O
the	O
next	O
level	O
.	O
she	O
can	O
identify	O
opportunities	O
and	O
adapt	O
strategically	O
to	O
meet	O
patient	O
needs	O
.	O
in	O
doing	O
so	O
,	O
she	O
builds	O
the	O
trust	O
and	O
respect	O
of	O
her	O
clients	O
,	O
her	O
peers	O
,	O
and	O
her	O
co-workers	O
.	O
ms.	O
eaton	O
believes	O
that	O
people	O
are	O
motivated	O
to	O
do	O
their	O
best	O
when	O
they	O
feel	O
validated	O
,	O
appreciated	O
,	O
and	O
understood	O
.	O
“	O
i	O
’	O
ve	O
learned	O
over	O
the	O
years	O
that	O
the	O
growing	O
pains	O
i	O
experienced	O
in	O
my	O
career	O
are	O
powerful	O
tools	O
to	O
share	O
with	O
others	O
as	O
they	O
grow	O
,	O
”	O
she	O
says	O
,	O
and	O
admitting	O
that	O
it	O
’	O
s	O
important	O
to	O
go	O
outside	O
of	O
one	O
’	O
s	O
comfort	O
zone	O
and	O
not	O
be	O
afraid	O
to	O
take	O
risks	O
.	O
“	O
taking	O
the	O
time	O
to	O
connect	O
—	O
sharing	O
experiences	O
,	O
failures	O
,	O
fears	O
,	O
and	O
goals	O
—	O
allows	O
me	O
to	O
truly	O
get	O
to	O
know	O
others	O
.	O
when	O
we	O
share	O
these	O
types	O
of	O
connections	O
,	O
we	O
intuitively	O
want	O
to	O
work	O
harder	O
to	O
meet	O
common	O
goals.	O
”	O
challenges	O
present	O
an	O
opportunity	O
to	O
teach	O
and	O
learn	O
,	O
she	O
maintains	O
.	O
and	O
ms.	O
eaton	O
and	O
her	O
team	O
work	O
together	O
to	O
break	O
down	O
the	O
issues	O
so	O
they	O
seem	O
less	O
overwhelming	O
.	O
colleagues	O
describe	O
her	O
as	O
passionate	O
,	O
fearless	O
,	O
and	O
insightful	O
.	O
“	O
i	O
lean	O
on	O
my	O
instincts	O
to	O
identify	O
who	O
i	O
think	O
likely	O
has	O
the	O
answer	O
and	O
i	O
push	O
that	O
person	O
to	O
speak	O
up	O
and	O
be	O
the	O
leader	O
the	O
team	O
needs	O
at	O
that	O
moment	O
,	O
”	O
she	O
says	O
.	O
she	O
empowers	O
her	O
team	O
members	O
to	O
confidently	O
lead	O
and	O
flourish	O
on	O
their	O
own	O
.	O
ms.	O
eaton	O
believes	O
leadership	O
is	O
about	O
motivating	O
and	O
influencing	O
others	O
through	O
one	O
’	O
s	O
own	O
character	O
,	O
humility	O
,	O
and	O
integrity	O
,	O
and	O
inspiring	O
them	O
through	O
passion	O
and	O
conviction	O
toward	O
a	O
shared	O
vision	O
.	O
“	O
innovation	O
thrives	O
where	O
there	O
is	O
an	O
environment	O
that	O
ensures	O
alignment	O
on	O
a	O
shared	O
goal	O
,	O
values	O
different	O
perspectives	O
and	O
experiences	O
,	O
empowers	O
people	O
,	O
fosters	O
collaboration	O
,	O
and	O
forgives	O
failure	O
,	O
”	O
she	O
says	O
.	O
(	O
pv	O
)	O
dr.	O
steve	O
shak	O
a	O
pioneer	O
in	O
precision	O
medicine	O
title	O
:	O
co-founder	O
and	O
chief	O
scientific	O
officer	O
company	O
:	O
genomic	O
health	O
inc.	O
education	O
:	O
ba	O
,	O
chemistry	O
,	O
amherst	O
college	O
;	O
md	O
,	O
new	LOC
york	LOC
university	O
school	O
of	O
medicine	O
;	O
post-doctoral	O
training	O
,	O
bellevue	ORG
hospital	ORG
,	O
new	LOC
york	LOC
,	O
and	O
university	ORG
of	ORG
california	ORG
,	O
san	LOC
francisco	LOC
family	O
:	O
parents	O
;	O
wife	O
,	O
gail	O
;	O
daughter	O
,	O
linda	O
;	O
son	O
,	O
joshua	O
(	O
emma	O
)	O
hobbies	O
:	O
cycling	O
bucket	O
list	O
:	O
give	O
back	O
to	O
others	O
industry	O
awards/honors	O
:	O
susan	O
b.	O
komen	O
greater	O
nyc	O
physician	O
of	O
impact	O
award	O
,	O
2015	O
;	O
the	O
solomon	O
a.	O
berson	O
alumni	O
achievement	O
award	O
in	O
clinical	O
science	O
from	O
nyu	ORG
school	ORG
of	ORG
medicine	ORG
,	O
2010	O
;	O
cancercare	O
’	O
s	O
beacon	O
award	O
,	O
2009	O
;	O
nyu	O
biotechnology	O
award	O
,	O
2001	O
;	O
prix	O
gallien	O
,	O
portugal	O
for	O
pulmozyme	O
discovery	O
,	O
1995	O
;	O
parenting	O
achievement	O
award	O
,	O
parenting	O
magazine	O
,	O
1995	O
;	O
distinguished	O
corporate	O
scientist	O
award	O
,	O
cystic	O
fibrosis	O
foundation	O
,	O
1993	O
;	O
cf	O
achievement	O
award	O
,	O
cystic	O
fibrosis	O
research	O
,	O
1992	O
associations	O
:	O
american	ORG
society	ORG
of	O
clinical	O
oncology	O
social	O
media	O
:	O
steve	O
shak	O
,	O
m.d.	O
,	O
has	O
been	O
a	O
pioneer	O
in	O
personalized	O
medicine	O
for	O
more	O
than	O
30	O
years	O
.	O
with	O
decades	O
of	O
discovering	O
and	O
developing	O
breakthrough	O
drugs	O
and	O
diagnostics	O
,	O
his	O
contributions	O
to	O
medical	O
science	O
and	O
patient	O
care	O
are	O
innumerable	O
.	O
as	O
a	O
leader	O
,	O
he	O
constantly	O
challenges	O
his	O
teams	O
to	O
think	O
innovatively	O
and	O
pushes	O
clinicians	O
and	O
scientists	O
to	O
answer	O
the	O
most	O
critical	O
clinical	O
questions	O
.	O
while	O
at	O
genentech	ORG
,	O
dr.	O
shak	O
is	O
credited	O
with	O
spearheading	O
the	O
discovery	O
and	O
development	O
of	O
multiple	O
breakthrough	O
products	O
in	O
the	O
biotechnology	O
industry	O
—	O
including	O
herceptin	O
,	O
approved	O
in	O
1998	O
and	O
the	O
only	O
targeted	O
biologic	O
therapy	O
approved	O
for	O
treatment	O
of	O
her2-positive	O
breast	O
cancer	O
in	O
the	O
adjuvant	O
and	O
metastatic	O
settings	O
,	O
and	O
pulmozyme	O
,	O
approved	O
in	O
1993	O
as	O
the	O
first	O
treatment	O
that	O
specifically	O
improves	O
lung	O
function	O
in	O
cf	O
patients	O
.	O
in	O
2000	O
,	O
dr.	O
shak	O
co-founded	O
genomic	O
health	O
with	O
the	O
goal	O
of	O
developing	O
high-value	O
diagnostics	O
to	O
enable	O
more	O
personalized	O
cancer	O
treatment	O
decisions	O
based	O
on	O
the	O
genomic	O
activity	O
within	O
a	O
patient	O
’	O
s	O
individual	O
tumor	O
.	O
the	O
company	O
,	O
which	O
started	O
17	O
years	O
ago	O
with	O
a	O
small	O
group	O
of	O
like-minded	O
colleagues	O
,	O
has	O
now	O
grown	O
into	O
an	O
organization	O
with	O
more	O
than	O
840	O
employees	O
worldwide	O
serving	O
more	O
than	O
800,000	O
patients	O
in	O
more	O
than	O
90	O
countries	O
around	O
the	O
world	O
.	O
genomic	O
health	O
is	O
a	O
provider	O
of	O
genomic-based	O
diagnostic	O
tests	O
that	O
help	O
optimize	O
cancer	O
care	O
.	O
with	O
its	O
oncotype	O
iq	O
genomic	O
intelligence	O
platform	O
,	O
the	O
company	O
is	O
applying	O
its	O
scientific	O
and	O
commercial	O
expertise	O
and	O
infrastructure	O
to	O
lead	O
the	O
translation	O
of	O
clinical	O
and	O
genomic	O
big	O
data	O
into	O
actionable	O
results	O
for	O
treatment	O
planning	O
throughout	O
the	O
cancer	O
patient	O
journey	O
,	O
saving	O
the	O
u.s.	LOC
healthcare	O
system	O
more	O
than	O
$	O
3.5	O
billion	O
.	O
under	O
dr.	O
shak	O
’	O
s	O
leadership	O
,	O
genomic	O
health	O
has	O
revolutionized	O
the	O
quality	O
of	O
treatment	O
decisions	O
for	O
cancer	O
patients	O
and	O
made	O
precision	O
medicine	O
a	O
reality	O
for	O
hundreds	O
of	O
thousands	O
of	O
patients	O
worldwide	O
.	O
in	O
2004	O
,	O
he	O
played	O
an	O
instrumental	O
role	O
in	O
the	O
launch	O
of	O
the	O
company	O
’	O
s	O
first	O
product	O
,	O
the	O
oncotype	O
dx	O
breast	O
recurrence	O
score	O
,	O
which	O
quantifies	O
the	O
likelihood	O
of	O
breast	O
cancer	O
recurrence	O
for	O
early-stage	O
breast	O
cancer	O
patients	O
and	O
predicts	O
chemotherapy	O
benefit	O
to	O
help	O
inform	O
decisions	O
about	O
treatment	O
and	O
improve	O
patient	O
outcomes	O
.	O
dr.	O
shak	O
believes	O
in	O
the	O
power	O
of	O
data	O
to	O
help	O
guide	O
treatment	O
decisions	O
.	O
he	O
has	O
made	O
it	O
a	O
mission	O
to	O
foster	O
a	O
team	O
dedicated	O
to	O
building	O
an	O
unmatched	O
database	O
of	O
scientific	O
evidence	O
supporting	O
the	O
use	O
of	O
genomic	O
health	O
’	O
s	O
products	O
.	O
he	O
led	O
a	O
collaboration	O
with	O
the	O
national	O
cancer	O
institute	O
’	O
s	O
surveillance	O
,	O
epidemiology	O
,	O
and	O
end	O
results	O
(	O
seer	O
)	O
program	O
to	O
gain	O
important	O
clinical	O
insights	O
from	O
patients	O
whose	O
treatment	O
information	O
and	O
outcomes	O
has	O
been	O
gathered	O
and	O
tracked	O
by	O
the	O
government	O
registries	O
.	O
partnering	O
with	O
seer	O
,	O
dr.	O
shak	O
helped	O
pioneer	O
a	O
new	O
model	O
for	O
government	O
and	O
industry	O
working	O
alongside	O
one	O
another	O
,	O
using	O
big	O
data	O
to	O
improve	O
breast	O
cancer	O
diagnosis	O
and	O
treatment	O
.	O
colleagues	O
say	O
dr.	O
shak	O
’	O
s	O
leadership	O
style	O
is	O
infectious	O
.	O
he	O
consistently	O
and	O
passionately	O
facilitates	O
the	O
connection	O
of	O
everyone	O
at	O
genomic	O
health	O
to	O
that	O
common	O
mission	O
,	O
which	O
is	O
to	O
help	O
patients	O
receive	O
optimal	O
treatment	O
and	O
experience	O
better	O
outcomes	O
.	O
dr.	O
shak	O
has	O
been	O
recognized	O
on	O
multiple	O
occasions	O
for	O
his	O
impact	O
in	O
optimizing	O
cancer	O
research	O
and	O
care	O
,	O
and	O
in	O
bringing	O
the	O
patient	O
voice	O
into	O
product	O
development	O
.	O
in	O
2009	O
,	O
he	O
received	O
cancercare	O
’	O
s	O
beacon	O
award	O
,	O
in	O
recognition	O
of	O
genomic	O
innovations	O
in	O
diagnostics	O
for	O
breast	O
cancer	O
.	O
in	O
2015	O
,	O
he	O
received	O
the	O
physician	O
of	O
impact	O
award	O
from	O
susan	O
g.	O
komen	O
honoring	O
him	O
for	O
his	O
commitment	O
to	O
raising	O
awareness	O
and	O
saving	O
the	O
lives	O
of	O
breast	O
cancer	O
patients	O
.	O
dr.	O
shak	O
says	O
his	O
most	O
challenging	O
assignment	O
has	O
been	O
transitioning	O
his	O
skills	O
in	O
scientific	O
innovation	O
and	O
drug	O
development	O
into	O
becoming	O
a	O
transformational	O
leader	O
who	O
inspires	O
innovation	O
in	O
others	O
.	O
“	O
i	O
try	O
to	O
ask	O
good	O
questions	O
and	O
look	O
at	O
strategy	O
and	O
decisions	O
in	O
the	O
context	O
of	O
near-	O
and	O
long-term	O
considerations	O
and	O
the	O
larger	O
industry	O
and	O
healthcare	O
ecosystem	O
,	O
”	O
he	O
says	O
.	O
“	O
i	O
try	O
to	O
inspire	O
by	O
providing	O
opportunities	O
for	O
others	O
to	O
excel	O
and	O
make	O
a	O
difference.	O
”	O
dr.	O
shak	O
would	O
like	O
to	O
be	O
remembered	O
as	O
someone	O
who	O
has	O
made	O
a	O
difference	O
in	O
the	O
lives	O
of	O
patients	O
and	O
colleagues	O
.	O
and	O
it	O
appears	O
as	O
if	O
he	O
already	O
has	O
.	O
(	O
pv	O
)	O
dr.	O
kenneth	O
koblan	O
cns	O
innovator	O
and	O
collaborator	O
title	O
:	O
head	O
of	O
global	O
translational	O
medicine	O
&	O
early	O
development	O
(	O
tmed	O
)	O
and	O
head	O
of	O
discovery	O
sciences	O
company	O
:	O
sunovion	O
pharmaceuticals	O
inc.	O
education	O
:	O
bs	O
,	O
biology	O
,	O
massachusetts	O
institute	O
of	O
technology	O
;	O
phd	O
,	O
biochemistry	O
,	O
johns	O
hopkins	O
university	O
hobbies	O
:	O
woodworking	O
,	O
building	O
furniture	O
out	O
of	O
heirloom	O
pieces	O
of	O
wood	O
,	O
fishing	O
,	O
rowing	O
bucket	O
list	O
:	O
riding	O
the	O
rapids	O
at	O
the	O
base	O
of	O
the	O
grand	O
canyon	O
a	O
problem-solver	O
by	O
nature	O
,	O
kenneth	O
koblan	O
,	O
ph.d.	O
,	O
is	O
focused	O
on	O
driving	O
innovation	O
to	O
develop	O
medicines	O
and	O
solutions	O
for	O
patients	O
struggling	O
with	O
psychiatric	O
and	O
neurologic	O
disorders	O
.	O
in	O
his	O
role	O
as	O
head	O
of	O
global	O
translational	O
medicine	O
and	O
early	O
development	O
and	O
head	O
of	O
discovery	O
sciences	O
at	O
sunovion	O
,	O
dr.	O
koblan	O
is	O
using	O
novel	O
technology	O
and	O
quantitative	O
methods	O
and	O
approaches	O
from	O
target	O
identification	O
to	O
clinical	O
trial	O
end	O
points	O
,	O
to	O
bring	O
new	O
medicines	O
to	O
patients	O
.	O
passionate	O
about	O
central	O
nervous	O
system	O
(	O
cns	O
)	O
development	O
,	O
dr.	O
koblan	O
joined	O
sunovion	O
because	O
of	O
its	O
core	O
therapeutic	O
focus	O
in	O
this	O
area	O
of	O
research	O
.	O
he	O
is	O
using	O
his	O
abilities	O
to	O
organize	O
and	O
synthesize	O
scientific	O
data	O
to	O
address	O
the	O
challenges	O
associated	O
with	O
studying	O
mental	O
health	O
disorders	O
and	O
the	O
brain	O
,	O
which	O
present	O
unique	O
and	O
unparalleled	O
opportunities	O
for	O
innovation	O
.	O
before	O
joining	O
sunovion	O
in	O
2011	O
,	O
he	O
held	O
scientific	O
leadership	O
roles	O
at	O
merck	ORG
research	O
laboratories	O
and	O
alnylam	ORG
pharmaceuticals	ORG
.	O
with	O
global	O
healthcare	O
needs	O
evolving	O
rapidly	O
and	O
the	O
increasing	O
prevalence	O
of	O
psychiatric	O
and	O
neurological	O
disorders	O
associated	O
with	O
aging	O
populations	O
,	O
dr.	O
koblan	O
knows	O
that	O
while	O
there	O
is	O
greater	O
understanding	O
of	O
disorders	O
of	O
brain	O
functioning	O
,	O
neuropsychiatric	O
illnesses	O
rank	O
among	O
the	O
leading	O
causes	O
of	O
disability	O
worldwide	O
.	O
for	O
dr.	O
koblan	O
,	O
a	O
career-defining	O
experience	O
has	O
been	O
the	O
opportunity	O
to	O
build	O
the	O
early	O
clinical	O
development	O
and	O
translational	O
medicine	O
groups	O
at	O
sunovion	O
and	O
create	O
innovative	O
clinical	O
trial	O
designs	O
in	O
special	O
patient	O
populations	O
.	O
these	O
trials	O
have	O
been	O
translated	O
into	O
phase	O
iii	O
registration	O
programs	O
in	O
the	O
areas	O
of	O
adhd	O
and	O
binge	O
eating	O
disorder	O
.	O
dr.	O
koblan	O
continues	O
to	O
push	O
sunovion	O
’	O
s	O
pioneering	O
systems-based	O
approach	O
to	O
find	O
new	O
psychiatric	O
drug	O
candidates	O
.	O
he	O
and	O
his	O
team	O
have	O
built	O
an	O
exciting	O
library	O
of	O
compounds	O
they	O
continue	O
to	O
mine	O
.	O
they	O
are	O
characterizing	O
the	O
molecules	O
based	O
on	O
their	O
neurobehavioral	O
effects	O
in	O
animal	O
models	O
,	O
and	O
then	O
studying	O
how	O
these	O
effects	O
compare	O
with	O
known	O
active	O
agents	O
.	O
this	O
process	O
allows	O
for	O
a	O
better	O
understanding	O
of	O
the	O
range	O
of	O
possible	O
therapeutic	O
indications	O
for	O
new	O
molecules	O
and	O
provides	O
guidance	O
for	O
optimal	O
pathways	O
to	O
take	O
to	O
early	O
clinical	O
development	O
.	O
he	O
recognizes	O
that	O
he	O
has	O
a	O
major	O
responsibility	O
to	O
fulfill	O
for	O
patients	O
,	O
noting	O
that	O
many	O
of	O
the	O
larger	O
pharmaceutical	O
companies	O
have	O
retreated	O
from	O
drug	O
development	O
in	O
many	O
of	O
the	O
areas	O
in	O
which	O
sunovion	O
is	O
conducting	O
research	O
and	O
development	O
,	O
particularly	O
the	O
fields	O
of	O
neurology	O
and	O
psychiatry	O
,	O
where	O
the	O
global	O
disease	O
burden	O
is	O
so	O
significant	O
.	O
he	O
is	O
optimistic	O
about	O
the	O
future	O
because	O
of	O
the	O
boundaries	O
being	O
pushed	O
by	O
multiple	O
factors	O
,	O
including	O
patient-reported	O
outcomes	O
,	O
patient-centric	O
endpoints	O
in	O
clinical	O
trials	O
,	O
and	O
the	O
elucidation	O
of	O
genetics	O
of	O
disease	O
states	O
,	O
as	O
well	O
as	O
novel	O
modalities	O
,	O
for	O
example	O
cell-based	O
therapies	O
and	O
a	O
new	O
generation	O
of	O
therapeutics	O
.	O
he	O
believes	O
that	O
evolving	O
technologies	O
,	O
including	O
regenerative	O
medicine	O
,	O
have	O
a	O
transformative	O
potential	O
for	O
patients	O
.	O
he	O
is	O
also	O
excited	O
by	O
the	O
possibilities	O
of	O
new	O
computational	O
chemistry	O
and	O
big	O
data	O
approaches	O
,	O
which	O
have	O
the	O
potential	O
to	O
reduce	O
the	O
time	O
and	O
cost	O
needed	O
to	O
attain	O
the	O
ind	O
milestone	O
.	O
additionally	O
,	O
to	O
address	O
the	O
“	O
inaccessibility	O
”	O
of	O
the	O
brain	O
during	O
clinical	O
development	O
,	O
he	O
is	O
applying	O
non-invasive	O
imaging	O
.	O
he	O
also	O
continues	O
to	O
emphasize	O
the	O
use	O
of	O
cutting-edge	O
translational	O
approaches	O
,	O
such	O
as	O
new	O
modeling	O
and	O
simulation	O
techniques	O
,	O
and	O
other	O
methods	O
for	O
demonstrating	O
the	O
desired	O
cns	O
activity	O
and	O
target	O
engagement	O
.	O
he	O
encourages	O
his	O
team	O
to	O
take	O
an	O
entrepreneurial	O
approach	O
to	O
accelerate	O
timelines	O
while	O
maintaining	O
high-quality	O
standards	O
.	O
dr.	O
koblan	O
would	O
like	O
to	O
be	O
remembered	O
as	O
an	O
innovator	O
across	O
the	O
entire	O
continuum	O
of	O
development	O
,	O
and	O
for	O
focusing	O
on	O
the	O
genetics	O
of	O
early	O
mental	O
health	O
that	O
point	O
toward	O
the	O
next	O
generation	O
of	O
targets	O
.	O
he	O
is	O
an	O
active	O
leader	O
,	O
who	O
closely	O
watches	O
,	O
acts	O
,	O
and	O
teaches	O
his	O
teams	O
and	O
he	O
puts	O
a	O
great	O
deal	O
of	O
attention	O
on	O
getting	O
the	O
right	O
people	O
in	O
the	O
right	O
roles	O
and	O
letting	O
them	O
do	O
their	O
jobs	O
while	O
providing	O
oversight	O
,	O
so	O
they	O
can	O
stay	O
focused	O
on	O
critical	O
objectives	O
.	O
“	O
i	O
encourage	O
each	O
individual	O
to	O
have	O
a	O
single	O
point	O
of	O
accountability	O
and	O
help	O
teams	O
focus	O
on	O
driving	O
core	O
timelines	O
and	O
objectives	O
,	O
”	O
he	O
says	O
.	O
“	O
at	O
the	O
same	O
time	O
,	O
i	O
drive	O
toward	O
collaboration	O
and	O
alliances	O
with	O
external	O
partners	O
,	O
and	O
embrace	O
a	O
global	O
role	O
working	O
with	O
my	O
colleagues	O
worldwide.	O
”	O
dr.	O
koblan	O
is	O
a	O
big	O
believer	O
in	O
the	O
power	O
of	O
cross-stakeholder	O
collaborations	O
and	O
consortia	O
,	O
and	O
he	O
is	O
a	O
member	O
of	O
the	O
neuroscience	O
consortium	O
of	O
massachusetts	O
life	O
sciences	O
center	O
.	O
he	O
is	O
committed	O
to	O
developing	O
the	O
next	O
generation	O
of	O
“	O
drug	O
hunters	O
”	O
in	O
his	O
group	O
,	O
fostering	O
valued	O
relationships	O
,	O
and	O
working	O
with	O
people	O
who	O
have	O
diverse	O
skill	O
sets	O
and	O
personalities	O
.	O
(	O
pv	O
)	O
elise	O
felicione	O
leading	O
transformational	O
change	O
in	O
r	O
&	O
d	O
title	O
:	O
senior	O
director	O
,	O
research	O
&	O
development	O
operations	O
innovation	O
company	O
:	O
janssen	O
,	O
pharmaceutical	O
companies	O
of	O
johnson	ORG
&	ORG
johnson	ORG
education	O
:	O
bs	O
,	O
molecular	O
biology	O
and	O
biochemistry	O
,	O
university	O
of	O
idaho	O
;	O
master	O
of	O
public	O
health	O
,	O
epidemiology	O
,	O
emory	O
university	O
;	O
mba	O
,	O
drexel	O
university	O
family	O
:	O
carlos	O
,	O
alessia	O
,	O
and	O
matthias	O
sattler	O
hobbies	O
:	O
running	O
,	O
art	O
,	O
cooking	O
,	O
wine	O
bucket	O
list	O
:	O
becoming	O
a	O
sommelier	O
social	O
media	O
:	O
as	O
a	O
founding	O
member	O
of	O
janssen	O
’	O
s	O
r	O
&	O
d	O
innovation	O
group	O
,	O
elise	O
felicione	O
helped	O
establish	O
a	O
dedicated	O
clinical	O
trial	O
innovation	O
unit	O
within	O
janssen	O
,	O
where	O
she	O
currently	O
serves	O
as	O
the	O
team	O
lead	O
and	O
right-hand	O
to	O
the	O
head	O
of	O
r	O
&	O
d	O
operations	O
innovation	O
and	O
oversees	O
strategy	O
and	O
execution	O
of	O
a	O
portfolio	O
of	O
initiatives	O
that	O
develop	O
novel	O
models	O
and	O
methods	O
for	O
clinical	O
trial	O
operations	O
.	O
ms.	O
felicione	O
was	O
instrumental	O
in	O
shaping	O
a	O
companywide	O
strategy	O
and	O
roadmap	O
for	O
patient	O
engagement	O
in	O
clinical	O
r	O
&	O
d	O
.	O
during	O
this	O
time	O
,	O
she	O
led	O
an	O
effort	O
that	O
tested	O
several	O
tried-and-true	O
market	O
research	O
methods	O
,	O
including	O
social	O
listening	O
,	O
patient	O
interviews	O
,	O
surveys	O
,	O
and	O
simulated	O
trials	O
to	O
seek	O
direct	O
patient	O
insights	O
and	O
apply	O
them	O
to	O
the	O
design	O
and	O
conduct	O
of	O
clinical	O
trials	O
.	O
this	O
program	O
,	O
known	O
as	O
patient	O
voice	O
in	O
trial	O
design	O
,	O
won	O
the	O
2017	O
clinical	O
&	O
research	O
excellence	O
(	O
care	O
)	O
award	O
for	O
most	O
patient-centric	O
initiative	O
.	O
“	O
there	O
were	O
so	O
many	O
quick	O
wins	O
up	O
for	O
grabs	O
that	O
represented	O
quantum	O
leaps	O
in	O
patient	O
engagement	O
,	O
”	O
ms.	O
felicione	O
says	O
.	O
another	O
quick	O
win	O
and	O
industry	O
first	O
involved	O
use	O
of	O
a	O
general	O
patient	O
satisfaction	O
exit	O
survey	O
in	O
eight	O
countries	O
in	O
a	O
multinational	O
phase	O
iii	O
trial	O
,	O
creating	O
the	O
blueprint	O
for	O
systematic	O
use	O
of	O
satisfaction	O
surveys	O
.	O
colleagues	O
remark	O
that	O
ms.	O
felicione	O
is	O
a	O
steadfast	O
champion	O
for	O
open	O
innovation	O
and	O
cross-industry	O
collaboration	O
.	O
pharma	O
r	O
&	O
d	O
,	O
ms.	O
feliciosne	O
says	O
,	O
needs	O
to	O
develop	O
solutions	O
and	O
offer	O
them	O
up	O
to	O
other	O
companies	O
,	O
developers	O
,	O
or	O
entrepreneurs	O
to	O
further	O
improve	O
on	O
.	O
she	O
also	O
encourages	O
a	O
community-of-practice	O
approach	O
among	O
the	O
innovation	O
units	O
in	O
other	O
pharma	O
companies	O
.	O
“	O
how	O
to	O
innovate	O
in	O
operations	O
successfully	O
is	O
certainly	O
not	O
a	O
trade-secret	O
,	O
”	O
she	O
says	O
.	O
“	O
we	O
should	O
all	O
support	O
one	O
another	O
.	O
“	O
one	O
of	O
the	O
best	O
examples	O
of	O
collaboration	O
and	O
entrepreneur	O
enabled	O
innovation	O
is	O
electronic	O
informed	O
consent	O
,	O
or	O
econsent	O
,	O
”	O
she	O
continues	O
.	O
“	O
informed	O
consent	O
has	O
been	O
prone	O
to	O
lengthy	O
and	O
highly	O
technical	O
paper	O
forms	O
for	O
patient	O
education	O
and	O
is	O
prone	O
to	O
avoidable	O
errors	O
such	O
as	O
use	O
of	O
outdated	O
versions	O
.	O
in	O
parallel	O
,	O
a	O
revolution	O
in	O
electronic	O
learning	O
systems	O
and	O
norms	O
has	O
taken	O
place	O
,	O
which	O
sparked	O
a	O
few	O
brave	O
entrepreneurs	O
to	O
develop	O
econsent	O
technologies	O
aimed	O
at	O
providing	O
an	O
interactive	O
,	O
educational	O
experience	O
for	O
prospective	O
clinical	O
trial	O
participants	O
and	O
electronic	O
signing	O
and	O
archival	O
capabilities.	O
”	O
ms.	O
felicione	O
and	O
her	O
team	O
introduced	O
econsent	O
technology	O
into	O
janssen	O
clinical	O
trials	O
in	O
multiple	O
countries	O
around	O
the	O
globe	O
while	O
actively	O
shaping	O
policies	O
and	O
practices	O
through	O
cross-pharma	O
organization	O
transcelerate	O
and	O
direct	O
interactions	O
with	O
health	O
authorities	O
.	O
she	O
attributes	O
her	O
success	O
to	O
her	O
a++	O
team	O
.	O
“	O
you	O
need	O
to	O
attract	O
and	O
retain	O
the	O
best	O
people	O
,	O
foster	O
a	O
teamwork	O
culture	O
,	O
and	O
inspire	O
them	O
that	O
their	O
work	O
will	O
change	O
the	O
world	O
,	O
”	O
she	O
says	O
.	O
“	O
they	O
must	O
also	O
strive	O
for	O
measurable	O
results	O
in	O
their	O
projects.	O
”	O
she	O
says	O
partners	O
and	O
customers	O
who	O
share	O
the	O
same	O
vision	O
are	O
important	O
for	O
helping	O
to	O
foster	O
innovation	O
.	O
“	O
innovation	O
requires	O
dedication	O
:	O
dedicated	O
people	O
;	O
dedicated	O
funding	O
,	O
organizational	O
leadership	O
that	O
supports	O
trying	O
new	O
things	O
and	O
has	O
a	O
tolerance	O
for	O
failure	O
and	O
prudent	O
risk	O
taking	O
,	O
”	O
ms.	O
felicione	O
says	O
.	O
a	O
career	O
highlight	O
for	O
ms.	O
felicione	O
was	O
being	O
part	O
of	O
a	O
clinical	O
development	O
program	O
for	O
a	O
cervical	O
cancer	O
vaccine	O
that	O
ultimately	O
was	O
brought	O
to	O
market	O
.	O
occasionally	O
still	O
to	O
this	O
day	O
,	O
when	O
in	O
a	O
room	O
full	O
of	O
children	O
,	O
she	O
thinks	O
how	O
they	O
have	O
one	O
less	O
form	O
of	O
cancer	O
to	O
worry	O
about	O
thanks	O
to	O
this	O
breakthrough	O
.	O
ms.	O
felicione	O
is	O
inspired	O
by	O
her	O
mother	O
,	O
who	O
bravely	O
battles	O
a	O
devastating	O
progressive	O
brain	O
disease	O
.	O
she	O
would	O
like	O
to	O
be	O
remembered	O
for	O
the	O
impact	O
her	O
work	O
has	O
made	O
.	O
and	O
she	O
aims	O
to	O
inspire	O
by	O
communicating	O
a	O
cause	O
,	O
a	O
reason	O
,	O
a	O
mission	O
that	O
others	O
can	O
identify	O
with	O
,	O
buy	O
into	O
,	O
and	O
then	O
together	O
,	O
do	O
something	O
great	O
.	O
she	O
views	O
any	O
situation	O
,	O
even	O
adversity	O
,	O
as	O
a	O
gift	O
,	O
saying	O
it	O
teaches	O
lessons	O
,	O
it	O
helps	O
you	O
grow	O
,	O
and	O
it	O
has	O
a	O
purpose	O
.	O
“	O
the	O
glass	O
is	O
always	O
half	O
full	O
,	O
”	O
she	O
says	O
.	O
(	O
pv	O
)	O
